0001201800-13-000026.txt : 20131114 0001201800-13-000026.hdr.sgml : 20131114 20131114160128 ACCESSION NUMBER: 0001201800-13-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131114 DATE AS OF CHANGE: 20131114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL, INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 131219873 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 516-997-4600 MAIL ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 FORMER COMPANY: FORMER CONFORMED NAME: VASOMEDICAL INC DATE OF NAME CHANGE: 19950517 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10-Q 1 vaso10q-sept2013.htm FORM 10-Q vaso10q-sept2013.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM 10-Q


[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended September 30, 2013

[   ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _______________ to ______________

Commission File Number: 0-18105


VASOMEDICAL, INC.
(Exact name of registrant as specified in its charter)

Delaware
11-2871434
(State or other jurisdiction of
(IRS Employer Identification Number)
incorporation or organization)
  

180 Linden Ave., Westbury, New York 11590
(Address of principal executive offices)

Registrant’s Telephone Number
(516) 997-4600
 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes x    No  o


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.
 
Large Accelerated Filer  o
 Accelerated Filer o
 Non-Accelerated Filer  o
 Smaller Reporting Company x
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yeso      No  x
 
Number of Shares Outstanding of Common Stock, $.001 Par Value, at November 8, 2013 – 155,433,747
 
 
Page 1
 
Vasomedical, Inc. and Subsidiaries

 
INDEX
 
 
 
Page 2
 
Vasomedical, Inc. and Subsidiaries
(in thousands, except share data)
   
September 30, 2013
    
December 31, 2012
  
ASSETS
  
(unaudited)
        
CURRENT ASSETS
            
Cash and cash equivalents
   $ 9,147     $ 11,469  
Short-term investments
     111       110  
Accounts and other receivables, net of an allowance for doubtful
                
accounts and commission adjustments of $2,606 at September 30,
                
2013 and $3,179 at December 31, 2012
     4,739       9,145  
Receivables due from related parties
     21       25  
Inventories, net
     2,054       2,166  
Financing receivables, net
     -       16  
Deferred commission expense
     1,959       2,480  
Deferred related party consulting expense
     -       85  
Other current assets
     374       220  
 Total current assets
     18,405       25,716  
                 
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
                
$1,326 at September 30, 2013 and $1,161 at December 31, 2012
     418       473  
GOODWILL
     3,297       3,212  
OTHER ASSETS, net
     3,290       2,980  
    $ 25,410     $ 32,381  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
                
CURRENT LIABILITIES
                
Accounts payable
   $ 441     $ 342  
Accrued commissions
     1,591       2,337  
Accrued expenses and other liabilities
     3,970       4,627  
Sales tax payable
     164       177  
Deferred revenue - current portion
     7,684       10,580  
Deferred tax liability, net
     112       112  
Notes payable due to related party
     3       3  
Total current liabilities
     13,965       18,178  
                 
LONG-TERM LIABILITIES
                
Deferred revenue
     5,043       5,022  
Other long-term liabilities
     366       171  
Total long-term liabilities
     5,409       5,193  
                 
COMMITMENTS AND CONTINGENCIES (NOTE M)
                
                 
STOCKHOLDERS' EQUITY
                
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
                
issued and outstanding at September 30, 2013, and December 31, 2012
     -       -  
Common stock, $.001 par value; 250,000,000 shares authorized;
                
164,695,382 and 162,917,996 shares issued at September 30, 2013 outstanding
          
and December 31, 2012, respectively; 155,759,952 and
                
162,917,996 shares outstanding at September 30, 2013 and
                
December 31, 2012, respectively
     165       163  
Additional paid-in capital
     61,441       61,229  
Accumulated deficit
     (54,065 )     (52,416 )
Accumulated other comprehensive income
     97       34  
Treasury stock, at cost, 8,935,430 and nil shares at September 30, 2013
and December 31, 2012, respectively
     (1,602 )     -  
Total stockholders’ equity
     6,036       9,010  
    $ 25,410     $ 32,381  
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
Page 3
 
 
Vasomedical, Inc. and Subsidiaries
(Unaudited)
(in thousands, except per share data)
    Three months ended September 30,      
Nine months ended September 30,
  
   
2013
    
2012
     2013    
2012
  
Revenues
                      
Equipment sales
   $ 1,353     $ 688     $ 3,320     $ 3,197  
Equipment rentals and services
     391       375       1,213       1,407  
Commissions
     5,862       4,659       18,262       14,858  
Total revenues
     7,606       5,722       22,795       19,462  
                                 
Cost of revenues
                                
Cost of sales, equipment
     381       282       1,015       1,304  
Cost of equipment rentals and services
     207       148       665       699  
Cost of commissions
     1,831       1,229       5,502       3,685  
Total cost of revenues
     2,419       1,659       7,182       5,688  
Gross profit
     5,187       4,063       15,613       13,774  
                                 
Operating expenses
                                
Selling, general and administrative
     5,507       6,591       16,843       17,256  
Research and development
     172       131       474       403  
Total operating expenses
     5,679       6,722       17,317       17,659  
Operating loss
     (492 )     (2,659 )      (1,704 )     (3,885 )
                                 
Other income (expense)
                                
Interest and other income (expense), net
     (63 )     93       20       120  
Amortization of deferred gain on
                                
sale-leaseback of building
     -       4       -       31  
Total other income (expense), net
     (63 )     97       20       151  
                                 
Loss before income taxes
     (555 )     (2,562 )      (1,684 )     (3,734 )
Income tax benefit (expense)
     91       44       35       (72 )
Net loss
     (464 )     (2,518 )      (1,649 )     (3,806 )
                                 
Other comprehensive income
                                
Foreign currency translation gain
     29       30       64       29  
Comprehensive loss
   $ (435 )   $ (2,488 )    $ (1,585 )   $ (3,777 )
                                 
Loss per common share
                                
- basic and diluted
   $ (0.00 )   $ (0.02 )    $ (0.01 )   $ (0.02 )
                                 
Weighted average common shares outstanding
                                
- basic and diluted
     157,864       159,018       160,796       157,162  
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
Page 4
 
Vasomedical, Inc. and Subsidiaries
(Unaudited)
(in thousands)
      Nine months ended  
   
September 30, 2013
    
September 30, 2012
  
Cash flows from operating activities
            
Net  loss
   $ (1,649 )   $ (3,806 )
Adjustments to reconcile net loss to net cash
                
(used in) provided by operating activities
                
Depreciation and amortization
     266       286  
Amortization of deferred gain on sale-leaseback of building
     -       (31 )
Provision for doubtful accounts and commission adjustments
     23       (7 )
Share-based compensation
     300       559  
Amortization of deferred consulting expense
     87       416  
Changes in operating assets and liabilities:
                
Accounts and other receivables
     4,304       12,303  
Receivables due from related parties
     6       159  
Inventories, net
     71       (47 )
Finance receivables, net
     -       14  
Deferred commission expense
     521       (491 )
Other current assets
     (138 )     (170 )
Other assets
     (349 )     61  
Accounts payable
     99       39  
Accrued commissions
     (746 )     (2,126 )
Accrued expenses and other  liabilities
     (678 )     496  
Sales tax payable
     (13 )     (1 )
Deferred revenue
     (2,875 )     (230 )
Other long-term liabilities
     195       154  
Net cash (used in) provided by operating activities
     (576 )     7,578  
                 
Cash flows from investing activities
                
Purchases of property, equipment and software
     (126 )     (344 )
Purchases of short-term investments
     (111 )     (70 )
Redemption of short-term investments
     111       70  
Net cash used in investing activities
     (126 )     (344 )
                 
Cash flows from financing activities
                
Proceeds from exercise of warrant
     -       343  
Repurchase of common stock
     (1,602 )     -  
Repayment of notes payable due to related party
     -       (190 )
Net cash (used in) provided by financing activities
     (1,602 )     153  
Effect of exchange rate differences on cash and cash equivalents
     (18 )     10  
                 
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
     (2,322 )     7,397  
Cash and cash equivalents - beginning of period
     11,469       2,294  
Cash and cash equivalents - end of period
   $ 9,147     $ 9,691  
                 
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
                
Interest paid
   $ -     $ 5  
Income taxes paid
   $ 61     $ 411  
                 
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
          
Inventories transferred to property and equipment,
                
attributable to operating leases, net
   $ 57     $ 8  
Fair value of assets acquired
   $ -     $ 291  
Liabilities assumed through acquisition
   $ -     $ (291 )
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
Page 5
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. The Company since 2010 has been operating in two distinct businesses or segments, the Equipment segment and the Sales Representation segment. In the Equipment segment we design, manufacture, market and support certain medical devices.  Our principal products are Enhanced External Counterpulsation (EECP®) systems, which are non-invasive heart therapy devices based on our unique proprietary technology, and currently indicated in the United States for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, “MI”) and cardiogenic shock.  In addition we develop, manufacture and market certain ambulatory patient monitoring systems including recorders and analysis software.  In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (“GEHC Agreement”) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”), respectively – to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment.  VasoHealthcare activities are included under our Sales Representation segment (See Note C).

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC. These condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

 
Page 6
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2012, includes a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.

Revenue and Expense Recognition for VasoHealthcare

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured.  These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets.  Under our agreement with GE Healthcare (“GEHC”), GEHC pays the Company a commission.  In accordance with the agreement GEHC pays the Company fifty percent of the commission at the time the order is received and fifty percent of the commission when the order is completed by delivery and acceptance to their customer.  At the time the order is received therefore, the Company records a receivable for the fifty percent of the commission and offsets this to deferred revenue.  At the time the order is completed the Company records a receivable for the remaining fifty percent commission and records this as recognized revenue including the amount previously deferred.

Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded.  Commission expense is recognized when the corresponding commission revenue is recognized.  Cost of commissions includes commission expense and, beginning in 2013, costs associated with the medical device excise tax imposed by the Affordable Care Act.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments – the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:

 
Page 7
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
               
     (in thousands)  
      As of or for the three months ended September 30, 2013  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 1,744     $ 5,862     $ -     $ 7,606  
Operating (loss) income
   $ (364 )   $ 199     $ (327 )   $ (492 )
Total assets
   $ 8,398     $ 8,040     $ 8,972     $ 25,410  
Accounts and other receivables, net
   $ 1,229     $ 3,510     $ -     $ 4,739  
Deferred commission expense
   $ -     $ 4,145     $ -     $ 4,145  
                                 
                                 
         As of or for the three months ended September 30, 2012  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 1,063     $ 4,659     $ -     $ 5,722  
Operating loss
   $ (838 )   $ (1,358 )   $ (463 )   $ (2,659 )
Total assets
   $ 8,595     $ 11,319     $ 9,595     $ 29,509  
Accounts and other receivables, net
   $ 1,059     $ 6,645     $ -     $ 7,704  
Deferred commission expense
   $ -     $ 3,635     $ -     $ 3,635  
                                 
                                 
        As of or for the nine months ended September 30, 2013  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 4,533     $ 18,262     $ -     $ 22,795  
Operating (loss) income
   $ (1,489 )   $ 870     $ (1,085 )   $ (1,704 )
Total assets
   $ 8,398     $ 8,040     $ 8,972     $ 25,410  
Accounts and other receivables, net
   $ 1,229     $ 3,510     $ -     $ 4,739  
Deferred commission expense
   $ -     $ 4,145     $ -     $ 4,145  
                                 
                                 
        As of or for the nine months ended September 30, 2012  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 4,604     $ 14,858     $ -     $ 19,462  
Operating loss
   $ (1,191 )   $ (1,473 )   $ (1,221 )   $ (3,885 )
Total assets
   $ 8,595     $ 11,319     $ 9,595     $ 29,509  
Accounts and other receivables, net
   $ 1,059     $ 6,645     $ -     $ 7,704  
Deferred commission expense
   $ -     $ 3,635     $ -     $ 3,635  
                                 
 
 
 
Page 8
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
For the three months ended September 30, 2013 and 2012, GE Healthcare accounted for 77% and 81% of revenue, respectively.  For the nine months ended September 30, 2013 and 2012, GE Healthcare accounted for 80% and 76% of revenue, respectively.  Also, GE Healthcare accounted for $3.3 million, or 70%, and $8.1 million, or 89%, of accounts and other receivables at September 30, 2013 and December 31, 2012, respectively.

NOTE D – SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the condensed consolidated financial statements based on their estimated fair values.

During the three months ended September 30, 2013, no common stock grants were made.  During the nine month period ended September 30, 2013, the Company granted 400,000 restricted shares of common stock valued at $74,000.  Of these, 180,000 shares valued at $32,400 vested at the grant date, 20,000 shares valued at $3,600 vest 50% after three months and 50% after six months from the grant date and 200,000 shares valued at $38,000 vest 50% after one year and 50% after two years from the grant date.  During the three month period ended September 30, 2012, the Company granted 500,000 shares of restricted common stock valued at $130,000 to an officer, of which half of such shares vest in one year and half in two years.  During the nine month period ended September 30, 2012, the Company granted 1,000,000 shares, valued at $250,000, to officers and 2,392,500 shares, valued at $598,000, to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC agreement in June 2012.
 
During the three and nine month periods ended September 30, 2013 and 2012, the Company did not grant any stock options.

Share-based compensation expense recognized for the three and nine month periods ended September 30, 2013 was $29,000 and $300,000, respectively, and $328,000 and $559,000 for the three and nine month periods ended September 30, 2012, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the condensed consolidated statements of operations.  Expense for share-based consulting fees with non-employees was $0 and $87,000 for the three and nine months ended September 30, 2013, respectively, and $128,000 and $416,000 for the three and nine months ended September 30, 2012, respectively.  Unrecognized expense related to existing share-based compensation and consulting fees is approximately $124,000 at September 30, 2013 and will be recognized through May 2015.

NOTE E – LOSS PER COMMON SHARE

 Basic loss per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2013 and 2012, because the effect of their inclusion would be anti-dilutive.                                                
     (in thousands)  
      For the three months ended       For the nine months ended  
   
September 30, 2013
    
September 30, 2012
    
September 30, 2013
    
September 30, 2012
  
Stock options
     1,780       1,810       1,780       1,810  
Warrants
     -       1,500       -       1,500  
Common stock grants
     585       3,260       585       3,260  
      2,365       6,570       2,365       6,570  
 
Page 9
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
NOTE F – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

The following tables present information about the Company’s assets measured at fair value as of September 30, 2013 and December 31, 2012:
         
      (in thousands)  
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
    
Significant
Other
Observable
Inputs
(Level 2)
  
 Significant
Unobservable
Inputs
(Level 3)
    
 Balance
as of
September 30,
2013
(Unaudited)
  
Assets                                
Cash equivalents invested in money market funds
(included in cash and cash equivalents)
   $ 8,076     $ -     $ -     $ 8,076  
Investment in certificates of deposit
(included in short-term investments)
     111                       111  
    $ 8,187     $ -     $ -     $ 8,187  
                                 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level I)
  
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3) 
      
Balance
as of
December 31,
2012  
  
Assets
                                
Cash equivalents invested in money market funds
(included in cash and cash equivalents)
   $ 9,124     $ -     $ -     $ 9,124  
Investment in certificates of deposit
 (included in short-term investments)
     110                       110  
    $ 9,234     $ -     $ -     $ 9,234  
 
The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.

 
Page 10
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTE G – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2013 and December 31, 2012:
 
    (in thousands)  
   
September 30, 2013
    
December 31, 2012
  
   
(unaudited)
        
Trade receivables
   $ 7,162     $ 12,193  
Due from employees
     183       131  
Allowance for doubtful accounts and
                
commission adjustments
     (2,606 )     (3,179 )
Accounts and other receivables, net
   $ 4,739     $ 9,145  
 
 
Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.  Due from employees is primarily commission advances made to sales personnel.

NOTE H – INVENTORIES, NET

Inventories, net of reserves, consist of the following:                                  
 
    (in thousands)  
   
September 30, 2013
    
December 31, 2012
  
   
(unaudited)
        
Raw materials
   $ 844     $ 909  
Work in process
     519       483  
Finished goods
     691       774  
    $ 2,054     $ 2,166  
 
At September 30, 2013 and December 31, 2012, the Company maintained reserves for excess and obsolete inventory of $571,000 and $576,000, respectively.
 
NOTE I – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $3,297,000 and $3,212,000 was recorded on the Company’s condensed consolidated balance sheets at September 30, 2013 and December 31, 2012, respectively, pursuant to the acquisition of FGE in September 2011.  All of the goodwill was allocated to the Company’s Equipment segment.  The components of the change in goodwill are as follows:
 
 
Page 11
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
      (in thousands)  
   
Carrying Amount
  
       
Balance at December 31, 2012
   $ 3,212  
Foreign currency translation
     85  
Balance at September 30, 2013
   $ 3,297  

The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:
 
      (in thousands)  
   
September 30, 2013
    
December 31, 2012
  
   
(unaudited)
        
Patents
            
Costs
   $ 469     $ 469  
Accumulated amortization
     (451 )     (438 )
      18       31  
                 
Customer lists
                
Costs
     800       800  
Accumulated amortization
     (238 )     (152 )
      562       648  
                 
Software
                
Costs
     619       541  
Accumulated amortization
     (413 )     (386 )
      206       155  
                 
    $ 786     $ 834  
 
Patents, customer lists, and software are included in other assets in the accompanying condensed consolidated balance sheets and are amortized on a straight line basis over their estimated useful lives of ten, seven, and five years, respectively.  Amortization expense amounted to $41,000 and $126,000 for the three and nine months ended September 30, 2013, respectively, and $137,000 and $155,000 for the three and nine months ended September 30, 2012, respectively.
 
 
Page 12
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTE J - DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:
 
    (in thousands)  
     For the three months ended September 30,  For the nine months ended September 30,  
   
2013
    
2012
    
2013
    
2012
  
   
(unaudited)
    
(unaudited)
    
(unaudited)
    
(unaudited)
  
Deferred revenue at the beginning of the period
   $ 13,270     $ 15,198     $ 15,602     $ 15,228  
Additions:
                                
Deferred extended service contracts
     410       288       848       987  
Deferred in-service and training
     8       13       23       33  
Deferred service arrangements
     30       20       60       75  
Deferred commission revenues
     2,076       2,037       5,355       6,116  
Recognized as revenue:
                                
Deferred extended service contracts
     (245 )     (283 )     (755 )     (840 )
Deferred in-service and training
     (10 )     (10 )     (20 )     (25 )
Deferred service arrangements
     (16 )     (22 )     (54 )     (64 )
Deferred commission revenues
     (2,796 )     (2,243 )     (8,332 )     (6,512 )
Deferred revenue at end of period
     12,727       14,998       12,727       14,998  
Less: current portion
     7,684       9,418       7,684       9,418  
Long-term deferred revenue at end of period
   $ 5,043     $ 5,580     $ 5,043     $ 5,580  

NOTE K – RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (”Kerns”).  Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.  In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.

On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was also appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company.  Fees of approximately $66,000 and $187,000 were billed by the firm through the three and nine months ended September 30, 2013, respectively, and fees of approximately $60,000 and $194,000 were billed through the three and nine months ended September 30, 2012, respectively, at which dates no amounts were outstanding.

Mr. Rios currently is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company’s consulting agreement with Edgary Consultants, LLC.  The consulting agreement (the “Agreement”) between the Company and Edgary Consultants, LLC (“Consultant”) commenced on March 1, 2011 and was for a two year term and expired on February 28, 2013.  The Agreement provided for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy.  

In consideration for the services to be provided by Consultant under the Agreement, the Company agreed to issue to Consultant or its designees, up to 18,500,000 shares of restricted common stock of the Company, 3,000,000 of which were issued in March 2011 and the balance was to be earned on performance. Mr. Lieberman received 600,000 of these restricted shares.  The Company recorded the fair value of the shares issued to Consultant as a prepaid expense and amortized the cost ratably over the two year agreement.  The unamortized value is reported as deferred related party consulting expense in our accompanying condensed consolidated balance sheets as of December 31, 2012.  No performance-based shares were issued and no further compensation is expected to be paid in conjunction with the agreement.

 
Page 13
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
 
During the nine months ended September 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company’s acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.  In addition, receivables due from FGE management aggregating $8,000  and $6,000 were collected during the three and nine months ended September 30, 2013, Receivables due from FGE management aggregating $3,000 were advanced during the three month period ending September 30, 2012, and receivables aggregating $159,000 were collected during the nine months ended September 30, 2012.

Biox leases a part of its offices to Genwell Instruments Co., Ltd., a company partially owned by certain officers of the Company’s subsidiaries.  The lease term is for twenty months ending December 31, 2014 at a monthly lease amount of approximately $750.
 
NOTE L – STOCKHOLDERS’ EQUITY

Common Stock

During the three and nine months ended September 30, 2013 the Company issued 1,044,332 and 1,777,386 shares of common stock, respectively, to employees.  During the three and nine months ended September 30, 2012 the Company issued 1,771,000 and 2,333,500 shares of common stock to employees, respectively, and 2,400,000 shares of common stock to former owners of FGE.  In addition, see Note K for discussion of common stock issued during the three and nine months ended September 30, 2012 in connection with related party agreements.
 
On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.  The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.

As of September 30, 2013, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company of which 945,000 were forfeited and 2,845,000 had vested during various times through July 15, 2013.  In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 shares vested immediately with the remainder vesting a year thereafter.  At September 30, 2013, 1,176,222 shares are available for issuance under the 2010 Plan.

In June 2012, 2,392,500 additional restricted common shares, vesting at various times through July 1, 2013, were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, of which 373,500 shares were forfeited and 2,019,000 had vested as of July 1, 2013.  In July 2012, 500,000 shares of restricted common stock were granted to an officer, of which half vest in July 2013 and half a year thereafter.

No options were issued under the 2010 Plan during the three and nine month periods ended September 30, 2013 and 2012.

In April 2013, the Company’s Board of Directors authorized a share repurchase program of up to $1.5 million, which was subsequently increased in July 2013 to $2.0 million, of the Company’s common stock.  During the three and nine months ended September 30, 2013, 7,929,432 and 8,935,430 shares had been repurchased at a cost of $1,420,000 and $1,602,000, respectively, which cost has been recorded as treasury stock in the accompanying condensed consolidated balance sheet as of September 30, 2013.

 
Page 14
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
 
On October 30, 2013 the Board of Directors approved the 2013 Stock Plan (the “2013 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2013 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2013 Plan is 7,500,000 shares.

The 2013 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.  The 2013 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer the Plan with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.

Preferred Stock

Pursuant to its conversion terms, all Series E preferred stock was deemed automatically converted to common stock effective July 1, 2011, and all converted shares were issued as of June 30, 2012.

NOTE M – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010.  The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.  These circumstances include: not materially achieving certain sales goals; not maintaining a minimum number of sales representatives; and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

NOTE N - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Adoption of New Standards
 
Other Comprehensive Income:  Presentation of Comprehensive Income
 
In February 2013, new guidance was issued that amends the current comprehensive income guidance.  The new guidance requires entities to disclose the effect of each item that was reclassified in its entirety out of accumulated other comprehensive income and into net income on each affected net income line item.  For reclassification items that are not reclassified in their entirety into net income, a cross-reference to other required disclosures is required. The new guidance is to be applied prospectively for annual reporting periods beginning after December 15, 2012 and interim periods within those years.  The adoption of this new guidance did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows.

 
Page 15
 
Vasomedical, Inc. and Subsidiaries
 
 

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC Agreement and the risk factors reported from time to time in the Company’s SEC reports, including its recent report on Form 10-K.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

Vasomedical, Inc. was incorporated in Delaware in July 1987.  Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries.  Since 2010 we have been operating in two distinct businesses or segments, the Equipment segment and the Sales Representation segment. In the Equipment segment we design, manufacture, market and support certain medical devices.  Our principal products are Enhanced External Counterpulsation (EECP®) systems, which are non-invasive heart therapy devices based on our unique proprietary technology.  In addition we develop, manufacture and market certain ambulatory patient monitoring systems including recorders and analysis software.
 
In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (“GEHC Agreement”) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.
 
In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns and controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment.  VasoHealthcare activities are included under our Sales Representation segment (see Note C).
 
The Company expects to achieve profitability through reaching a higher commission rate under the GEHC Agreement, growth in our China operations and by expanding our market presence and product portfolio.  In addition, the Company plans to pursue acquisitions or partnership opportunities in the international and domestic markets and to expand our sales representation business.
 
 
Page 16
 
Vasomedical, Inc. and Subsidiaries

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2012.

Results of Operations – For the Three Months Ended September 30, 2013 and 2012

Total revenue for the three months ended September 30, 2013 and 2012 was $7,606,000 and $5,722,000, respectively, an increase of $1,884,000, or 33%. Net loss for the three months ended September 30, 2013 and 2012 was $464,000 and $2,518,000, respectively, a decrease of $2,054,000, or 82%.  The improvement was primarily attributable to a $1,124,000 increase in gross profit and a $1,084,000 decrease in selling, general and administrative costs.  Our total net loss was $(0.00) and $(0.02) per basic and diluted common share for the three months ended September 30, 2013 and 2012, respectively.

Revenues

Revenue in our Equipment segment increased by $681,000, or 64%, to $1,744,000 for the three-month period ended September 30, 2013 from $1,063,000 for the same period of the prior year.  Equipment segment revenue from equipment sales increased by $665,000, or 97%, to $1,353,000 for the three-month period ended September 30, 2013 as compared to $688,000 for the same period in the prior year primarily due to a $570,000 increase in EECP® revenues as a result of higher sales volume, and a $99,000 increase in international sales by our China operations.
 
Current demand for EECP® systems domestically will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.  We continue to pursue strategies to increase and expand the reimbursement for EECP® therapy.
 
Equipment segment revenue from equipment rental and services increased 4% to $391,000 in the third quarter of 2013 from $375,000 in the third quarter of 2012. Revenue from equipment rental and services represented 22% and 35% of total Equipment segment revenue in the third quarters of fiscal 2013 and fiscal 2012, respectively.  The increase in revenue generated from equipment rentals and services is due primarily to increased accessory part revenues.
 
Commission revenues in the Sales Representation segment were $5,862,000 in the third quarter of 2013, as compared to $4,659,000 in the third quarter of 2012, an increase of 26%.  The increase in commission revenue in the third quarter of 2013 is due primarily to an increase in volume of equipment delivered by GEHC.  The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet.  As of September 30, 2013, $11,357,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $4,443,000 is long-term.  At September 30, 2012, $13,689,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $5,062,000 was long-term.

 
Page 17
 
Vasomedical, Inc. and Subsidiaries
Gross Profit

The Company had a gross profit of $5,187,000 in the third quarter of 2013 compared to $4,063,000 in the third quarter of the prior year, an increase of 28%.  The increase is due both to higher commission revenues in our Sales representation segment arising from increased equipment deliveries by GEHC and higher equipment shipments in our Equipment segment.  Equipment segment gross profit increased to $1,156,000, or 66% of Equipment segment revenues, for the third quarter of 2013 compared to $633,000, or 60% of Equipment segment revenues, for the same quarter of 2012.  Gross profit margin on EECP® equipment improved as a result of the more favorable mix of higher margin products sold and higher sales volume of EECP® systems in the third quarter of 2013.  Gross profit in the Equipment segment is dependent on a number of factors, particularly the number of systems sold; the mix of new and refurbished EECP® systems and the mix of models sold; their respective average selling prices; the mix of EECP® units sold, rented or otherwise placed during the period; the ongoing costs of servicing EECP® systems; and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was $4,031,000, or 69%, for the three months ended September 30, 2013 as compared to $3,430,000, or 74%, for the three months ended September 30, 2012.  The decrease in the margin percentage was due to lower commission rates on equipment booked in 2012 but delivered during the third quarter of 2013 while the commission expense is at the same rate, partially offset by higher revenue in this segment.  Cost of commissions of $1,831,000 and $1,229,000, for the three months ended September 30, 2013 and 2012, respectively, reflects commission expense associated with recognized commission revenues, and, beginning in 2013, additional costs associated with the medical device excise tax imposed by the Affordable Care Act.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.
 
Operating (Loss) Income
 
Operating loss was $492,000 for the three months ended September 30, 2013 as compared to $2,659,000 for the three months ended September 30, 2012, a decrease of $2,167,000.  The decrease in operating loss was primarily attributable to the increase in gross profit in both segments as described above, as well as a $1,084,000 decrease in SG&A costs, mainly arising from a $955,000 decrease in such costs in the Sales Representation segment, where operating income was $199,000 compared to an operating loss of $1,358,000 in the same quarter of the prior year.  Equipment segment operating loss decreased by $474,000, or 57%, to $364,000 in the third quarter of 2013 from $838,000 in the same period of the prior year.

Selling, general and administrative (“SG&A”) expenses for the third quarter of 2013 and 2012 were $5,507,000, or 72% of revenues, and $6,591,000, or 115% of revenues, respectively, reflecting a decrease of $1,084,000 or approximately 16%. The decrease in SG&A expenditures in the third quarter of 2013 resulted primarily from the completion in the second quarter of 2013 of certain non-recurring costs attributable to the renewal of the GEHC contract.
 
Research and development (“R&D”) expenses of $172,000, or 2% of revenues (10% of Equipment segment revenues), for the third quarter of 2013, increased by $41,000, or 31%, from $131,000, or 2% of revenues (12% of Equipment segment revenues), for the third quarter of 2012. The increase is primarily attributable to an increase in product development expenses.

Interest and Other Income (Expense), Net

Interest and other income (expense), net for the third quarter of 2013 was $(63,000) as compared to $93,000 for the third quarter of 2012. The decrease was due primarily to a $130,000 charge associated with a potential liability to a workers’ compensation fund resulting from the 2007 closing of a trade association that previously provided workers’ compensation for the Company and others, as well as lower interest earnings on the Company’s cash balances.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of the deferred gain on the sale-leaseback of our Westbury, NY facility for the third quarter of 2012 was $4,000, during which period the deferred gain was fully amortized.

 
Page 18
 
Vasomedical, Inc. and Subsidiaries
Income Tax Benefit (Expense)

During the third quarter of 2013 we recorded an income tax benefit $91,000 as compared to an income tax benefit of $44,000 for the second quarter of 2012.  The increase arose from higher refunds due on prior period returns.

Results of Operations – For the Nine Months Ended September 30, 2013 and 2012
 
Total revenue for the nine months ended September 30, 2013 and 2012 was $22,795,000 and $19,462,000, respectively, an increase of $3,333,000, or 17%.  Net loss for the nine months ended September 30, 2013 was $1,649,000 compared to a net loss of $3,806,000 for the nine months ended September 30, 2012, a decrease of $2,157,000, or 57%.  The decrease in net loss was primarily attributable to a $1,839,000 increase in gross profit, as well as a $413,000 decrease in selling, general and administrative costs.  Our total net loss was $(0.01) and $(0.02) per basic and diluted common share for the nine months ended September 30, 2013 and 2012, respectively.

Revenues

Revenue in our Equipment segment decreased by $71,000, or 2%, to $4,533,000 for the nine-month period ended September 30, 2013 from $4,604,000 for the same period of the prior year.  Equipment segment revenue from equipment sales increased by $123,000, or 4%, to $3,320,000 for the nine-month period ended September 30, 2013 as compared to $3,197,000 for the same period in the prior year, primarily due to an increase of $311,000 in international sales made by our China operations, partially offset by $236,000 lower EECP® revenues as a result of lower sales volume.

Current demand for EECP® systems domestically will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.

Equipment segment revenue from equipment rental and services decreased by $194,000, or 14%, to $1,213,000 in the first nine months of 2013 from $1,407,000 in the same period of 2012. Revenue from equipment rental and services represented 27% and 31% of total Equipment segment revenue in the first nine months of fiscal 2013 and fiscal 2012, respectively.  The decrease in revenue generated from equipment rentals and services is due primarily to decreased time and material charged to on-demand service customers and decreased service contract revenues.

Commission revenues in the Sales Representation segment were $18,262,000 in the first nine months of 2013, as compared to $14,858,000 in the first nine months of 2012, an increase of 23%.  The increase in commission revenue in the first nine months of 2013 is due primarily to an increase in volume of equipment delivered by GEHC, partially offset by lower commission rates on orders booked in 2012 and delivered in 2013.  The Company recognizes revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet.  As of September 30, 2013, $11,357,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $4,443,000 is long-term.  At September 30, 2012, $13,689,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $5,062,000 was long-term.

Gross Profit
 
The Company had a gross profit of $15,613,000 in the first nine months of 2013 compared to $13,774,000 in the same period of the prior year, an increase of 13%.  The increase is principally due to the increase in commission revenue discussed above and an increase in the profit margin in our Equipment segment.  Equipment segment gross profit increased to $2,853,000, or 63% of Equipment segment revenues, for the first nine months of 2013 compared to $2,601,000, or 56% of Equipment segment revenues, for the same period of 2012, driven by a more favorable mix of higher margin products sold and lower production costs.  Gross profit in the Equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold; their respective average selling prices; the mix of EECP® units sold, rented or otherwise placed during the period; the ongoing costs of servicing EECP® systems; and certain fixed period costs, including facilities, payroll and insurance.
 
 
Page 19
 
Vasomedical, Inc. and Subsidiaries

Sales Representation segment gross profit was $12,760,000, or 70%, for the nine months ended September 30, 2013 as compared to $11,173,000, or 75%, for the nine months ended September 30, 2012.  The increase was due to higher revenue in this segment, as explained above, partially offset by lower commission rates on equipment booked in 2012 and delivered in the first three quarters of 2013.  Cost of commissions of $5,502,000 and $3,685,000, for the nine months ended September 30, 2013 and 2012, respectively, reflects commission expense associated with recognized commission revenues, and, starting in 2013, additional costs associated with the medical device excise tax imposed by the Affordable Care Act.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.
 
Operating Loss

Operating loss was $1,704,000 for the nine months ended September 30, 2013 as compared to an operating loss of $3,885,000 for the nine months ended September 30, 2012, an improvement of $2,181,000, or 56%.  The decrease in operating loss was primarily attributable to improved operating performance in the Sales Representation segment, where operating income was $870,000 for the first nine months of 2013 compared to an operating loss of $1,473,000 in the same period of the prior year.  Partially offsetting the improvement in the Sales Representation segment was an increase of $298,000 in the operating loss of the Equipment segment to $1,489,000 in the first nine months of 2013 from an operating loss of $1,191,000 in the same period of the prior year. The increase in the operating loss in the Equipment segment was principally due to an increase in sales and marketing expenses for this segment.

Selling, general and administrative (“SG&A”) expenses for the first nine months of 2013 and 2012 were $16,843,000, or 75% of revenues, and $17,256,000, or 78% of revenues, respectively, reflecting a decrease of $413,000 or approximately 2%. The decrease in SG&A expenditures in the first nine months of 2013 resulted primarily from $754,000 lower costs in the Sales Representation segment, partially offset by $477,000 higher costs in the Equipment segment, mainly associated with the expansion of the Equipment segment sales team.

Research and development (“R&D”) expenses of $474,000, or 2% of revenues (10% of Equipment segment revenues), for the first three quarters of 2013, increased by $71,000, or 18%, from $403,000, or 2% of revenues (9% of Equipment segment revenues), for the same period of 2012. The increase is primarily attributable to an increase in product development expenses.

Interest and Other Income, Net

Interest and other income, net for the first nine months of 2013 was $20,000 as compared to $120,000 for the first nine months of 2012. The decrease was due primarily to a $130,000 charge associated with a potential liability to a workers’ compensation fund resulting from the 2007 closing of a trade association that previously provided workers’ compensation for the Company and others, as well as lower interest earnings on the Company’s cash balances.

Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of the deferred gain on the sale-leaseback of our Westbury, NY facility for the first three quarters of 2012 was $31,000.  The deferred gain was fully amortized in the third quarter of 2012.
 
Income Tax Benefit (Expense)
 
During the first nine months of 2013 we recorded an income tax benefit of $35,000 as compared to income tax expense of $72,000 for the first nine months of 2012.  The decrease in expense resulted mainly from a Federal tax refund due on a prior period return.
 
 
Page 20
 
Vasomedical, Inc. and Subsidiaries

Liquidity and Capital Resources
 
Cash and Cash Flow
 
We have financed our operations from working capital.  At September 30, 2013, we had cash and cash equivalents of $9,147,000, short-term investments of $111,000 and working capital of $4,440,000 compared to cash and cash equivalents of $11,469,000, short-term investments of $110,000 and working capital of $7,538,000 at December 31, 2012.

Cash used in operating activities was $576,000 during the first nine months of 2013, which consisted of a net loss after adjustments to reconcile net loss to net cash of $973,000, offset by cash provided by operating assets and liabilities of $397,000. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $4,304,000, partially offset by decreases in deferred revenue of $2,875,000 and accrued commissions of $746,000.  Under the GEHC Agreement the Company earns progressively higher commission rates as calendar year targets are met, and this commission structure has a significant impact on our cash flows. As we achieve these targets, the higher commission rates are retroactively applied to all sales in the calendar year, and therefore, the significantly higher commission billings and recognized revenue generated in the fourth quarter of 2011 resulted in significant cash inflows early in 2012.  As we previously reported in our Annual Report on Form 10-K for the year ended December 31, 2012, lower commission rates were earned in 2012 than in 2011, resulting in lower cash inflows in 2013.

Cash used in investing activities during the nine-month period ended September 30, 2013 was $126,000 for the purchase of equipment and software.

Cash used in financing activities during the nine-month period ended September 30, 2013 was $1,602,000 for the repurchase of common stock.

Liquidity

The Company expects to achieve profitability and continued positive cash flow through reaching a higher commission rate under the GEHC Agreement, growth in our China operations and by expanding our market presence and product portfolio.  In addition, the Company plans to pursue acquisitions and partnership opportunities in the international and domestic markets and to expand our sales representation business.

While we expect to generate positive operating cash flows for 2013, the progressive nature of the commission rates under the GEHC Agreement can cause related cash inflows to vary widely during the year.
 
 
Page 21
 
Vasomedical, Inc. and Subsidiaries

 
Evaluation of Disclosure Controls and Procedures
 
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.  Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
 
Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2013 and have concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2013 due to insufficient controls and management review over the recording of certain transactions, and the lack of accounting personnel with appropriate level of knowledge and experience in accounting principles generally accepted in the United States of America and related accounting systems and the closing process at our China subsidiaries.  The Company has engaged additional accounting personnel, and has implemented a review process of its closing procedures, related disclosures, and the approval of certain transactions, and expect that these actions have resolved the issues.  Management expects to test the effectiveness of these modifications in connection with the 2013 audit.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
 
Page 22
 
Vasomedical, Inc. and Subsidiaries
 
 
 

 
Exhibits
 
10    2013 Stock Plan
31
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


 
Page 23
 
Vasomedical, Inc. and Subsidiaries



In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


VASOMEDICAL, INC.

By:           /s/ Jun Ma                                           
Jun Ma
 
President and Chief Executive Officer
 
(Principal Executive Officer)

/s/ Michael J. Beecher   .
Michael J. Beecher
 
Chief Financial Officer and Principal Accounting Officer

Date:  November 14, 2013
 
 
Page 24
 






 
 GRAPHIC 2 vaso10q2012.jpg begin 644 vaso10q2012.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`"L! M$`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[^**_FM_X+3?\`!4[]J7_@G[\9_AKX3^$EEX'N/"7CKP3>^(U? MQ'HLVI7AN["_@TVXC25;B!(D68RN`!*7!`(3;D]I_P`$2_\`@J+^T!_P4!\8 M?&7P[\:K+P?;V_@3PUH^M:+-X8TR3397GO\`5([2:&YC>:?>B0OE)`Z[FS^[ M&*_1*GAAQ/3X,CQVUE\LAE0AB%*&-C+%J$\7]2L\-R74XU[QG'FTBN;8_/X> M)7#<^,)<#IX^.>1KSP[C+!M85SAA/KMXXCGLX2H:QERZO2U]OZ'JHZCJFFZ1 M:R7VK:A9:99PJSRW5_=06EO&B`LS/-(XO@!\0--URW\+>'K>^EM;6?4/"NJ6VE:I?7,5ML\_P"W MS/YT<,C,HCW*Z.#Q^/\`%>;8GAGAK%\3?V9B+QRJO# M0K5Y*2ASJC4=HPG*R^%73/ZO^CAX.4OI!^,&1^$E/B[+>$L?G&59SG<,7CL- M6Q^(K8#(:-*OCZ>7X"A.D\5C'3JITH5<1AJ/NSXL?$_QS\(/JUN7232=*N9-1O1)'D,F((S#G*D9$I''N*^+?%O\`P7B_8X\. MRR0:78^/O%$JLRQOIVE6T%M*1T*W-S`_B5\1K];?POX M:\4>*;^>98FCT;2=2U.?S9`"%E^QV\@0D$-F9T4`Y+`&OOCX:_\`!(_]M[XD MI9WMC\*-2TG2[E8Y#?\`B2]L]'2-'SC]S/<-<%Q_%&T2<=&R<5^%KQ0XZSB; MCDF34.6]DL+@,7CY+;XJLI*E?S<8Q[KM_K;6_9Z_1`\+<)"MXM>+.;*O&,95 M9<0<8\-<&4JDK)OV&6TJ%7,N23ORQAB,1/5+G;U?[A:Q_P`'"7P93=_8/PF\ M57)`R/[0U#3(AR>.8+L@G&O'^KN#^ M)XKY<\&?\&^G[0NK1V\WB3XB^`_"H?!N()8=1U.>(-C*J;6?RV9>%W*A5SQ9]6I74OJ.<>(. M=*JM[E6W5:,J+_P<):C(^(O@3HI7N7\1W(YSQTE/YX]/6NFT MO_@OXEPR_P!H_!.QA4XW?9==FD89]/,F"GCU(]`2>OI^D?\`!`/X%6RK_:?Q M1\9SO@;S:6.CH"V.2HEM#WY'L:[NR_X(/_LO6P7[1XV^)%R5ZE;C3;:<3_LLZ2G3PO"7%>(TLJF# MPO&Z;VUC+%YU2\]91_R.5T#_`(+M?"R[V_VW\+?$5L2,G^S]0T^49XR%\^Z7 MGTSCT([U[CX:_P""SW[+^NE$O=&\>:)*Q4-]ITVUN8%SU/GV]QM(!XX!/?IS M7/6W_!#W]E2W`'_"0_$:0C`W-JMIG`X_Y]C_`)]3DG6A_P""*O[+]NH$/B+X MC(0W_D(!_GVXKJI4O'VA_R_X7Q2O\.(]BM/\5&G2?X[GY;G6,_9NYAS M?V?EWB[E$G\,\#]=E&-^U/'XO&Q:7FKGTQX:_P""D7[(_B)(F?XG6&B/*0!' MK,,UNRLW16*)(`>N1VQ7T+X;_:+^!OB_RQX;^*/A'53*`4$&IHA(.,<3K%CK MT./T-?GC%_P1O_9[M_\`CU\9?$.+C@27EC<`'CD+-"R@X&.`./>M*V_X)+?" MK3\?V;\1?&L)4D@O#I).<="PM"Q'8@D\5[.&S7QIP[BL;PMPGCXJW-+"YQ5P ME1][>T=6"^<.NETC\=SWAGZ'&,YY<-^)?BID\VWR4\XX3PV94(;6YGAJ>%K. MW;VE]]=%?]4[76M'OD62RU73;M'^X]M>VTZMGT,4K`]:T@P)V9QTZUZ;I/[.?[1_AV96 MT?\`:4U">U7&++5;.>X@.WINVQEC[\\^W2OH\+Q)Q>K+,N`<;2?6>79WE&.C MTUY:U7!2[Z:O3K<_*,TX'\-DY/(/&#+<9%*\89SPKQ%E%26ND>;#T,TIIVZR M<5Z'W=17SUH6C_M%:*BQ:KXG\$>)HU(4R_V=?6MR5Y^8LS+EOKQSSP*]9T:] M\4L`FMZ7;HW`,EG,#&.<$A7._'!(!YP17U&$S5XCE57+Q^>YADD<$Y.AG&39G33TJ8#%SO)=U2Q=#"UEZ.G?NCK**!GN,?K1 M7JGAA1110`45\^?M5?&^S_9Q_9Z^*_QJO3;@>`?".IZS:+=_\>TFI)%Y6FQS M#(W1/>R0B11RR;@.37\D7[)?_!=__@H!^TO^TC\)_@M8:)\+Y+;QSXWTG2M4 M%IX:N8;BUT&:[1]5F2X%Y*4>TT_SF24Q,&D1-R1*2R?><+>'7$?%^5YOG65K M`T\NR12>.KXW%QPR7L\//%5/9)PE[3V=&'-/:W-!:N1\1Q-X@\/<*9IE.3YI M+&3S#.7%8*A@\++$M\^(IX:G[5J453]I5J';+4=8^'7B#5;J_P!4LX$75KQ;VW"1 M2VQNRZ6ZH"-J;E?YL#^B3]@SXE_&;XQ?LK_"KXG?'W3+'1OB=XRT>36=;TG3 M["?3+>PBGN)%L(38W&9;>8VJI++&Q;:9``S8W&.(/#WB#AG(= M>P>"HTL;"MC;8C#?6XNMAHQ4J7)2Y?::2YI=%=] M#CS#'8;+,#C,QQDW3PN!PU;%XB:7,XT:%.52HU'[4N6+Y8KXG9=3[6HK^/#_ M`()U?\%JOV[OVR/VMOA9\$=4TKX;?\(?KFM2R>-;[3/#=U:7ECX:M;>5[J[A MG%W<".43>0BAEVD2'YU(57_K`T?XM^$];\;:A\/[4ZDOB+39)UFCFTZYCM'B M@BFE:>.\9!"R,L+A/FR6VCJ0*^FXOX#S_@K,(99G$<)/%2P*S&<$9+B[_9K\:B/]W9:1XF\/O+CO/?/? M+'G'JN['X_3Q+_@UMU;ROV@OV@=()(-U\,-'N-N>HBUX\D9R?]4,9'T)QQ^E MO_!RY\.=0\6?LI_#'Q#I-FMS=Z#\3([2X6>EZ#X=^"%Y-!#-,BR:EJT>HRR:;I\0+[W:ZN%6' M"!F7S-V,#!_IGAK"8[/_`*-N-PN!P>(Q5:E];R^E"A2G4E4Q"SW#5:5**BG[ M\Y8B"4=_>3ZW/YJXES+*^'_I&X*MF&88/!1K+"9A5>(KPI1XB%:M)3:M M",,-4RN#'>Z-X M*W+);6!,;;E;7RLT4J$H?LZENH`;X/\`^"=_@[]G3XC_`/!.VW^+/[:-QKWA MCX1?LM^//$7_``CTEHTUK-\1)/$EW-JEUX=T5U*OJ4XOU@T][*$,Q,N"-B.X M_*9?AG^T=_P5,_;HNKV^MKBY\0?%GQK)>7$?#NDV=SI7PY7 M3X-5USQ3K5G`!J/B1=,)11=7=X9KC[1(W$7C]P7QU1X%P_"F4YQPWPYQ1+'+"X?!?VM@YX#V7UI3A[*53#X MF6)Q;H3ABO;8FA1HN,^5P_GB'_!<;XB:;XIB^&W_``3T_9)\!>`-.CEGT[0H MX/"+^+/&/B"S@/_!,PZW\0==@;36US68GE*QI<+)%Y#Z2EVFCRRS^4 M[".6&=ES&Q=!)7Y%_P#!6'XZ?MU?M*_$?PIH/[4WPTT;X7:CX4T[^T=`\"V- MO`MWI5MK8<+]MO!)-*ACQ]UPSX>Y&\WP7#L/!K(>'\HC@9 MU9T?L$?L^QZM'9/4NU6)E#*?$_V7_P#@G-\;OBK_ M`,$6_BI:_"VQN9?B;\3_`(K:?XI_X16.1H)?%'AGP'?_`+JQMOF7SKB]B"]?\`>*=2TUM!\06WB/PDUW M;7NEK.MTUE7OA35_AXVB:G M>::\O^ML)X!<2/!,JLJ3V_FB,D;MK8`_IU_9X_X*0?"+XJ_L7VO[8WQ*$OP? M\+Z7%>V/C/3_`!$&ADT[Q%I:HMWIVD"X\F35/MDKA=*5`'NB<#`5F'\UGPI_ MX+K?%K4O&FAG]J/]EGX)?$^VBEM]-U/QC=>'[2?QAI&EB=#<'3EO;":V<1J9 M)5MVD"EP%1CZ):P:% M::GXG\3QRRR-JNF:<+>SDN-)2U$<8DB8QRN)%^;FN?.O"/'\19OP[PYBO#+# M\%8BK.KB\PXCR#&O%X#$X+!4X_7<+0P2I?N\16G5PZPOUJ2JTI2E+][34T;9 M-XQY+P_E/$7$.%\4O]5"G&EB'B? MJT94JBC&*]E4<&_IS]H[_@Y<^)/B#Q?>^%?V0OA/91:9#?/:Z/XB\6V,VN:O MK\(;"7"^'8K9S:!NJPDF4<[P%PS?,_@O_@Y)_;B\#^,(K7XN^#_`?B'2[2]7 M^UO#I\+'PMJPB+*9+=;E4:>V8ICRRZ)@,&Q@@U^J_P#P;Y?\$^OAOX)_9Z/[ M2OQ&\(:'XG^)?Q%U74;30)M>TVTU./PUX:TN:6T5;&WO(IX$GU-F6X>XV^:A M1A&5!!K\K_\`@XZ^'W@JY_:T\$0?"SPSX=TK5[;X>HGCP:':6FGBXUF?4`^G M->6]FD,8NTL<*S%=[(5+9+"NCAW*_#',^.L=X899X=T\>LLH8VEC,\Q%2MB, M:\7ET;8MS=U6ITXU7*@J].K2_?6<*,:=D\^(\Y\1,JX#P/B?FGB+_9T,SKX" MM@\GHPP^&P/U3,9)X-4Y-.C4G.C;$.C4I5?W'-SU934F?THM_P`%4_ACXM_X M)V>,?VYOA];*?^$8T62UO_"NI.K2Z)XZ;R8$T&[?Y5N%2XN8620!%FB)P.#G M\)/V>/\`@Y1^*FM_$FTA^/.A^#]&^&MAIFJ:EK,OA_1S)K-]-9HKV6F:>@5) M#<7SL85,6YE*Y"GDU^;8N?B?\+/^"3,?PR-K/:Q_';XZW.HRV$K%%ET+PQIE MG<0:DB%AO@N;FU:.-P-KX7DD`5]*?\$"?^"=7A/]H7XV>+OB?\<_"]IXD\$? M"6PLY=/\.:BGF:7JOB?5'D-A)=QG*W*:8+=;DV[9C?S/FZ4UX7<#\(<+%674 MJ.*]E2G!RA5E3C)*:DNN^.G_```O!<5W*NFV?B+1X MO$VKW%I%*RP37=S*(5BEN(0DDL<6](W'?"_A:V:S\/>+HI+*.==6O;I1Y>@6UO'/!\GAOP3:6_C6'P[9VVF6-]K&H2V]U82 MFSM4A@BEALQ)$X5>2Q)QTK]/?^"`_P#P37^$L7P.US]I+X]?#[0_%WBOQ3J5 M[IWA2#Q/:1:GHVE>$K."(W%]%972R6YNKJY24O.4.R--N6VJ5.(^'/"[!>&. M1\9YAP)B.>75\!A,)6E1S7&U*\I^RPE?,Y/,'FF.P"S&EF%?$TH5LNP-.@J4:V+HY9#E="OA:] M6%"E14U35>].K*I!._YMZK_P$;K3 M;J/7;.]E22X;Q'I;FUO=*T2$NCZC<7=W&XL;>$EG!QNPN:_@8_;U^&>FZI^V MA\>8O@]X4L])\#3?$S6[3POI&F!?LR6\=X;58K**/$:QR7`80QQJ$`*X`SS] M%_\`!0#5_B7X=^&?[.7[&OAT7%I\/O@]\/M-\4:CIZ3O%#JGC7QU;V^LZE/? MPJZK-/I;--#;M,C%%N#@[AQ[O$O@MPYQ-1X*PV3<-2X9K9E*.:8Z>$H3CBZ> M14\!2KXNC5A*4Z=;%?6,5@L/2K33<*M:'?&_-N&ZO&F)SGBS#\2 M4,KOE>$CBL52>$EGE7'5*&%J4Y14)T'?VAOAGX51K:2&[U+PIK/@F?P9K4UC,V0 M(IWA-Q$CH&"3*C@'T^[7G7_!*_\`:=\9_L'>`=?U71OV+=0^*GC?QIJ:7VO[*.O_``XO?"_AYM'O;BWT+6)[S5U-Q+,KW<[VH>40&4K&TC%E154< M5M@O#C(%J3 MITW&JVW4I2C^[!_`_AZWO+7QKI M>I2QR:AHOB;3@J7&@6B;D;4+B[N&$6EE`#=Y)7(1FK^:?]HK_@YC_:!\0^-+ MVR_9F\"^%_!_@ZVNY+;3Y_%FE)XDUO5K:.1EAO9[>1(TLI+I0'^RQ.[1A@C# M=N%?D1\2O#O[0OPL_90\"_`?69-3\/:5XM\6ZYXS\2>!KX36#_`()T?#V]\#^+OVG?C5X)T?Q7XCGUQ_#G MP\L])\->!/#3)>(> M-^(#\3>,?$K/,@X(X=SO#9!F4,GH8[B'&X91^M^UCAZ5?$UW27[W#T(PK8 M>,,/3=&<\37<*E2%-1BOSF_:F_X+J?$7]K+]BGQ=^SM\4O!MEI7Q*\1ZY8KJ MOB?P]"=/T?4_#]H\=PUE+I8P+2']OA'2?^$XL=`@MK"Q'BJ66X:9_L%HL5O;3-;-!YL<:* MN[!VKD`>J_!+P=K7[,'_``1+^-OC"WA_LCXH?M1_$33O`^E`MY4UWX-TNY6. M[E0G:TD+PF20;205)/3`K[:668"/AGEM#A?A_$Y!0\3,RRO"X?+;5*CI3S^M M1IX_V4GJZ4,JPF)G3Y;1C2M.,8)\J^+CG=9^)>9U.)N)<%GE?PSRS-,7B\>Y MTJ=Z>0TJD\%+$0O:-5YIC,-"HY^\ZUX2E*6K]%^$7_!>']H3X]_'SP5\,M%^ M!?P9O+SXC^/],\/6#77A.SN-4>#5M1CA5KBXDA_>745L6GFE9V.49OFQ@_NG M_P`%"O\`@L5\#OV`-+L?``L;/XB?'C^R+*2?X=^'[F.VTCPY))`HD_MV_MA* MFFJLVY[>Q6/SI(`"OS';7\C/_!)WX:ZWX(^-GCC]I#Q%H4=S8?L[?"OQC\2= M%:4!K=_&5E:QQ^'(=QROF&0W3`<'N.E>$?!_X)_%C]O']M[PQH_CR^O+S5/C M1\4Y+KQ-JUU)K3J5)TL/A,MPT:]54G"I4>(A M"$HJ3D=^2^,_$.$X>P=*EQ#ALUXGXUSIX'(ZF*GA)QP>$P]6E@IU,)1A"$*] M?%YEB)8>G[55*=/V$YRC-I1?Z?:__P`'$7_!1/Q;_:OB3X?^"?!NE>#M/N'E MD>W\!S:]#80`EA#>ZJ85C&Q/ON[*<#+**^M?V%O^#D#QWXU^*OA3X;?M5>$/ M#9T;QAK%CH,7CGPG:_V0=!OM2N8+*QFO=+6,PS63W,ZKOA1\)].^$'ACX5^![+P5I_A_^P;JVG\/Z3<37]L]F;6\N=1OKFT> MXN+FY5I))+B:0LC/E-FT`?`GAK_@B)_P3<\.^(KKQQ_PK)=4NX=4F\01->^* M[W^R-*=)S>!HK:"Y2WAM[67,B'*)&JKP`BX_&Y<<>#&9X+-L!C/#BIE4%&5' M*,;E"A5S";DI0IUZ]6=;#^PK0E&G4Y)3Q<*G-*G-2LW+]FAP7XPY9C,JQN$\ M0Z6:2YU5S7!YMSTL#%1<)5*%&C&AB%7I3BZE-3C'"SIM*<7&Z4(O@+:?M'^.= M/MK3PU^%_V(/\`@GAHOPL^#_AC0]1\KQ7J-O$` MR2&ZD:XFF#*66<,9=B:GA'+%9ABY498C/?$',\)D^4UH5K2 M3P%"O7I5TFI0C0HPPLZTU+GE4J2<8+Y7B7CJGF?$^886CXO4*&"P<:T:&0^' M^`Q.<9M1G1?+-8ZOAZ-:CHX5'7K3Q,*5-QY5"FDYGR?\#/\`@Y0_:C\/_$O2 M=`_:*\!^#]?\-G6K71_$-MH^B'PMKFE)+>Q6=[=;%C8FXT]7>8VTFWS#$8R, ML,_7_P#PWFTPW,0.=K MRWVW:<@2@@C%?R^_#WX5_%;]IK]JGPK'XEL8+KQ!\5?BOHK^('L8$@B#:[X@ MM)=4EBM[?]W#%';23N%4;55/7K^BW_!=._U_QK^UUIGPM\*2IJ/@?X"?#GPC M\,?#ZB7>(KO3-.A.M`8.%_TF&,$+SN5L]./U"MX79'@O$O@>>3\.0RK'8/+< MUS[-<%@:=9X5QP:PN%P-6-.>D91S+%N-.HH0]K3HMR@Y1LOS*EXL9CC/#7C9 MYMQ53S3+\3F>59!E>.QM>@L2IXQ8C%XVE.K"S?/EN%4YTY3J>RG45I.,_>^U MO^#7OX%2:M\3?C5\?;VV$MCX5T.W\#:9)+&"(M5UC[)J<\L3$'Y_L8V<8*E< MYR,5_:2MC9)=/>I:6Z7CIY;W*PQB=DSG:TH7>1GL37XP?\$%_P!GM_@7^P;X M1U+4;`Z?XC^*FJWWC/6H73;-L$LUEIAE[[OLB\`G@$`<8K]JJ_D_QASN6=^( MG$==2DZ.#Q2RF@KO2EEL8X62WM9UZ=6>FCYK[ZG]6^$63PR?P^X7=Z7K.GVFJ M:==)_)X:JYTJF;5\RHUX9A#"PIJ MO2P\?92IRPU9MQJ4'/G4E\2LDXW/R#QH^C=6\5N+0E;KPSX1DC\VRLU251-:WVH&:22_0A&VJB%=I7'\\/_!6VR^- M6K?MG_%&_P#B#HVOK##J5O9^'7:TU!]+?P[#;QC2_P"S9Q$;5HGB4/,+=L^< M#Y@)"FO[W(HHX(XX88TAAB18XHHD6...-`%1(T0!415`"JH"J```!7G_`(U^ M$?PH^)+P2?$7X8?#SQ]):KLM7\:^"O#?BI[9#_#`VNZ;?M"O^S&5'M7E<&>/ M>.R+Q)X@\0L_RB.>5\_PE7!.A3Q'L*N5X9UJ-3#8?+JM2G5A&A1I4*>&E2<8 M^TIWESJ3ES^MQQ]'?`<0>%_#GAMPYG+R##\.XNACO;U,,\11S;%*A6I8O$9E M2IU*4Y5\16KU,5&JI2]E4:@HN"CR_P`OW["7_!2BP^#W[.W@?X$_"#]CSQCX ML^-<2S:5_P`)!I&GVHT/7M?NGN);;7-:N4M6U&&)=Z).))52..+(`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`L?)]Q_X*R_\`!/+Q MQ^SYX^\*^)?AQX9USQ#\)9O!WA[0;/6=/LKO49;/7-'AG74H=46SCG:T2X>= M);:615B*@J6!Q7]K>@^&_#OA73X])\+Z!HOAO2H3F+3-!TJQT?3XC@#,=EIT M%O;(<`#Y8QP`.U6-7T?2-?T^YTG7=*TW6]*O$\N[TS5[&UU+3[J/.?+N;*\B MFMITR`=LL;+D9Q7O?\32Y]0XIR/,(<5B^+>(, MSHYS7XHA@,/AJ&%QE"=>JL+A_MXH\W4 M5O*28%5"Q&$==N17G'P-_8T_:T_X*6_M":G\2_B+I^NZ/H^O^(8]4\<^/O$N MF7NF6-EI[2IFUT:VNU@FNVCMHUMK"*U22*$@.6)!4_V@1_LM_LR0W0OH?V=/ M@3%?!_-%Y'\(OA^ET),Y\P7"^'A-OSSOW[L\YKVC3=,TW1K*WTW1].L=*TZT M01VNGZ;:6]C96T8Z1V]K:QQ00H.RQQJOM5XSZ1>0934SW-O#_P`.L%P[Q7Q) M[1YCQ%C<8\=6A4K3]K5JX?#*"I*2,%G@OHS<1YQ3 MX>R?Q'\3&XN9"(MTZL/WW_P"")'P>;X._L7IXQ\2:9<:/KOCC7=<\ M1:HMU;2072Z+IY)TUI(Y%64XMFD*C;_"0`2:_5G5_@W\(?$&H76KZ_\`"KX; MZWJM\Y>]U/5_`WAC4M0O'889[J]O=+FN;AV`P6FEWKXFK."H4W"IB\PQ-3&3(KA=;\=ZGIU@Z:3J3L] MGIMV='L-F+9E_>+:*T85L%75N]?V7:+9VG[&O_!-NTLOL=P;CP'\$WB\BRMI M9KR36=0S6DL:%5*I)$RK@8`P*T\0O&O`<;Y;P+D-#ANM ME>0<(8G"UL3@?K\*T\QHX.AA<)1I0G'#TH4''"T<1!2<*EI8ERM:-GGX;>!. M8:'X4UK4OAGXO MTS2KCPUJ^FV-Y?V=FVGV$-K>Z5>O:PR+9RVLBL8?.")+&#M(VJ&_LVT/X1?" M?PQJ4&L^&_AA\//#VL6JNEMJNA^"O#>DZE;K(,.L%]8:9;W42N``ZQRJ&`Y! MKJ/$/AGPWXMTR;1?%?A_1/$VCW!!GTGQ#I-AK6F3E<[3-8:E;W-K(5R<%XFQ MDXZU]OC?I48RIQQDO$V"X9]AD^79)B\DQ61U/P6!^B+@:7`.>\*X_BEXC.LSS_!9]A<^I9;R0PU3 M`8.MA*>%Q&$GB9SQ%&NL7C)UG&O3DIU*4X>]2M/^1K]DK_@LK)^S_P#LX^%O M@MXB_9WO/%OBGP1I-QH_AOQ!9QV-K:7,1EGFMI-3:5H>A>'Y)T M-PT.L7!MI+V>*T^6%88+AYIV4N(@Q8?O^G[*O[+\4PN8_P!F_P"`L=P&W"=/ M@_\`#U)@P.0PE7PZ'#9YR&SGFO8]$T#0?#.GQ:3X;T32/#^E0$F#3-$TVSTK M3X20`3%96$-O;1DA0#LC&0`.PKY#/O%CPTQ,,\Q>2>$>">>Y]6KXBMF'$6;8 MK,\-@L5B)2J5<3@L#!TXTYNK.=54XU*5-U&G-2IKV1]KP[X/>*6%GD&#S[QD MQW]@G?M'Z!\5/["OM1\*>*/`/A_2UU31]-N6T>VU?P]"+?4;9(RQ9FKR#]@#]O#]MOX/^![C]G;X#_#B'QT?$>I74GAR7 M4=`U:]N/#6H7\#/!_CK2GT+ MQOX4\->,M$EUO+1W&>&:$D=C7/>"_@]\(_AO- M/OEGTA,G7A MQEG`W$O`&"XFJ9+0HT<#/&8R5/+*E3!2F\OQ.)PU.FL0JF'A-TZD*-:,:\%* M+E"-6:/%S/Z-V=?\10S7Q`X6\1<=PK3SS$5JV80P6"C5S6G3QL:2S'"87%5: MCPSI8B=)5*4Z]"<\/-PDHSE1A)_YVWQF\'?'GQK\>?%4GQ'@\0^*/B#K/B[R MM>UEK#4+F.[UNZDMHGCBE6W\LPV\LB6<04J@2#`/!:OU+_X*L66M^`O@Y^Q[ M^R3X?T#699_A;\*=,\5>)_L&FWK)YHNS=G23.;H2_O!<>9YHD^ MUF_%M",16XO-1TZYN! M!$`!'")/+0#"J*]S%_2?P6,S?@G'5.#9T\%P?3Q]6&7X?,*5"CB,RQ.6PRO" MXFC"&%5/"X?!8>>,]CAE"HHNO34)15*[\#`_10QV`R;CO+Z?&\:N/XUJY=1J M9GB,MK5Z^'RO"YI/-L9AJ\YXSVN+Q./Q-/!>VQ4IP:WNK M68O;JES:3QNRB:%Y$92DR[@NT_Z-&@>&_#OA/38M&\+:!HOAK2(&=X=*T#2K M'1M-A>0YD:*QTZ"VM8V<\NR1`L>6)-^(5T+WQ]\*/AKXXO0JH+O MQAX$\+^);H(@PBBXUK2KV7:HX5=^`.`!7!D?TFZN#SOCFOG?"\,XX>XTQOUF M>5O&\E?`T5@*65?4G6E1E2Q6&K8"C2IU8.%%J<93IM>TDCT,^^BI2QF0<`8? M(.+*F2<2\"X+ZM#-XX#GPV/KRS&IF[QJH0KQJX7$T77@6;78(;;Q!K'A2PUG4?$=T`4$UII M;VL,S6EM=L661EC,VTA`.04[KX.?LJ?\%`-#_9&^+_QR\7>/OBEI/E^";^U\ M)_"E]2O9]6U_1]0B=-4UB[L7:2ZMS9PD&QM5"W3,LCYYV1?U,^&_V?/@)X,O MXM4\'_!#X0^%-3@=7AU'PW\-?!FA7\+JBVMQ&ZD`JR2`@C(->N.B2 M(\RO+&C7A25"5=5:E6E1E*-!4FW)^Y@/H^ M<29KFN)S_P`1O%+/N)(H5*5/%U,-AJ].GBI8>I5>( MAAG2I4JM91EB)5E%17^;E^SCXIA^#/[0_P`/_B'\3OAIK'Q`T'PCXKM]5USP M??6=PEQK$<,CDP2)?PJGG^:PE(N!AFSO#$XK]Y?VRO\`@HI^T!^TQ^S?X[T' M]G']FOQS\*_A!;VMCIGC_P`9:W8+:7UQIUTUN;?3O#L>G0VL7V21S&ES+;1R MM'"IB*$,0O\`1W>?LR_LVZCJ,NKZA^SY\$+_`%:>8W$VJ7GPG\!W6HS3LVYI MI;V?0'N9)F;YC(\IE2PU;&J7-]6Q.)BXTY*E.K1K*E""\#@_P"C9QGP MGP]Q)PK@_$ZC@9XBO4POU6E'$9IB*U3%4,"X*/UK"X22 ME4BZL*->@ZTZC_AZ_P""/WPWO;/]K*W^(WC7P_JL>C?"OP3XN\?O'>:7>*MQ MJ&BZ7,]A&AG@0-*'4O'&NYG;9@9Q7QOXR\.?$7]I/]IO6]9A\.^)'N?BG\3; MVXM9+G2]2#+#XAUZ5;?)>`*GDV,\;!=V$5/FZ&O]#32/A'\*/#TES+H'PQ^' MNARWEM)9W"_#>FR75G,GERVER]EIL+3VTJ?))!*6B=/E92.*IV'P4^#6 ME7MKJ>E_"3X8Z;J-C,MQ9:A8>`O"MG>V=PA)6>UNK?2HY[>9225EBD1P2<-7 MJ4_I3X6EQ-GW$ZX0Q,L9F619;DF74YYM3<,MI8&>.Q-2;?U/]\L3CL73KU$H MTWRT(PN])1\FK]$?%5>%.'>$Y<9X:."RKB'-,_S.I#)ZBGFE7,(9?A:=.SQG M[IX7`8.KAZ;E*HN:O*:4=8NQ\(/!EI\._A;\/_!%C;K;0>&O".@Z4854*%N+ M;3K=+HD``!FN?-8^YKT:BBOY`Q%>IBL17Q-:3G5Q%:I7JR;; EX-10 3 vaso10q-sept2013ex10.htm 2013 STOCK PLAN vaso10q-sept2013ex10.htm
EXHIBIT 10
VASOMEDICAL, INC.
2013 STOCK PLAN

I.   GENERAL PROVISIONS

A.   PURPOSE OF THE PLAN

This 2013 Stock Plan (the “Plan”) is intended to promote the interests of VASOMEDICAL, INC., a Delaware corporation (“Corporation”), by providing eligible persons in the employ or service of the Corporation or its affiliates with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Corporation as an incentive for them to continue in such employ or service.

Unless otherwise defined herein, all capitalized terms shall have the meaning assigned to them in the attached Appendix.

B.   STRUCTURE OF THE PLAN

     The Plan shall be divided into two (2) separate equity programs:

     (i)  the Option Grant Program under which eligible persons (“Optionees”) may, at the discretion of the Board, be granted options to purchase shares of common stock; and

     (ii) the Stock Issuance Program under which eligible persons (“Participants”) may, at the discretion of the Board, be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Corporation (or any Parent or Subsidiary).

The provisions of Articles One and Four shall apply to both equity programs under the Plan and shall accordingly govern the interests of all persons under the Plan.

C.   ADMINISTRATION OF THE PLAN

The Plan shall be administered by the Corporation’s Board of Directors (“Board”), or in the discretion of the Board, a committee consisting of no less than two Non-Employee Directors or persons meeting such other requirements as may be imposed by Rule 16(b) under the 1934 Act (“Committee”).

The Board or Committee shall have full power and authority (subject to the provisions of the Plan) to establish such rules and regulations as it may deem appropriate for proper administration of the Plan and to make such determinations under, and issue such interpretations of, the Plan and any outstanding options or stock issuances thereunder as it may deem necessary or advisable. Decisions of the Board shall be final and binding on all parties who have an interest in the Plan or any option or stock issuance thereunder.
 
 
1
 

 
D.   ELIGIBILITY

The persons eligible to participate in the Plan are:

     1.   Officers, directors and employees; and

     2.   consultants and other independent advisors who provide services to the Corporation, or any parent or subsidiary of the Corporation.

The Board or Committee shall have full authority to determine, (i) with respect to the grants made under the Option Grant Program, described in Article Two below, which eligible persons are to receive the option grants, the time or times when those grants are to be made, the number of shares to be covered by each such grant, the status of the granted option as either an Incentive Option or a Non-Qualified Option, the time or times when each option is to become exercisable, the vesting schedule (if any) applicable to the option shares and the maximum term for which the option is to remain outstanding, and (ii) with respect to stock issuances made under the Stock Issuance Program, described in Article Three, which eligible persons are to receive such stock issuances, the time or times when those issuances are to be made, the number of shares to be issued to each Participant, the vesting schedule (if any) applicable to the issued shares and the consideration to be paid by the Participant for such shares.

The Board or Committee shall have the absolute discretion either to grant options in accordance with the Option Grant Program or to issue stock in accordance with the Stock Issuance Program.

E.   STOCK SUBJECT TO THE PLAN

The stock issuable under the Plan shall be shares of the Corporation’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the Plan is 7,500,000 shares.

Shares of common stock subject to outstanding options shall be available for subsequent issuance under the Plan to the extent (i) the options expire or terminate for any reason prior to exercise in full, or (ii) the options are cancelled in accordance with the cancellation-regrant provisions of Article Two. Unvested shares issued under the Plan and subsequently repurchased by the Corporation, at the option exercise or direct issue price paid per share, pursuant to the Corporation’s repurchase rights under the Plan shall be added back to the number of shares of common stock reserved for issuance under the Plan.

If there is any change to the common stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding common stock as a class without the Corporation’s receipt of consideration, then appropriate adjustments shall be made to (i) the maximum number and/or class of securities issuable under the Plan, and (ii) the number and/or class of securities and the exercise price per share in effect under each outstanding option in order to prevent the dilution or enlargement of benefits thereunder.

 
2
 
 
II.  OPTION GRANT PROGRAM

A.   OPTION TERMS

Each option shall be evidenced by one or more documents in the form approved by the Board, and which shall be subject to the provisions of the Plan.

     1.   Exercise Price.

          a. The exercise price per share shall be fixed by the Board in accordance with the following provisions:

               (i) The exercise price per share shall not be less than the Fair Market Value per share of common stock on the option grant date.

               (ii) If the Optionee is a 10% Stockholder, then the exercise price per share shall not be less than one hundred ten percent (110%) of the Fair Market Value per share of common stock on the option grant date for Incentive Options.
 
          b.  The exercise price is payable in cash or check made payable to the Corporation upon exercise of the option, subject to the provisions of Section I of Article Four and the documents evidencing the option. If the common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended (“34 Act”) at the time the option is exercised, then the exercise price may also be paid as follows:

               (i) in shares of common stock held for the requisite period necessary to avoid a charge to the  Corporation’s earnings for financial reporting purposes and valued at Fair Market Value on the Exercise Date, or

               (ii) to the extent the option is exercised for vested shares, through a special sale and remittance  procedure pursuant to which the Optionee shall concurrently provide irrevocable instructions (x) to a Corporation-designated brokerage firm to effect the immediate sale of the purchased shares and remit to the Corporation, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable for the purchased shares plus all applicable Federal, state and local income and employment  taxes required to be withheld by the Corporation by reason of such exercise and (y) to the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete the sale.

Except to the extent the foregoing sale and remittance procedure is used, payment of the exercise price for the purchased shares must be made on the Exercise Date.
 
     2. Exercise and Term of Options. Each option shall be exercisable at such time or times, during such period and for such number of shares as shall be determined by the Board or Committee and set forth in the documents evidencing the option grant. However, no option shall have a term in excess of five (5) years measured from the option grant date.

 
3
 
     3. Effect of Termination of Service.

          a.   The following provisions shall govern the exercise of any vested option held by the Optionee at the time of cessation of Optionee’s employment or rendering of services to the Corporation (collectively “Service”) or death:

               (i)  Should the Optionee cease to remain in Service for any reason other than death, Disability or Misconduct, then the Optionee shall have a period of three (3) months following the date of such cessation of Service during which to exercise each option held by such Optionee to the extent exercisable on the date of such termination.

               (ii) Should Optionee’s Service terminate by reason of Disability, then the Optionee shall have a period of twelve (12) months following the date of such cessation of Service during which to exercise each outstanding option held by such Optionee to the extent exercisable on the date of such termination.

               (iii) If the Optionee dies while holding an outstanding option, then the personal representative of his or her estate or the person or persons to whom the option is transferred pursuant to the Optionee’s will or the laws of inheritance shall have a twelve (12)-month period following the date of the Optionee’s death to exercise such option to the extent exercisable on the date of such termination.
 
               (iv) Under no circumstances, however, shall any such option be exercisable after the specified expiration of the option term.

               (v) All vested options shall terminate upon the expiration of the applicable exercise period or (if earlier) upon the expiration of the option term.

          b.   The Board or Committee shall have the discretion, exercisable either at the time an option is granted or at any time while the option remains outstanding, to:

               (i) extend the period of time for which the option is to remain exercisable following Optionee’s cessation of Service or death from the limited period otherwise in effect for that option to such greater period of time as it shall deem appropriate, but in no event beyond the expiration of the option term, and/or

               (ii) permit the option to be exercised, during the applicable post-Service exercise period, not only with respect to the number of vested shares of common stock for which such option is exercisable at the time of the Optionee’s cessation of Service but also with respect to one or more additional installments in which the Optionee would have vested under the option had the Optionee continued in Service.

     4. Stockholder Rights. The holder of an option shall have no stockholder rights with respect to the shares subject to the option until such person exercises the option, pays the exercise price and becomes the recordholder of the purchased shares.

 
4
 
     5. Limited Transferability of Options. During the lifetime of the Optionee, the option shall be exercisable only by the Optionee and shall not be assignable or transferable other than by will or, following the Optionee’s death, by the laws of descent and distribution.

B.   CORPORATE TRANSACTION

     1. All unvested options shall automatically vest in full if and when either of the following stockholder approved transactions to which the Corporation is a party are consummated: (i) a merger or consolidation in which securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such transaction, or (ii) the sale, transfer or other disposition of all or substantially all of the Corporation’s assets in complete liquidation or dissolution of the Corporation. However, the shares subject to an outstanding option shall not vest on such an accelerated basis if and to the extent: (i) such option is assumed by the successor corporation (or parent thereof) in the Corporate Transaction or (ii) such option is to be replaced with a cash incentive program of the successor corporation which preserves the spread existing on the unvested option shares at the time of the Corporate Transaction and provides for subsequent payout in accordance with the same vesting schedule applicable to those unvested option shares or (iii) the acceleration of such option is subject to other limitations imposed by the Board or Committee at the time of the option grant.

     2. Each option which is assumed in connection with a Corporate Transaction shall be appropriately adjusted, immediately after such Corporate Transaction, to apply to the number and class of securities which would have been issuable to the Optionee in consummation of such Corporate Transaction, had the option been exercised immediately prior to such Corporate Transaction. Appropriate adjustments shall also be made to (i) the number and class of securities available for issuance under the Plan  following the consummation of such Corporate Transaction and (ii) the exercise price payable per share under each outstanding option, provided the aggregate exercise price payable for such securities shall remain the same.

     3. The Board or Committee shall have the discretion, exercisable either at the time the option is granted or at any time while the option remains outstanding, to structure one or more options so that those options shall automatically accelerate and vest in full (and any repurchase rights of the Corporation with respect to the unvested shares subject to those options shall immediately terminate) upon the occurrence of a Corporate Transaction, whether or not those options are to be assumed in the Corporate Transaction.

     4. The Board or Committee shall also have full power and authority, exercisable either at the time the option is granted or at any time while the option remains outstanding, to structure such option so that the shares subject to that option will automatically vest on basis should the Optionee’s Service terminate by reason of the Optionee’s involuntary dismissal or discharge by the Corporation for reasons other than misconduct (“Involuntary Termination”) within a designated period (not to exceed one year) following the effective date of any Corporate Transaction in which the option is assumed and the repurchase rights applicable to those shares do not otherwise terminate. Any option so accelerated shall remain exercisable for the fully-vested option shares until the expiration or sooner termination of the option term.

 
5
 
     5. The portion of any Incentive Option accelerated in connection with a Corporate Transaction shall remain exercisable as an Incentive Option only to the extent the applicable One Hundred Thousand Dollar ($100,000.00) limitation is not exceeded. To the extent such dollar limitation is exceeded, the accelerated portion of such option shall be exercisable as a Non-Statutory Option under the Federal tax laws.

     6. The grant of options under the Plan shall in no way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

III.  STOCK ISSUANCE PROGRAM
 
A.   STOCK ISSUANCE TERMS

Shares of common stock may be issued at the discretion of the Board or Committee under the Stock Issuance Program through direct and immediate issuances without any intervening option grants. Each such stock issuance shall comply with the terms specified below.

     1.   Issuances.

            Shares of common stock may be issued under the Stock Issuance Program for past or future services rendered, or to be rendered, to the Corporation (or any Parent or Subsidiary) as the Board may deem appropriate in each individual instance.

     2.   Vesting Provisions.

          a.   Shares of common stock issued under the Stock Issuance Program shall vest at the discretion of the Board or Committee.

          b.   The Participant shall have full stockholder rights with respect to any shares of common stock issued to the Participant under the Stock Issuance Program. Accordingly, the Participant shall have the right to vote such shares and to receive any regular cash dividends paid on such shares.

IV.  MISCELLANEOUS

A.   ADJUSTMENTS DUE TO STOCK SPLITS, MERGERS, CONSOLIDATION, ETC.

If, at any time, the Corporation shall take any action, whether by stock dividend, stock split, combination of shares or otherwise, which results in a proportionate increase or decrease in the  number of shares of common stock theretofore issued and outstanding, the number of shares which are reserved for issuance under the Plan and the number of shares which, at such time, are subject to options shall, to the extent deemed appropriate by the Board or Committee, be increased or decreased in the same  proportion, provided, however, that the Corporation shall not be obligated to issue fractional shares.

 
6
 
Likewise, in the event of any change in the outstanding shares of common stock by reason of any recapitalization, merger, consolidation, reorganization, combination or exchange of shares or other corporate change, the Board or Committee shall make such substitution or adjustments, if any, as it deems to be appropriate, as to the number or kind of shares of common stock or other securities which are reserved for issuance under the Plan and the number of shares or other securities which, at such time are subject to Options.

B.   EFFECTIVE DATE AND TERM OF PLAN

     1. The Plan shall become effective on November 1, 2013, provided that no Incentive Options may be granted unless the Plan is first approved by the Corporation’s stockholders. The Board may grant options and issue shares under the Plan at any time after the effective date of the Plan and before the date fixed herein for termination of the Plan.
 
     2. The Plan shall terminate upon the earliest of (i) the expiration of the ten (10)-year period measured from the date the Plan is adopted by the Board, (ii) the date on which all shares available for issuance under the Plan shall have been issued as vested shares or (iii) the termination of all outstanding options in connection with a Corporate Transaction. All options and unvested stock issuances outstanding at the time of a clause (i) termination event shall continue to have full force and effect in accordance with the provisions of the documents evidencing those options or issuances.
 
C.      AMENDMENT OF THE PLAN

The Board or Committee shall have complete and exclusive power and authority to amend or modify the Plan in any or all respects, except for those persons ineligible to participate. However, no such amendment or modification shall adversely affect the rights and obligations with respect to options or unvested stock issuances at the time outstanding under the Plan unless the Optionee or the Participant consents to such amendment or modification. In addition, certain amendments may require stockholder approval pursuant to applicable laws and regulations.

D.      WITHHOLDING

The Corporation’s obligation to deliver shares of common stock upon the exercise of any options or upon the issuance of shares issued under the Plan shall be subject to the satisfaction of all applicable Federal, state and local income and employment tax withholding requirements.

E.      REGULATORY APPROVALS

The implementation of the Plan, the granting of any options under the Plan and the issuance of any shares of common stock (i) upon the exercise of any option or (ii) under the Stock Issuance Program shall be subject to the Corporation’s obtaining all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the options granted under it and the shares of common stock issued pursuant to it.

 
7
 
F.      NO EMPLOYMENT OR SERVICE RIGHTS

Nothing in the Plan shall confer upon the Optionee or the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining such person) or of the Optionee or the Participant, which rights are hereby expressly reserved by each, to terminate such person’s Service at any time for any reason, with or without cause.

APPENDIX

The following definitions shall be in effect under the Plan:
 
Board shall mean the Corporation’s Board of Directors.

Change of Control shall mean:

     (i)  any person who is not currently such becomes the beneficial owner, directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company’s then outstanding voting securities; or

     (ii) three or more directors, whose election or nomination for election is not approved by a majority of the Incumbent  Board (as defined in the Plan), are elected within any single 12-month period to serve on the Board of Directors; or

     (iii) members of the Incumbent Board cease to constitute a majority of the Board of Directors without the approval of the remaining members of the Incumbent Board; or

     (iv) any merger (other than a merger where the Company is the survivor and there is no accompanying change in control under subparagraphs (i), (ii) or (iii) of this  paragraph) , consolidation, liquidation or dissolution of the Company, or the sale of all or substantially all of the assets of the Company.

Code shall mean the Internal Revenue Code of 1986, as amended.

Common Stock shall mean the Corporation’s common stock, $.001 par value.

Corporate Transaction shall mean either of the following stockholder-approved transactions to which the Corporation is a party:

     (i) a merger or consolidation in which securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such transaction, or

 
8
 
     (ii) the sale, transfer or other disposition of all or substantially all of the Corporation’s assets in complete liquidation or dissolution of the Corporation.

Corporation shall mean Vasomedical, Inc., a Delaware corporation.

Disability shall mean the inability of Optionee to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment and shall be determined by the Plan Administrator on the basis of such medical evidence as the Plan Administrator deems warranted under the circumstances. Disability shall be deemed to constitute Permanent Disability in the event that such Disability is expected to result in death or has lasted or can be expected to last for a continuous period of twelve (12) months or more.
 
Eligibility. Incentive Options may only be granted to Employees other than the Chairman, Chief Executive Officer and directors.

Employee shall mean an individual who is in the employ of the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.

Exercise Date shall mean the date on which the option shall have been exercised.

Exercise Price shall mean the exercise price payable per Option Share as specified in the Grant Notice.

Expiration Date shall mean the date on which the option expires as specified in the Grant Notice.

Fair Market Value per share of common stock on any relevant date shall be determined in accordance with the following provisions:

     (i) If the common stock is at the time traded on the NASDAQ Global or Capital Market, then the Fair Market Value shall be the closing selling price per share of common stock on the date in question, as the price is reported by the National Association of Securities Dealers on the NASDAQ Global or Capital Market. If there is no closing selling price for the common stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

     (ii) If the common stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of common stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the common stock, as such price is officially quoted in the composite tape of transactions on such exchange. If there is no closing selling price for the common stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

 
9
 
     (iii) If the common stock is at the time neither listed on any Stock Exchange nor traded on the NASDAQ Capital Market, then the Fair Market Value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate.
 
Grant Date shall mean the date of grant of the option as specified in the Grant Notice.

Grant Notice shall mean the Notice of Grant of Stock Option accompanying the Agreement, pursuant to which Optionee has been informed of the basic terms of the option evidenced hereby.

Incentive Option shall mean an option which satisfies the requirements of Code Section 422.
 
Misconduct shall mean the commission of any act of fraud, embezzlement or dishonesty by the Optionee or Participant, any unauthorized use or disclosure by such person of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or any other intentional misconduct by such person adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in a material manner. The foregoing definition shall not be deemed to be inclusive of all the acts or omissions which the Corporation (or any Parent or Subsidiary) may consider as grounds for the dismissal or discharge of any Optionee, Participant or other person in the Service of the Corporation (or any Parent or Subsidiary).

1934 Act shall mean the Securities Exchange Act of 1934, as amended.

Non-Employee Director shall have the meaning provided under Rule 16(b) or any successor rule under the 1934 Act.

Non-Statutory Option shall mean an option not intended to satisfy the requirements of Code Section 422.

Option Agreement shall mean the option agreement issued pursuant to the Grant Notice.

Option Shares shall mean the number of shares of common stock subject to the option.

Optionee shall mean the person to whom the option is granted as specified in the Grant Notice.

Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

Permitted Transfer shall mean (i) a gratuitous transfer of the Purchased Shares, provided and only if Optionee obtains the Corporation’s prior written consent to such transfer, (ii) a transfer of title to the Purchased Shares effected pursuant to Optionee’s will or the laws of intestate succession following Optionee’s death or (iii) a transfer to the Corporation in pledge as security for any purchase-money indebtedness incurred by Optionee in connection with the acquisition of the Purchased Shares.

 
10
 
Plan shall mean the Corporation’s 2013 Stock Plan.

Plan Administrator shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan.
 
Purchase Agreement shall mean the stock purchase agreement pursuant to the Grant Notice.

Service shall mean the Optionee’s performance of services for the Corporation (or any Parent or Subsidiary) in the capacity of an Employee.

Stock Exchange shall mean the NASDAQ Global Market System, American Stock Exchange,  New York Stock Exchange, or Over the Counter Bulletin Board.

Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

Vesting Commencement Date shall mean the date on which the Option Shares commence to vest as specified in the Grant Notice.

Vesting Schedule shall mean the vesting schedule specified in the Grant Notice pursuant to which the Optionee is to vest in the Option Shares in a series of installments over his or her period of Service.

 EX-31 4 vaso10q-sept2013ex31.htm CERTIFICATION vaso10q-sept2013ex31.htm
EXHIBIT 31.1
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jun Ma, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Jun Ma .
Jun Ma
President and Chief Executive Officer

Date: November 14, 2013
 
 
 
 

EXHIBIT 31.2
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Beecher, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Michael J. Beecher .
Michael J. Beecher
Chief Financial Officer

Date: November 14, 2013
 EX-32 5 vaso10q-sept2013ex32.htm CERTIFICATION vaso10q-sept2013ex32.htm
EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending September 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Jun Ma .
Jun Ma
President and Chief Executive Officer

Dated: November 14, 2013
 
 

 
 
 
 



EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending September 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


 
/s/ Michael J. Beecher .
Michael J. Beecher
Chief Financial Officer

Dated: November 14, 2013
EX-101.INS 6 vaso-20130930.xml INSTANCE DOCUMENT 0000839087 2013-01-01 2013-09-30 0000839087 2013-11-08 0000839087 2012-09-30 0000839087 2013-09-30 0000839087 2012-12-31 0000839087 2011-12-31 0000839087 us-gaap:CorporateMember 2012-09-30 0000839087 vaso:EquipmentSegmentMember 2012-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-09-30 0000839087 vaso:EquipmentSegmentMember 2013-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2013-09-30 0000839087 vaso:GeHealthcareMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2013-09-30 0000839087 us-gaap:CorporateMember 2013-09-30 0000839087 us-gaap:CreditConcentrationRiskMember vaso:GeHealthcareMember us-gaap:AccountsReceivableMember 2012-12-31 0000839087 2012-01-01 2012-09-30 0000839087 2013-07-01 2013-09-30 0000839087 2012-07-01 2012-09-30 0000839087 vaso:EquipmentSegmentMember 2012-01-01 2012-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2013-01-01 2013-09-30 0000839087 us-gaap:CorporateMember 2012-01-01 2012-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-01-01 2012-09-30 0000839087 us-gaap:CorporateMember 2013-01-01 2013-09-30 0000839087 vaso:EquipmentSegmentMember 2013-01-01 2013-09-30 0000839087 us-gaap:CorporateMember 2013-07-01 2013-09-30 0000839087 vaso:EquipmentSegmentMember 2013-07-01 2013-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2013-07-01 2013-09-30 0000839087 vaso:SalesRepresentationSegmentMember 2012-07-01 2012-09-30 0000839087 us-gaap:CorporateMember 2012-07-01 2012-09-30 0000839087 vaso:EquipmentSegmentMember 2012-07-01 2012-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-01-01 2012-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2013-01-01 2013-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2013-07-01 2013-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-07-01 2012-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2011-01-01 2011-12-31 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-01-01 2012-03-31 0000839087 2012-06-01 2012-06-30 0000839087 vaso:GeHealthcareMember 2013-01-01 2013-09-30 0000839087 vaso:GeHealthcareMember 2013-07-01 2013-09-30 0000839087 vaso:GeHealthcareMember 2012-07-01 2012-09-30 0000839087 vaso:GeHealthcareMember 2012-01-01 2012-09-30 0000839087 us-gaap:AccountsReceivableMember vaso:GeHealthcareMember us-gaap:CreditConcentrationRiskMember 2013-01-01 2013-09-30 0000839087 vaso:GeHealthcareMember us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember 2012-01-01 2012-12-31 0000839087 us-gaap:OfficerMember us-gaap:RestrictedStockMember 2012-01-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember vaso:NonOfficerEmployeesAndConsultantsMember 2012-01-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0000839087 vaso:VestingAtGrantDateMember us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0000839087 vaso:SharesVestingAtFiftyPercentAfterThreeMonthsMember us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0000839087 us-gaap:RestrictedStockMember vaso:SharesVestingAtFiftyPercentAfterOneYearMember 2013-01-01 2013-09-30 0000839087 us-gaap:RestrictedStockMember 2013-07-01 2013-09-30 0000839087 us-gaap:RestrictedStockMember 2012-07-01 2012-09-30 0000839087 us-gaap:RestrictedStockMember 2013-09-30 0000839087 vaso:SharesVestingAtFiftyPercentAfterSixMonthsMember us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0000839087 us-gaap:StockCompensationPlanMember 2013-01-01 2013-09-30 0000839087 us-gaap:StockCompensationPlanMember 2013-07-01 2013-09-30 0000839087 us-gaap:StockCompensationPlanMember 2012-07-01 2012-09-30 0000839087 us-gaap:StockCompensationPlanMember 2012-01-01 2012-09-30 0000839087 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000839087 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000839087 us-gaap:WarrantMember 2013-01-01 2013-09-30 0000839087 us-gaap:StockOptionsMember 2013-01-01 2013-09-30 0000839087 us-gaap:CommonStockMember 2013-01-01 2013-09-30 0000839087 us-gaap:StockOptionsMember 2013-07-01 2013-09-30 0000839087 us-gaap:WarrantMember 2013-07-01 2013-09-30 0000839087 us-gaap:CommonStockMember 2013-07-01 2013-09-30 0000839087 us-gaap:WarrantMember 2012-07-01 2012-09-30 0000839087 us-gaap:CommonStockMember 2012-07-01 2012-09-30 0000839087 us-gaap:StockOptionsMember 2012-07-01 2012-09-30 0000839087 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000839087 us-gaap:FairValueInputsLevel3Member 2013-09-30 0000839087 us-gaap:FairValueInputsLevel2Member 2013-09-30 0000839087 us-gaap:FairValueInputsLevel1Member 2013-09-30 0000839087 us-gaap:FairValueInputsLevel1Member 2012-12-31 0000839087 us-gaap:FairValueInputsLevel3Member 2012-12-31 0000839087 us-gaap:FairValueInputsLevel2Member 2012-12-31 0000839087 us-gaap:CustomerListsMember 2013-01-01 2013-09-30 0000839087 us-gaap:PatentsMember 2013-01-01 2013-09-30 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2013-01-01 2013-09-30 0000839087 us-gaap:PatentsMember 2012-12-31 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2012-12-31 0000839087 us-gaap:CustomerListsMember 2012-12-31 0000839087 us-gaap:CustomerListsMember 2013-09-30 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2013-09-30 0000839087 us-gaap:PatentsMember 2013-09-30 0000839087 2012-06-30 0000839087 2013-06-30 0000839087 vaso:ServiceArrangementsMember 2012-01-01 2012-09-30 0000839087 vaso:ExtendedServiceContractsMember 2012-01-01 2012-09-30 0000839087 vaso:ServiceArrangementsMember 2013-01-01 2013-09-30 0000839087 vaso:CommissionRevenuesMember 2013-01-01 2013-09-30 0000839087 vaso:InServiceAndTrainingMember 2013-01-01 2013-09-30 0000839087 vaso:ExtendedServiceContractsMember 2013-01-01 2013-09-30 0000839087 vaso:CommissionRevenuesMember 2013-07-01 2013-09-30 0000839087 vaso:ExtendedServiceContractsMember 2013-07-01 2013-09-30 0000839087 vaso:InServiceAndTrainingMember 2013-07-01 2013-09-30 0000839087 vaso:ServiceArrangementsMember 2013-07-01 2013-09-30 0000839087 vaso:CommissionRevenuesMember 2012-07-01 2012-09-30 0000839087 vaso:ExtendedServiceContractsMember 2012-07-01 2012-09-30 0000839087 vaso:InServiceAndTrainingMember 2012-07-01 2012-09-30 0000839087 vaso:ServiceArrangementsMember 2012-07-01 2012-09-30 0000839087 vaso:InServiceAndTrainingMember 2012-01-01 2012-09-30 0000839087 vaso:CommissionRevenuesMember 2012-01-01 2012-09-30 0000839087 us-gaap:AffiliatedEntityMember us-gaap:WarrantMember 2013-01-01 2013-09-30 0000839087 us-gaap:WarrantMember us-gaap:AffiliatedEntityMember 2013-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2013-01-01 2013-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2013-07-01 2013-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2012-07-01 2012-09-30 0000839087 vaso:DirectorDavidLiebermanMember 2012-01-01 2012-09-30 0000839087 us-gaap:DirectorMember 2013-01-01 2013-09-30 0000839087 2011-01-01 2011-03-31 0000839087 vaso:ConsultantMember 2011-01-01 2011-03-31 0000839087 vaso:DirectorDavidLiebermanMember 2011-01-01 2011-03-31 0000839087 vaso:FormerDirectorMember 2012-01-01 2012-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2011-09-30 0000839087 us-gaap:SubsidiaryOfCommonParentMember 2012-03-31 0000839087 vaso:GenwellInstrumentsCoMember 2013-06-30 0000839087 vaso:EmployeesAndConsultantsMember 2012-01-01 2012-09-30 0000839087 vaso:EmployeesAndConsultantsMember 2013-01-01 2013-09-30 0000839087 vaso:EmployeesAndConsultantsMember 2012-07-01 2012-09-30 0000839087 vaso:EmployeesAndConsultantsMember 2013-07-01 2013-09-30 0000839087 us-gaap:CommonStockMember 2013-01-01 2013-09-30 0000839087 vaso:Plan2013Member 2013-09-30 0000839087 vaso:Plan2010Member 2010-06-17 0000839087 vaso:Plan2010Member 2013-09-30 0000839087 vaso:NonOfficerEmployeeMember us-gaap:RestrictedStockMember vaso:Plan2010Member 2013-09-30 0000839087 vaso:NonOfficerEmployeeMember us-gaap:RestrictedStockMember 2012-06-01 2012-06-30 0000839087 us-gaap:OfficerMember us-gaap:RestrictedStockMember vaso:Plan2010Member 2012-01-01 2012-03-31 0000839087 vaso:NonOfficerEmployeeMember vaso:Plan2010Member us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0000839087 us-gaap:RestrictedStockMember vaso:NonOfficerEmployeeMember 2013-01-01 2013-09-30 0000839087 us-gaap:OfficerMember us-gaap:RestrictedStockMember vaso:Plan2010Member 2013-01-01 2013-09-30 0000839087 vaso:Plan2010Member us-gaap:StockOptionsMember 2013-01-01 2013-09-30 0000839087 us-gaap:StockOptionsMember vaso:Plan2010Member 2013-07-01 2013-09-30 0000839087 us-gaap:StockOptionsMember vaso:Plan2010Member 2012-07-01 2012-09-30 0000839087 vaso:Plan2010Member us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000839087 us-gaap:CommonStockMember 2013-07-01 2013-07-30 0000839087 us-gaap:CommonStockMember 2013-04-01 2013-04-30 0000839087 us-gaap:CommonStockMember 2013-07-01 2013-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares vaso:State vaso:Company vaso:Subsidiary vaso:Segment xbrli:pure vaso:EquityProgram false --12-31 2013-09-30 No No Yes Smaller Reporting Company VASOMEDICAL, INC 0000839087 155433747 2013 Q3 10-Q 0 7704000 1059000 6645000 1229000 3510000 4739000 3300000 0 9145000 8100000 7162000 12193000 441000 342000 21000 25000 1591000 2337000 3970000 4627000 1326000 1161000 97000 34000 61441000 61229000 87000 0 128000 416000 2606000 3179000 155000 126000 41000 137000 1810000 6570000 3260000 0 1780000 585000 2365000 2365000 1780000 0 585000 1500000 6570000 3260000 1810000 1500000 8187000 8187000 0 0 0 9234000 9234000 0 18405000 25716000 29509000 9595000 11319000 8595000 25410000 8040000 8398000 8972000 32381000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Basis of Presentation and Use of Estimates</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC. These condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Significant Accounting Policies</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2012, includes a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenue and Expense Recognition for VasoHealthcare</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured.&#160;&#160;These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.&#160;&#160;Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets.&#160;&#160;Under our agreement with GE Healthcare (&#8220;GEHC&#8221;), GEHC pays the Company a commission.&#160;&#160;In accordance with the agreement GEHC pays the Company fifty percent of the commission at the time the order is received and fifty percent of the commission when the order is completed by delivery and acceptance to their customer.&#160;&#160;At the time the order is received therefore, the Company records a receivable for the fifty percent of the commission and offsets this to deferred revenue.&#160;&#160;At the time the order is completed the Company records a receivable for the remaining fifty percent commission and records this as recognized revenue including the amount previously deferred.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded.&#160;&#160;Commission expense is recognized when the corresponding commission revenue is recognized.&#160;&#160;Cost of commissions includes commission expense and, beginning in 2013, costs associated with the medical device excise tax imposed by the Affordable Care Act.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Reclassifications</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Certain reclassifications have been made to prior period amounts to conform with the current period presentation.</div></div> 2400000 288000 9691000 9147000 11469000 2294000 7397000 -2322000 0 0 8076000 8076000 9124000 0 0 9124000 0.08 4285714 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE M &#8211; COMMITMENTS AND CONTINGENCIES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales representation agreement</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010.&#160;&#160;The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.&#160;&#160;These circumstances include: not materially achieving certain sales goals; not maintaining a minimum number of sales representatives; and various legal and GEHC policy requirements.&#160;&#160;Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.</div></div> 155759952 162917996 165000 163000 164695382 162917996 0.001 0.001 250000000 250000000 -3777000 -1585000 -435000 -2488000 0.7 0.89 1015000 381000 282000 1304000 5688000 7182000 2419000 1659000 699000 665000 207000 148000 0.06 1959000 2480000 0 3635000 3635000 0 4145000 0 0 4145000 14998000 12727000 15602000 15228000 15198000 13270000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The changes in the Company&#8217;s deferred revenues are as follows</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the three months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the nine months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at the beginning of the period</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,270</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,198</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,602</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,228</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Additions:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">410</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">288</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">848</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">987</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">23</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">33</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">30</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">60</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">75</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,076</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,037</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,355</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,116</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Recognized as revenue:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(245</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(283</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(755</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(840</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(25</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(16</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(22</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(54</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(64</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,796</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,243</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(8,332</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(6,512</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at end of period</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,727</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,727</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Less: current portion</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,684</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,418</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,684</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,418</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Long-term deferred revenue at end of period</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,043</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,580</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,043</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,580</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE J - DEFERRED REVENUE</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The changes in the Company&#8217;s deferred revenues are as follows</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center; font-style: italic; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the three months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the nine months ended September 30,</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at the beginning of the period</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13,270</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,198</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,602</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">15,228</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Additions:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">410</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">288</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">848</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">987</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">13</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">23</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">33</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">30</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">60</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">75</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,076</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,037</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,355</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,116</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Recognized as revenue:</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred extended service contracts</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(245</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(283</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(755</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(840</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred in-service and training</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(10</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(20</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(25</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred service arrangements</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(16</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(22</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(54</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(64</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission revenues</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,796</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,243</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(8,332</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(6,512</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred revenue at end of period</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,727</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,727</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,998</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Less: current portion</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,684</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,418</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,684</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,418</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Long-term deferred revenue at end of period</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,043</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,580</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,043</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,580</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> 75000 987000 60000 5355000 23000 848000 2076000 410000 8000 30000 2037000 288000 13000 20000 33000 6116000 5580000 5043000 5022000 9418000 7684000 10580000 25000 64000 840000 54000 755000 8332000 20000 2796000 10000 16000 245000 2243000 10000 22000 283000 6512000 112000 112000 286000 266000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE N - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Adoption of New Standards</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br />&#160;</div><div style="text-align: left; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other Comprehensive Income:&#160;&#160;Presentation of Comprehensive Income</div><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br />&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In February 2013, new guidance was issued that amends the current comprehensive income guidance.&#160;&#160;The new guidance requires entities to disclose the effect of each item that was reclassified in its entirety out of accumulated other comprehensive income and into net income on each affected net income line item.&#160;&#160;For reclassification items that are not reclassified in their entirety into net income, a cross-reference to other required disclosures is required. The new guidance is to be applied prospectively for annual reporting periods beginning after December 15, 2012 and interim periods within those years.&#160;&#160;The adoption of this new guidance did not have an impact on the Company&#8217;s consolidated financial position, results of operations, or cash flows.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE D &#8211; SHARE-BASED COMPENSATION</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with ASC Topic 718 &#8220;Compensation &#8211; Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the condensed consolidated financial statements based on their estimated fair values.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three months ended September 30, 2013, no common stock grants were made.&#160;&#160;During the nine month period ended September 30, 2013, the Company granted 400,000 restricted shares of common stock valued at $74,000.&#160;&#160;Of these, 180,000 shares valued at $32,400 vested at the grant date, 20,000 shares valued at $3,600 vest 50% after three months and 50% after six months from the grant date and 200,000 shares valued at $38,000 vest 50% after one year and 50% after two years from the grant date.&#160;&#160;During the three month period ended September 30, 2012, the Company granted 500,000 shares of restricted common stock valued at $130,000 to an officer, of which half of such shares vest in one year and half in two years.&#160;&#160;During the nine month period ended September 30, 2012, the Company granted 1,000,000 shares, valued at $250,000, to officers and 2,392,500 shares, valued at $598,000, to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC agreement in June 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three and nine month periods ended September 30, 2013 and 2012, the Company did not grant any stock options.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Share-based compensation expense recognized for the three and nine month periods ended September 30, 2013 was $29,000 and $300,000, respectively, and $328,000 and $559,000 for the three and nine month periods ended September 30, 2012, respectively.&#160;&#160;These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the condensed consolidated statements of operations.&#160;&#160;Expense for share-based consulting fees with non-employees was $0 and $87,000 for the three and nine months ended September 30, 2013, respectively, and $128,000 and $416,000 for the three and nine months ended September 30, 2012, respectively.&#160;&#160;Unrecognized expense related to existing share-based compensation and consulting fees is approximately $124,000 at September 30, 2013 and will be recognized through May 2015.</div></div> 183000 131000 -0.02 -0.01 0 -0.02 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE E &#8211; LOSS PER COMMON SHARE</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;Basic loss per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.&#160;&#160;Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2013 and 2012, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the three months ended</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the nine months ended</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock options</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,780</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,780</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Warrants</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common stock grants</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">585</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">585</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,365</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,365</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td></tr></table></div></div> 10000 -18000 124000 0.8 0.77 0.81 0.76 291000 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables present information about the Company&#8217;s assets measured at fair value as of <font style="display: inline; font-family: Times New Roman;">September 30, 2013 and December 31, 2012:</font></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic; display: inline; font-size: 10pt;">(in thousands)</font></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,076</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,076</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">111</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">111</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,187</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,187</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,234</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,234</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE F &#8211; FAIR VALUE MEASUREMENTS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company complies with the provisions of ASC 820 &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;).&#160;&#160;Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following tables present information about the Company&#8217;s assets measured at fair value as of <font style="display: inline; font-family: Times New Roman;">September 30, 2013 and December 31, 2012:</font></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic; display: inline; font-size: 10pt;">(in thousands)</font></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,076</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,076</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="padding-bottom: 2px; width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">111</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; font-family: times new roman; font-size: 10pt;">111</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,187</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,187</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 52%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Other</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">as of</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; font-weight: bold; margin-right: 0pt;">Assets</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Cash equivalents invested in money market funds (included in cash and cash equivalents)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,124</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 18pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Investment in certificates of deposit (included in short-term investments)</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">110</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,234</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,234</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The fair values of the Company&#8217;s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.</div></div> P7Y P10Y P5Y 469000 541000 800000 800000 619000 469000 386000 438000 152000 451000 413000 238000 155000 648000 31000 786000 206000 562000 18000 834000 3297000 3212000 85000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE I &#8211; GOODWILL AND OTHER INTANGIBLES</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Goodwill aggregating $3,297,000 and $3,212,000 was recorded on the Company&#8217;s condensed consolidated balance sheets at September 30, 2013 and December 31, 2012, respectively, pursuant to the acquisition of FGE in September 2011.&#160;&#160;All of the goodwill was allocated to the Company&#8217;s Equipment segment.&#160;&#160;The components of the change in goodwill are as follows:</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying Amount</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at December 31, 2012</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,212</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Foreign currency translation</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">85</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at September 30, 2013</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,297</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company&#8217;s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:</font><br /></div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">469</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">469</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(451</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(438</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">31</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Customer lists</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(238</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(152</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">562</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">648</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Software</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">619</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">541</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(413</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(386</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">206</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">155</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">786</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">834</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents, customer lists, and software are included in other assets in the accompanying condensed consolidated balance sheets and are amortized on a straight line basis over their estimated useful lives of ten, seven, and five years, respectively.&#160;&#160;Amortization expense amounted to $41,000 and $126,000 for the three and nine months ended September 30, 2013, respectively, and $137,000 and $155,000 for the three and nine months ended September 30, 2012, respectively.</div></div> 15613000 5187000 4063000 13774000 -3734000 -1684000 -555000 -2562000 -35000 -91000 -44000 72000 411000 61000 491000 -521000 496000 -678000 159000 3000 -6000 -159000 8000 6000 170000 138000 39000 99000 154000 195000 -2875000 -230000 -4304000 -12303000 349000 -61000 47000 -71000 0 -14000 -1000 -13000 -2126000 -746000 20000 -63000 93000 120000 0 5000 571000 576000 691000 774000 844000 909000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE H &#8211; INVENTORIES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories, net of reserves, consist of the following:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">844</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">909</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">519</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">483</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">691</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">774</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,054</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,166</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">At September 30, 2013 and December 31, 2012, the Company maintained reserves for excess and obsolete inventory of $571,000 and $576,000, respectively.</div></div> 2054000 2166000 519000 483000 111000 111000 0 0 0 0 110000 110000 60000 66000 187000 194000 13965000 18178000 291000 0 5409000 5193000 25410000 32381000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE G &#8211; ACCOUNTS AND OTHER RECEIVABLES, NET</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table presents information regarding the Company&#8217;s accounts and other receivables as of September 30, 2013 and December 31, 2012:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,162</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,193</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Due from employees</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">183</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">131</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">commission adjustments</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,606</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,179</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,739</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables include amounts due for shipped products and services rendered.&#160;&#160;Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.&#160;&#160;Due from employees is primarily commission advances made to sales personnel.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE A - ORGANIZATION AND PLAN OF OPERATIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;Company&#8221;, &#8220;registrant&#8221;, &#8220;Vasomedical&#8221; or &#8220;management&#8221; refer to Vasomedical, Inc. and its subsidiaries. The Company since 2010 has been operating in two distinct businesses or segments, the Equipment segment and the Sales Representation segment. In the Equipment segment we design, manufacture, market and support certain medical devices.&#160;&#160;Our principal products are Enhanced External Counterpulsation (EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font>) systems, which are non-invasive heart therapy devices based on our unique proprietary technology, and currently indicated in the United States for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (&#8220;CHF&#8221;), acute myocardial infarction (i.e., heart attack, &#8220;MI&#8221;) and cardiogenic shock.&#160;&#160;In addition we develop, manufacture and market certain ambulatory patient monitoring systems including recorders and analysis software.&#160;&#160;In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (&#8220;GEHC&#8221;), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC&#8217;s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.&#160;&#160;&#160;In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (&#8220;GEHC Agreement&#8221;) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. (&#8220;LET&#8221;) and Biox Instruments Co. Ltd. (&#8220;Biox&#8221;), respectively &#8211; to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.&#160;&#160;Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.&#160;&#160;Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company&#8217;s Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174; </font>therapy business as well as other medical equipment operations.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment.&#160;&#160;VasoHealthcare activities are included under our Sales Representation segment (See Note C).</div></div> -126000 -344000 -1602000 153000 -3806000 -1649000 -464000 -2518000 -576000 7578000 151000 20000 -63000 97000 0 16000 3000 3000 48 2 2 17659000 17317000 5679000 6722000 -3885000 -1191000 870000 -1221000 -1473000 -1085000 -1704000 -1489000 -327000 -492000 -364000 199000 -2659000 -1358000 -463000 -838000 374000 220000 3290000 2980000 64000 29000 29000 30000 366000 171000 0 1602000 126000 344000 70000 111000 0 0 1000000 1000000 0 0 0.01 0.01 0 0 343000 0 70000 111000 10000 418000 473000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 41.4pt;">NOTE K &#8211; RELATED-PARTY TRANSACTIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (&#8221;Kerns&#8221;).&#160;&#160;Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.&#160;&#160;In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On February 28, 2011, David&#160;Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.&#160;&#160;Mr. Lieberman, a practicing attorney in the State of New York, was also appointed to serve as the Vice Chairman of the Board.&#160;&#160;He is currently a senior partner at the law firm of Beckman, Lieberman &amp; Barandes, LLP, which performs certain legal services for the Company.&#160;&#160;Fees of approximately $66,000 and $187,000 were billed by the firm through the three and nine months ended September 30, 2013, respectively, and fees of approximately $60,000 and $194,000 were billed through the three and nine months ended September 30, 2012, respectively, at which dates no amounts were outstanding.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Mr. Rios currently is President of Edgary Consultants, LLC,&#160;and was appointed a director in conjunction with the Company&#8217;s consulting agreement with Edgary Consultants, LLC.&#160;&#160;The consulting agreement (the &#8220;Agreement&#8221;) between the Company and Edgary Consultants, LLC (&#8220;Consultant&#8221;) commenced on March 1, 2011 and was for a two year term and expired on February 28, 2013.&#160;&#160;The Agreement provided for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font><font style="display: inline; font-size: 10pt;">&#160;</font>therapy.&#160;&#160;</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In consideration for the services to be provided by Consultant under the Agreement, the Company agreed to issue to Consultant or its designees,&#160;up to 18,500,000 shares of restricted common stock of the Company, 3,000,000 of which were issued in March 2011 and the balance was to be earned on performance. Mr. Lieberman received 600,000 of these restricted shares.&#160;&#160;The Company recorded the fair value of the shares issued to Consultant as a prepaid expense and amortized the cost ratably over the two year agreement.&#160;&#160;The unamortized value is reported as deferred related party consulting expense in our accompanying condensed consolidated balance sheets as of December 31, 2012.&#160;&#160;No performance-based shares were issued and no further compensation is expected to be paid in conjunction with the agreement.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the nine months ended September 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Through the Company&#8217;s acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.&#160;&#160;In addition, receivables due from FGE management aggregating $8,000&#160;&#160;and $6,000 were collected during the three and nine months ended September 30, 2013, Receivables due from FGE management aggregating $3,000 were advanced during the three month period ending September 30, 2012, and receivables aggregating $159,000 were collected during the nine months ended September 30, 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Biox leases a part of its offices to Genwell Instruments Co., Ltd., a company partially owned by certain officers of the Company&#8217;s subsidiaries.&#160;&#160;The lease term is for twenty months ending December 31, 2014 at a monthly lease amount of approximately $750.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br />&#160;</div></div> 190000 0 95000 190000 403000 474000 172000 131000 -54065000 -52416000 0 22795000 18262000 4533000 0 7606000 5862000 0 1744000 1063000 5722000 0 4659000 14858000 4604000 19462000 0 0 4000 31000 3197000 3320000 1353000 688000 19462000 22795000 7606000 5722000 164000 177000 1213000 391000 375000 1407000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Inventories, net of reserves, consist of the following:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Raw materials</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">844</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">909</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Work in process</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">519</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">483</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Finished goods</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">691</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">774</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,054</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,166</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2013 and 2012, because the effect of their inclusion would be anti-dilutive.</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the three months ended</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="6" valign="bottom" style="text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">For the nine months ended</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Stock options</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,780</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,780</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,810</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Warrants</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,500</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common stock grants</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">585</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">585</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,260</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 4px; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,365</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">2,365</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,570</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company&#8217;s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:</font><br /></div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">&#160;(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td align="left" valign="bottom"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Patents</div></td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">469</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">469</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(451</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(438</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">31</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Customer lists</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">800</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(238</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(152</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">562</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">648</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Software</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Costs</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">619</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">541</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accumulated amortization</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(413</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(386</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 2px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">206</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">155</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="width: 76%; display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td valign="bottom" style="padding-bottom: 4px; width: 76%; font-family: times new roman; font-size: 10pt;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">786</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">834</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">All of the goodwill was allocated to the Company&#8217;s Equipment segment.&#160;&#160;The components of the change in goodwill are as follows:</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; font-size: 10pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Carrying Amount</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at December 31, 2012</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,212</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 88%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Foreign currency translation</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">85</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 88%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Balance at September 30, 2013</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,297</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">There are no intersegment revenues.&#160;&#160;Summary financial information for the segments is set forth below:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt;">&#160;</font><font style="font-style: italic; display: inline;">(in thousands)</font></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the three months ended September 30, 2013</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,744</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,862</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,606</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating (loss) income</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(364</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">199</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(327</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(492</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,398</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,040</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,972</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,410</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,229</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,510</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,739</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the three months ended September 30, 2012</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,063</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,722</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(838</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,358</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(463</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,645</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,704</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the nine months ended September 30, 2013</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,533</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18,262</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">22,795</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating (loss) income</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,489</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">870</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,085</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,704</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,398</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,040</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,972</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,410</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,229</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,510</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,739</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the nine months ended September 30, 2012</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,858</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19,462</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,191</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,473</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,221</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,885</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,645</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,704</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The following table presents information regarding the Company&#8217;s accounts and other receivables as of September 30, 2013 and December 31, 2012:</div><div style="text-align: center; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(in thousands)</div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">September 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: #4bacc6 0.5pt solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">December 31, 2012</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Trade receivables</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,162</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">12,193</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Due from employees</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">183</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">131</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 76%;"><div style="text-align: left; text-indent: 27pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">commission adjustments</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,606</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,179</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="padding-bottom: 4px; width: 76%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,739</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 4px double; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="border-bottom: black 4px double; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE C &#8211; SEGMENT REPORTING AND CONCENTRATIONS</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The Company views its business in two segments &#8211; the Equipment segment and the Sales Representation segment.&#160;&#160;The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.&#160;&#160;The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the fulfillment of the Company&#8217;s responsibilities under our agreement with GEHC.&#160;&#160;The Company evaluates segment performance based on operating income.&#160;&#160;Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.&#160;&#160;Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets &#8211; primarily cash balances &#8211; are reported in the Corporate entity below.&#160;&#160;There are no intersegment revenues.&#160;&#160;Summary financial information for the segments is set forth below:</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: center; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt;">&#160;</font><font style="font-style: italic; display: inline;">(in thousands)</font></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the three months ended September 30, 2013</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,744</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,862</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,606</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating (loss) income</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(364</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">199</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(327</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(492</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,398</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,040</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,972</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,410</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,229</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,510</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,739</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td valign="bottom" style="border-bottom: black 2px solid; width: 52%; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="border-bottom: black 2px solid; text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the three months ended September 30, 2012</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,063</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">5,722</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(838</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,358</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(463</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(2,659</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,645</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,704</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the nine months ended September 30, 2013</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,533</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">18,262</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">22,795</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating (loss) income</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,489</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">870</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,085</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,704</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,398</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,040</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,972</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">25,410</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,229</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,510</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,739</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,145</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160; </td><td align="left" valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">As of or for the nine months ended September 30, 2012</td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt; border-top: #4bacc6 0.5pt solid;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Equipment Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Sales Representation Segment</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div style="text-align: center; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td colspan="2" valign="bottom" style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Revenues from external customers</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">4,604</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">14,858</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">19,462</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Operating loss</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,191</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,473</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(1,221</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">(3,885</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">)</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Total assets</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">8,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">11,319</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">9,595</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">29,509</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="white"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Accounts and other receivables, net</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">1,059</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">6,645</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">7,704</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" style="width: 52%;"><div style="text-align: left; text-indent: 0pt; display: block; font-family: times new roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Deferred commission expense</div></td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">-</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td><td align="left" valign="bottom" style="width: 1%; display: inline; font-family: times new roman; font-size: 10pt;">&#160;</td><td valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">$</td><td valign="bottom" style="text-align: right; width: 9%; font-family: times new roman; font-size: 10pt;">3,635</td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; font-family: times new roman; font-size: 10pt;">&#160;</td></tr></table></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">For the three months ended September 30, 2013 and 2012, GE Healthcare accounted for 77% and 81% of revenue, respectively.&#160;&#160;For the nine months ended September 30, 2013 and 2012, GE Healthcare accounted for 80% and 76% of revenue, respectively.&#160;&#160;Also, GE Healthcare accounted for $3.3 million, or 70%, and $8.1 million, or 89%, of accounts and other receivables at September 30, 2013 and December 31, 2012, respectively.</div></div> 16843000 5507000 6591000 17256000 559000 300000 29000 328000 945000 373500 1000000 2392500 400000 0 180000 20000 200000 0 500000 0 0 0 2845000 250000 2019000 2392500 500000 1176222 7500000 5000000 0 0 0 0 111000 110000 18500000 3000000 600000 250000 74000 598000 130000 2333500 1777386 1771000 1044332 2000000 1500000 6036000 9010000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">NOTE L &#8211; STOCKHOLDERS&#8217; EQUITY</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Common Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">During the three and nine months ended September 30, 2013 the Company issued 1,044,332 and 1,777,386 shares of common stock, respectively, to employees.&#160;&#160;During the three and nine months ended September 30, 2012 the Company issued 1,771,000 and 2,333,500 shares of common stock to employees, respectively, and 2,400,000 shares of common stock to former owners of FGE.&#160;&#160;In addition, see Note K for discussion of common stock issued during the three and nine months ended September 30, 2012 in connection with related party agreements.</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br />&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the &#8220;2010 Plan&#8221;) for officers, directors, employees and consultants of the Company.&#160;&#160;The stock issuable under the 2010 Plan shall be shares of the Company&#8217;s authorized but unissued or reacquired common stock.&#160;&#160;The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.&#160;&#160;The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">As of September 30, 2013, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company of which 945,000 were forfeited and 2,845,000 had vested during various times through July 15, 2013.&#160;&#160;In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 shares vested immediately with the remainder vesting a year thereafter.&#160;&#160;At September 30, 2013, 1,176,222 shares are available for issuance under the 2010 Plan.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In June 2012, 2,392,500 additional restricted common shares, vesting at various times through July 1, 2013, were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, of which 373,500 shares were forfeited and 2,019,000 had vested as of July 1, 2013.&#160;&#160;In July 2012, 500,000 shares of restricted common stock were granted to an officer, of which half vest in July 2013 and half a year thereafter.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">No options were issued under the 2010 Plan during the three and nine month periods ended September 30, 2013 and 2012.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">In April 2013, the Company&#8217;s Board of Directors authorized a share repurchase program of up to $1.5 million, which was subsequently increased in July 2013 to $2.0 million, of the Company&#8217;s common stock.&#160;&#160;During the three and nine months ended September 30, 2013, 7,929,432 and 8,935,430 shares had been repurchased at a cost of $1,420,000 and $1,602,000, respectively, which cost has been recorded as treasury stock in the accompanying condensed consolidated balance sheet as of September 30, 2013.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">On October 30, 2013 the Board of Directors approved the 2013 Stock Plan (the &#8220;2013 Plan&#8221;) for officers, directors, employees and consultants of the Company.&#160;&#160;The stock issuable under the 2013 Plan shall be shares of the Company&#8217;s authorized but unissued or reacquired common stock.&#160;&#160;The maximum number of shares of common stock which may be issued under the 2013 Plan is 7,500,000 shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">The 2013 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.&#160;&#160;The 2013 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer the Plan with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; font-style: italic; text-indent: 0pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Preferred Stock</div><div style="text-indent: 0pt; display: block;"><br /></div><div style="text-align: justify; text-indent: 36pt; display: block; font-family: Times New Roman; margin-left: 0pt; font-size: 10pt; margin-right: 0pt;">Pursuant to its conversion terms, all Series E preferred stock was deemed automatically converted to common stock effective July 1, 2011, and all converted shares were issued as of June 30, 2012.</div></div> 1602000 0 7929432 8935430 8935430 0 1420000 1602000 157162000 157864000 160796000 159018000 P2Y 0 85000 57000 8000 P5Y P5Y 5502000 1831000 1229000 3685000 -7000 23000 3 0.5 0.5 0.5 3790000 P20M -87000 -416000 750 P3Y P3Y 2 2 4285714 18262000 5862000 4659000 14858000 3600 38000 P1Y P2Y EX-101.SCH 7 vaso-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - GOODWILL AND OTHER INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - DEFERRED REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090302 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - SHARE-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - INVENTORIES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - DEFERRED REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vaso-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 vaso-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 vaso-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Award Type [Axis] BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract] Accounts and other receivables, net Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $2,606 at September 30, 2013 and $3,179 at December 31, 2012 Accounts and other receivables, net Accounts and other receivables Trade receivables Accounts Receivable, Net, Current Accounts payable Accounts Payable, Current Receivables due from related parties Accounts Receivable, Related Parties Accounts and Other Receivables [Member] Income taxes payable Accrued Income Taxes Accrued commissions Accrued Sales Commission, Current Accrued expenses and other liabilities Accrued Liabilities, Current PROPERTY AND EQUIPMENT, accumulated depreciation Accumulated other comprehensive income Additional paid-in capital Adjustments to reconcile net loss to net cash provided by operating activities Living Data Technology Corporation [Member] Allocated share-based arrangements Allowance for doubtful accounts and commission adjustments Accounts and other receivables, allowance for doubtful accounts and commission adjustments Amortization expense Antidilutive securities excluded from computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Assets Assets, Fair Value Disclosure CURRENT ASSETS ASSETS Assets [Abstract] Total current assets Assets, Current Total Assets Total assets BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Number of shares of common stock contingently issuable (in shares) Unsecured notes payable assumed Business Acquisition, Purchase Price Allocation, Notes Payable and Long-term Debt Cash and cash equivalents Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period NET INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) Cash equivalents invested in money market funds (included in cash and cash equivalents) Exercise price of warrants (in dollars per share) Class of Stock [Domain] Number of shares of common stock called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES [Abstract] COMMITMENTS AND CONTINGENCIES (NOTE M) Common Stock Grants [Member] Common Stock [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common stock, $.001 par value; 250,000,000 shares authorized; 164,695,382 and 162,917,996 shares issued at September 30, 2013 and December 31, 2012, respectively; 155,759,952 and 162,917,996 shares outstanding at September 30, 2013 and December 31, 2012, respectively Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Software [Member] Concentration Risk Type [Domain] Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Percentage of accounts and other receivables (in hundredths) Corporate [Member] Cost of sales, equipment Total cost of revenues Cost of Goods and Services Sold Cost of equipment rentals and services Cost of revenues Credit Concentration Risk [Member] Customer Lists [Member] Interest rate (in hundredths) Debt Instrument, Interest Rate, Stated Percentage Title of Individual [Axis] Deferred commission expense Deferred Costs, Current Deferred commission expense DEFERRED REVENUE [Abstract] Deferred revenue at end of period Deferred revenue at the beginning of the period Deferred Revenue Changes in Deferred Revenues DEFERRED REVENUE Deferred Revenue Disclosure [Text Block] Deferred Revenue Arrangement, by Type [Table] Additions: Deferred Revenue Arrangement Type [Domain] Deferred Revenue Arrangement [Line Items] Deferred revenue Long-term deferred revenue at end of period Deferred Revenue, Noncurrent Deferred Revenue Arrangement Type [Axis] Deferred revenue - current portion Less: current portion Recognized as revenue: Deferred Revenue, Revenue Recognized Deferred tax liability, net Deferred Tax Liabilities, Net, Current Depreciation and amortization Depreciation, Depletion and Amortization RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Director - Edgar Rios [Member] Director [Member] SHARE-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] SHARE-BASED COMPENSATION [Abstract] Due from employees Weighted average common shares outstanding - basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted LOSS PER COMMON SHARE Loss per common share LOSS PER COMMON SHARE [Abstract] Effect of exchange rate differences on cash and cash equivalents Unrecognized expense related to existing share-based arrangements Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Percentage of revenue (in hundredths) Entity-Wide Revenue, Major Customer, Percentage Revenue, Major Customer [Line Items] STOCKHOLDERS' EQUITY [Abstract] Equity Component [Domain] Fair Value, Hierarchy [Axis] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair value of assets acquired Assets and Liabilities Measured at Fair Value Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE MEASUREMENTS [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Significant Unobservable Inputs (Level 3) [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] Significant Other Observable Inputs (Level 2) [Member] Useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Assets, Major Class Name [Domain] Costs Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Other intangible assets, net [Abstract] Intangible assets, net Finite-Lived Intangible Assets, Net Goodwill, Beginning Balance Goodwill, Ending Balance GOODWILL Foreign currency translation Goodwill, Translation Adjustments GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] Change in carrying amount of goodwill [Roll Forward] GOODWILL AND OTHER INTANGIBLES [Abstract] Gross profit Gross Profit Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) [Abstract] Income tax benefit (expense) Income Tax Expense (Benefit) Income taxes paid Deferred commission expense Increase (Decrease) in Deferred Charges Accrued expenses and other liabilities Receivables due from related parties Receivables due from related parties Other current assets Increase (Decrease) in Other Current Assets Accounts payable Other long-term liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Accounts and other receivables Increase (Decrease) in Accounts and Other Receivables Other assets Increase (Decrease) in Other Noncurrent Assets Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventories, net Increase (Decrease) in Inventories Finance receivables, net Increase (Decrease) in Finance Receivables Sales tax payable Accrued commissions Interest and other income (expense), net Interest paid Reserves for excess and obsolete inventory Finished goods Inventory, Finished Goods, Net of Reserves Raw materials INVENTORIES, NET Inventory Disclosure [Text Block] Inventories, net Inventories, net Inventory, Net INVENTORIES, NET [Abstract] Work in process Investment in certificates of deposit (included in short-term investments) Fees for legal services Total current liabilities Liabilities, Current Liabilities assumed through acquisition Liabilities Assumed Total long-term liabilities Liabilities, Noncurrent CURRENT LIABILITIES LONG-TERM LIABILITIES LIABILITIES AND STOCKHOLDERS' EQUITY Total liabilities and stockholders' equity Liabilities and Equity ACCOUNTS AND OTHER RECEIVABLES, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Major Customers [Axis] Changes in deferred revenue [Roll Forward] Name of Major Customer [Domain] ORGANIZATION AND PLAN OF OPERATIONS Nature of Operations [Text Block] Cash flows from financing activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities Cash flows from operating activities Net loss Net loss Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract] SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Total other income (expense), net Nonoperating Income (Expense) Other income (expense) Financing receivables, net Notes, Loans and Financing Receivable, Net, Current Notes payable due to related party Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products Number of segments Number of Chinese operating companies acquired Number of Businesses Acquired Officer [Member] Operating expenses Operating Expenses [Abstract] Total operating expenses Operating Expenses Operating loss Operating (loss) income ORGANIZATION AND PLAN OF OPERATIONS [Abstract] Other current assets Other Assets, Current OTHER ASSETS, net Foreign currency translation gain Other comprehensive income Other long-term liabilities Other Liabilities, Noncurrent Patents [Member] Repurchase of common stock Payments for Repurchase of Common Stock Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Purchases of short-term investments Payments to Acquire Short-term Investments Plan Name [Domain] Plan Name [Axis] Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at September 30, 2013, and December 31, 2012 Preferred Stock, Value, Issued Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock, shares outstanding (in shares) Proceeds from exercise of warrant Redemption of short-term investments Proceeds from Sale of Short-term Investments Consulting services Professional Fees PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,326 at September 30, 2013 and $1,161 at December 31, 2012 Property, Plant and Equipment, Net ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract] RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Related Party Transaction [Line Items] Related Party [Domain] RELATED-PARTY TRANSACTIONS [Abstract] Related Party [Axis] Repayment of notes payable due to related party Debt repaid Repayments of Related Party Debt Research and development Restricted Stock [Member] Accumulated deficit Revenues from external customers Amortization of deferred gain on sale-leaseback of building Amortization of deferred gain on sale-leaseback of building Equipment sales Total revenues Revenue, Net Revenues Revenue, Net [Abstract] Sales tax payable Sales and Excise Tax Payable, Current Equipment rentals and services Inventories, Net of Reserves Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Other Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Changes in Carrying Amount of Goodwill Schedule of Segment Reporting Information, by Segment [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Related Party Transactions, by Related Party [Table] Summary Financial Information for Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Accounts and Other Receivables Segment Reporting Information [Line Items] SEGMENT REPORTING AND CONCENTRATIONS [Abstract] SEGMENT REPORTING AND CONCENTRATIONS Segment Reporting Disclosure [Text Block] Segment [Domain] Selling, general and administrative Share-based compensation Share-based compensation expense Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Granted during period (in shares) Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares authorized (in shares) Options Issued (in shares) Award Type [Domain] Short-term investments CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) [Abstract] Business Segments [Axis] Statement, Equity Components [Axis] CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) [Abstract] Class of Stock [Axis] Restricted shares issued for consulting agreement (in shares) Value of stock granted Stock Compensation Plan [Member] Stock Options [Member] Share issued (in shares) Stock Issued During Period, Shares, New Issues Stock repurchase program, authorized amount STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY Total stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Fast Growth Enterprises Limited (FGE) [Member] Subsidiary of Common Parent [Member] SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION Title of Individual with Relationship to Entity [Domain] Treasury stock, at cost, 8,935,430 and nil shares at September 30, 2013 and December 31, 2012, respectively Treasury Stock, Value Treasury stock, at cost (in shares) Treasury Stock, Shares, Acquired Treasury stock, at cost (in shares) Treasury stock value Treasury Stock, Value, Acquired, Cost Method Warrants [Member] Warrants [Member] Warrant [Member] - basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Represents the term of an agreement the Company entered into. Term of agreement Term of agreement The engagement of consultant to assist the Company. Consultant [Member] Consultant Managed by Director - Edgar Rios [Member] The amount of deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which will be charged against earnings within one year or the normal operating cycle, if longer. Deferred Charges Related Party Current Deferred related party consulting expense The value of inventories transferred to property and equipment, attributable to operating leases in noncash financing and investing activities. Inventories transferred to property and equipment, attributable to operating leases, net Inventories transferred to property and equipment, attributable to operating leases, net David Lieberman who serves on the board of directors (who collectively have responsibility for governing the entity). Director David Lieberman [Member] Director - David Lieberman [Member] The amended term of the sales representation agreement. Amended Term of Sales Representation Agreement Amended term of sales representation agreement Document and Entity Information [Abstract] A period over which the holder of the warrant has the right to buy more shares of the same security at a certain price. Warrant, Term Term of warrant Total costs related to commissions earned under the sales representative agreement with GE Healthcare. Cost Of Commissions Revenue Cost of commissions A type of deferred revenue by arrangement relating to service arrangements. Service Arrangements [Member] A type of deferred revenue by arrangement relating to commission revenues. Commission Revenues [Member] Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts and commission adjustments for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). Provision for doubtful accounts and commission adjustments Provision for doubtful accounts and commission adjustments A type of deferred revenue by arrangement relating to in-service and training. In Service and Training [Member] The number of wholly-owned subsidiaries owned by the entity. Number Of Wholly Owned Subsidiaries An employee of the entity who is neither and officer or a member of the board of directors. Non Officer Employee [Member] Component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Sales Representation Segment [Member] Person formerly serving on the board of directors (who collectively had responsibility for governing the entity). Former Director [Member] The percentage of shares vesting after three months from grant date. Shares vesting after three months Shares vesting after three months (in hundredths) The number of grants made over the life of the plan on other than stock (or unit) options plans. Share Based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted to Date Granted to date The percentage of shares vesting after six months from grant date. Shares vesting after six months Shares vesting after six months (in hundredths) Component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Equipment Segment [Member] Time period of lease term for property. Lease term The increase (decrease) during the reporting period in deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Increase Decrease Deferred Charges Related Party Amortization of deferred consulting expense The percentage of shares vesting after two years from grant date. Shares vesting after two years Shares vesting after two years (in hundredths) Monthly payment for a property lease. Monthly lease payment amount Monthly lease amount Represents the Genwell Instruments Co which is company partially owned by certain officers of the Company's subsidiaries. Genwell Instruments Co. [Member] The vesting terms of share awards. Share Awards vesting Terms [Axis] The vesting terms of share awards. Share Awards Vesting terms [Domain] The shares vesting at grant date. Vesting at Grant Date [Member] The 2010 Plan was approved by the Board of Directors for officers, directors, employees and consultants of the Company. Plan 2010 [Member] 2010 Plan [Member] A type of deferred revenue by arrangement relating to extended service contracts. Extended Service Contracts [Member] Sales Representation Agreement [Abstract] Sales Representation Agreement [Abstract] The percentage of shares vesting after three months from grant date. Shares Vesting at Fifty Percent After Three Months [Member] Persons who are on the payroll of the entity and work in the normal operations for the entity and the engagement of consultant to assist the Company. Employees And Consultants [Member] Employees and consultants [Member] Initial term of Sales Representation Agreement. Initial Term of Sales Representation Agreement Initial term of sales representation agreement The number of equity programs in an equity-based payment arrangement. Number of equity programs Number of shares issued on exercise of warrants. Shares issued on exercise of warrant Shares issued on exercise of warrant (in shares) Aggregate revenue during the period from commissions earned from the sales representative agreement with GE Healthcare. Commissions Revenue Net Commissions Major external customer that accounts for 10 percent or more of the entity's revenues. GE Healthcare [Member] Value of shares vested over a period of six months in stock based compensation award. Value of shares vested in six months Value of shares vested over a period of two years in stock based compensation award. Value of shares vested in two years The percentage of shares vesting after six months from grant date. Shares Vesting at Fifty Percent After Six Months [Member] The percentage of shares vesting after one year from grant date. Shares Vesting at Fifty Percent After One Year [Member] The percentage of shares vesting after two years from grant date. Shares Vesting at Fifty Percent After Two Years [Member] Disclosure of non-officer employees and consultants. Non officer employees and consultants [Member] Non-Officer Employees and Consultants [Member] Represents the vesting period for first half shares granted to an employee. Vesting period for first half shares granted to an employee Represents the vesting period for second half shares granted to an employee. Vesting period for second half shares granted to an employee The 2013 Plan was approved by the Board of Directors for officers, directors, employees and consultants of the Company. Plan 2013 [Member] 2013 Plan [Member] EX-101.PRE 11 vaso-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2013
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
NOTE L – STOCKHOLDERS’ EQUITY

Common Stock

During the three and nine months ended September 30, 2013 the Company issued 1,044,332 and 1,777,386 shares of common stock, respectively, to employees.  During the three and nine months ended September 30, 2012 the Company issued 1,771,000 and 2,333,500 shares of common stock to employees, respectively, and 2,400,000 shares of common stock to former owners of FGE.  In addition, see Note K for discussion of common stock issued during the three and nine months ended September 30, 2012 in connection with related party agreements.

 
On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.

The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.  The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.

As of September 30, 2013, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company of which 945,000 were forfeited and 2,845,000 had vested during various times through July 15, 2013.  In March 2012, 500,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 250,000 shares vested immediately with the remainder vesting a year thereafter.  At September 30, 2013, 1,176,222 shares are available for issuance under the 2010 Plan.

In June 2012, 2,392,500 additional restricted common shares, vesting at various times through July 1, 2013, were granted to non-officer employees in conjunction with the extension of the GEHC Agreement, of which 373,500 shares were forfeited and 2,019,000 had vested as of July 1, 2013.  In July 2012, 500,000 shares of restricted common stock were granted to an officer, of which half vest in July 2013 and half a year thereafter.

No options were issued under the 2010 Plan during the three and nine month periods ended September 30, 2013 and 2012.

In April 2013, the Company’s Board of Directors authorized a share repurchase program of up to $1.5 million, which was subsequently increased in July 2013 to $2.0 million, of the Company’s common stock.  During the three and nine months ended September 30, 2013, 7,929,432 and 8,935,430 shares had been repurchased at a cost of $1,420,000 and $1,602,000, respectively, which cost has been recorded as treasury stock in the accompanying condensed consolidated balance sheet as of September 30, 2013.

On October 30, 2013 the Board of Directors approved the 2013 Stock Plan (the “2013 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2013 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2013 Plan is 7,500,000 shares.

The 2013 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as compensation for services rendered to the Company.  The 2013 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer the Plan with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.

Preferred Stock

Pursuant to its conversion terms, all Series E preferred stock was deemed automatically converted to common stock effective July 1, 2011, and all converted shares were issued as of June 30, 2012.
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"4*VK8[`$``-X8```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4%/VS`8AN](^P^1KU/C MVAZ,34TY;.P(2+`?X,5?FZB);=D&VG^/DP)"J"NJ5FGO)5$:^WN?^O`?MR2!NLB*']N%0U;%M/==6^N42?F#->]2)L\)9=XYKHE- MZ^/GC,'XSH3AS=\#GO==YZ,)K:'B1H=TI?N,P=<=?W1A]<>Y5;E_R`Y*MUBT M-1E7W_?Y!,KH`VD3&Z+4=^5X+WO=VA?N/?GCXLC'FS@RR/#_QL$'.8#^K+F#8=Q2-7#MNA'R4W M.I"Y32'W[$<'>#M['T=NH6^"\S'W\8$./X67PGW8/?%Y$(74TFOEOJNZ?DW, M7?[A@>^Z]=J>*V?5@^@8B)G:13'&HX<85?= MWFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B] MSCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`:799%/P!``#G M%P``&@`(`7AL+U]R96QS+W=OK,4>MN?!Q"V$HV'F)B"92!_C.>=(OKYYVVV+ M%Q_BIN\J0[.Y*7Q7]\VF6U?FZ?'VSX4I8G)=X[9]YRNS]]'<+'__NK[W6Y?R MGV*[&6*15^EB9=J4ABMK8]WZG8NS?O!=?K+JP\ZE/`QK.[CZV:V]Y?E\8B/3PAF65F8[_!R?70Q;E`.+Q0QN$%PI%+91RY1#A,RCA,"$=*91PI M$4[)4^+$U@7?/*20G2/FA3_4=3*-:,ZGA!DU?009ISYD?HY@)JW,N//W,(Q@ M2%OC!#7..2)4'9#GJ#JL;3D,+:>=N/" MOB7UTL#:L'88,`P#T;8\@9XGVG$@,`_*23TOY=.Q/XKZ,+2'7]@Q9\J^>P9] M1IN&(`YKWQ(8WA)8^Y;`\)8@VD8LV(DG5=-/0@J>($C[!$'P!"':.270=;1C M"J:4]IN"+XJT2T.P-JR=X`P3G+43G&&"B[;G"/0 M;*,*AL73H-P5(HK+C1#5-AWHPZ$YV$9)IAX4KHK/:.3K=;(23KYZWHJL.H@4 M(HTJL%]NDEVIWERODU0L#Q4IT6[G15OP_9*J2AJ5%8F32L03=0S#?"\Z%XKG MW>USDL+=2V-HJ(.;MLAYH<1B'3VG50CE'=6A7_I(U\WZEW4KEHG8E^^3ZJ'R M\I!D<;ZO?PJM?6U'!AC8-[<>DKC:P/WA<-A>NQ?)TZ8Z7@3Y`=)O.@C/:8Y* MUI1W[`B'I#C)JJ1ZY30[=#_)(<*ZZQ0JTU2EN$K@I*"Q5AO'*K;O.<0+B,/A M+/!=ZE@A#&XMU_)L@E1&4$LKHW]-!ART;D;83M/Q3]@)0G`UZ]A!;D:?=/.F M@MU`^]NBQGT9GTTMC_YCA=3WN.4Y?`Y-X?X=]^>$6;@F'+:)GJX-^]/O+,KXTG(7 MA,^(%2P8Q.J%`1:XP`(2L)9M^PN8T53OA_?@A!&;T*5UZY*.#FQC;;::1"SU MEO!@GU$2<(]T8KC$$R5$I[[O/%#7108HA.I-:<_`&*\838+4(7>$,8B!$7"R MP#T<71F>U8S9A<^[MA2?1YF'T*X4WX/L.-L:`ZA*@'Q!^0@<#JDN` MG@>]4Q8&5I>`[9$N&S$QJ+H$ZGG@L1$3"SFSE'9HR. MF0;@04,E?)>NHG0%'\SUH5XT#96#X]^%F_\```#__P,`4$L#!!0`!@`(```` M(0!TI@;9^P8``/$>```8````>&PO=V]R:W-H965T&ULG%G; M;N,V$'TOT'\0]&Y;I.Y!G,7JLNT"+5`4O3PKMAP+L2U#4C:[?]^AAK8XH\12 M^M)N?`Y'/)RKQ/M/WX\'ZUO9M%5]6MMBZ=A6>=K4V^KTM+;__NO+(K*MMBM. MV^)0G\JU_:-L[4\//_]T_UHWS^V^+#L++)S:M;WONO/=:M5N]N6Q:)?UN3P! MLJN;8]'!G\W3JCTW9;'M%QT/*^DXP>I85"<;+=PU!6OP-+#_;8"!>K8K:;W/ MXBYWI;UZN.\/Z)^J?&V-?UOMOG[]I:FVOU6G$DX;_*0\\%C7SXKZ=:M^@L6K MT>HOO0?^:*QMN2M>#MV?]>NO9?6T[\#=/BA2PNZV/[*RW<")@IFE])6E37V` M#__^UVG;[M>T&2S]T7`%TZ[%LNR^5,FE;FY>VJX__(DEH M4VA$:B.P0AL1%JAHP3_?'B+O?O4-CG2C*0E20ML:*`&EI!>*.D!E-KO\ M,*P1=$E^82CO@:*K+#@L+LL%M[_ML(L*M8BI\.GSDC%%4D8Z9D0AI61C"C.2 MCQF&$2+4I4)O"U1DB#W3!Q'=6X(4SZ"P(T@G&=DD([_%(/)@(Z8?;\M3Y+4- M9S>$6,SD(27J0U2XODOAU(2#B)U-9J*N*QVZ.">PB`>O$T609/,5*3)5%+.G M)DCQ>D5NS/(C)6C(7)DAZN-I2,%.(R>PY[PC*/B(($5F@MB6$Z3@IOPH8*F1 MFK`7^,S!F0F+2/+E.<&]R!]\3+P$=6J^EQ29B6*[3I""HL+`X97/A/U0LM69 M"4L9QLR/N8F+V#-$$U%J'#%J_>UD4F1:*V(6'PE2(.RO^<8VEDXRLDE&?HM! MY,4?D:?(S&>\8R%%9U;$PC0U41EQCR&J,\L1[%QR`KO.\&0B2$#'FN^PGLTD ML>+" MF&UT')JXYP2L\&1D/OF!2G!-&1:Y*<$A,%E*9@070>0Q#^>4 M$$I_2'JJ3?7S^=JP^U-M;&^)0!)6.1&RI$DIS(M-1F#/B+L^/'(*.X-LJDHU M]/FJL/U356S;B3!G!#\(1[7$Q(/Q"$+6B]`5S.4Y(YC5B&I3_7R^-NS^5-MP M:CKG+B.">O%<>#'3G@K$,5H7TMQ:;R"C!!$:#5F[C5APHW=[@&KL\\7A& M$\$?G0@DW2PHDY1LVDI^DT)<*-EC*WO1EQ%CPPI\2 MF,^C&4%'KV<$%09,M;'Q9*:V\9@B^)"?2"1A86$5-27@T*TP/@G(5N8$-.H1 ME07'/C\PI6+345+P83'1))3SAJO0!L+&R[!69**&+S#=B&GA#Q6::E)3PNQD MDSA3P'.OS5LX?##1)*W)]UEXIAJ_5!+X\D9'JHP25&>CA)P2W-`="%2<&A+F MB\.1@HIC)3Z1E[E#E4G>DE.">L.NM+_,M2X[EIRL71@MDTKZT!RBOFGR&!0L M]A--TO[R`K;M5.-7?PGF\(P21."Q0\LIP8V,K*;B/C2(2)PQ2.470YCW9YYH M$IS\-6+9P:?3E&R:DM^D4)4?&DSD&X.)8!F3:!*ZD+^;I01UF?LS@G+GYP0U M+%-%JK//SS.<`TB>\9>/1"()/S(N/)XM*<6E-_K.2`G"-Z8-71_)$^#U9AC& MJ+@/C2/RC7%$L(Q*-.EF4$Z/(]-6\IL4HE*-'J8+Y[7L?A7KM$DG8!X0?1KQ8I-K,A1$[HU9!&8$3\@]1Z@IR M>"N&IPAC/$"%>,.(%W#'LGDJT_)P:*U-_:)N#R5$TO57O-E,Q%W:7P.RWS.X M\>Q_7UT!N'`\%T_E[T7S5)U:ZU#NP*2S#*&/-GAEB7]T];F_Y'JL.[AJ[/^Y MAZOE$B[- MP9L*`P``F0@``!D```!X;"]W;W)K&ULG%9=;YLP M%'V?M/]@\5[`?(0$):D:4+=*FS1-^WAVP`2K@)'M-.V_W[6=T$"F-ML+";[G M'I][?&VSO'UN&_1$A62\6SG8]1U$NX*7K-NMG)\_[F_F#I**="5I>$=7S@N5 MSNWZXX?E@8M'65.J$#!T!4[3_:"DM(D MM8T7^/[,:PGK',N0BFLX>%6Q@N:\V+>T4Y9$T(8HT"]KULL36UM<0]<2\;CO M;PK>]D"Q90U3+X;406V1/NPZ+LBV@;J?<42*$[=YN:!O62&XY)5R@.MUX:?WXQ>I!G_Y&L^>&38.47UE$P&Y9) M+\"6\T<-?2CU$"1[%]GW9@&^"532BNP;]9T?/E.VJQ6L=@P%Z;K2\B6GL@!# M@<8-8LU4\`8$P!.U3'<&&$*>S>^!E:I>.>',C1,_Q`!'6RK5/=.4#BKV4O'V MMP7A(Y4E"8XD$:@_Q@,WF,"GY`T#0PI^R);D&<`K.N M+`1__EX9E*1S[G22206TA-5X6D?A;.D]@87%$;.QF,1!`R88([)+1(C'D/P2 M,D\&B`ATX:UQ'Z`[TI=6,AIK?,0#8=R,\&1HK"_U&DDV`%SEV+ M)Z9L+`86:W`V'HO.WD7D;R%&5<`TY[Z^W1<:O'+`D$%9$$=C;1N+F9NN2?!L MVA3G81S@13A.SVT[.A7(G:L MDZBA%4SENPDTB;!WBWU1O#>'TY8KN!/,WQH^`2BT7+MH-'8= M4B8TSZ7S5^?5B?*7OB!$.&`A9*OW8,0 MU=+S>'(@!>8C6I$2)#O*"BS@DNT]7C&"4Z54Y)X_'D^]`F>EJRTLV2TVZ&Z7 M)>2))L>"E$(;823'`OCS0U;Q#VM%.NWPP_T]#?+TN]922#:D">9@2VE+Q+Z+96W0-GK M:#^K#/QD3DIV^)B+7_3T#\GV!P'IGH!'TK%E^OY$>`(1!3,C?R(M)30'`O#I M%)DL#8@(?E/?IRP5A[4;3$>3V3A``'>VA(OG3)ITG>3(!2W^:)#RJ#'BUT8" M8%_+_9$_GZ#)]+H53S-2#CYA@3P9N"1U MODHEI0IH#NEXW80!6GFO$,*DQD0:,W.=!N.;B+B+:!GQ@%]#$ER_GZ14,DD& M8Y-!I"$SE3'I6-RZ81"`R-@$PM[\?T1)*D$T6Q$(`RL&D<:$+?Y>&:)X[9X@?RPT3;80;1L=M?K3"K9[&:- M?56+D<:$BAU"5A7&IO2_TA<;46>[V15O0-:` M&&X.A;9YG>M;=T<-ZFT/0][?'T@>UE;QW1`Y?<2W3[RPU8$U0PT:*C_U]+5[ M&6+4'Y(GN,7S>I,HK6M=4H,NDU"NQ(,0DR>8>8"GU+(S;HV("&F0KL1SH=4, M+PM-;@^-#_F*UN'6Z9+VB.APNRPTN=TU/M`M\Z,&]<1+6["%)J>'A@>Z-#VL MV1#5($A:[_@8A)@\'QH@Z)8)4H,&>=X\0]!#0T1I7>T-/2?L=-:]<5EHQ-!_ M:((H+9N;W1LUZ#*W'J')[:[IX>N-H'TV^Z$]/6J0?AVU^[5'J#GI]4YO/P5A M>Q*3/.=.0H]R=?/A;:VYJ]?*""UA18!USKH?RW53+8R-`+:]"N_)#\SV6>KG`?9Z`LO'>`3@':7BXT)NI,T_!9O_ M`0``__\#`%!+`P04``8`"````"$`3&8>MM`#``#]#@``&0```'AL+W=O3 MJ>_1*N,YJ\Y;_Z\_GS^M?$\J4N6DX!7=^N]4^I]WO_ZRN7'Q(B^4*@\4*KGU M+TK5ZR"0V8661$YX32L8.7%1$@67XAS(6E"2-T%E$433Z2(H":M\K;`6CVCP MTXEE-.'9M:25TB*"%D3!_.6%U;)5*[-'Y$HB7J[UIXR7-4@<6<'4>R/J>V6V M_GZNN"#'`GR_A7.2M=K-Q4"^9)G@DI_4!.0"/=&AYZ?@*0"EW29GX`"7W1/T MM/6_A.LTG/G!;M,LT-^,WF3OMR7T1*Z%^H/?OE%VOBA(=PR.T-@Z?T^HS&!%0682Q:B4\0(F`'^] MDF%IP(J0M^;_C>7JLO5GBTF\G,Y"P+TCE>J9H:3O95>I>/F/AL*[E!:)[B(0 M<1<)HTFTBL-XX58)](P:@PE19+<1_.9!U<`S94VP!L,U*+?.]#PZKQ]9!8\H M\@55&BUP(2$_K[MY%&^"5UC3[,[L-;/TO8Y9+4SDT"*X@JB;M#=^QH1F2-H2 MF#ZPU/F"U;)]S2#O_YVQU@8&F39F4_-Y^R$2F<1A2*R6)I(,$4LD'1(]$G`2B9-(QPC#)TS$3JC;)P9M?5C, MKN;FD96,O6;BIFJCV<(VV1]>P#MKI;(_/(Q.^\-&M.$-\M7W-EZD"-N>5N:L M]IJ!AW>^;5M.(G$2Z1AA^%N8_O`CX\X=!KEJ5#-C/IU$XB32,<+P"1^W?AX? M\XE!=C[M&M6,KM%PN;**\&`,KT)K.#&&!]&I,=R/-KQA+]/;*,9K%&';TY-5 MHYH9RYV32)Q$.D88_IY,?X_E#H-<-:J9,9].(G$2Z1AA^`QA%^PG\C&C392= M4;M*[]"\^91:17BX#]YK.)Y:X\E8G3AF[&2RK.]$"+ M0GH9O^))(H*7J+NK3SG[<`T=,C2ZUOT$3S_-^:4;@,-'3<[T=R+.K))>04\@ M.9TL8<<6^OBB+Q2OFW[WR!4<.YJ?%SAF4NB]IQ.`3YRK]@([[.[@NOL7``#_ M_P,`4$L#!!0`!@`(````(0"-;[D@RP8``*XF```9````>&PO=V]R:W-H965T M7*^YW535.>M&\Q\ MU\G/6;4KSH>M^\_?GS^L7*=IT_,N/57G?.O^S!OWX\.OO]P_5_6WYICGK0,1 MSLW6/;;M9>-Y37;,R[2959?\#'?V55VF+7RL#UYSJ?-TUS4J3U[H^TNO3(NS MJR-LZBDQJOV^R')194]E?FYUD#H_I2WTOSD6E^8:K]RZT7*VN/.C`'#G M,6_:SX4*Z3K94]-6Y7\:"DPH'20T0:"%"1*$LW"U"!9+/HJG>]0)%&F;/MS7 MU;,#50//;"ZIJL%@`Y&ORG0_;EI?DPH:59!/*LK6O7,=4-%`?KX_S/WHWOL. M8YH9)AXRJR5&DBNB1E#%%=<++W$#W$1>"94^D'33!:/5US6>J6OW%:RZ?WUN MK"]`[)N>$#\W&1*K.XR((6(%D4.B%P3)B;`YD MK)EYCUE@(F$)P1*2(I!.Z,CTM"EXZ\(@WK(T]ZW>QYJ9=S7I6\J(>X*X)\?O M(1V0F^DZ%&SKL*9&K)E5IR-<^[ZMI7\_"E<#0"``;ML19!]8+-`CD+0EEJ9* M,8(5E9YAJI$MT9HOL686G<0@G`]ZF&@`1O^6;RO;@@LAJ1!():QETQ.H8%O= M"A=;K!FB\PE+"):0%('T*6MBK?O\@J(:<0N*9BB=+"%80E($TKG&.NDJ5;"= M1ZO$8LV,+RCZGJ[@Q<@<$WU`%?A@$EZCCY4XTA7`E.LGD!;6T;:RM56A!J)2 M9Q`S1Z.A`(&(N^$DEN13L$2UM_=JE)&HG0#:#0)KE8P##>G^1TM[^!-SGQ@" MP8209`BL3VW_T_5ILX#U66XH#C1D]`UW@<0`I$`FAB1C8(5JW^\IG+97!-HM M8*66=8H-U!2TPR`EF( MX!%)(EBO\@QOSZ]V&CB_MM]17Z]@4/IZ+2D)CP@>D22"U2KS8*GE]\Q`6PZH MZ9MK&;IP`Y%J*>MBOBVQB"0?A-4J*]%3RZR^VGB@G`Z\>$"YDTY"PB."1Z1! MS#;5[;,O.P%6J8S$=)7:=F"5@VV4\B9&)8N(@$6D0;3*L/,;MQT=BU2NHB=R MVK?'0'L1)#:P/;N!R,*E/(TI7!:1Y(.0VM!R1M/4=JTX;VL@2BV/"!Z1)(+5 MOLDDA2,F:3!-#42JU'$(1/!1I$%,`4=K5$099FK=/,^L;D21#(*E*5C^=TXJW:V5MK*']#L)`E%0>$3PB202K MM4S21+7:Y-!3-6*=4,(C@DTXUC21Y'.PR!'+-&&NCEBFP983 M\9:)1X1!7I^KU%.P5,LO,KM^-&G4!T> ML:['P2;ISO!8UP4<5^JN>[<;<%KHDA[R/]+Z4)P;YY3OX5'^[`Y6HUJ?-](? MVNK2G=EYK%HX)]3]>81S83D&PO=V]R:W-H965T>>WW-ZOZYKJPGS#BAS=KV'<^V<)/1G#2'M?WK9WJW ML"TN4).CBC9X;;]@;M]O/GY8G2A[Y"7&P@*&AJ_M4H@VE;A&W*$M;F"E MH*Q&`A[9P>4MPRCO-M65._&\F5LCTMB*(6*W<-"B(!E.:':L<2,4"<,5$J"? MEZ3E9[8ZNX6N1NSQV-YEM&Z!8D\J(EXZ4MNJL^C+H:$,[2O(^]D/47;F[AY& M]#7)&.6T$`[0N4KH..>ENW2!:;/*"60@;;<8+M;V@Q^E<]O=K#I_?A-\XH/? M%B_IZ1,C^5?28#`;RB0+L*?T44*_Y#($F]W1[K0KP'=FY;A`QTK\H*?/F!Q* M`=6>0D(RKRA_23#/P%"@<293R931"@3`7ZLFLC/`$/3<_3^17)1K.Y@YT[D7 M^`"W]IB+E$A*V\J.7-#ZCP+YKU2*9/)*$H+ZU_6),UE,_>GL/UC@?9V46<]R MNQ17I=6YE""!-BM&3Q9T'@CG+9)][$=`+.T)_VD/^"+W/,A-W59`\7$"C.WK1XST1';,2+P=4@RABSF.F0WUF*\)QTC!N]QP8?>#*B3 M:48`'?=^KYS-D)L,,SQ=8ZP@79=W!F[-0&(&=N^P+IL;)B!4&%/3':ZIWQ_8J(KF*V%U% MI)<0F@,P7&YW0(+7-O1WGYT_F>GYQ0JSZ,9/.`^,P[$=+B_]T'`G&2[/YUZH MD^^&RT$PZMSA\L(?+&LIP_`;IBQGZ_5Q(C?IJ8>>T7BQPEPJ_E5$KN5P^"MMW( MWE,!=W;WLX1/-`S#SG,`7%`JS@_R!?U'W^8O````__\#`%!+`P04``8`"``` M`"$`>0&>@8D'``!])@``&0```'AL+W=OKO5N?FJ:VW:YK/>G_)+5 MB_*67P5R+*M+UHBOU=NROE5Y=FB-+N>EMUIMEI>LN,Z5AVTUQ4=Y/!;[/"WW M[Y?\VB@G57[.&C'^^E3.IW/+OOM M;V_7LLI>ST+W-^)G^\YW^\5P?RGV55F7QV8AW"W50$W-T3):"D\OSX="*)!A MGU7Y<3?_F6PY7<^7+\]M@/XM\H]Z\/^L/I4?OU3%X??BFHMHBWF2,_!:EE\D M];>#O"2,EX8U;V?@SVIVR(_9^[GYJ_SX-2_>3HV8[K50)(5M#]_3O-Z+B`HW M"Z\=QKX\BP&(S]FED*DA(I)]:_]^%(?FM)O3S6(=K"@1]-EK7C>\D"[GL_U[ MW927_Q2)R$'U3CSM9"-&KW%OX85KLMZXO2S5B%J!:=9D+\]5^3$362/N6=\R MF8-D*SQWRM0X>JV?217#DTY^EEY:7T)%+>;GZPL-P^?E5Q'3O>;$BA/,9STG MW$!*TE&D;.DW[2[<;0@T81VC,^'J0ANZI=#8"Q7APT*I2(3Q*>QT22.D:P4' M$"O*4)8'&8G)"`-(2QMUF@#2P%.@I4/W3.`BW*(`L.[VX\M M#B`\>D2X)&/AN!(KCE+FK7V"$B(!>+1>8>4`-^T9P$U[/L2I1\/[D@2ZB2C/ MTV>\96/E:.2Q)BGI?D`1G@`\,.8T!;AISP!NVG.`1\2_YP14+IN8R;E.5,L# MMWJ8C+'F:.'#&[>U,`$XW=#[P'0CIN[QF3USV'.-3UCF1+8QT[6KI@=J1RLY M;EWNYN,WU_J5'PLE=7MA;@JW4F`2R(9H>B!4^S3L>&B$=SRB2!:5B9N2NBG, M3>%6"@R$&.\#@9!LN`_0".W-,5&DC=K\5XL`->0))@SV*+T@D`>TQS+L($!E ME6N"<#/2?$']LDF:G@BJI8(K`BWG6#Z\BB"-WURO"""\I' MPX_)L#$+:83P!.)KW.JG$#?L&<0->Z[Q"7/O/=0:MFQ8$@B>FEB3=.)['FX- M(;XR'@<@;M@SB!OV7.-3Q#_4'7H3ND/-T=40MHZ)#4QM(+.!O`>=F>Z)K!UF M^K1MO[6"DTXC5(1C31H/NJJ#;DKJIC`WA5LI8.?S9!LW6/H3`Z*:/WL=;%W; M&P,W)753F)O"K108$#&!PX#8ZZ`GV3`SS#JH26H[6(?XM44"<-]\.P!P$GK8 M`8,$/URCW99KPGAN0OD/-8CRQP)#/JZ$FJ1V!!(9FZ'RT14ZB@>?`OLP0&\8 MF(8[>_$D#3<=WMN[=P?4%#KF7G5H]CKH*9(:7;CRT>@3@!-""0I/"@BF`P;P M$0=<$Z;,_4,MH#?6`J+1QYJDY-.U\7H(X)O-X"6&ZH(!;MHS@)OV7.-3Q#_4 M`GIF"XA?`,6:H[3[YGL2@(^\)P&X:<\`;MISC4_1_E#_YYG]'XW00V^L2>,W MU]50^;%04K<7YJ9P*P7L?O+'H.'F/ZT:ME:NWP8TR:(V<5-2-X6Y*=Q*@0%Y MJ#^D9G]H5D--&F\0;6!J`YD-Y#WH+`$4-8CV$M"RJ"8`CXPG MN13@H6'/`&[:,2P?ST[:N)MTW&KC-O M*TXMF'ZX)TX?R>O+_@;B\,\M>\O_R*JWXEK/SOE1#%F\9A:J*W5\2'UIREM[ MO.2U;,2QG_;?DSCFE8NS+ZN%(!_+LNF^R!OT!\=>_@<``/__`P!02P,$%``& M``@````A`%93^KTC`P``X`D``!D```!X;"]W;W)K&ULG%;;CILP$'VOU'^P_+X00JXH9)6PVG:E5JJJ7IX=,,%:P,AV-KM_WQF< M$"!IFNT+"<.9,V>%*"UF&U',&E/`REHDHMR']^>/Q;D:)-JQ, M6"Y+'M(WKNG]\N.'Q5ZJ9YUQ;@@PE#JDF3%5X+HZSGC!M",K7L*35*J"&;A5 M6U=7BK.D=BIR=S@83-R"B9):AD#=PB'35,3\0<:[@I?&DBB>,P/Z=28J?60K MXEOH"J:>=]5=+(L**#8B%^:M)J6DB(.G;2D5V^20]ZLW8O&1N[XYHR]$K*26 MJ7&`SK5"SW.>NW,7F):+1$`&6':B>!K2E1=$GD?=Y:(NT"_!][KUG^A,[C\I MD7P1)8=J0Y^P`QLIGQ'ZE*`)G-TS[\>Z`]\427C*=KGY+O>?N=AF!MH]AHPP ML2!Y>^`ZAHH"C3,<(U,LSRY%'[XF,X$[DOB&RAF[D^>7(,)RWYXS@3N2^(;*&3N39X'+D23IJ6%M,6V>_U><(?W;"=%1ZT-GWE[/VZNOLO0W7!]`UH0T$ M&W[J1U05[+\?U`715F>49V6W0=,`JLPO5[IN"JRV/>)YK M$LL=+LLA^#369I&OZ@7:LZ^'P;JVN\T#V*\5V_*O3&U%J4G.4Z`<.%-XR2B[ MH>V-D56]Y3;2P&:M_V;P)<5A00P<`*=2FN,-?@,TWV;+/P```/__`P!02P,$ M%``&``@````A`-R:A1%$"P``5S0``!D```!X;"]W;W)K&ULK)M;<^HZ$H7?IVK^`\7["=A`N%224SO<;#!@N\[,/+,)2:@=0@K8 MMW]_6I:7&W6#*TR=ET`^+ZV6W9(LR?CNSU_;M\J/]?ZPV;W?5[V;>K6R?E_M MGC;O+_?5__PU^J-3K1R.R_>GY=ON?7U?_;T^5/]\^/>_[G[N]M\.K^OUL4(. M[X?[ZNOQ^-&KU0ZKU_5V>;C9?:S?Z:3Z'UXW'P>X;5>?L=LN M]]^^?_RQVFT_R.+KYFUS_)V95BO;52]\>=_MEU_?Z+Q_>[IXV=`;FLE?VZ^?[ZA>OE_K-:NWA+KM`_]VL M?QY.OE<.K[N?X_WF*=J\K^EJ4YY,!K[N=M^,-'PRB`K75.E1EH%X7WE:/R^_ MOQW3W<]@O7EY/5*Z6W1&YL1Z3[\'Z\.*KBC9W/@MX[3:O5$%Z&]ENS%-@Z[( M\E?V^7/S='R]K_J=F[97[S;:Y/)U?3B.-L:R6EE]/QQWV_]9D9=;61,_-Z'/ MW*1Q>]-JUQL>Q?RL23,WH4_4Y,;OM+S6K3$IB4Y'LU.@S[Q@^Z;IM]J=+'I) MP=N\('TB8FF@=JZGSUSO>3>=5JMYVS$7JR02];:LBO2)2)\[MVY>D#ZO.S>/ M6I)-K&E2>=*NSHF'S)HOU]7<:Z`"]*6H^Z<2ZJ$IF"^(6GI]38NW9\N-@')3 M-,&2U'AH!>8+@GTN.1X:A/ERY2FB17C<)$[J6][O:K8/9T/"8'E_K%\'!I=*!AP;A\,3;W53HGZO@'&M)^/#3:C;O: M#QJ&5KGF46L\5]&'PHPYQG8@P5""D01C"0()0@DF$DPEB"2823"78"%!+$$B M07H":I2>(D?4D?Z)'!D;DR-82+"2()4@D2$^`DQ`:GOZ)A!B;^RK]+3J-WY6=)M?08%Z(6B))A:3( MDB)#14:*C!4)%`D5F2@R52129*;(7)&%(K$BB2+I*7&21C>&?R)IQH8&2_HH M$M)H-]V4/%I1HRQKA:3(FB)#14:*C!4)%`D5F2@R52129*;(7)&%(K$BB2+I M*7&R1C=G)VOG)ZFX#1EUEAQ:*+!2)%4D424^)<^%I7G7%A3=J]\);TJ+Y!7<" MK^V.6?U"5'0"18:*C!09*Q(H$BHR462J2*3(3)&Y(@M%8D421=)3XN2"YLA7 MY,*HW5SDA*=A?44&EC3I@_/5O77S-2Q$R-=(D;$B@2*A(A-+O&XQ4YSFA"L= M%:5.JRB:U*P0H8IS11:*Q(HDBJ26V"HZZ:%;KI,>NYZY,8OMX^MF]>UQ1Y>4 M.L*9^TB#UBUV-6-,W*Q9XF<;*W;H4F1@2:.5+7_\NB>FP.R-F MP3-6KD%1RBRJR%5,T,`]\&FF#@,684S M&L'K)*E`W'H"+EAB'[(*]A-XL?T4B.TC+EAB/V,5[.?P8OL%$-O'7+#$/F$5 M[%-X9?9NOLWB5VY$^+=F!_)<7SU-L5TVTXP<81X]BWQ:OW'RNAUW`.VS"@4' MC+B@UQ';%$.HS(#QX\%K^.VZ:SV"@NLT!O*+:@:,2J*%4.716IX\D0D4'&T* MQ-$B1B719E`AVFU=##AS*#C:`HBCQ8Q*HB50(9KOBR2E4&31W!9C5N>G+>;, MD'[:3.QBWFDF%ODT[SII)ETWEWVSCTEW@P9WB4&.J"!:SA"(;Y$CH$ZA&FNO M`"KV"H'8:P+$7E/M%4'%7C,@]IH#L==">\50L5<"Q%XI4.;EILXTA?$]@49#H'8V"HO+,\)1;N1C(+8--`J!K*V)PYNN.MV;WX(ITVLT&)YT6 MB=6.=!H"-3-%T-ML7H=0<#M?0S$SH%&(1"<&V+\FD#`SE,@ M=HXTF@%9YU:C)2[^'`)V7@"QG)]RVX4H_FH:OM3Z>#J!A/ M^JSB0;0H"#2$BG)93&@;==&,1U!1^4+E=81J#!6W[$"C$,B-*)KW!*K2B%.H M.&*DT0S(C2@&@3E4I1$74''$6*,$R(TH)API5)XHMG8;1*G5^<[ M)[0X*9)X9B95J-!&!K1GEM^T@89`=(\]\1+KH!%4-#DK5&>:C;(/4)#[6`A4 M&G$"56G$*51L'VDT`W(BRF7`'*K2B`NH.&*L40+D1A1SW12J2Q&=9D-[5MB&)U3J"Y%=)N-W%LKWRGQ M]89:CL0<0ESX/JNXV10[<4!#J-Q^(6X9(Z@N]8N\V2C[``6YT\>75?C7;XLHUS@KOU06>V^FS<`:';Z<%=@^WK"8ZN79FMCR6][:59ER=L] M^C4%M0C!Z1%KSSQ`U4?HZ6C///O41^C!9L\\MM1'Z)EDSSQQU$?H=8HO68\3 M\1_I-8OLF8[D/KU^<<;GL=%+&V?XER;Y9WU1&C5[Z3D^Z/3H1Q>ZHE&GEYSC M@VZ/?CN@]4&W1T__-8^Z/7I^KWG<[249KQ45I=UL^4 M]'KV:XF]?3'$_G/,'[9_W1WIA0YJ%_1#<7J!9TT;0/4;FG(\[W9'_$.!:\4K M00]_`P``__\#`%!+`P04``8`"````"$`WGTL7Y3X)\_GNXF&$E%^HJTO*<%?J,2WR\^?ICON=C*AE*%(*&7!6Z4&F:^ M+\N&=D1Z?*`]?%-ST1$%CV+CRT%04IE%7>M'09#Y'6$]M@DS<4L&KVM6TD=> M[CK:*QLB:$L4^,N&#?*8UI6WQ'5$;'?#7+N([5@HN>:T\B/.MZ&7-4W_J0])B7C&H0+<="5H7^"&D#V#-^5:CSY7^$RSV+U8_F0/X)E!% M:[)KU7>^_TS9IE%PVBD4I.N:56^/5);04(CQHE0GE;P%`7A%'=,W`QI"7LW[ MGE6J*7"<>6D>Q"'@:$VE>F(Z$J-R)Q7O?ELH/$39D.@0$H/]X?O(BR9IF&;_ M3O&MD2GPD2BRF`N^1W!I8$\Y$'T%PQDD7Z\(2M'L@X;-$I"5<`HOBR2>S/T7 M:%UY8):73.02JTLB#D^(#UXG.2CY=CD-0V,Q.LE%67S*-04L+9.,F-0E5N\1 MCAML=+N;A@L,V2.WS-UY:9F):>LD28(@<('5&)@&TS'@F$%YMYMI^-PL=S=> M6B8U9FGH;&S:NAH#R23^JQE<]MO--'QN=G[9+&/-LFDXWMB:C8$\=YKJ]"S[ M'S,-NV;Q>HE:6H-EX.70?F''I7U0?##S8\T5C#GS ML8%?-0K#)?``KCE7QP<]D$^_DXL_````__\#`%!+`P04``8`"````"$`V^W" M"&8&``!!(@``&0```'AL+W=O8D\=CC2>*:7IWI5UIM=K#-8.QC6*,!4PF>?NMIMH.U9`NYB89 MX\\_77]W5Y5I/WW\6IV=+T73EO5EZ_J+I>L4E[S>EY?CUOWG;_EA[3IMEUWV MV;F^%%OW6]&Z'Y]__NGIK6X^MZ>BZ!Q0N+1;]]1UUXWGM?FIJ+)V45^+"[QS MJ)LJZ^!E<_3::U-D^_Y#U=D+ELN55V7EQ46%33-'HSX5U>0>"G/9?>M%W6=*M_\=KS43?9RAKB_ M^E&6W[3[%R/YJLR;NJT/W0+D/!SH..9'[]$#I>>G?0D1*-N=ICALW4_^1H9+ MUWM^Z@WZMRS>VL'?3GNJWWYIROWOY:4`MV&>U`R\U/5GA?ZV5Y?@P][HT[*? M@3\;9U\,[4&_0THWR+#<=QC_5&H M$*,2^:14MNZ#ZT`4+422Y((($`P]B\E0#S.$!*!:8-) M\#X4OOF3W]-F^$8UWVEH^N;H`(\('DEY1%H1:H3JCP:[8%Y7X&-7!07WGNZC M:&TD!`U9#4$="R)XE91'I!6AAJB&:F"(/2WXV'[1[N#1-`(A2Y2)UK$@8@*) M8K-%F(",+"6M"+5"-53SK<#VBZX)LTCX"%GB3'A$\$C*(]**4"-@O.\P0M$T M6P1KLV?V$=+9:L%@E6)&4%Y$V$>J"ZJ[F+P?LQ88[(UB;?;/ZT@Q6 MH0L?HGBB:FC$:@.KDO(JTAA+N!Y."35"-5GSC<"6;&A$%!F;QI[DN6ABQ;..$1P2,ICT@K0HTP MFDS[F@BP*1RNB7']U!`F3)4OS:1="Q^3!Y@42-4$S@[1038,@Z7P[A^:@A# M@`?@$\N![3P%*Y)JPF*F)"*KB)1RZ@*HO,,%1=/E$,7F0Z@`($3P2,HCTHI0(XP^ MDRFAV!<.<^9$"44(<^;*G_@*&O#MI49^+)+R(I*(Q/39(75!]7#SEP-V?-2% M40E%2!>_R`\G2L>XMHH'J.OH!K" M`ZA@.7[\FFC"$H%@15)>1!W=J]2.(_'I"Z*IICD13G<^OD]:LZ M=0_A!.E^]?Z+@$^!.KXUKN_\#9PRCZ\+?P-'R7#=NW\`#O"OV;'X(VN.Y:5U MSL4!;K5_P<``/__`P!02P,$%``&``@````A`+K.@OY5!@``L2(``!D```!X;"]W M;W)K&ULG)I9DZ(\%(;OOZKO/UC#OZIJK"\ MJN32D@LC^[2Q#_[)K2J_W5#Y]O;_?Z^??O`CW+MNE`.' M4UA5]E%TKA0*H;-WCW:8]\_N"92M'QSM"+X&NT)X#EQ[DU0Z'@J:JA8+1]L[ M*=RA$F3Q\+=;SW$;OO-Q=$\1-PG<@QU!^\.]=PZO;D7I/Q67GN9YCZG`OW_F<[\#8#[^3" M8,,TQ1/P[OL_8K2[B8N@^?WB;:5Q6]F#`Y][= M,&IYL:62PZ)W$P M7'U8GAGJ,U/"K@/"RE\N:MYB:EFWGH@/".ND4]K7W.HL\]@4>,PF*="P(_OM M-?`_<["LP!"%9SM>I%@EMKX?]!#M,?P]II,Z$,\A).K/-\,T7@L_(;N<"U/C M#,S@C=%$HBX3AFF*3$-F="8B31DI62+2DA'=0DQ;9@RS*/IT.`.O?^M35R9P M8WHR@@:F+Q/89"`CR&0H$]AD)"/(9"P3V&0B(\AD*A/89"8CR&0N$]AD(2/( M9"D3V&0E(\AD+1,IDP+DTRVI8.$0DBJ^HNB0P(^3*ZXE)I>NBG%8XXB57#GB MA*SC@@8N:.*"%BYHXX(.+X#NWJ+=,%'6=#,PO0Q,/P,SN,>4Q)$99F!&&9AQ M!F9RCRF+[9EF8&89F'D&9G&'*:+(669@5AF8]6-&R`*XFOQ#%L2U(%O2P5=$ M*W^-,[!?N04HNGS42:)!$DV2:)%$FR0Z)-$EB1Y)]$EB0!)#DAB1Q)@D)B0Q M)8D92$D4KHY6SQIE2LIMCFJ6A ME;XNZ+IFH96E(>AF4467S::@&V7\^RU!-QG6VZ*N::C]':[#ZZV/:#'HDD2/ M)/HD,2")(4F,2&),$A.2F)+$C"3F)+$@B25)K$AB_8@0$@ANM80$>KP7BVF< M..@27^,,-.!O@526CJ$4[Z95K802L)=62P92^VFU MG-HP)S>4@[2*:@[3&M/%_=4H+6I('*=%'8D3040]G:9%#8FSM(@W6/.T:*$5 M:,%%,UEC-=5"MY=+4=;1"KQ*RZ:.;Y77:;G(V)>Y$/_P-\03\1_38OSK*K[1 MY\RC^">)!DDT2:)%$FV2Z%R)./Y?-`/-7U>42RBD>H)LX0GJ"W+)0&$U$&2< M>\.'ZDA0<<".115U:B*HJ;!),G,JJ!JZJ,\$%?\%-!?4(HJ;!5=Y,KQH5ODK M8)-?7HJZ9J#17@EZ2==1V]:"7C39ERXD!/Q#]41"Q#1*"#S<-<[PCMW;20GZ MG9V4H-_920GZG9V4H-_928FZO)/B^H.$[I)$CR3Z)#$@B2%)C$AB3!(3DIB2 MQ(PDYB2Q((DE2:Q(8OV($!(G/O;*_I=Q3./$P??SG.&)8Q5+:,&H<_E!7#;2 M!DPU2VB);:;ULL'03J-%_D";)#HDT26)'DGT26)`$D.2&)'$F"0F)#$EB1E) MS$EB01)+DEB1Q/H1(20/'`()R9/MK^&X%DZBK\M:+X(MU>W4O[D0(U5 MX,P$CNQ1>9U5X.A$+F^P"IR@R.5-5H&#%+F\Q2IPGB*7MUD%CE6@O'#[87AB MX&SOW*$=[+Q3F#NX6V@RG`/#W5O`GSG@7R+_G!P"O?L1/"N0?-S#HR$NG/:H M>8"WOA]=O\0_<'O8Y.T/````__\#`%!+`P04``8`"````"$`BLWTZTP&``"$ M&P``&````'AL+W=OM;-JJ/JU],0M\KSP5]:8Z[=;^WW]]?ECX7MOEITU^J$_EVO]1 MMOZ'IY]_>GRMFZ_MOBP[#S*B/IXAQ7-UJ+H??5+?.Q:K+[M3W>3/!]CW=Q'FQ5ON M_L,@_;$JFKJMM]T,TLV1Z'#/R_ER#IF>'C<5[$#+[C7E=NU_%*LL#/SYTV,O MT#]5^=HZ?WOMOG[]I:DVOU6G$M2&<](G\%S77S7TRT9_!8OG@]6?^Q/XH_$V MY39_.71_UJ^_EM5NW\%Q1[`CO;'5YL>GLBU`44@SDY'.5-0'(`#_>L=*EP8H MDG_O_W^M-MU^[:MX%B6!$@#WGLNV^USIE+Y7O+1=??P70<*DPB32)%'`WL3E M3"XB$<7O9YDCHWZ#G_(N?WILZE] MJ%\*Z!:.X]N37#[.OX&"A8&D"$E\ST(H(ALBE+A`YD#OPA%V/IVC7D0YJN"2 MOM]&BI"D5UGO*W.^(`1`&)?`?7$T&$1T=JXD^V&$A`XDHHCL'H)0@R3CJ6GP MVH==7@Y%*?K#*4(6_:$N19C0<.:&A0AC>^R$%53U>%8:S%B%]&=3A(0]*R%L MF?3GF-&H/65"*::4=*$GL/#^6>I%C!H[J10A44\M3)05!+FY8=#3KB;DH$_& MZZ7!C%3,]$((ZB6Y7"1X@Y">7(XMW%=)@QDA5C[[BUJ7[7S8&8K25SHFY<+F^VYR2[%T._#ZTA&6*(,?X:A6+`S`4H MJ1:VB:AFDXQ?H&]#H5\N*/@50VHP4&D7S*`1,,UU"*4W:02(X0P(68VG!F-: M@'M+1L(JO%%I!%ID00W?(,J:UZM,OV:":8M6_#S#5_X9BHJ;!;85I@D\Q? MWZ?R-N/$;S'7K-`>)::Y#*+U)YB_1M=U)'MFV,C6&&%0N"O@%2&9RO,6E M[1Y*;)+MRZ'M1_9`##'$F"IS;CB,9FY8)-9K""W]H&1\3_9HUI/<]@W&Z!$& M+)[1N%C:GJ;$F.V/>ZJCAM?_,;/WU&#<8HJM.BC>?0PE.FD,*!P#;D/$MF+P M8`W&)29) MJ4T:$&HX(+A=I`:#U!ZB,.#D,X:0X:V;/<5&Q,C618\G)<>]N,_\=NL^N*Z?FAH,BYGZLW$'Q(.*`]75F`/=[8M*84,,QX3S.-&V* M&%-S@6+C-S,Y,+X,G-LNHAN\FQ@TJ[;R^[KUJVBO\LOMU&#P>:V\][LJE/K'"]@"!"B)*N%7N]6VI-.I]N]9P>RB-G29MK@]IP/\9?C-C M#Y/EE^>V<9[8(&K>K5SB!:[#NI)7=;=;N3_^>;B;NXZ0M*MHPSNV>3#H]@S)AWPT(F5NY>R7_B^*/>LI<+C/>M@9=N#BTW=U/)%.W6=MEQ\VW5\H)L&XGXF,UJ^^M879^[;NARXX%OI@3L? M0<]CSOS,!T_K955#!"KMSL"V*_1"2M_^BB"BHR4DX.HF`?EP/O7`>DSCYV(N/1#K`>RKI>CGPHP.[!IXI M>JKV(%F`9Q79[&)D0*-LOBHC;0IJ`>5X6J=DZ3]!!LM1DJ,D=9U)$IJ*XEP1 MO3GQ`6]BA,AMQ@AJ^'[V7QF5D<5H$>0H276655S%R0T#`!)S"G#]P4H,!3Z) M/+(?C)+9B22VDG--8:"!DU.TS]5/&:UE&5V"QJ8A<5 M)9"8*:EV4:\IC+S!L;D];\K(RIL%D*,DTT4-O.`M,3JMQ<5E`TZ]U*R.\7%1 ME9$%9U4M1TFLX4B@_\RR%]<4!F+V?Q"5D868F@`Y2F:8/W.M>'_-P"+0M&Y/ MG;:RP.;FP_-1\S[9A443[9WWP,=5)=C#C4;RU@KPK(X:W'3DMSNKT127UTU` MU9MOWG8$._HIX#RP4;J-8!S0EJQC.2 MS)(LCN96'RHL49A!>\[>#IN)JOKX[:C8_0U4BR(GJ!E1XSB-LRRV1(4I2JZC M6B^3Z_U:36?6:9Y;.R\?-8@XSZ)X%IV5'=W8YPISB.,B3E,M&W:L8$TCG)(? MU"@80I>8[N*8FI,%S!PPTUGW"QA?]7U_6H#IL:<[]B<==G4GG(9MP67@I<`S MX/R)%Y+W>LC9<`ESH_ZZA]\)#*:9P`/QEG/Y>J$FW.F7Q_H_````__\#`%!+ M`P04``8`"````"$`*>EI?8@X```AN@``%````'AL+W-H87)E9%-T&UL[)W;N?O-V+?H4(AK]@1$)O@022[>^2`0%#"#$5R"$H=[0E?@$"1 MQ#0(T#B(XH0O_`Y[Y0@[HI]@'Z(?Q4^RO_^7F56%+!0(J<>SWHWUV!X1E96' M+[_SJ7[X^\]WP^13.ID.QJ/?/:MO;CU+TE%OW!^,;G[W[,/E\''(]GMQU9_PYN?EV>C])N_WI;9K.[H;?;F]MO?KVKCL8/4MZX_EH]KMGVWN' MN\^2^6CP3_.TZ7[:J^\^>_W#=/#ZA]GKHW%O?I>.9@G[2%JCV6#VF+1';@'V M_<.WL]<_?*NA;OAA\GX\FMU.&=I/^_'33GJ_F>QLU9+MK?I._/!T_&DSV3I8 M_O");21_:EQ-9Y-N;_:/\;0OXA_\(2[2FX%>X6BGW;LT'O7B8Z-S]KYUU&XV M3FI)^[09#_#3-('-I#L$)OWT<_*']#$>]V*+_SG8.=PZV(\?->>3":\GQX-I MCRE^2KL3P2TYZL[*^WGYLK[]S^&W\6,Z'+[\>31^&"6=M#L%7_I)>SJ= MIY/XA1>GX_@G/\?'\7`^FG4GCVQH"%I6#`N[ODCOQY,9R)IT9MW9O#3\Q4]I MZ3>_DLV?-#GFS7A2AECGKCMD`TF^0G-\=]\=E4;ZZ7AZ-^;@LW'OYUK2N>U. MTFER-I\9\;#!^"`9,A4!?PRBE_;[8AFBQJ^?IY/!N)\LG^"/.Y6K7S[>EZ^Y MOO7RC_$;#0BP;T1X/.R63O/BNCN9'N47-Z.YU/X MQ+0&/QFFTVDRGMVFDX?!-$VF]VEO<#TH\X2CM`=/J!O9;\>3-C]<7+1.+Y-& MI\,V2D^[TUOC2SW](_VG^>!3=YB.9J5K[-R"J2]GZ>0N&8P^I=.9@%D:U>@9 M2YS:E+;S9)+V4B:]XC"U9)3.DO$U3Q/0<_S0'?72!$:8],?SJ]GU?)ATBQ/T M0,K!5+P]Z?;_//=K:H+GV[576Z^2[@Q2O9^E=U>@>F"*MO;SG5I]_U`#`(Y_ M7@&@BWR#27_.?B;C.W8]A+3ZR7T7^BP381L0C&;C"8_L4#%8CP3Z9+]SD,OJP(?ZBBG0R''2O!L/!,FSK0)+3 M9-;]##HN73E#HDD*7H+#+[.;-`%35C*R-S1K6/IQ*=1.QS-6]RL;AG;U]>MB[>)RO`GFW5'RX&N\-N]+L;QYY6K.5_BX"]^_>777^(-=B[/FG]X=W9R MU+KHO#"ZN?PI'G,^"<0]G9D(?KZY51?W2>#'\_3[I%Y#!]+_)5,GG+OS&2QY M\)>T_WTR&@S#S_!+X:!4S7$NOI=SRIH->Y)!>MT@W]CBSK;W;%]5>ZN_VJV] M.MRK[1QLVW+U5]NUP_I^[?#P5;SG2FY>VF(-!)0XG`T^I<-'H+.W5]O?.ZP= M[E4N\B0TE@-C<:7XVAI])#HL#M9YWQWT7PY&2:][/X"5ED8N,,?K06\P6S7$ MR4YD`FST%F'`.9&[_%WB.I?8)M,Y&J>_'T1>;SR=U9*#VN'.7FUW9\L.5D"1 M:JGY!)SC#3MRLG5OQ\,^^NX+4R%F%1RA0)FVIW7>_`KEZASE%0,JG0TP"=94 MMM+//10)I_@F_>ZL^R7Z5R88C.I,V"Z(_:_7=6*(5TE@U*:EHK?T?LQF,@Z3 M;("[_?%PV)W`[%$7C,V4&%R)3Y6XD4WD?EW[;<^TM(4O?+-(U2M>7V1A7WKH MQ;>_Z,1+7WWZN$M?6_.L%0QAU;U4$%GG$D/&B<"SXT2Z7^.RC8GC!>+[\XO6 M.PR?]L>6K'M,_63CY*S3$.B7KDI/6W"RZ5`/_7<]E@S M]FN;CK<;YI&)YTZUWK;=ZKVGMB^1LVJ;;R=C;-G[R?BZ+/?.8#<8"AA+02V. M-]_!->8[0QN4+;,INT])O)"3C$]96X* M*O&YH;_"I,L6MX-*\`G7!5.IV?$T+Y.K[G30LPOL#X9SN0C6$YP_LM];#>_B MKN[>I`O+X.7)=?4UUHR'K,6_FXW.N^3XY.S'M7Q13?F#KO'13)U#)*<0/,2# M3TOMU$;!26,V(JZ)'GY0<_L(Y@F_R@5DSB:8P:=!'XA9M=W2#C2UBSAB1 M<],8IA7TYN]*RQ8=9HZG%'3/>+3S2Z5(DT6G7#S.\;/EGB)1[U==8(Q2SH\H MOE^-4N=S>#BPAT*N)3X`SPPW12[%A`C3\?7L80FU+KP\79'VT[O[X+5: M[YT,('/A")>XSL%B8%QG'L,5P)B,>VG:]Q29?DXG/?F%@0RG5Q@FOD:\_QY^ M&A08FQP,2T9V'TW98>#HBST^&0@V/`R^T65EY+W.X5K7U]CSVB?*H!%$@DA. MD_Z`!^@J*%42=89YNG3[A_"@PF%]VKJ45GK1:G2DGB;&_N2XM'_(>_FQ<=+" MO1.#PFYFV0IXU:Z(>(U&0EGV"2X2M/B2UXE!5+_8^7!^?F+J=N,D.6IWFNC2 M'RY:":JW;;E]>GQV\=XT\'C-3+&0$Z+\D(M/G=0V+T4\8&'A3O-=Z^C#B2U[ M>G;ZTB_]L=61^\LT_^/V*8$-^ZMYV?ZXU%=:<)`[V>R]W`B`0,7&VC)"QA'7@7F0`;>&8/M,"G'A_T)'>Q:BA!V7XRNYV, MYS>HB7IG:LZ<^+6SB[>-T_8_&.0-`.<$=G0MN47T%:^LB+>:<[$!NGWQRA/% MFS\2O.1H\GX0=AT1&WKH2KCTQA.\P1;6@$D=$>$0TQ3#^OU\^)C4#P_V-Y,/ M+NJ$@@B_0%_]/$-8&#@+H2@N:SCD]XPPN:[_^)=_>TC_XU_^O:9_C>>3\,_Y M-/RKB?0D`AG^G&31X_!+8>/\E!`78JJ[[@AU2:Q)O]F:PH["6'](D>Q@-DVF M\ZOIH#_H*CBS24`M3?S"R108I`J<;R7(%(@Y+0I.) MP(GOX`Y);RSB50-CTJ0%1)P5Y7\W9-:3COGJ8;PH^K(+393X09O<1L7K#S"Z M=(I*6TLX\/P:(3"?I/IC\C/RUJ3<_%[._*2'")3>[Z^8]\SBW)3K^6P^@;[8 M_N!>+LG)N#_O`1)=[:_N?_LV]<_],9#P,%1[\BGJ.N7R3&(XL9<#NX`UVGZD%R, M.8>>7G?O!F"736'#O[599Z]__5^52]6W_JHK?9-,'Z=$"6$A#[<#V83`8S0> MX:[]A#J/:_466W&F0TVZ]X\!HM+U@1="!W3VZ1W&O<`LB_'/TM[M"'#C/R_T0K1 M"C`P-M/-6D)^"J8C''[T#7\0[N#/?._77(U1;#CI9W4GA_=B.!KIOF_K77<>O37&YL;B017J_6PX!@YWO=L[ M,;0UVWH!;^UMC[H!7;MW5XH-DJS`&8AR@3*860,%41&G_H+88&](E)Q?4%'' M$_F4;3*8P/!Q.H"ZO:X7MO*^^V@4[>C24[K^<&Q=#.$!Y_3P\26)'=Q`QAT> MC84D1X/NS0CGQ:`'=K3%+/O?7GW;M8?OTNYP=@OL($1L>J[8+A3NHRLUCPO; M7*#TP#223X.N<:/NS20U[I4\#&:WR=M6DL]JE_6V]:[I;DN3;O\*$0, M9S$D3#6WO0XC#)!)!G==,/$F9R@@KL]&Z`46%1ADP/C=`Q,@@YLY&0W";D41 MP?,R-8AT].N1G#D#IP,V2:2YNQIT[9I__06<^_U\9+Q[>^&F2?>23T5TQLF5 M5P"7MD0/KLPT2IW=R3>7'U$+FU@*D/RZ1$@"8]((-VAT@4!D`0%#6\8!-1-= ML8<[-R^WG3S"3::F;J.V:FAA_2W=T+4VY48%1+7C^12&O9K0],^Z"08SV7"` M7T)KP`Z,>.>@(IX*+PEZ@PGN?Z7JH"1O9EPURRDSK0`0YKD2R$"R(72"@$.F M_PB0QUVX#.ZZ!["U)>`B3\2B3@9WQL(VC@W/NLF;"6?'2?!Q,`$Y2)4: MG\SZFT8X)ZW+C%.]&8P_0[W@#TH=>2D<:S,?J:>.Q(I10Y2+_VGP-$XNB'6'Q/6R`+T]UM4XF6KO2F\P_54N*)P<#^,)##46$5XD)Y+DU^/A M8&P(WAA.QZ*;51,NF,?0Y M`*/S!6VK`V,2"09IX6`==WMH92:1)I_29^A8 M2<8.8GWNKZQD"1FE/&58R"T_X+?7;3N_5`!A9O,%^@>:2[C6[/6/A` M/:?X4Y+F-_Z,>:;OFT:GW9$A>7[1ZN"*R"W,Y@56-6FS2:/9//M@F2?).9F% M2CYQ%_I;9WG*_'P#(_XK[0\5VZ[LO&@2Z9H^2`1<)RVT+W*MRS&%2Y@$D6UG M-AH/'B/WR(R3)W8TA7T2J>[,_$@!R*^C(/#:KI)W_(. M31_3WW-2LDVY,;M)J58^S(0BSW,E&%;H\6R>Q%)T%I3T9Q\V.YO)VT;C_)G3 MGG&]3>?*C899"W\+2^GPR(L>/G'I[).Y%M6/V,12DL5?@IK220ERF+O=1K2" M22#4W_K--J/OMF,VEZI0!5WU+8)8X6UYMB^Y#!58,UA@:(=KR.=&Z1RC3`BL12!-YYAF2V&QF33LWKBF(;86QP5S\OF>1@:L ME_F02(,82M4MZ?I-QT#%&NZ1YU MZ,4T:8Q&-8]YA82DI7_D*GA4@E1*G0A1W':*M8'G,#I&7J9CYNZ&;-O^,.6`=&G.E"@-JC<+8;^P6B2^)\+EI'#E* MRY=ZT4TPEN4G`8N"AX;=8T%`RDK]53JM,]*%%?X&#=#90\9[Y56D:K.B\X8I MG&?8NQEFV?+R@WC/@`P`Y@AK@3C@IN+&/:%4F"_$B-W&_*S>9"-;>F@V1$FL M7+)I#@?/<\8"ZRSED+!#X,E:T"+ZNLS3G&XSIU]^J6)D=]V?V6=@V,98S)-J M(1.I=227=9TG7[!SXIL3=>_$9@W+@I,6=E<(;)F:X*Q#,?7`_=C@N@S)X5R! MK7)N(2N(P34SO]*>;F2'`I7R&[* M86_VYY*+RQ#=[IBM(9@R!]@M1(>C1I:17)/CR107E,\G7[`^,P`(E_&3R>&J MC?YYWC?_:;C7G"WF^.7VZ)\DJ1)?I168;5.]+EJ./-_\"D'NY3N.)!8C:_:]6 MLJ>YDHW$PJL/[J%[F=\+[S@6,T8>6Z%W#P\CK-LY"&#RLEP!@`:@0Q)J0@J9 M=<'!(4MQ&P.5([.^/(1FU",$[G#WVQET2V9E#!^%V;G5E,4NN':GG,)T[4[G M4"GZ*($.$'B)MJM!F=].1\C$_M2,F,S[97L5OK,JS%-*5V`[%"D,[=S.`M*4 MV6O+?)S:1O^3:=P>_%!=VWV^LIS!'^@%)A>WQU19N1K[ M"@>S?8'!^MOXG!ZY,AW'W8/(=Q0FB?]I@,\,`U@D5*@>8P_9M#(\!#3'&WG7LP1X.8'BZ=V4/0\"F\U!)(/ MMDBWC-H%<1)6!F%JJ-HABP/FI/)401%)($X=CI49A<%KY<*L@**GG!N530WN M[M&QC%:$.XUK(-TWUM@4]T)=*]W;1=H;LHC);;/R8\$8K'=N9'%@P9"^Z_8M M00*Y!)DX13%CS]POTH6=W.5F8M#4_%`0+#-\2COLM-XJXSNY:)V?760I'R08 M-OG5YW_'FU[GG:?\34USQZ\ST^+J%MNX+)#NIT%*SN*"/YQ;5M0ABU"9XY]7 M6K$#T%B=[G*5NF%XIQ7+KX/7Z>B&=`73O$!!Z6C*6T;)]3%]_Z>B^D)R,;"I M"^SKS[^EQ_AO%X!?[IL.T9,^-(4NHHP$TV*+&0DA+'R%)4QU"LD%!&K-K$*,85W#1 M9VUB41%68,]EISBY"L9XZH3=!]S!LTE5FQ0X38"AC]MG:)$PKPK`4N\MD^9? MQ6O%,:<#&+KS$CJ]3/R_I,^\:V;(ZZ9E&N/9\.U2/#U%<4MS5XWS*31/?DSN0`FJ29JJ9*:;S4/LX:> M`8LR9?8Z9^T=E_<5#UC*!RK&9K<73R(#*P0QXF<7OBK)>7-R#NEMIY+/XGD\ MP*-8J'2A5T3IE:^YW-*F-@YV#N*9-^A/L%?^=??53FDDK2?V M#N-?2VB'W,>6_S*L8Q.[!Z6I^77K8"]>D%_WMTH7]37;*,.'5@R'I2XYVMQ^ M&1KUVO9V>>Q.[:"\Y>,OH4AC^^CFI/LLAOR](P#F*`K?W_\[&WE0_SN9`9[G M+19M&Y\,BZ]S+VNN?;#EUMY_]<3:2N]8?8SG.YL["28="2&H)SK7UM\Y@?+\ M8+.^\.3@D"<<-7.(+"6?Y07_=K`ED27I$`J&J9B^;!&\:URT7A(+M@8W[\^I M^%R:A-ZI&/>4YG_D-/^*MV.\OS1Q:.H/`AYWA4)59JPU.LWDDFA4+]FO'S#G MOTG%P=QT01")W8XJ'\S&#S_CS+%<(KW+6\ZWXW)$LP"(@E#30A&0LJ;[YFF@ M4F0X?O3Z0,A;O%$AAO&I\)BHM-8=NQ@)W@\+]L#K@CO`*WKR"LH\7B>ZG2EF M\$U<,=*+%4*'*+*$^+(;_"@/+ZPE%2E&E#7IRN'L#/YP#WARL&GZ3@TL3)M3 M5[!+JR3NHA/(YF7WN[['!0AIJ8#\9*`W>"[L1-$!GN()>[Z_J]X31N5GYAN? MHG'6#Q:Z912&[VS76(:N<:0$VP32L&P#*OSGU>W*-VDZY%Y,]D3[UVA;J"-* MD/*<7K28/YH./H<'UE1H<2'/92H7.[".&MIF84JZDEG0SU[.5Y)YZ_()ERQD MD"E<4F''3]Q2E&L9;FEOL1.)\=WLOJINJ8ZNI?8E8#^F`$X[G.H3XV2.WFZ[ M0XPO\J"E?OM+M\-#'0NGMH$BF7#F^'QK(V'%\>)6*S77@\4A6^AVHG/X0V"- M<.W;M9W#[1J@\9M?>&OOT&[3:%^)Y_[-)+`(.:W,9U%M+3(`!O%G;V/ESAU+ M2+5*1X`G##.7?;[C<'E18_"B=V?; MT:`-W*.]C/#WMZP/F!9$K6S52XL(Y88MG-4'_7R>BG-P!FON>PRSQ6)XM]G% M:OC@L9VZ!$86);-$9BU'+GA%LF%"/UU@A0@JI%6!9'GB@U%>RSMU!9BBG&2N MT)=,-K/#6"%_CO1V&ZX_S?.#_2?!6XV'BW#UUUZ%*; M,HT"%F]5;;XZ8J]$<>K3D=#0@Y:%[]^?G=*D$"4OUK66#GI*G6N9.K?TU7C^ M7W]Y0XRV9[T`)(DR74/L0#X(\0(J6."\7'UW`F-2P.(>I:]G?G;`7!0WO@D1 M[">K/!52/_C2^Y>A]'Y$:0&K@&JZ0_;B\H4A+W05')SD:8SIUC-)!LBZ/+1S`"UY>JMCB= M=8J)=FG*5TC'8C*!C7:$YB^*`%*Z=I@-)U/K16$F\6KBU^3HB#](:0W@,%U/ ML5C4)GM@F_<+^PR'3-%PEY2E&H6V"-E]"5)&`QE,G0(B],]%335M%V3,5=KK MSA5]X1BNND.7R%^HP,8T30X^A%P_%/'!2W]8< M]A0]'QL]K[F&\(L=FQ(@O,BM,UT9?,TU93!U7C;7P?:6++5C&2T?I=$G[ZV; MF"52'_+''4)JGB3D&+)\"/66+:&N2 MJ=)T5<0&([?WH6LL?)CU[$'%I[Y$[EY-1E6R*1KTL?V['`YFEI305Z".2#G+ M%F-II#$&H1;K7L'7C&3\S5BI@_=&^V5,M\U-1_%;"*OL)W4W`KAXA?:>!4L;)8T+`11>CY" MR);/7FRL&[^R<:*.2DF][!AV#[:K'NR4'BS?T\8\ZR`6KVW]&8K"R<5BN$3N M!#L\?0QT14"J/U5_GCPIS^(MIG@IZ[(P2VE?ZF#@.@YK7@5Q7-1>>L(U7(78 MOWH<%2=?WBZD-'/1`1@P&>(9,1MW(PQE>^38`/UY5XCZ]*<8W@7-O=BU:S14>--R>M3BVA]T9\ ML#5>>4H2O35)M,9$\=I+6"5LVNL\159)^85*GJ4:Y8+,LX:;27I:=8@VTS%`?W]V"CC\H[%XHXGM@PD'#YER;=&SYU/(^3:Q)(&UFL M:UHLTK50:*%Z-C^9R%C1=T@'?N@]7\0Y76F(9K(Y7;;EU/(A76*436N:9,,$_?CBG?KD5@L8XA@R#,R+MX97\8D#+S6AW+ MM25EI"H-P)*$E0$04O3,F+#_6!O*NWX^/6^=@XBHH^!4-&,(5(.;.9JZJ M,GAD]Z"ZW%&.3Z[KW'0LXM)V=T5JP@V`@J5^Y?)7HQ=YY:OR0IWI5<)_P;P0 M1B^BLB6;3LT_+<7-[14K9*J2GV'I;MJG'TEM.KN@M&XIYXJ?/\6FWAF;BM^* M247BI=A!7IQ>+(FR3:Y$;@'I&G-7E]T'S@H?FALS1+7^)$29&$] M1`95E1Z3PD[]-D1X,Q[W2T\;L[7UOT7GGY(CU:"$B<.!S/(C:0 MXC(3PCHH&,(^W]LWUZL-X0]SV"QZ=DJ7%WK!6U\>)XG:%%*>OFU+$L5`7SWZ MJ8MMV\6NGJ.T(J`UC._>T$;@QL7?^3C!]J%S=PD:^A,/JIR+&QAWAQ.58DF.FL1(LX')`*B M]XM5%[BLH0)#\`W&+3?J'M)'EEFF$UQCCIM=^?]#U348&85V*6'("G#]^LMJ MC\BYK57B$TUE6<4P(+-#,BZE\;C-G;WRLD#N^7TC.;"R4JS;)??V*CO ME1(;.A5]`C=VRY]2VM@Y>!6OXR$0`]JYFS-(F^^R8'*X*_7V-N@K(E#PWKPD MDK-K$C6@=/Q!ZJ"\"NHLRAW3F@0+02Y:)6;++,0&,9OI@^L**??+!@0 M1Y4O\%^W_[PG2<1R9<5#0=D=AJ"!%^YL!"'[?+?`NNO;O\'7OK.X?/#E[Q3X MI;K]/Q6*J?0G1BRO)%&.6L>MBPMR'2Y:Z`4?2D[Q^/E34N/W%-+'[\2(91PO M;P(J#"DRA3C%7BI:D?/%TP6/9-EW6>#<<*2J]TJ>S-6O'85VQ#Y&)8ZJ(^1I M]IZ%.U]ZO&KXAD*9@6<3NZ8[8)JW$$0RX#U.\GBR[)7!Z&48+!DK*E'XH')\ M-CBO#ZN>'.(-EE.(R\437^3I'2;3K>"C)*(VMG?WXCQN ME<;5RS]M+_FI/%F]Q.TVMDL,=&.OE'&V4NG7[&X+>(:A*+5C.6:=H&]^%_*KK>4._M`89"?9AV/Z2_!XY?P7K1-] MZ>OE>4,?1:(Z@LPH.F+2(3]>I'KD4^SC#Z9T5K\?KW06POWFF]W:I^4=L9*% M)EE0,[:T2Q8_#_UA&ZBGYG5W<=H_D)`_3=X7RQ9@26J>0QW`G.-*A7XNHA="7S#_,3&[_^=;FUH$%$*<6.93>Z;^QP%JV65,LVR-.I#"X MTWS=&<-TN`_1F<(>Q3/")DE+6K)+\0`T=$ML*`D1;N$XO9K,5:]+%%H+*2O_YR,D@)/RHA7JNT^OB50>=U97]&:,3TK'/+(L=FJO MI?2&?'0GRW.!80=]/Z'[55A%EW`O9DF(`6V#5G_CB9RD7A6Q\F5-KZZ-/UG3 M*J>WT],IWXOL:-FF6EJ\_:-`W[S%4ZES\+9^M)W:!MYAVA4K&]!3Z")HT93) MC!;^0430@A0$H5:)&=ZDO9^9K);O//D?W;O[[Y,W-#+`[,$L/CDY#RT]VD(=A6JDNT)@:GK7ZK66%[$D@VY3"FWH4,7_B]NZ*LW$>D^8(9JC=414YEO MJI7(''6V7B$@'J&XQ7B$9H:XN6N.6S_'ZE?)]4R@-NQ^A'58+H@"7+K%9NW7 M7W0Z0[0,W[L94@LW$?'E9*>B5L2`X`#+&(YC7A6+&@Y<_XCXN;\;4[#P,P&2(-"6VNFZ"> MD5:B/L;R!,3L9"<[3;9A^7E__K+_%Z#ZP=*/C2[R*2@<3I(,>31"@V#O-+]%2Z^ENSH/7N7)XXC&`/P M4A3$R`2GPUJ]';Q.HF(VP)&5\^'0U;-G57]M)@OB2/XM%VTGF38LR70H`X7= MNB-D.!Y(+_.-:?U"O-J?QQ\\E_T%P+%)R4':XA#/#_E:(C+OGV#?FE2N%#6> M)PR#4Q)TMU\STK3+$4%E6R-0F5GDEF4LR9?WO2D45(H6WE)G_^2A8=4\9(%"P1`Z"L)ON1YF!Q)(+/F1.ZJ#8QL M&%(HL^D<2K%Z6D@X74-H(J\*0L&?@HL2_?E/GF9$%Z@PH$K1X1H)_+KA7231 MB,+YI#FA@9_%Q_Z>]H%2$8B2FO643PLY(MK8\^T#ETH*Q.:D^",P.<;(.LN$ M+VL"5ZU\7A2?]#@U(:'6!I1YXL,I9$P_YZN*N=,X7$B&!$[GU*T^KQ_:B57Y M3G`']FZ%@O`&*0!4KP!9EB$M#NT*.@E3932_;8C41F'UC9_EH\E*M?*OYLH] MC`KG^[5C!Q1\WG9^^9)L1T[E,O3SO5.`1S^N3S"47*.0JI9^,286J1X9)/5T@*D(L`63AXW2<.5Q]V'4HH8:N:VE*4#').TC*P<3CB8(:K_XTR8B&]_>V2B!9]J'5I^SK$[.OBV]RL(J/M,(4)$(MCV\%8_LRNZ`HB(/5 MBB]U=U>.$<,L*OWV]_E^ZJN"C>EFVX M2-,&5)&P>34,&RU%V!(C;*/9@L+%H:6=Y_>FDT`C8BA.<&:?**8K\`S!YP'/ M-FF/Y3_2LH`NV0;NNF3`S^^2/%4[7V8!/9RRJK0#]$\__[+MPHE,6A90K<0_ M=/+\@+S!2CB95)$G.%D+$1@EIK)ECJE%TV1,490^+*&SG_DNB&_-S77NGNE# MLK*DW$;IJ>3B>HC<*5J,)4RP\U!:Y;.#13;!_51)]2(?+>OPHHWR83T;OFA= M#[$*X(:^"6`0W2%-%\X;6PPP:^F_#3"RG0*E8OD6]XPV(2"&>DN3!IG*%M)\ M=%H=Q.-.A@3Y78@4,+CD>T)(:&R98M",9$4+.]1;UHS4JI$N)._;5W`NE#>K M(;6FFO[+VEPO^\HRYVQ5\VOX_!K-C=`?W.M;%L:6]$NX0/;B@1JN*4?ETI@2 M)C9LOI*J@1-I!]^Z,YM*UE*)]YK&$3!K&5%PON75:-IS-9O00@Z=#W>]"BK/ M)>SG&CR!6AQC/_`/;^FXZS,4/Y"8F5`=?22K#&4:P,FTM8H+.(VDE]Q="66`55;G!PBS:L2@ MLG>'8&O)&V"%+Y0JAA/H.S[5=^.N1B$%KCL@5B428>N`0V7K<'G%8B,$(`H6 MSL[^@FYAR\98ME5W=7D%+(/I@*&%CVYDV&2_P5;0V0,RY:QO"7BL$"8^[5+$ ML:I4@5'*05AFQRC!'G5+N!%KD-CI@3'8BBN$V1.:B[=8*D/@;EL"PS(L:B#R MAMYE+8[FN;))]#+733RWM$X]#I7!LTPB>`&I^W!NJN?US;V\GX%W-7%A>9XA M-$;6J/IGPDD6@`FF/=_>W,I?9]9XAV+_PURB^\=K]V2*GHKE?##VJ' M.WO\%0I\ZTS/#5Y.+)?+GJRU+](HU80<'>RWK M[HEL<7E@0&(8D5U9WD;ZRHN@6%D_]7**I^NZB=^Y$GMW0[EY`EY)N_`=;_?T75VM3^ MGU)4_5W\9RNJ8G=&6/^EU-5S^RRC7)IFB\22[;R0("`'%5H!CG6KU41)DO4D M"NV0Q(PVV)*3GCH[S>:XG5R2OD4RPH;O"H8>@&X>*9Q(AB+C7_[I+Z)NXL): M*W_3B_^BQ'5,TI0IS_O*AL9FEGIEXV>_5GV[(D,"T>DD&$/VY#ZL+B M6J`($PBX2B,OZ(#6>21/1-^GO&]D`/^=H/K\FY?>GZ>Q<_R"9M1OUH MOY._/TO6!R1T+1S0ZI=M!E>K*U6X&9/+_[T?[7+IG75!Q_'8*6)E*L6;1@5U M/1^"'N_R(H3XKM>T^L.KZH*8!A:,3%>[A`]9/8V19+CDS)&U&*-$2&6%)-"> M\]42ZZ0N7^0H<43=/GV)L@1O*R:Q'\9WY,W*YDI)5O5?32N).]66 MG5Z>_)2T.YT/9&86/XIT<7;*!Y*:RTN>UW[Q*2(\)8ES[G?B-%`!$[JS-H3BZWL?@TH8`!(9FHGOZQ">P)'(V4F@SA+, M78*U<"Z'AM^GT!X*PLU!,;?_#19DB[K/E+!$X9DE46LW=K!C,#7?#*BM5.D5%5_AT3W1!+&+WR M%1`X##LNW"%/>1T?(A$2ZNVMIBYOYV8>-\7VS/Z_5QHW#`?O(Y\NUR>00R=L MU\PJB\G4G1O&!2`L6LB7<<);8O7RC4,@4 M.FB3EU91Z)*UQO1M9-5-PXINN06SG^PK/>!"WH_&7(!6'WM-BXNR[WV=]M+) MQJ658);*=D,+5A%0@? M('.?##..+A[$)]N-,KB*(]\BI16:M9PC!#IR,L6,Z7AYTXKJS;DZ&!%T\3/N MOEV$V=UY%XEXL35JAJL7+E;^.@Y]D0>;XY7BLK_*:1?J_T[A3D#O`G5-]7_Q MI*M+SBJ7Z/#%Z#Z?EM/4S;RZ("J+TM.WOF(K7KB!JLQCH5U6="4.C4:7=U_6 M4Z%!B/K\YQ9U%0_E;J.=%TLM[R405U]4`JP`I"S7_,)3:`R:LXNWC=/V/^2? M;#P_:9SJ6XYG=%6R7SO)QA'?"1\,IR564D_>NU!X"ZVK'T^-Y;$9--)2$KR' M=/Q.)VLK7GH"=9:H[[30`0FJ7_A&,YS=N:.B7G298PHYXS.4*>GT7Y=>5$%- MZ"S8`H7/PR;MZ&O2\8[;T4>5G59<7`$QG"FF\=LO=IP9$/_>0-<%V"XO`:3^ MPEGWEL^:`S)\.S;OE-XSHI!-&V*=\9[\VV?7R8_VC?+DS)(OLLODW?B5]418 M0+QDXT/G*'E>0L"*3M7Y:8*4*2WO!=>%?<50JD11"/[I1,DZ;6E(_QB_N8@. M?WIO+61*HSRYU;`2_XS`R^K^5LV,C%&_>)^7&HI#5,QX2^`$/P*=OTL0R+F4 MAT52M25G37/@HOK]U$NJE;`F&M73KO&AC1J,%?50M4XF82\&TY]SKE)UN11? M*FD&M$-8EB16Y8::0(HXZ)(5JR"S;.@*#%B\)Y5`9KL,RF^>4_;$]54V&\YX M;A5T3!OQ69!BIEEHNI%7?BEEMSCNW/5*2!J4A_235;AHH7^XC+8_M>!:"?.* M$XM%9!OP2:DQX7Q5HT$KM7&?.2NQ$-2,D!1L[KI*C'`=N<0K+0[F`W[Q_O)1 M=MX0ZA4`LOZWZ[\3,FU+N_[H0Y3."#$)0T4&\38+KSE8%V.2F!_47= MF'G\\Y(5R-2DXOYKEMA>+B\J89_\N)67L>J=T_IJQG>;X6VU,8`(%+E MREJV3Q4AKYHY0`5[UY";*B92/KYF)D/\:5*8\-B^<^;Y`A]0DLN(+%P\>5X_ MJEK&3_4IA*W+G9B?X!^K3KS>/CL@]Q.[_.V+G"%.?R)GMQ+>CH`7^)B%!ZH` MAT;O-7>C&,\'5W&+"ALR:!@Q$2T8D85"PY5F8]E<7,ED%]:P9&KG93)U5#J> MF:;BK073=$5?RE7,VCC?F4_LJH+JCZZR<5IY35Q0;DT;&56/K;2,`\BK)%MN M_]9\IS=C`$O-931HK-CPV618'`P$-Y;_06U9V>`*6;[0-D]..M<,3^DZ?-G* M9?VV502FSS6%W61=XRKA5&BXYS67O`\>FJ;ZU"5^ENUOUIJEV"TOFF&G>H:U M'`9/W8=H[<'^ZJ"78TK)'*L8Y/1CGVV)C%3YQ@._E3XTK]='HS4H[*3@77`R'>1&-)>XQXS#EB4TIY%0]1-Z99^O*$NAOTKE&F*>PJ>@+V8FWB[<:1XDO MIHP?MOBHG!G\Q)7554Z&C>L94;F]MCH;N<$RG2Y]SXC*\6%P([<[-K5E%/=*.!IN[&^'10:2*GLEH*U5T,[U*:K MV8FJW`M%W%585'BE4`-?-3I78Y$QJC"RNLHOF^.XB[GP=C)^X*-F+;GA+6=F MRE[)&);11EU!M4PHGK_DEB.E*O/9E3H:0=/B3"C.W>0R[=V.QL/QC8I"G8]` M*%%U;#BD2A^RCU4)AKE:5N_0(DNQ=["\3'#E"I=$D6[`#3NK,M:6X, MS%#+F$VP:E.>$(10$O%`IF0J?ZBH,/3UB?'^C](KQ3!5]1<_0@X1NH)JK.CA M"9OJ1"F;YE^-IWE!FV^P`#]<_,0L*'(ABM5>\9AB<=8+7YKU-#/OM@C!IF)S5!A M%#\,?H*JF?/,PJH1'9%W2!Q883T]S1!`"C`9Q4A9OTIW5\^[+YFQD'Z\UFN* MHQ<*=V+8!/^=$A:6Q$W"8Y^`[7U1*Q:&?_N:B!6#Y!&1^$'<._Y0XF0E0'87 M"@5NK.!HQ?O!@&T#XM4K.8<"W"!TZ/$9W&0MY-5<3J&/87>YF*3\2?W\XS$K M\]ARHHY?6^J#;X2,MJ7Z^[?3Z>SU_Q8```#__P,`4$L#!!0`!@`(````(0!Q M8$50V`L``/]K```-````>&POV_CQA'_OT"_`\%KBP:H MK1=E28[EX*0SVP.NUR#GH@6:HJ`ERF:.#X6B[NP4_>Z=6;YF19%+._.:YLP^2-]\]>Z[VQ0YW3N#/]<%E7]=L?Q6L'?]QKO_]WKR8ZMHNLORU MY0:^/==?[)W^W>UO?W.SBUY<^].3;4<:D/!W<_TIBK;7O=YN]61[UNXRV-H^ M_+()0L^*X#!\[.VVH6VM=]C(KP-M: MD?/@N$[TPFCIFK>Z?O_H!Z'UX`+4YX%AK5+:[*!`WG-68;`+-M$ED.L%FXVS MLHLH9[U9#RC=WOA[S_2BG;8*]GXTUX?9*2W^Y?UZKE_I6BSR,E@#B#_\O`^B M;W\7_WGSIS=O^O_YYMM__6"O__WC'XN__?B-WDO9$)I@@VJ:E_U*LO!S3+F7 M2'![LPE\(L@0U(3:NO[L!U]]$W\#9P#Q\++;F]TOVA?+A3,#A+<*W"#4(K`R MR,?.^)9GQU88R76>`V;"D[V8PWGY/"":5*8I MPN!D&N$9*I,'(EEXLEHFZZ.9^^TC_97[8?`LWQ4+.W4V-5'^^3)Y00OEDJ;*6@' MFG-<-ZL&1V.LE^#,[0T4II$=^B8<:,GW^Y%RR&BWI(Y=7=^;RCO$ER$11E!`US>6D`Z)WB]E2/M+E;":; MZ-"$CV2B;\?XD4S4A/^6TG2:9$E#%LB,GA8Y.*;J7TYFL]ET<#6=3F?&:&`8 M3,D/B4<[_MI^MG&8)4U-101C0#`;36=70P#2-Z:,U5D1C`#`9#R>C@>SH0'_ ML[3W9EL:J)8F4FKCQ->6,0WY\5&C3!.?0C"-2SQI.L6@PF,$>-S MMS>NO8E@1!HZCT_X-PJV\.]#$$6P(')[LW:LQ\"W7/C:2UND?RM:PI(1K`[- M]>C)67T&9MRL0:R;F$57'+*L9^!HPI@8_8DQ'E[%`S9)K#U[[>R]HG09[Z-^ M"6I$W=8+3G3H9TP2=\AGQ7IHA<1\@BV8J9FE!1N`3Z0N(=A"AHSY#+&HC*2% MF(RD@:",I(6HC!`ZQX(KU>0ZV,-JY:&!37/:[\>3<:)\J@D2X$<\YC@(TJ:H MS]HF1S1:VZ:IK)!?"K&Q&.*'S4\I=3GBV=0% MIN$:]8"&=> M7O-P%.NJ6S:BU(EJ19NT-G6E5@F@QK8^IMM"0!._.DV2`I>#N&CF*4D=!&75 MRG;=3UCH_'.3U58P77E[\[PAFS=@1PWN;L"](?@5U@22KW$=%1\`Q+)&L#>C MI)%F;;?NR\>]]V"')MMFPUBPLR;PR8\6K`#,C]^ZSJ/OV6S"58_)?!\&D;V* MV#8@ME92AF=4@F>0$!+!TX:_4<(?]"2LCS;\84+OJ#U`+TKY@W,)\Y?I#[CA M*7%J,`%UZBH\,A'`M$V*`(R@`@%NT$IT`.ZI`@$,AU,$X*`Y`H!3X15MXF!` MLAGX0,X2^'?%$G),*B7'LD,IR](O\*^0TN32;RLUDWP+CIZK&0XJ`+1B699B M5:488G:(M%P%<%"A`A-Z73E=WJ`LYRM3"$FZ@"'7"*2!*HW(\TJ2J/06A\PL,,O'6N!5,IMJACK=21LZ*GOD:6MM[^QF&HO%ZWO.FE8`UF'+^ M,"^O:TV82]=/"RP"EJY11*WD.*]2.R]_X!C\W':M@]1B8!,+JD&@KA,,TEU` M4HA@Y*I6$W22RC$04[6/$&H;7"EOF"U0'\F<-V#A:IC6V?25P?EIOXNOT6)K M0&WU=3BGI<8%2T)TU#&Z7X/RCCI;6I7@K->$I"$$S+3V8(FCN1&7\<5::5]!)^:TY(!ID!WTNS`#SD*J& M&UW"%:I7<1Z=A]N\8#U)"*F%0TWDG@10.$[HT@CU"P#UP.:_<+VO6#F*Z+E; MX!A5R9Q:IW..PIH4`50,>3Z^SJ8R:NHN)AQ.[?-Y+,7XYM7%SW"=I#S![%F6 MCN`\"9-?:3HZN])?9?H\U67Y3"FK1*9A@\[A8>S]W^O76AO5YBCLL`=X"[#O>/",Y&P?,0=?RM8 MVP^\17PRV:-512N+I2%VL806)-BFM(!"/$H8XBY00@O68IO2RO+["*0EM."& MY,:TLDP,SS3E:$$=T1175GJ,>-V/!75O'+,CV\U.]`4BB^"BM'([@N:(OE#D MIK1R.X+A*"T0N2FMW(Z`D-`R@$E36KD=P0J4%KA;4UJ9'0TP'*$U%M3]U5$[ M\KZ*6T]%<%%:N1UY7QT)^BJEE=N1]U44N2FNW(Y`E>C+@!^:TLKMR.<)0S!/ M4!ES._*Z'POJ_C"C\AX_%/3XF$IN._A&=(3EBXB.8BJYU7@O'PEZ>4PEMQ?O MWX:@?\=4SL*W5N(Q$!,(;:80H/=FKS]H2GI21$>+C`;M1$4)WSUO7\JTH"%\TW$Z= MD>.-/A8D]^<@R'3$4QC"H0B@O\"K;.`M.1KH)>G$.07A%$$3,EDL\.K!>RN; MD('6,1K>_[#:;D(&6L=D^*2*]9,(F??^=I]9B,^EV'6+D/C@^)_M->\Y?)88 M`D@12A_M?11:F?_Q(3445,Q'?+Y*1H-/$?&CY=.'P23UYT=XG$JJ1!Q>DMC! M&EH$^-_V$5$CMB)$<#`@0N3>B>#Q8FD0?_^`3T2$*(9=*Y!N/NS@*7OP5]N'SES_[]UB,GMW M9PXOIOW%],(8V>.+V7CQ[F)L+!?OWIFS_K"__!^H#-^,=0VO5FKQYBGVABRX M961@7.]<>#]5F`B;@/^4GYOKY""&SQZ#!K!A)V,J1&^7O;GK]O\```#__P,` M4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q M+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE] M&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_ MW^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$CO MVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T M0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I M@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$N MCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+ MKS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX M.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-Z MAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@ MK,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D) MQW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)Q MTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2 M(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-% M[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@ MA_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/ MR"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR M@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NM MK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1 M?F#R`Y+<:`@`` MEP8``!D```!X;"]W;W)K&ULE)5?;YLP%,7?)^T[ M6'XO#B$T:112-:FZ3=JD:=J?9\=F9+8UP/-NDJK9=#*Y9(K+ MA@:'I7F+ARX**>!6B[V"Q@43`S5WR&\KV=JCFQ)OL5/G>#,WLEA=%6%RY".Q9`SVN^8E<,G=:K7&(% M/G9BH,CH3;S(8@_5FTR?31*D M?WZ>1K-I.E^\P84%HJ[`6^[X>F7T@>"FP7?:EOLM&"_1^5A9X.AK_5^IB.=- M;KQ+1N>48!46E^=AG<;3%7O`3,6S9A,T>.TUR?QRK-F>:^)>P9"XQ\8PAMC_ M7H@CG1=[.I^FQ]V$&V.4>?^B3K,]UYP*&J%@:D,4GV"".^QU)#\)=8,PTC@9 M$VR"9C;4C!7;UQ0C1C1Y/Z.?E%',X;1@BU,&(EFVG76OH'V!=:7L(W;DK96%)#@5,GT1S?;T)G"0.GV^YT[K3#CM#]K?`# M`+A_)Q&*"ZW=<>![5_])6?\%``#__P,`4$L#!!0`!@`(````(0#2@))A`PD` M`*(]```9````>&PO=V]R:W-H965T^'PQ[WG(9,L?RR@ M[<6MZ?N_?NVVC9_Q(=TD^X>FTNHT&_%^G;QL]F\/S2C4OPV;C?2XVK^LMLD^ M?FC^CM/F7X___<_]5W+XD;['\;'!,NS3A^;[\?@Q;K?3]7N\6Z6MY"/>LT]> MD\-N=61_'M[:Z<K3;[IL@P/M3)D;R^;M:QEJP_=_'^ M*)(;X.TO:;.S68^MM MGQQ6SUNVW[\4=;4N[U\V;`]X MLS<.\>M#\[LRCI11L_UXGS70_S;Q5WKQ>R-]3[Z,P^;%WNQCUMKL>^+?P'.2 M_.#4>N$AMG"[M+2>?0/NH?$2OZX^MT<_^3+CS=O[D7W=?;9'?,?&+[^U.%VS M%F5I6MT^S[1.MFP#V,_&;L.[!FN1U:_L_Z_-R_']H=F[:_4'G9[">.,Y3H_Z MAJ=L-M:?Z3'9_5\@)4\EDG3S)&R)/$E7;2EJY^Z&''=YCM$I1Z_?4KO]P?"6 M+5%8`XK]85M<[%"G->SWU;OAH/X>*<4N*;U3'F5TZSXI:K$U@U.6;N_F+*Q6 MQ3Z=VZ;;OS5+MV@9_LN_:)ENT6/X+WF>VBW3%KTOZ\S:ZKAZO#\D7PUVA&"Y MTH\5/]XH8YZXZ,:BTYTZ]I_Z->O0/,MWGN:AR1J;==F4%>//1W4XNF__9`6T MSLVD;'J#.]D\%8;7"T^LB0#[>4H\),M,RT21L^I%UC\G,0I2K-@L`N=E2%:K M$,4B,Q%@/T_;6MK!>=F0M'8ABK0+&G!$X+*Q:9LL"U(D<8O`>=O(>KU"%(OX M(L!^GG:'KB8HECD3DC4L1)$U*K*R0)OUP5-'9'4O=<3KQ]&BOW'-^UN1=B(" MEQNKCCIR-WBZ9KJRTZ M&_H^UU+?%P&Y[Y,Z?*IAM!IF6L/HUTQ/[MY/6,%8-,[MF5'E[YC6,?#6,7\,$-4Q8PT37S+GVI*I@UW`W5`774E6(@+A>YI<2 M3S2@T<"4!G0:,&C`I`&+!F9%X'R.5#M#N=?,:QC[BAF12Z%%88K3HE,$+E;> M)2M?UC!N#>/5,/X5,R+;$]0PX35#2CJZ9LX-)G4U=G]R0U?C6NIJ(G#1U6A` MHX$I#>@T8-"`20,6#WR00T3UC!1 M8>CU)+NME;Y2?F.C,EQ]7\:H?TJXDPK'>=KHO)2>`)"@V**10Z M%`84)A06%#,HYE#84"R@<*!80N%"X4'A0Q%`$4(150GIV,;N$Z5"J"X`KA^: M[,KUW+D[Y#YJ(DQ5`4"A03&%0A>BGSUN4#JJVNN1:W1#$H.!TJ'[8A(QZ-%[ M7.M2='N]7I_FF`E1T1YS*&PH%E`X4"RA<*'PH/"A"*`(H8BJA%0`_(D[?<35 M8\_BJ@N!+T4+@=Q4382I^.*?H-"@F`HANGE795V8=D`=YC"@,*&PH)A!,8?" MAF(!A0/%$@H7"@\*'XH`BA"*J$I(A<">8O^#0N!+T4(@Q]F),%6%`(4&Q10* M'0H#"A,*"XH9%',H;"@60H@#`SLKE0\,#LRQA,*%PH/"AR*`(H0B$D*TQT`T MR.D^6RH$/E@E54+UJ2#CM`3(`ZU)CJIJ`!,-DRDF.B8&)B8F%B8S3.:8V"?" MAY;(T6=Q^O#BHO7TQ6?#2`XF2TQ<3#Q,?$P"3$),HA.1&TTN!3X>X-1^70856:1RX*/W=Q0%F*H1RX+\E1HPE]M8%=2E64!B8:S3#'1 M,3$P,3&Q,)GE)+_!Z8VZI3OL.)GY/+ZSOYK!;@)"$F M4261JX*/WMQ0%6*P1ZZ*\Q/X[,P\X>_YH*J`1,-9IICHF!B8F)A8F,PPF>>D M..*5GTS9.,D"$P>3)28N)AXF/B8!)F%.1,N-5'ZO()=65)E$+@IV0+^E*#BG M-Q/D78D)?W\-%04D&LXRQ43'Q,#$Q,3"9):3_%314?A)7O[BYCB+C3 M)28N)AXF?D[R=LEN?>5F"60QO-+E0[R>J)+(5<''Y2Y/%7S\#3]UY6_0EJJ# M#!!/_N$R8:)E-,=$P,3$Q,+$QFF,PQL7,B^I*B#.ZZW=(-M_B6 M*KX`!Z]HB8F+B8>)CTF`28A)5$GD\N##=Y?E`6Z[Q6B??"5U?FTFOY*J&A+, MR),"B8;)%!,=$P,3$Q,+DQDFRZD.WZD.OZD/_].$? M#Y3R MX$-ZE^4!S@YB!/"R+(:EX8FJ4<+\Y`")I@@BK@T&H^Y(I:]<3"4R'/7Z:H^4 MGYZ3BMHR,#$QL3"983+'Q,9D@8F#R1(3%Q,/$Q^3`),0DZB2R%7!Q_=NJ`HQ M''A9%7V%OL'!9@C"&VU(M#R+..4H:G;2D4\Y4YG<=;B1B8ZWQ<#$Q,3"9(;) M'!,;DP4F#B9+3%Q,/$Q\3`),0DSXU-4_=TQ1%F)JJIC-MXL/;_%3O-VFC77R MR:>=#MCUSRDJIL0&RIC-QV(ORI(XFRK[/9NB2N(39XH8S8AK1QWE;&7Q=NG%;,9LA^KMWBQ.KQM]FEC&[^R7>FT^`32@YAC M*_XX)A_9W,7GY,CFQF:_OK.YT#%[S[_38O@U28[%'VS%[=/LZL>_`0``__\# M`%!+`P04``8`"````"$`$2Z.JL\(``"E/0``&0```'AL+W=O*\FN48X"@B#?=VT,2:Q1 M28F9S/S[W6V#V@N'5_=-9K+RL&C:7IS:?OCGUW93^YGLLW6Z>ZPKC5:]ENQ6 MZ4UW6^7!_;K_JV9?>R3YLWM M6/NS]_5'5F3;KFY)MUWN?WQ^ M?%NEVP^6XGF]61]^'Y/6:]O5R'[;I?OE\X8=]R]%7:Z*W,=?2NFWZ]4^S=+7 M0X.E:XJ&EH]YV!PV6::GAY[;5]\OI8_ZZ,8F58;SX]'#OH?^OD*[OX M?RU[3[_,_?K%7>\2UMOL<^*?P'.:_N#4?N$AMG&SM+5Q_`2"?>TE>5U^;@YA M^F4EZ[?W`_NXN^R(^(&-7GYK2;9B/.TYR0[&FJ>LUU:?V2'=_E\@)4\EDK3S).S?/(G2 M;:CM;G]P3Y9.GD4]9VDWVH.NTNW=T1;6ZN,!#4]9.K6+?M8\I.#,N*IBS$G1LAI%/YI$++1Q[-\YVD>Z_UZC8VOC%7. MSR>UUWYH_F2C?96;L3#LY\D,>C*9E-,HLM`*P4<_W[->!/Z28TH!3!,XYZ.&Y!2F2>#0PHP&_")RSDI8%A2B2SD6`_3SUL]KK MR-T8%J;8*"JRG#N7S9D1T%9T!W-RT3MDE-&>,7T6W)CHK(A MC5F4!6U,7"9JMWO:D50![.HG50`_J7;8:;^Z$OA64B70P(0&-!K01>!R3*N] M8*P;C'V#F5XSY%-VKAE2S^XU,SA]0,=C]VXPLQN,?X,);C#S M&TQX@XFNF#X]@5\SI`[B:^9\[9`&.;NUDP9Y]>#F6AK<-#"A`8T&=!$0MZO\ MVF_0@$D#%@W8-#"E`8<&7!KP:&!&`SX-!#0PIX&0!J(B<+X\J6UREET4IKAX MQA%#$4`QAR*$(H)B`45<):0"Z-U5`%P_UMD5_S2XU3X9WF-A MJ@H`"@T*'0H#"A,*"PH;BBD4#A0N%!X4,RA\*`(HYE"$4$1ET1F04;8H&R+B M*B&5`'LZEZX!M]V5\JUH*9"[L[$P5:4`A0:%#H4!A0F%!84-Q10*!PH7"@^* M&10^%`$4>%'\_X5K00R"/( M6)BJ0H!"@T*'PH#"A,*"PH9B"H4#A0N%!\4,"A^*`(HY%"$4D1##8R&T&BWR M_+J`">(J(54!>YO]'ZJ`;T6K@#1R+$Q5%4"A0:%#84!A0F%!84,QA<*!PH7" M@V(&A0]%`,4KU6B[S[-"2@#/HE8>*]6%(2OA.R%UL"RE`MB2G>BX.)BXF'R0P3 M'Y,`DSDF(281)@M,XDHB%P2?V;F\00(%(2:"I*?E`1D@8T6@RH*`1,-9=$P, M3$Q,+$QL3*97B*J01SSG"B+$Q<3#9(:)CTF`R1R3$),(DP4F<261"X//`5T6 MQFV/T(J8.I(+A+R='^=(7/.409>?9$D137)3440:)CHF!B9F3D1[CY<$TEH+ M)[$QF6+B2$WI'#N.M,7%63Q,9ICXF`28S#$),8DP66`25Q*Y//CLT65Y@.N& MF&R2RX),2(T5@2J&_`03#1,=$P,3$Q,+$QN3*28.)BXF'B8S3'Q,`DSFF(28 M1)@L4Q2+P7D&]CB+/58$JBP*2#2<1QWLP,#$QL3"Q,9EB MXF#B8N)A,LO)GSO7QTD"3.;2?H;\+EK^!E"(+R*3##1,-$Q,3`Q,;$PL3&98N)@XF+B83++24\MWO:3>54? MYP@PF6,28A)ALL`DKB1R4?#IO#N*0LS^719%AW3G6*F:()C$F`R MQR3$),)D@0E?>,H'IICH[7?/%S]1$F)1J5C:MTWV;\DDV6RRVBK]Y`M&V=S? MT\,I+%:S1LJ(K>EBWQPG\7%[-%:OQ"?M$?N.?MEK[1'[JGXYSE;+?K\6GR@C MMHJO['5EQ!;FE>.6,F*+[#HPMDOU8OB7>V//;XWW>V'#IA:PU:#89?T_10 M_,)W<%I@_?0O````__\#`%!+`P04``8`"````"$`R_Z7@+T#``";#0``&``` M`'AL+W=OY(L])J3W/M@)-8#9BUG4[WVV\9$[!-)T-ND@`_?WTN5]G.YNM;602O M5$C&JQCAR10%M,IXSJI#C/[Y^_GS%Q1(1:J<%+RB,7JG$GW=_O)I<^;B11XI M50$X5#)&1Z7J=1C*[$A+(B>\IA4\V7-1$@67XA#*6E"2-R^511A-I\NP)*Q" MQF$MQGCP_9YE](EGIY)6RI@(6A`%_/+(:GEQ*[,Q=B41+Z?Z<\;+&BQVK&#J MO3%%09FMOQTJ+LBN@'&_X3G)+M[-Q<"^9)G@DN_5!.Q"`SH<\T/X$(+3=I,S M&(%.>R#H/D:/>)WB)0JWFR9!_S)ZEM;O0![Y^5?!\N^LHI!MF"=%=G_1@F:* MYC!S*-`SLN/\1;_Z#6Y-(8AL!#J(_.\2YC'24<(NC/W[$O*YF;8_1)#3/3D5 MZD]^_HVRPU%!I`6D06=CG;\_49G!-$"L2;30KADOP`(^@Y+I>H(TDC=#QW)U MC-%L.5FLIC,,\F!'I7IFVA(%V4DJ7OXP(MQ:&9.H-8'OLWD>W6\R:TW@NS7! MT5B2T(RJ2=@3462[$?P<0+D"MZR)+GZ\!N./LP+IT-I'+8[1"N8M1A*FYG4[ MW82OD/RL521&`9^=`KN*]*+0\P<,'0BD9CR(%FL0/5V:+#$W[+B1%W>HF'4* M!P2R8(/H>IE!J=[.C'X)=-:XYYV[(32*N:58N(KTEL(A!!.;\#:9%L<(1M_- MR-*-FQB%3;9R%>E0T;,[9-`1X\FTV"7[XL9-C,(F>W`5Z5!QA6QY#YD6NV38 M+W0CL=&P7^E#R14V:*CQ6=-BC\TK]<1('+:^UIMJ3(>2*VQZ[QR]/FBQQ^:W M@9'<9!M*KK`]W,.FQ1Y;;VM:U$@<-J]7TJ&D-W$Z`<.2,3YQC=JC\YHP:34. MGM::WQZ';8F=MPRA\WJ;:\FV&O)I-78G#V#J;Y6LFBV$+Q8S&>SU;P? MKYM(O7!;H+=7.VR6>1LP\ENWU=B`D=^['VCZ0;A\>MD>SV<6>8?/;U\\W`@B MOW\_T%SC@W'>P:?5;B%&?@MCHW'RUP=O9WBHZ25N_N[:,_3)S>?S>C1I-0Y? M7UPMW^B-`PZT]^1ON'5$7I,FC6.,EDWUS_'"JOP6[N<[ASGZFI-<2<6!IK0H M9)#QDS[*8K#N[G9G\_;0W#V`4VY-#O1W(@ZLDD%!]_#J=+*"U`AS3C87BM?- M.7''%9QOFY]'^!-$X=PUG8!XS[FZ7.A37?>W:OL_````__\#`%!+`P04``8` M"````"$`P@T8=JD)``""*@``&0```'AL+W=O:#(]IO#_6IO!_^+)OAGP]__]O=1WW^UKR693L`AE-S/WQMV[?5 M>-SL7LOCMAG5;^4)SCS7Y^.VA9_GEW'S=BZW^\[I>!C[D\EL?-Q6IZ%D6)VO MX:B?GZM=&=>[]V-Y:B7)N3QL6[C^YK5Z:Y#MN+N&[K@]?WM_^V-7']^`XJDZ M5.W/CG0X..Y6^=0/^MRH_&^G_0O-8?FW.U_T=U*D%M MF":?=#/SK/-B7S]OW0_OO^B,KJY?7%J9["A&)P%;[ MGW'9[$!1H!GY4\&TJP]P`?!W<*Q$:H`BVQ_=\:/:MZ_WPV`VFLXG@0?F@Z>R M:=-*4`X'N_>FK8__DT:>HI(DOB*!8P_)!<=`.<)1.7JSD1=.9F+P"WZA\H,C M#CA:3*?A;#&_[`AGNW#AB`.",(NI-_UJR)GRA*/R]$=S;[(,OAAQKOS@B"-> M%2(LT.Y*X:A#O.I"E\H1CLIQ?EV$'B2?S`61A7*>+\8XEKG4I6:\;;=N*ZN&M!"LFI9Q1G::?92FDIV!Y%#3W0Q`.$K"!I?7](9@M[\;? M83GLE,V:VWBN1806(O<%;4R!A`(I!384R"B04Z"P@#'(HK6!-?([M!$T0AN, M:HV`$6$ M/R&&0(6U&ZA$IE!K]"3[WMQ='I$V MTI/,D(0A*4,V#,D8DC.DL!$G=M&W\ZUU))J0]K7:?5O7$!.D;\_D!["%RHU5 MD+B22,3O>LW.)F)(+)%`C(3[L3\/7=D2;82RI8JHZQB=4*#R7`SEK_KMLU"@ M/<18!(L;BT3L6!@22R18Z%Q/&)(J+W[AHJ5QKKQ';.L*.W/W$A7DP]YH:4DW M*6.%8L8&,H[>@A2H!*W$C$/3Y'ND%4C1(!3Q.Y/BB;[%3K`O8I-M#FPU>(GK MCN%^Z,/RM6*;N7D2&2MTC#F4(#3O`ED0@5(\W4VC&X;H.NPP9`MZXSKQ9._B M1""A'L#+12<3KUI,GFQ/2 M/)`$6BNKB]V#L3$BV)U/5V<2;I5R:,.AC$,YAPH'V7E]DNFQ'G%R0 M4.AL)/,%S71M961@4"+TACH&7&B5>3#&'%ONT'(I%%F',5F$'ILS\Z-!5(7 MR-.S^8G6Y))05Y89V>$X2DG(48I!L2>A*1QT'?5#LC,DQ@I#2A7DVVHQ^DQ9 M69U!SJ'"X7+S2+0[MCQ?5!79'3DR*,B^!_$7Y.XM\E1;928Z5E!@'@HD'$K1 MT9:!<67<,>=0X7"Y,HCFZ0899*_ER*#:+]@0S3S33B?RM!7.FO2(E)7=!BIH9M9M@I#7I:)'^H<42:Q,1,@,E2&) MX*M%U)5[TR.363$&!*3X1AV(%02%[7C&$7@_P(-]=-9%RM+(G M5A`X&AD4EWR3(W;\%*WL])!6%E>&5H8K1\AP%0CUI(1H3^V4^$(&V>/+FMC1;O MM^C:D!#)$U:IM17&$2LN)T^4%1RLG"/WX"DZ0M#:JJ=2LQ$S=+2SJ7=$TL06 MZ/C9B&ZE_BTMN4@XJK2$G"JD6G*3"[%R#$R0"4+RN0J\,G07<:K.^W;>,>(, M60QQCI`DGH5D#R@<8E((/LA!T9=%=MR\!JM;;" MF&.?00E"LOF=>>2Y0(KG[=1@+!E:V:FAK"3Q-"275Z`+SQ/QEO$&@3IS=T]7 M$,D34@XB8Z4%XE""$&2ZE7-4)K2"=-%6O%:CE4F=C$,Y0LZ(2[*)%FCUV8A. M&8*UX$I*R]!5[R4Z%J(T[ZJ5E55R8@79735"LOOU)W3S0Q8K[Q`R298AB]56 M(Z3:]2GIY`IDZ)&";Z)^1\+(3M>N71TQ/(TTDQ@IR$D8U2+#P5I.I(0DR"5+S'S! M(LF_X6!FR7!PK1RLYUB*@-[E(;*65_"A,?GES+,\O950>#LU@5[^+ M#[[@_N[A3L/R:[3U?`6O%N%B"?[H!:M'&(&?@2?]*_$0O>],"&>ZRR%L\$08 MSG3;/SD#SZA6XJ$49X,G3BOQB(F?@2_H'KO))%QK^+*NRW>*^ROXYH3SK"&0 MOC@>P]4CO%7I<8#X>L.#Z/J"6\]6\,Z:\\00:()/=V:LE8(O`-^V+^4_M^>7ZM0,#N4S),RD>SMVEM\0 MRA^M>@7[5+?P[1]49OB6"[[U+.'&&PO=V]R:W-H965TWZFJ\X+HIR6UKHMG<-/"M(,?R M=MZ:?_V(OJU,HVGSVS&_DAO>FC]Q8W[?_?K+YI743\T%X]8`AENS-2]M>_SQ=6E9R_=F1FD95 M^.GY1NK\\0IYOR$W+SAW]T.CK\JB)@TYM3.@L]A$]9S7UMH"IMWF6$(&5':C MQJ>M^8#\##FFM=MT`OU=XM=F]'^CN9#7N"Z/OY4W#&K#.M$5>"3DB9JF1PJ! MLZ5Y1]T*_%$;1WS*GZ_MG^0UP>7YTL)R>Y`13BI& M8O[?US+6]Y:K+ M\'X^<2@_W8!8+Q*XFM>S<8>1PHH8F$$'QF M"TY+C2WF9$H6*YBN_H*\S7>;FKP:L*FA))I[3H\(Y%-67GDLN*C%CTH1:I"R M/%":K0DZ094UL']>=L["VU@O4/-%;[/7;9!L<>`6M,`I;:`"H0I$*A"K0*(" MJ0ID(\`"680VL!'^#VTH#=6&9[7GP""6K0C!+;A+H`*A"D0J$*M`H@*I"F0C M0!("-K8FA`/%\O[QQ&N">L%!-*H)VU-6?-_;0.&+PE'*YB!,A!@:$FI(I"&Q MAB0:DFI(-D8D3>#LTC2A1_87-PZE@;T'@Q#`62SD[.LZ4:).)Y[?GB$NE*%0SO8<6;F#,.)N@8:$ M&A)I2*PAB8:D&I*-$4D6:$22+-,;B5K+N3/$@X-KR!TME=R%D4$E/:^*&W\FSA&`R. MG"OD$/L[C^ZGB$-#Q%CG2KC50)]R:.#*.-1QR3+0Z]\79&"W14D&!BEUHARR M!R2L>,Z!#H4\/I>WQKCB$X@X[RX=-7N,8C_:_O+Q2%IX1`*=X;T`'@TQG%%S M>J<_$=+R'S2`>(;<_0L``/__`P!02P,$%``&``@````A``CH5*?M!@``N!P` M`!D```!X;"]W;W)K&ULK)EMCZ,V$,??5^IW0+R_ M$!/(`TI27<*S6JFJKNUKEI`-VA`B8'?OOGW'V`;;D\MM3GUSW/Z8&3-_C\TX MK'_[6IV-MZ)IR_JR,5Y8_[])?RT-(VVRRZ'[%Q?BHWYK6C- MW[:__K)^KYN7]E04G0$1+NW&/'7=U;.L-C\55=9.ZFMQ@3O'NJFR#OYLGJWV MVA39H7>JSI8]G.!6F*<];!\[>G\MJ* M:%7^D7!5UKR\7C_E=76%$$_EN>R^]4%-H\J]Y/E2-]G3&?+^2IPL%['[/U#X MJLR;NJV/W03"6>Q!< M2O\WVE/]'C7EX??R4H#:,$]T!I[J^H6:)@>*P-E"WF$_`W\VQJ$X9J_G[J_Z M/2[*YU,'T^U"1C0Q[_#-+]H<%(4P$]NED?+Z#`\`_QI524L#%,F^]M?W\M"= M-N9L/G$7TQD!<^.I:+NPI"%-(W]MN[KZEQD1'HH%L7D0N-X(U.U]8;+(FL$^I=2$-N,[;@,K8"@<5]-B,!G$0"1`)$0D0B1&)$$DE8FB M">QH2!.ZHS^X<&@86'MP&03`*X<9S>ZI-)@,*B$2(!(B$B$2(Y(@DLI$40D$ M452Z7S'4NA=#)+%CQ(%:D^2QM0H9C(2;CTB`2(A(A$B,2()(*A,E=W@#/9`[ MM59S9P1F7:2U1\1')$`D1"1")$8D0225B9(H;/L/)$JMU409T29YIDWR8"34 M\!$)$`D1B1")$4D0266BY$X;=/G]>;_`J;6:.R,NO(+&`B<++??!:,@=D0"1 M$)$(D1B1!)%4)DKNL!\IN;/>84+[K.Y4YB^[&G*"S&YH,H,>@74.-(@J"2?C M"W./B,^(N^I;#8>XCB99,!@(R4(>9%Q.$0H;#UZT@W&(O7#4F4@&`Q$VE<,J MZM!NZJX\7^KK]^2!'E?HTX=1!>*(G5=Z%?<8^1RY4+IC:3G:VS48K41&H8C% M#@^T#XL$Z@\Y_8@Q1[/EL#TE&*7"L8^ERD.[KH^O',*:-'A1BN?<<61#US(F MZ&HSMA^MA*,_HM&1++76)!!6M%3?M@LRUUX[H3`8'RD2R!Z>,A[1G<$28<4& M(S99:?M?*BSZT50E:=OV@)*LRU.49,B&'5Y24BN5/1FL1B41"H35HI>-++4\ M0G%_K)M(H+FD&@J<""L>>*;-5RKN]X%5@6@3]X!`K.=3!&)(*[6YNCGL";-R MQ]GW.0)'H5D@$#OFT^45"B17$HH5"ZLQ5B+0&"L5Z$:=T"[M`1E84Z?(P)!6 M)]K6NPW*4J:2BLX!TT5"99:I49":MQQ!BC1"!UQ)4Z M8BJLOC>B6EFT^9,E_:E7(#TV:.]`CI2"(TOM6?>CU:@TB^5"^4B":6LEX(ZN MP]Z?BYD6.121Y8IDD:52CD68NX,EPHH-MB+Z.RA5!E/UI3WG/7T_^`YEK2M, MK=!I1^1NEK]#$?*Q58!1B%&$48Q1@E&J(%4+VH/*6MQHJ^2^@9IK?0-#\HF" M(.1C%&`48A1A%&.48)0J2,V9]IYRSG1]V>X$2O'!\'-_C"@[/U#0X/=?N9(!#LD3<\"(2" MG03?\5<>'`G.CQZRL%WX/O1Y[XOT_6`[TK]SJ%S M&P2\$6&PO=V]R:W-H965T MVILX_M#]-XD&0*(%^=/O?ST_G?W8[`_;WG!V.JY?[U=/N97,[^'MS&/S^^9__^/1S MM__S\+C9',](X>5P.W@\'E]GP^%A_;AY7AW.=Z^;%VIYV.V?5T?Z=?]M>'C= M;U;WC=/STW!T<7$Y?%YM7P:MPFS_'HW=P\-VO5GLUM^?-R_'5F2_>5H=Z?H/ MC]O7`ZL]K]\C][S:__G]];?U[OF5)+YNG[;'OQO1P=GS>A9]>]GM5U^?Z+[_ M\B:K-6LWOX#\\W:]WQUV#\=SDANV%XKW?#.\&9+2YT_W6[H#U>UG^\W#[>"+ M-ZO'X\'P\Z>F@_Z]W?P\:/\_.SSN?@;[[7VZ?=E0;U.>5`:^[G9_*M/H7B%R M'H*WWV2@W)_=;QY6WY^.]>YGN-E^>SQ2NJ=T1^K&9O=_+S:'-?4HR9R/IDII MO7NB"Z!_SYZW:FA0CZS^NAV,*/#V_OAX.QA?GD^O+L8>F9]]W1R._E9)#L[6 MWP_'W?-_6B.ODVI%QIT(_>Q$O.MS;W)QJ31Z_":='_WDX!*[QX]4FXNFGYW? MS?F5=W$SONJ/=]GY79W\WG>=-%F:>/2SBS=]S^W==&[TLW.;G(^NI][T5_WB MT3!H`GK4[YWK^Z[4HSRVGI+0RW<&Y2QZDL9WW:;':53C[F-7RPGQZ#^=Y_A= M(\"C%+;W*;F\>9\G)].3;/;V[;"=,=S1W:>*;% MG"W4#%>R"QLL;>#;(+!!:(/(!K$-$AND-LALD-N@L$%I@\H&M0:&E)Y3CF@6 M_#]RI&14CKAW[QAH2;,2PA;LLK#!T@:^#0(;A#:(;!#;(+%!:H/,!KD-"AN4 M-JAL4&O`2`BM+9"0,2UW[N<5SQ'E14\F8XY,S`Z_ZVQHL3U-I*EI,C^9G)(" M9`G$!Q(`"8%$0&(@"9`42`8D!U(`*8%40&J=&#FB]1QRI-;V#RYL2H;61OIQ M2@BN;*W1N"]K)Y-3UH`L@?A``B`AD`A(#"0!D@+)@.1`"B`ED`I(K1,C:Y0@ M(VO],TI9-\GA3KUKR83FHI8N>P:=C-AM`60)Q`<2``F!1$!B(`F0%$@&)`=2 M`"F!5$!JG1BYH->9#^1"69NY:`G-"N[F.9`%D"40'T@`)`02`8F!)$!2(!F0 M'$@!I`12`:EU8G0\O489':_>R4;3M/0YL>E]80Y&7'B M%D"60'P@`9`02`0D!I(`28%D0'(@!9`22`6DUHF1)GI;-M+4OU8I:S,7+='G M!Y`%D"40'T@`)`02`8F!)$!2(!F0'$@!I`12`:EU8G0\/6<_T/'*VNSXEE@/ MB2MK$IR,3I,`R!*(#R0`$@*)@,1`$B`ID`Q(#J0`4@*I@-0Z,7*A=OD?2$9C M;F:C0U-*M[8F75OI$*M3/A`M$?F(`D0AH@A1C"A!E"+*$.6("D0EH@I1;2`S M/6I/J>_O^Q&,F<2E6G$2?M>0M(6`D$4-QU,;( M^,*4C\2*Y6/6$OF$DGEY5,D0Y.XI6P4BT2G2L$-7LV&B9&5.;S@]D MK-VCT@:%[_E.E<\HB:.FYMK44>:(%AV:D+%,N[%5D5F*%&A"96+%\SEHB7S`2^5(<]:NW"EJ5 M6+%\S5J-O)E7M5/]0%[;C:V1UQ89>06T4(5/RKZ55ZO.L!0KOG2_0R/IF8"1 M]$PHCGK/6#NL2*Q8/F8MD4\8B7PJCKJ\]8*:B17+YZPE\@4CD2_%49>W'OV5 M6+%\S5J.O*J][`?RVFY]C;RVR,@KH`5Y./)J/2:78L67[G?(R"O(A^*H]XRU M@$=BQ?(QRB>,I.-3<>R1S\2*Y7/6TO,*5U^*HR8_L9:#2JQ8OC;DS?FJ]L5Z M7MO*^+GZ=.;XN%W_>;>C=9.>EXXGZI@JX%U=O-U=4Q@.>:>*4/;R#&C168U5 MM%-)?0++<^M(5BSOL[QT6,!(\A&ZY6%Y!OF8M40^823RJ5O>6C\SL>*KSUE+ MY`M&(E^*8_-)PX5G*5=BP,HURS3*9J;51KPOTW_L7M_*-'TV>$IUNY\W4MTA M,XG66CQ7GQN9`V+1H?'U*:]+1#X[2F<%C*2S0G2,$,7L*%H)(]%*T3%#E+.C M:!6,1*OLT)3VU]H(MYXDE5A))KO^7A2"Y*^\:YFWGJ!:*'Y^O+ZXL99]E9-T(&$FP4%!/L(BM M]%'H75MS/68KB9@PDHBIH)Z(&5OU1LS92B(6C"1B*:@G8L56;W5HS09-,'/Z MJSJ#/6A&E*`/K/)MJ<(80"T:T5C51K?UIC%7G[BJ`20;CP6B):.K9K1XGC6: M?&Z7U2+HT%BF8,A(^C9BU!SM:!Y8,6HE;"5:*2/1RAB)5HY:!2.YX1)1Q>B- M&ZZYO;EA,YFJ4&$GTZ/#(%TZ>2G_0&[;TH>1VQ9-Y>[G7HN,E:"SHO?QTPAP MK`2=U:1=";QK:XCXK"RS)&`D\<,.37N#16S5.R]CEI>("2.)F+)6;\2,K7HC MYBPO$0M&$K%DK=Z(%5N]U:$U*^-*0&_@CL$SE5<^'CW]CY-&QJQQ=4B;CG-$ MBPYIJ\&2D108?$;:;$>MD*UDHD6,1"MF)%H):J5L)5H9(]'*&8E6@5HE6XE6 MQ4BT:D8XP6D;8^;H%[G`@E:C0)_#2QEGCFB!:(G(1Q0@"A%%B&)$":(4488H M1U0@*A%5B&H#&8NM>CLR%MM?Y*(M]N@K::-@EJH0+3IDEC1&UMYT*5;\INBS MECRY`D;R(AJ*HRS4(R@NBA7+QZPE\@DCD4\[-);AG2'*V5&T"D:B5:)CA:AF MQT;+S!BMG1_)F#*W5K(6T03E;IB/`"TZ9&8,BHMBQ5H^:TDW!(PD8BB.>L:L M-]I(K%@^9BV13QB)?"J.NKQ53<7,[&MH!@S$8HJ\Q&@18>LO%H;VJ58\:7[K"4]$S"2G@G%4>\9:TL8 MB17+QZPE\@DCD4_%49>WMEZ96+%\SEHB7S`2^5(<=7GK?:X2*Y:O6E;DU7UMDS%=`"]H,*TB841[UGK`4\$BO6 MBEE+Y!-&(I^*8X]\)E8LG[.6R!>,1+X41TU^8G5.)58L7[.6(Z^JA*'/U_^I MN*@VEW:ZN]J(7/Z\L])&P*)#OR@NBA7?D<]:TF$!(XD8BJ/>8;`\MY>JU2YC MUA+YA)'(IVYY:_W,Q(JO/FC7E<01%H(ZI-[)M#19#YVY M6/&86@@21ZP?L%5;^+KQ1M8`\-E`]M8!(]E;AX)Z@D5LI0\YK"2RE41,&$G$ M5%!/Q(RM>B/F;"41"T82L134$[%BJ[6]&6ZI1UG/1LU=:X;D9C>]*SLDR(@)$$"UFF-UC$5KU3 M,&9YB9@PDH@I:_5&S-BJ-V+.\A*Q8"012];JC5BQU5L=6K,R3GJ:(?T#YGT/ M^$;&&C%M[4HO5'56&EH@6B+R$06(0D01HAA1@BA%E"'*$16(2D05HMI`1MEC M_+%"56-NY:*M76D=/^^L-+1`M$3D(PH0A8@B1#&B!%&**$.4(RH0E8@J1+6! MS%S03#06V/XG(WWMV-[C=,@\Q#ZQ=I-SL9+%M=4B1T9+M/(1!8A"1!&B&%&" M*$64(E`09PP*X;17`1SW\64R^^(,?#>9UY#-KV=U\\YB<=K1SY;TJHA=3IOQ6>1LH7WT3.V2T8>V MP#.UR\66Q>B*XKBNC':"%,?50OLZBN-JH5T:Q7&U4*&1XKAZDFJ$%,?50N4] MBN-JH4*(ZKA8X< M41Q7"YV:I3BN.Z4#KQ3'U4)G52F.JX6.F5(<5PN=XJ0XKI$84HLZ7HE]0&SI\T#/8XNFL_D]^U? M"FE_.7:']+[NCO07/NCMC?Z6`?U%EPV=3[]0QS\>=KLC_T*=/#S]C9C/_P4` M`/__`P!02P,$%``&``@````A`*4D3&]Z!P``XR$``!D```!X;"]W;W)K&ULK)I;<^HX%H7?IVK^`\5[`^8>5T)7N/@"F(NK>^:9 M@!-2>WIZJ?_]E_=&O5N)D<]IM#M$I>*K^"N+JGX-__^OQ,[K\B/=! MD%1(X10_5?=)8TNQTU"/R]O]?A\"3:[M-#Q4&\V M&MWZ<1.>JE+!O'Q'(WI]#;?!.-J^'X-3(D4NP6&34/OC?7B.6>VX_8[<<7/Y M\7[^8QL=SR3Q$A["Y%GZK/AND;W6I]\)AVT'_"X#,N?*_$ M^^C3OH2[>7@*J+?))^'`2Q3]$*'N3B`J7(?25NK`ZE+9!:^;]T/B1Y].$+[M M$[*[0W+$"H5DM;)]CY/H^%\99&124J29B="G$FGV.T:G2Y5^5;*5 ME6SG)8U>K=WL]/K&_RE)NFG#Z3.K\Z'VK2J[64&:`5G![U;YD)6DS_NJ-,A6 MVS5Z7):^W%DM]:RL]MM=7)>C,AWDXTVR M&3Q>HL\*/3EHW,7GC7@.&:9!68)NG' MH&DT'^L?-+&V6!IX.% M#I8Z6.E@K0._`.ID3^X1C>G?X9&0$1YQ[PX9%$S3#.$(+C+6P40'E@YL'3@Z M<'4PU<%,!W,=>#I8Z&"I@Y4.UCKP"Z!D"#TH?H!Z5)TRH[,,QBZ(F8 MSZQ..624A^0N`9D`L8#80!P@+I`ID!F0.1`/R`+($L@*R!J(7R0ET^A9_3M, M$S+TL*2/W!!\U,F@UE>NY2&Y:T`F0"P@-A`'B`MD"F0&9`[$`[(`L@2R`K(& MXA=)R37*/DJN74^[^#4DHE-SN%.'DK0I/RC8U=9F4![$Q<9`)D`L(#80!X@+ M9`ID!F0.Q`.R`+($L@*R!N(72$`60)9`5D#60/PB*74\Y55W=+R(+G>\)&W*+PJ30'^-Y$'L MSAC(!(@%Q`;B`'&!3(',@,R!>$`60)9`5D#60/PB*7E!.?(=7HCHLA>2%"("F0*9`9D#\8`L@"R!K("L@?A%4NIX>IG>T?$BNMSQDFB3 MH*N]"?*@?!(`F0"Q@-A`'"`ND"F0&9`Y$`_(`L@2R`K(&HA?)"4OQ'K[#C/2 M\+(;&>J4GTD]S0X5E?N!:(+(0F0C,U&IQA&BJH)2& M5GLJ@J47K*.DEXR4]$H5O-'JM8I@:9]U4NFRO6)5^I6]?T7G6_;2-FWNKUS< MEOR5J$F>JBG8;)3']4AL;=+KD**XL6-$$T9B0'T,C%Y?D[$X0#TH;$9*V4'D M,LJ4^X:F/.4`I3QCI)3GB#Q&M]J\X`"EO&2DE%>(UHQNM=GG@%2Y;+=8SA;M MOC)KB[;*U6_)5HF:M"0HV`K[I7F4LA70A'13\RFES;5@%EH1?'88G09XF]6OE&=<1BG/$7F,OFSX@J.4_)*1DE\A6C.ZU7"?`U+E MLL%BC7R'P7))37KLTU`<(IN1F@(.(I>1G`*M9A>LS>Y"*<^XC%*>(_(8W6CR@J\KX24C);Q"M&9TJ\D^ M!Z3*95/%^KMHZC][!\M5?,GK;&&O7CDC.K%,[5/A@TB*'YI;.C0:=*J?Y M@':%CIN?TQ&H\:$XAKZFU#3I&.%*#2V3MJJ1/[?-9[I1O#!LF[1+>H5W3-JQ MN\*[)FTH7>$]DS8WKO"^26MOY)3DFR+MQBN44YLBR\4KE$^:(F/$*Y0.DMJU M*Y3-F2)?PS*4C%$]Z95ZWNMTQ'[>O`7>YO(6GN+*(7@EBQMIOGR1A_3R1Y(E M5B]10H?K:8ZUIW^F""A;;=3HZ?4:10G_H*KK^;]G#/X'``#__P,`4$L#!!0` M!@`(````(0!C9V6K]@(``,H(```8````>&PO=V]R:W-H965T&ULC%;+;MLP$+P7Z#\0O$$)?N:8WZ\^?5GNIGG3)N2'`T.B$EL:TL>_KM.0UTYYL>0._Y%+5S,"G M*GS=*LXRNZBN_"@(YG[-1$,=0ZPNX9!Y+E)^)]-=S1OC2!2OF('\=2E:_<96 MIY?0U4P][=JK5-8M4&Q%)>EO_2!:;W*!#C`LA/%\X1NPO@VG%!_O;(%^B/X7O?>B2[E_JL2 MV7?1<*@V[!/NP%;*)X0^9!B"Q?YH];W=@1^*9#QGN\K\E/MO7!2E@>V>@2,T M%F>O=URG4%&@\:(9,J6R@@3@26J!K0$582\)C4!89*9,Z&3NS1;!)`0XV7)M M[@524I+NM)'U7P<*;5*.RZ9VQPQ;KY3<$]AO0.N68?>$,1"?S@620.P&P0E= M4`(R&@KXO(Z"VYC_I1@8!]&G'=?8@?J8 M=Z2A+_K2:#Z:8W>=\8_K;!9=O0^10<>2@>'Y4/7C4B-X*.4B4]NV_8:! MOCLV$P:1MSCK!A<.)0X1:**N2Z/@^K0;O'XO/B$('DJYR-C-F?- MX+JAPB$R-+,\;2:$UK_`SW5,VJ(/E)SH1-^3EP&!&3)2.82&GHXO1C8)"TK^"-3A6@TJ7@.G($]/_SU[/] M]^?M[>?.Z/'A;'I^?GGV>'O_=&H]+)Y?XV/WY/M\^__/K]7W>[Q^_BXM/]P_W+'YW3TY/'NT7Z]6GW M?/OI0?K]^V1^>P??W7_(_>/]W?-NO_OR\D;G8XO,? MJ^W^3LZHN'DSO3">[G8/T@#Y]^3QW@P-.2.WOW<_?]Q_?OGV[G1V^>;BZGPV M$?G)I^W^);HW+D]/[G[=O^P>_\^*)KTKZV3:.YE)Z]E)P'#>&\K/WO#FS7QZ M<77=10\82MNZ9LO/WG!Z]>9J5G;R@S(:"_ZO7R\[BNB=NN MA?+SN*[=](;R$UV[>3.9GU^:A`1:.I&Q8U-I!I%-0[AODT/RY9?C>C=!RLTO MQ_5O(J/$ME.'RRN3-\%X,;^\KHL8*&9.'-E%#)6)CI57CLX)1HWYI8\Z?5T2 M,6PF.FY&DWAFYW&W+*QN7V[?OWW>_3B1M592N?]^:U;NR<(XP8)@1\YAB?C9 M"B%+@_'RP;AY=RK-E\F_EV7MM_>3J_.W9[_)4G37:SZ.:%S%$@JS[ABW*Q^L M?1#Y(/9!XH/4!YD/;>)#B( M#I.`R)I(1"0FDA!)B61$7E MV_W=+Q]WUE/H+G;#(_7W@U=!H$&RX$T6*$H$*R$RJR$AUKF MM1=Q`Y5&K(`T8JUHZ,L[EPU4MGM7E^?>VM="T`5SY[*YD3YBG-C[;F><6#1U M5M]K_X9`++IQ13R&+VU$HFAHZ)W@ M%*HK.UAOO.4SPW%=D7(@C54H"L0JH7([[&5T`U6PPQ54VHA:4:`1#51N([QK M7@O5SQKACC29#\>,-"/W]G,6>2N2=Z5,$R/WUA*+G+7$ M;\#2_#757TH.*-"U-0QE6@TN1][)C*#2X1L#Z:Q+%`U]T16J;Y>==?/)W+OV M97"CP7(@#58H"@0KH0IV;P.51JR`-&*M*!"Q@>IGW6LAZ(*Y8\44@89KRE\K M+Q@OWA"R2/YLAT5D:?[^+:J9[NU70-KE-=#L8!CU:*KS*H9*?25`ZBL%4E\9 M^\JA4E\%D/HJ@=37AGU54*FO&DA]-4#JJW5\N2DRM:%0BEYY0VE+3,[EH*\Z MV2>1S!W^4FH9)D=S12M&:T81HYA1PBAEE#'*&16,2D8;1A6CFE'#J'60DR.Y M)P_GZ%55NLZ+.XV`!E4Z()T-JQZY5;H;;V>Q5A6F9,0H9I0P2AEEC')&!:.2 MT891Q:AFU#!J>R3)DVZ[6?O'JW123_$7PAY)*W#6EXQ6/?J3*IVJX"N"+UUP M8B"-F*CAX#IRY=VQI*J"^PR^U'T.I.X+-1RZ]^X02E7!_0:^U'T%I.YK-1RZ M]S9$C:K@OH6OSKV;>E,E^_N+JMDA>1>^'CGYMJH!6O6J896.401?>GIB(#T] M"1NFC#(8JJ\<2'T5;%@RVL!0?55`ZJMFPX91"\.1'!U7I9MRE:Y')L1@I^FM MBTM58>"L%`T-O6WE&BJ[[YJ<7WIUG0@"W>3%0+H;2!0%@J50]9N\RPMO_&<0 M:+`<2(,5B@+!2JC">UBH-&(%I!%K18&(#52V>Q=74^]^H(6`][!34]X:SN5P M-;>3>U?9L6+;N9?-96\H=\\Z3L8,KVF<]"JY"]%A>..I(KB77;*JKKT[E1@J M;42B:&CHN4^A4,JF`C"=Z`U6P$154VHA:4:`1 M#51N([RB:0O5SQKA7DY,B>B((6CDWA"TR%NJO$OHTCRC(H:BTB%X0($^KV%H MI]?UQ8TWKB((="['0!HL410(ED+5KXN3V836JK[1&BV'D48K%`6BE5#9:#?4 MM0T$&JP"TF"UHD"P!BH;;'IS<>YUK85B9)TRY:$C!HFM)@UOV$SASJ1??@R6 M"*\%2U7I(!DU]):(-0S[^MVY?XF)(-!;CQA(9V&B:-A*+U@*E0UV>4DU&0@T M6`ZDP0I%@6`E5,Z4I[\Z0:41*R"-6"L*1&R@LMV[NCJG]:5/21?,74RDE<>, M$R/W%A.+G,6$ZG?3@TB'R0$%NK:&H"\'(FB*7 MIV/&BI%[8\6BN79D*84VHQJ@%:,UHXA1S"AAE#+*&.6,"D8EHPVCBE'-J&'4 M.LB=MWZA[D_VH5R0FU+U;0C13DY$\#(UG[.X_-=1Z]#/)C<[UJ6*#IT9\4Y%2E M&>S=:VTD9O>)&@XN#%204Q7<9_"E[G,@+;T4:CAT[]U-E*J"^PU\J?L*2-W7 M:CAT[^U#&U7!?0M?7.R9_3,%NFX."HV6 M`VFT0E$@6@E5>%<*E4:L@#1BK2@0L8'*]F\ZO?)K!BT4733W\GM<259*#H=Q8J/L;[SFR""K9#ZN*2G)0Z3UBHFAHZ-_6 M0&4?G+OV/]&=X;AN+'(@C54H"L0JH7([[/T%:`-5L,,55-J(6E&@$0U4;B.\ MRU(+U<\:X8XT4TEZ?5%E9N3>]<$B;TWR&K7L#8>5-T6!/J^ALM-HY,$Y"'3. MQD`Z9Q-%@6`I5'TP?G`.`@V6`VFP0E$@6`E5'XP?G(-`@U5`&JQ6%`C60-6O M1B,/SD$QLAJ94LL18\169H:%-[,-E&'CK4;>AF>I*EV-1@V]A6`-P[[PQ@_. M0:`K00RDDS!1%#B3*50VV,B#QNH-&(%I!%K18&(#50_ MZUX+PZ\/:[P9EXDX>>""V^]:O@D'*,UHXA1S"AAE#+*&.6,"D8E MHPVCBE'-J&'4.LC)A7DWA#,O_E+AK?/B3A>@0>$-2"\;JQZ9+:3NV/U/I*Q5 MA14X8A0S2ABEC#)&.:."41`6F(IU'#H MWKN9*%4%]QOX4O<5D+JOU7#HWMN'-JJ"^Q:^N*@S_V<*;YT;+]]<>.M53KZY M\-:K9,%'^R,8ZNF)@?3T)&R8,LI@J+YR(/55L&'):`-#]54!J:^:#1M&+0Q' M<&[P/7(V9ARX4U5./$K18,11X4WJ/J-U*7_U^X(`MVUQ4"Z:TL4 M!8*E4-E@D_GUA3>_,B@T6@ZDT0I%@6@E5.%=*50:L0+2B+6B0,0&JKY_-W._ ML-A"P=M2V3JZ"WGX;Y"=W)NU8_4S>A:N-Y0;8ATI8X8\4GJ5W/`%1LN!-%JA*!"M MA,I&&WD6#@(-5@%IL%I1(%@#E0TV]BP<%"/KE*F+'3%(;!EM6)*;CU;6O*W0 M4E6Z3HT:>I-_#<.^),?/PD&@FY082&=AHBAP)E.H;+"19^$@T&`YD`8K%`6" ME5`-I[S\]A8.@"^8N)M+*8\:)D7O7,XN< MQ81*RT$(VN*7)Z.&2M&[HT5BZ2Z@6&PG!-: M,5HSBAC%C!)&*:.,4UQ);LXEN1XYN;"J`5JQ M:LTH8A0S2ABEC#)&.:."4%:,UHXA1S"AAE#+*&.6,"D8EHPVCBE'-J&%DOG7"K#9R"N7D MV/38;Y&PKXM_W#Y_W2ZW#P_[D[O=K^8;(B[,N\`.V'Y]Q+7'&CLBGC"7.6-OD,\,29^R(?`)8XHP=D<_S2IRQ(_*6T(5Y/R:W3=X^ MN3#OEN0C\N+(A7DM)!^1=SXNS!L=^8B\KE'BC!V1MQY*G+&VR3L,)<[8$7DC MH<09.R+O%Y0XW9&SPP26K^GY?OMU6]X^?[U_VI\\;+_((GW>O=;QV7[1C_W/ M2_]JST^[%_F"'KF.RI=^R!7M&N?F_9]?=KL7_$>Z>';XBJ?W_R\````` M__\#`%!+`P04``8`"````"$`$E$4->$#``!@#@``&````'AL+W=O`'6"PV)DY MJ[:2"+4M0U*:]M\O*3FN9#M?E[1AJ$<^DH^6E_?O91&\,:FXJ%8A&<5AP*I, MY+S:KL*?_SU_O0L#I6F5TT)4;!5^,!7>K[_\L3P(^:IVC.D`$"JU"G=:UXLH M4MF.E52-1,TJ^&4C9$DU?)7;2-62T=P<*HLHB>-I5%)>A19A(:_!$)L-S]B3 MR/8EJ[0%D:R@&O)7.UZK(UJ970-74OFZK[]FHJP!XH477'\8T#`HL\6W;24D M?2F`]SM):7;$-E]Z\"7/I%!BHT<`%]E$^YSGT3P"I/4RY\``RQY(MEF%#V3Q MF,S":+TT!?K%V4$Y_P=J)PY_29[_PRL&U88^80=>A'A%UV\YFN!PU#O];#KP M0P8YV]!]H?\5A[\9W^XTM'L"C)#8(O]X8BJ#B@+,*)D@4B8*2``^@Y+C:$!% MZ/LJ3"`PS_5N%8ZGH\DL'A-P#UZ8TL\<(<,@VRLMRM_6B9BD+)9)[8EJNEY* M<0B@W^"M:HK30Q8`?,S)(K19GDH2LD.0!T19A;,P@/@**ONV)I/9,GJ#:F2- MSZ/U@<]/G]8C@FS:E"`--Z7A\APCHS-&QG)A*H_6X(9)AL.,_3#(?`P]/1\. M#X&?2V)RU^+;#*Q/ZOA,6@^/*+A<3Q2=H4DN;+_&ULGU.1$:!L8-C>23*8[= M!?YXSF31UKNQN`4GD_DPX:D?]7RIT=D/92VIF6=W8&#N7#+G8='9AVTL0.1S M,J?Q,`/?L&'RPW(C9+=G!L3 M_'&&:7QBF&Y2-^G+NS$-U+XC#Z"M,XKQ1SL!!E4_'2X M2\E-BC?>G6AV"0Q0ZB@>IXZDD-L%0GWI)XW)'[O/^Y$GVN2F=6"\.X1.K0-\ MNE^_#HQW![E9!_ZL?5Y_?!XH\*O76H+>G6C6--"8@74P!F5(AP<7?M:>+!_M^$;6_P/V^ MIEOVGV.KV&KN;Z:=O>I*IN@6(C*VE?.U)*ZC1^ M+!JE^:8"WR_!E*<'[N[AA+Z6J59&Y=8#.N82/?6\8`L&3*ME)L$!EIUHD2=T M'<1W04#9:MD5Z(\4.S.X)Z94NR]:9M]D(Z#:T"?LP$:I)X0^9AB"P^SD]$/7 M@1^:9"+GV\K^5+NO0A:EA79'X`B-Q=GKO3`I5!1HO#!"IE15D`!<22UQ-*`B M_"6A(0C+S)8)GG66%7_=:#.$7-<76KWW/+54JL= M@7X#VK0(@?B0DV/HLWPO2<@.2=;(DM`Y):!OH++/JR`*ENP9JI'N,7<. M`]0[*"$9E+!>F4<:!F8HC>;#&8[=?_SCN2Z+ MOM[[R+#@030Y;W@V5KU<:@2/I5QDVGUDPX&!N3LV,_47'L`O*^"YL<(^`C/T M-J31]+P97,N#+^>R%(+'4BYR:F8QINTZLX".7N;'4V/^?61LY9UI"&#NK_?2 MH<=B^]"I&]BG(V:T,Y]?,6C=P2,1Y(+0V-+LJ#MN_;H=5PM=B,^BJ@Q)U197 M:PC+J8_V:W\=XDP=QZ?QVOT.6/\&UG'+"_&=ZT(VAE0B!T[?F\-'H-U"=P]6 MM9`H+&5E81%WMR7\>`4L*-\#<*Z4/3R`,NM_Y:M_````__\#`%!+`P04``8` M"````"$`G)MI*.(&```F(```&````'AL+W=O68PMM$:8P&SL_OWJ:8: MW%5@C/=E9FP.Q>'4Y71//W_XEIV\KTE1IOEY[8MIX'O).U+Z'UY^_NGY/2^^E,UG\]-OA MG!?1ZPG>^YO04=S$KC]TPF=I7.1EOJ^F$&Z&1+OOO)JM9A#IY7F7PAL8V;TB MV:_]C^)IJ^?^[.6Y%NC?-'DOG;^]\IB__U*DN]_3&9YB4P-BB>( M;-Y,@3[(HWW76Z\*[VB"?#11UO["]^#V$O+S]46(Y?/L*V@:6\RF!T,1VP9A M4@'T6H[PYB['?M4;*@9LJ)@L&&X;_`)BM]PD>VX7L5RT$,($%!K/Q(!!3>?! M0JS:N$@.,=K!A!2Q'4(0;A!D/#<#7OOPXJTH0@3TR1O$+.MT3L14&,58^Y3X?U7.O3Q;N=2+>BO(;YF7`G)=BHB$& M>1E:G;9P`6%(^H8P$Y##QZ6K[^(<->-H04AR2<1!\0A`B]NU)\Q8?CB_]5V\ M=UEG;BQHJ'D'(51,,\8=GL-Y%CCTR024O#LL"$74*M#=5!.(D"H@=4H)FE$^ MGB`.?I>@ZO!##/(C&;0Y=J^+H4(T@WP\-1S[A-K5,.M';P1BD-J"#`_+S05, M-*E0*IN9W^.YX;1WN0G9(==8@EFI\+%G%G8P`I"Y("FGO!ZR"]'U"\47`Q:# M3PYEGVBN84STBD`H.V89=[JAZQ6:FYD@?B#`[3MSCT%,3J_J4GK,-.[0ZW.+ MSOJ2V('J6ZX(%S(?$.\ARQ!=S]`=Z9(Q0BA208RH^YQ1U^N.1WNS6\5@Q.$HD8RV^^Z*D[`M&K`7;P MI/&S1!HT52_D76$QEIT@TQ\SRQ`W6T(^9`\UFG'C8\YB+#>Y7(3NPRT[UR(F MX%\NA&;V(8^078\(>5-8#/(3JSYVKDF(\/8P-CM@-['-/O9.^?691:<_7#^8 MA`M2759$%[((:8E2$1\R#8GC'E+4;FZ@PMA*SX)`J1;$UEG;00CEQVQCI(Y= M^Q"JTRG4/^@,L3H2B-(#^7[(/V2/?RB^V["@II-A/^R8E^7G^D>]X[@F@\KX MD('(KH$(Q3<=%F2;I9>=:R$#WFMVCFZO#/=(C::#1BB^V["@1KN^W%+(4&[5 M0Q92H]E&0[$&V%C04(\,0DARU4,F4J.Y?GPA;T']^W![$<55L`UQZI(2>\A! M%$Y^UWN%XA9B04UBYP'\Y_E:\]@5%L/)4VIFD#N+^'%S1>'XIQ2YBU@0?[SE MAA$:_F9==:5/&?Z0@Z@>!^FLZRVH(=$OHFLA(AQ(,G.0D4JBDQ`E]56)6JR- M0E##LV>A11!F0%Y#4#%_R$94CXUTMB$69$E*)?LJTO61A5K=WEPJYB,CU>SQ M$\W]I`[=[B.%GI-%O2U/UU"D7-TV/,4<9231'F?1W%GJT`W1E:!;<H@V:T^+>8D'X9+KIQ>02@*8K"TJ.^8O)[?U_XFOT&?C9KD^AQM@BUH(& M&Q+)Y:9DEQ2+;) MZ51Z2^^4 M["%D,%V`7`6>\^*'*K_49Z6O>07GL_6?1SB/3^"`,9@">)_G5?/!'%^V)_PO M_P,``/__`P!02P,$%``&``@````A`+A"&/&ULK)A=CZ,V%(;O*_4_(.XW!`(D04E6DQ`"J)6J M:MM>,\1)T`0<`?.Q_WZ/,3;89S::K>9FF#PW\FJ\D+HI:+4V M[6G;6V!937XA9=9,Z(U4<.=$ZS)KX6=]MII;3;)CUZB\6LYTZEME5E0F M5PCJCVC0TZG(24CSYY)4+1>IR35KX?F;2W%KA%J9?T2NS.JGY]N7G)8WD'@L MKD7[O1,UC3(/DG-%Z^SQ"GF_V6Z6"^WN!Y(OB[RF#3VU$Y"S^(/BG)?6T@*E MS>I80`;,=J,FI[7Y8`>I[9C69M49]&]!7IO1_T9SH:^'NCC^450$W(9Q8B/P M2.D3"TV.#$%C"[6.NA'XJS:.Y)0]7]N_Z6M,BO.EA>'V(".66'#\'I(F!T=! M9N)X3"FG5W@`^&N4!2L-<"1[ZZZOQ;&]K$UG;AJ/I&FC@DF91O[PG>V.D;P[5O;,\FPV7?4.XBA[?B[>XQ=V(A5F;;58U?35@&H"9 MS2UCD\H.;!AI,5;\6>7H_6SP8-28R@.369LP2C`^#53 M&K*3(=(=1/:(1(@<$(D121!)QT0Q"=:*SZ@6)@.3$2[2@)F_4"W8\J#9/9=D MB'0)D3TB$2('1&)$$D32,5%<@M5,<>G]/4$L*RRZ,T,DL>7$A2DK[7%\O4)D MD&@6(K)')$+D@$B,2()(.B9*[OXOYT0B1`Z( MQ(@DB*1CHN0.6X,R[GR?F;!ML;T4^=.6PGA"9N_4PPSV$[[+,!'5DIX,B^L. MD9`3;]EM2Z[MN9IE>QD@+(MZD:5'$Z8YKG84[1$)./'BV84:YVHS:RR"12]0+ M\<,7VZP/2#KF9+:0-B:(I&,=Q1-8W!1/WJF,4>XL6LV=$P?VM"$OWU?':"># M1%ZA)$,S>Z$=5/9]$+/^9;-PM9&/^MNNS/L@544_L21W^DF4?I;3I?KTZ;@? MQ3MVDOL%\[IPU;T>.3"A1_9I,V,;=KRZ;A6L&<:35E[91[_J&$#48)!L*M!=1 MO)[\I59ND;@_*BB!!N$8HT0@+CS7EZA4W.^$58/867!LT/]:L.$M$_G&T6Q8 M.'9]%-2:<"3LD3LN/SP-110??V?JZ1-1*(\KB_<_ZBP6,G<[2T14WYFMKR7L ME9HEZXRJC;\B\Q>NDM1GLB/7:V/D])F]_D*#S4IB_FZ^]0(X0(`/.O<#V%PQ M#^(\OX(">$I`DX+>58K5=6U?9T-!J(E&"79W;MO MWW%L)[&'HTNU;R['SS/CS-]C,WA77[^79^.-5'5!+VO3'HU-@UQRNB\NQ[7Y MU[?PR\(TZB:[[+,SO9"U^8/4YM?-K[^LWFGU4I\(:0R(<*G7YJEIKIYEU?F) ME%D]HE=R@9$#K&:567$Q>02O^D@,>C@4.?%I M_EJ22\.#5.2<-?#^]:FXUC):F7\D7)E5+Z_7+SDMKQ#BN3@7S8\VJ&F4N9<< M+[3*GL^0]W?;S7(9N_V`PI=%7M&:'IH1A+/XB^*S)(7L]-W_2]Y@4QU,#RSV%C%ABWOZ'3^H<%(4P(V?*(N7T#"\` M_QIEP4H#%,F^M\_W8M^KO"$I_"%#=9.",_'WG0I'.'YR)O:4#I\)5D-B=6ZKZK%:Z$M+3]KLLVJHN\& M[%=8]?J:L=UO>RRN+"I>"EV9_:S*H+Q8E"<69FV"=%!(-6R-MXTSSQ""A5F;\.^@2"9JYEMA`SNB M,YJJ)KO.I%,'D0"1$)$(D1B1!)%T2!21X)SZ#)%8&-B,\.@$P%N)&TWNJ=29 M="HA$B`2(A(A$B.2()(.B:(2',J*2K>_O.2QPJQ;,6026TY<.*D&\KA:A71& MTLU')$`D1"1")$8D020=$B5W^(9Y('=FK>;.":RZ3&N'B(](@$B(2(1(C$B" M2#HD2J+P/?!`HLQ:3903%\[EP2+KQT!G)-7P$0D0"1&)$(D121!)AT3)G77; MPR_4^P7.K-7<.9DJN=MSK<`[HRYW1`)$0D0B1&)$$D32(5%RA_-(R9TW$Z,Y M[(CF5.0O6PKK"9G=T&0"30-O)5@051)!^F_0'2(^)]-EVWNX]M35)`LZ`RE9 M*(+TVRE"8>/.B[4TKNW,M:,FZ0QDV'085E&'M5=WY?E&KS^3!WIEJ4\;1A5( M(*?]_="JN,/(%V@*I=MO*U?;5D%O)3,*92S^BX`U9I%$_8RQ0)-%=SPE&*72 ML8VERL/:L(_O')N9:S)PY$`;TR!(HGZNN$=WYDJD%9]K.5ZJ2:1RO)U+E9$U<0_(R'L^Z#>D&EN; M(P>.]X&,VG[:]5;2T<:C:UM3Q".=X73231K'NC&*-$(A[876A]9"K' MV\"J0*R#>T`@WO`I`G&DU=E"7:*=W5GU`B$42"N^T+.E5G2A'._7)Y)H6%0H M<"*M>."Y?G"EK[T_1%?;GR$Y80:WU(G$K=UA^-S:C ML.+K[XRG:#=R`V=860+UD\5B_ON3)=)*3&;K9THJT[A1;:P;O"?F!P]]WE3" M/%*G+;OZ`8&'[2!&/D8!1B%&$48Q1@E&J8+4G<<:QJ$6-_J`X1<=[R^5G#E2 MO[*82'#:K#O-K MU*T]E_>H^LC4@Q]7D)_.9Q[\%KG!(5#;-.KV"P]ZV!OV-DP`Y7MK!*:`1<8C M_M*#UA+S>.E!;X@Y=&$>Z['P"#10'NN8\`A<+#^UA[V>![MPOF&_=3RXRL%Q MMA,/KB\P?W*])U@)/+!U/?@E#]SJ9H8+Y6MV)+]GU;&XU,:9'&`9QVV+7_$K M:?ZA$;WL,VW@2KEM:T_PIP,"S>-X!"?7@=)&?F`3='^,V/P+``#__P,`4$L# M!!0`!@`(````(0!-J=SMK@L``+\W```9````>&PO=V]R:W-H965T]Y\O#[4__-7\$>W7CLZF_'XV>_T3BLWM;;Y>%F][G^H"LON_UV>:3_[E\;A\_]>OFNU[:H?O7[L]LNO[_3'W?*RIMBE/)@-?=[MO1AH]&T0W-]3=09Z!=%][7K\L MO[\?L]W/<+UY?3M2NCOT1.;!^L]_#]>'%=4HV=SX'>.TVKU3`>C?VG9CF@;5 MR/)7_OES\WQ\>ZC[W1N_V_$ZMZ2O?5T?CL'&>-9KJ^^'XV[[/ZOR"B_KXA%2;LPH4\4Y:0D%=&IG/DST&=QX]U-V^_<=?/H%3?>%C?2 M)R)6/N9=H:?/0N]Y-]U.IWW;O:/@%9&HN^5%I$]$^KUGZQ4WTN=US^914[*9 M-6VJ2-K5.?&06?/'=27W6B@`_5&6G9M616UY:`KF#T2MK%_3Y.W3&H3YX\I'1(OPN$FZWS5L)\['A.'RN'R\W^]^UFB@ MI5YZ^%R:8=OK&V.,!O;QR_'ATO!`XX)Q^6)L'NKT3-3Q#S2F_7CT>_Y]XP>- M0ZM"\Z0UGJL80&$&'6,[E&`D02#!6()0@DB"B013"6()$@EF$LPE2"582)"= M@`:EI\P1=:1_(D?&QN0(M?L$<)(TD1`H<,M0@I$$@01C"4()(@DF$DPEB"5( M))A),)<@E6`A078"G(30\/1/),38/-3IWY-.TW(S\%1H:#`O11U7,B@E9984 M&2D2*#)6)%0D4F2BR%216)%$D9DBR4.!5/ZZHK*MZHW8JW1'0".8V4(F1GJ,A(D4"1 ML2*A(I$B$T6FBL2*)(K,%)DKDBJR4"0[)4XN:(U\12Z,VLV%)>TV=P)%AHJ, M%`D4&2L2*A(I,E%DJDBL2*+(3)&Y(JDB"T6R4^)4/$VF5U2\4;L5;TF'%MD\ M$WAW8B8H164G4&2D2*#(6)%0D4B1B2)316)%$D5FBLP52159*)*=$B<7YJC@ MBF3D3GAXZY:J#1L$"MCCT;:'IBGS-B`9P#V-B#0W,> M,`;B8"'?F)\Z-#UQ[!"Q`,X3V+#S%(B=8[ZQ[LIM9L4ZM2^]?N\U)JZ;"US*W=[3JYMTQ3;S;&38HM\RB$GK]=U1]B! M.9FE%),*Y1LRXAN]KCC1&T%EAI`?CU[+OVNZU@$4/*2,@3A:R*@B6@15$:WC MR0>90,'1ID`<+694$2V!"M%NFV+HF4'!T>9`'"UE5!%M`16B^;Y(4@9%'LT= M(B_%9?1[/3>7`[K#-),6=XEA@>P+K7QZ&`'Q MY!D`=(53YR['<*P)BKPD0>TVU5PP5>R5`[#4#8J^Y]DJA8J\%$'ME M0+F7FQZSX[XB/7:#3G[HC$_F98;MGYR>5E-TM0&K<.-0HQ&0G:K;GG`)<)W# MCX&X48<:14#%&J`KVN\$U]EX"L3&L48)D#7NMH7Q#-?9>`[$QJE&"R!KW.N* MU5R&Z[FQFU*SE[\BI7;K[Z34(J?'M9IB?!V8-U`F\=STAAJ-@.[R45A43X"K MW,C'0&P;:A0!65NYI)O@,OM.@=@WUB@!LKZ^6';-<)E]YT#LFVJT`+*^+>&; MX?*9#FI.`Z[(ICT\<+)ID3/-MN1\,3`O!>4TJ]`(*MLJ6ZI_%G=P:Q_C#F[M MH4814-$_A>\$E]EW"L2^L48)D/6]%;XS7&;?.1#[IAHM@*SOG5AP9KA\IG.: M,X8KTFF/))QT6B0ZIVA0`_,^579.A490]8JMT9W8W@80<'L?`W%[#S6*@.#< M$N/7!`)VG@*QG)Y>Z948%$KQ/C MR8!5Y2I'HQ$0#9;EOJ?5%,TX@(IZ;:GRND(UAHI;=JA1!.1&%,U[`E5EQ"E4 M'#'6*`%R(XI!8`959<0Y5!PQU6@!Y$84"XX,JDL1G944G0Y M.8EZ)<4J;C;%T1:W^!%4M-XN&T2K*?9!`52T'2I59YJ-L@]Q(T>,@"HC3J"J MC#B%BNUCC1(@)Z+&&D5`;D2Q M0IE`51EQ"A5'C#5*@-R(8O*<0549<0X51TPU6@"Y$<7HG$%U*:+;;.396O5) MB:\/U`IDHI9]O]44%3]@%3<;=<8V@LKM%V+*"*"ZU"^*9J/L0]S(G3,"<0,#.4R!VCC5* M@"Z5>08!.\^!V#G5:`%TJ#2! M,P>;`G&P&#:5P1*H+CW9#,X<;`[$P5+85`9;0'7IRWZ[WK^N!^OW]T-MM?MN?BU#J]/'^Q+;G_(\=?I9OC>6_+:?Y466_*Y/7SRB M%B%YMT_?BSG#>WWZCH;F]$JV;UZXZBOT-K5OWI7J*_0BM&]><^HK]`ZS;]Y0 MZBOT4Z4OY_@3_80I?P+2=PO([=P5^FX`5=:Y*_1NG^+D5QIE$>CG M4Y_+UW6RW+]N/@ZU]_4+-9AF/M;L[0^P['^.Q8OZK[LC_6Z*9A'Z/0;]4&Y- MAT?-&YI%7G:[(_Y#V6B4/[U[_#\```#__P,`4$L#!!0`!@`(````(0":LH*@ M?PP``$`Y```9````>&PO=V]R:W-H965T\?MJ]/M_W__.7_<=7O M'4^KUX?5R_YU<]O_>W/L_WGW[W_=_-P?OAV?-YM3CQ1>C[?]Y]/I;3(8'-?/ MF]WJ>+9_V[Q2R^/^L%N=Z-_#T^#X=MBL'DJGWJVWN'S>-M_XLS*=R+_N#NINR@_VXW/X_&W[WC\_[G_+!] MB+>O&^IMRI/*P-?]_ILR#1\4(N>!\/;+#.2'WL/F]KO_54:.EJI$1EJ$?D.$-3K\*$(9G'YK MO^NS2^?\>GA)I,./!F_I1[^UW_C,&9U?J$ON<+O6;O1;NXW.W*NQ,_Z=HT.] M4P94?VC7BP^Z#N%*?WSF8IT+.-(?VG'XD;MT+N%(?VC'JP['034BR@'FK4ZK MNYO#_F>/9BWE_/BV4FN`,W&HJS&TJAZN!]M[8XT&F5+YHF1N^W0M-(R.-$%^ MW`TOAC>#'S2HU]KF7MHX38LI+-0(5K*>#68V\&TPMT%@@]`&"QM$-HAMD-@@ MM4%F@]P&2QL4!AA0>NHOAYCCB@O6GF-.>*Z MHV:'WVL;6KSJB31NFDQKDSHI@LP$\069"Q(($@JR$"02)!8D$205)!,D%V0I M2&&21H[H,25RI)Z9GUS8E`RMC?2K3LCPPLY:933LREIM4F=-D)D@OB!S00)! M0D$6@D2"Q((D@J2"9(+D@BP%*4S2R!HEJ)&U[AFEK,ODH%/O*S*BN5BGRW4O MK1E4&\'-$V0FB"_(7)!`D%"0A2"1(+$@B2"I()D@N2!+00J3-')!6Y)/Y$)9 M-W-1D3%M*HQ<7%FYJ(WJ7`@R$\079"Y(($@HR$*02)!8D$205)!,D%R0I2"% M21JYH)W5)W*AK)NYT(0?_E-!O(J,FOFZ;N9K5ALA7[X6NJ[W%7,A'=1>QE`8 MGC>EP]H(T@LA'0GIN"+C\O15;AH305*ADPF=7'@M!2E,G49ZJ,\^D1YEW4Q/ M1=SR%%C>Q%00KR(CVI/P=!I:.^A9;80^]+50=993F^JYD`YJ+U/:V@N&M1&D M%T(Z$M)Q[65*6YE/:B-(IT(Z$])Y[65*6X>.96T$Z<*4;B21'M^?2**R;B:Q M(F82!?$J8B71VD[,:B-P8AU20T&6* MZHA-VWF$O'@)-G=H*%^7 MEK(/&5XWYD!N/28"1AW!0EB9H]"YLN;Z`E8<,0+BB#&CCH@)K#HCIK#BB!D0 M1\P9=41-RH^O\E5YH3&`*D0?TO!ENR-KGS$E MCW+J\V'"DV@&=%F.%L>Q1I./=EXMYAH->0H&0-RW(="P'E(+J17!BK5B(-9* M@%@KE5H9$-]P+M$2Z)T;+M!>WG`SF33D1#(=^NQ)IQ-+^2=RJQ2M#5N%QGSW M4U7H4VLX(T^C,4WU>@EI60FTUJA:"9PK:XCX4.99,@?B8,&'@H6PHIC&)8F5 M0-\+1XQDQ!A:G;>7P*HS8@IYCI@!\3WFT.J,N(35>QU:0+EE)5#5$'LE<,:\ MY?>Q&P\.8CE.)/(VJ#W;+_>,,B.LH/I`YVX5\`"N> M:"$0:RV`6"O2R+C4&%:LE0"Q5@K$6IG4RF'%6DL@UBJ`6B:X*HF8.?I-+G0% MQ;*CV,/(EF$OD2S24*)`HE6D@4211+E$B42I1)E$NTE*AH MH.9BJRH;G\A%50AIS`M=&^%MX51])JQ64D:>1LVCKVN=36=LA;SZT.(GUQR( MY0-VY%71%<5"MH+\`EHL'P&Q?*S1D(=W(E$*1];*@%@KEXY+B0HXEEK-C*DR MQB07 MT&+Y"(CE8W8TY:UJ0L)6D$^AQ?(9$,OG[&C*BR-LU:O4A9`OH"7S2K/E,WDM MS9M[&HV,:3>5R-/(RJMUH)VQ%2[=AQ;WS!R(>R9@1[-GK"-AR%:07T"+Y2,@ MEH_9T92WCEX)6T$^A1;+9T`LG[.C*6_MYY9L!?D"6BUY586AC\]75U:;-*(0 M"#>5R-/(RJM=7&0K:/G0XIZ9`W'$@!W-GK$6\)"M(+^`%LM'0"P?LV.'?,)6 MD$^AQ?(9$,OG[&C(CZS.6;(5Y`MHM>15E3#,O%9O0?%.\T/%156=H$>EN3QK MU$BW+I?P'7G:ZC?%1;;"'?F0YPZ;`[%\P(YFA]G+,UM!?@$MEH^`6#YF1U/> M6C\3MH)\"BV6SX!8/F='75RT+GS)!E`N(-.2:57IZ;1R M1]9:/-6.QH#P-#*+BQ+Y<.3.F@-Q9P72,91H`4?6BH!8*Y:.B40I'%DK`V*M M7#HN)2K@V)*VMJ+0[RN)KBP$::1&2'WF=D?60V?*5AA3'B-VE/4#6%6%KVO' M?L'+AP&?@.9`O+4(&'4$"V%E#CE928051XR`.&+,J"-B`JO.B"FL.&(&Q!%S M1AT1E[!ZKT,+&)3!&KMK*BG+N>[2*[W$NX^II:OVQ)W-5D&D\F2MD%@W+6,VBH4:_*1K"JJIQ M7;M#:]7WHJ-YMWVT.3YOIYN7EV%OOOZLO1M#'6G`D;&VAC=Q$;=.D#^W! M)FJ;)5MH\T)QVFZ>MB(4IZV%-A84IZV%M@D4IZV%3KH4I]Q06'=*AU2*T]9" MYTN*T]9"1T.*T]9")R^*TY9\.C11G+86.N]0G+86.JI0G+86JJ%-5(5,]BB5 MOR9A:PM5KB:J5"5]J`XU484GV4*5'XI3UE'M?J,659*1/E1OH3AM+50JH3AM M+?1^!,5INU-ZM8'BM+706PD4IZV%7BB@.&TM]$D\Q6D;B?2Y.L5I:Z%/R2E. M6PM]YDUQVEH\ZK:V^PRHT]IX3%W6QG/JL#9.KP_1?;2-0'KSA^ZCK85>VJ'[ M:&NA]VWH/MI:O,L)O;$I&ULK)E="HJ(UNWM-$",5$0M(,O/O M]S1--W0?S29;HBR/T\M(U5MM58DN87J(+\\C M]:\?]K>!JN1%<#D$Y_02C=1?4:Y^'__YQ_`]S5[R4Q05"BA<\I%Z*HJKI6EY M>(J2(&^EU^@"WQS3+`D*^)@]:_DUBX)#V2@Y:T:[W=.2(+ZH5,'*/J.1'H]Q M&,W2\#6)+@45R:)S4$#^^2F^YDPM"3\CEP39R^OU6Y@F5Y!XBL]Q\:L4594D MM-SG2YH%3V>X[Y^Z&81,N_R`Y),XS-(\/18MD--HHOB>'[0'#93&PT,,=T"& M7%@.T-]Q])XW_E?R4_J^R.*#%U\B&&WPB3CPE*8O)-0] M$`2--=3:+AWP,^40'8/7<[%/WYTH?CX58'<7[HCV#&15)7P-2_2Y!\: MI%=25,2H1.!:B1AFRQAT]6Z/J'S0LE.U-'E+W6B91K<_*/O_H"7HEHG#M>JS MD?<'[7I5.U@`5;O/]OA0M83KEWK4P50ZQO7X?+9/G0T0^>=KO<*0TE[ACK]X MIWJ?M85_OM8K#"OM]=/CJ]$964[P65`$XV&6OBNP:\"!+8.%#!P9N#)8RF`E`T\&:QEL9+"5@2^#G0SV#:"!/=PCF-&_PR,B0SQB MHSMAH#;-$"V;L@C69":#N0QL&2QDX,C`E<%2!BL9>#)8RV`C@ZT,?!GL9+!O M`,$0V"9^AR%$!AX%C45CZ!W1@4D5`]LA7UE=,63*0[A+B,P1L1%9(.(@XB*R M1&2%B(?(&I$-(EM$?$1VB.R;1#`-MNK?81J1@D%)5_2B+WG!@[@7B,P1L1%9(.(@XB*R1&2%B(?( M&I$-(EM$?$1VB.R;1/`"2JTO>$&B12\J4E<#4T1FE)A0%3;6SD#T:\Z#F%\V M(@M$'$1<1):4Z`^\8%E5I$[:XZV:*3Z(*:YY$$MQ@\@6$1^1'2)[2FB*@CTP M9H(]M*QN]6%M%:Y-71](SSR7!S#9)9)=(5F/MZ*R M*-LU#V"R&R2[1;(^;W4GVQT/8++[IJS@)3S%/_3R1WJ]YR6\F#,SB8IH)B4& M%)GU\C+:XMR=\B"6YPR1>47(Q'D;Z_V!I&%7WYM\(2V0AH.(*ZH.=$EUB517 M2,-#9"VJHEPW2'6+-'Q$=J(JRG7?5!6\)<<&@KDW%F3#Q#)<=+%"!NS4#1O1 MFRWI9Z1"%/>Q;LC0G"'85K@66F@VBQIPK05#M;R#D;ZCR*N3G#:,X0V1;>QMV!]"IGL^\;2Y6A\GBSW/,=C%R&Z![0,7K(VBJ_ M6GG%VM3*'D9KANZDO&'?U\);AFIA'Z,=0_=2WK.`4EDTE;R8-TW]7X]7.#%& M7E/4J9^$TRI*6+DTRJPG[;R*,ONEL4:GAYRE;8QZ[B^PLL-D:F67(:K<@U-C M\0FQ9#*U\HJA6L9C,C5:,W0OYPV3J96W#-4R/I.IT8ZA&SE3'^E).SV(3*+L M.9I&YW.NA.DK.46'E^OQD&-^Q/]8SB>)3\C1/]D(96Y8<'QS@W&ULK)K;;N-(#H;O%]AW,'P_<22?C22#1&=A%U@L9F:O'4=)C+:MP'8ZW6\_ MI%A4%8N*8S?VIMWYQ*+$OU@LZG#S^X_MIO>]VA_6]>ZV'UQ=]WO5;E4_K7X[;\> MCV^+P>"P>JVVR\-5_5;MX,ASO=\NC_#G_F5P>-M7RZ=FT'8S"*^O)X/ME7%]>I]6^V.Y&1?;99'N/[#Z_KMP-ZVJW/<;9?[;^]OOZWJ M[1NX>%QOUL>?C=-^;[M:%"^[>K]\W$#[FZ>UA`!RM[;5\^W_?M@40YG_<'=32/07^OJX^#\OW=XK3^R M_?KI7^M=!6K#/.$,/-;U-S0MGA#!X($:G38S\)]][ZEZ7KYOCO^M/_)J_?)Z MA.D>0T08V.+I9UP=5J`HN+D*Q^AI56_@`N#?WG:-J0&*+'\TOQ_KI^/K;7\X MN1I/KXJ\,Q7:/+?F_U?CC6V_^146!*#U`>9#W(?%#XH'3``65IM(.7_']J@&]2&HWI@X(CE M"<$6/"3V0>*#U`>9#W(?%#XH'2"$@#6OA!A"LG07(,X)'`6E1N2$-^,/Q@86 M0)LX8T^+UJ050Y%$D5213)%"G[:II\ M&1&V0V[>^A']4;]]%A$TV&U(U%7!SL;G?`@(B9`4BHT5W5`U@2<:I>RKX_JQ MBW&OOT-Y]SJIZ1'722B$'T=4OR\)6BL.,+;(#@QF7L^3L!5.__>[81AX^UG* M!HUT1&R$0BCF3FP3F3!1T%K9V!1*V&K:!#+S!$KY<'-G+,/` M?L$-PT^Q\Q8-=1TB.D+>S/FE!$;@:@,K&QVA,039RM(Q<\9J9&9N[GE.V7/' MS&&;<"KD,U<5NO$*!2&W3\`^%*P<%&N4:)1JE&F4:U1H5`HDIQ\["5>++U8H M-1YBG@EY?>',S^+6RLZS0DF@4*I1IE&N4:%1*9"4`3N'"V2@1D/(0$CNG-.Y M+T-K9650*`D42C7*-,HU*C0J!9(R8%_ARO!KQ8"Z$Z$.(;'=*!0'A$;S9DV/ M@O'(6]2)M6#]4H-">D2&CRHR1G:_SNU`+/2C()QZ&W-A+=AUR7XZ-C9L0DX) M=68)H5Y&*$5(**50'!`:0Z*T-3(<>54_L58<4FJ04$NYSXV5L^\7&I7"E\@C MN'HIS^FJTIC+2LH(>A(;X,Q[C!49*_CA`&.#AO893Z)1R@.=I&%D?>5Z8*%1 MR0-UEH#*%\E`#9B;#8V'9GMT9?"ZF,A:61E,,^?V37H3Y8'8*L*JF'CE*N7C MMG',&-D-.[?(7J0Z5\%6GYRKY.-ZO\860BRV+[*)FD$AH^D/87MQLLGK]:+F M/"#VQ,FF=B`KF["56'HS[SXX92NH:.T9`[\MR]C*GC'7J&`DS^C5KY*M/CNC M7*#809ZJ7V=U?2'UH4)I0F.;'I&Q@NMC#6.#)G:M)8R")A4#KW](V8F;B70J MQV_.3JS?@A'Y'7I+IQ1^I4388)Z2Z+P2'U*?*C0B-+3%)S)6#HH-R;.[1,^\K9RN99PH%` M:.[M^X2PF+5U,YRI2MU:<5+$H4()(T@$QY=W?YVR%2S*UJJC4BOW.0]TL\E8 MR3-Z36S)`S\[HRQ#V!.[DOY22QY29RU2D9!3,R/%DY.T!I7`L1<(6]I1(9]9JZH2%2J;1MI<9 MA0K%!CE;4<+(%I:4D5NDE*^P9"T;65\E(%RE\&2BT.%VD&G.Y!@W"9=ZN MB'#FS49DK)S\B>U`SI^$D=UF4D9.?FA?.5O97"P865\E(UV*X+HNDD'WWHT' MM65Y#41DK3CF6*.$$36_D\!OM/FXDQJ,;![D&A6,R/%XY%U>R<<[\@1;6W?- M?)$GU`F[:V/8-L=NGGCE(+)65J!V(*.$K:"`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`C]!T)[@73\+<"8YLB@51&^ MD'Y;OE3_7NY?UKM#;U,]0V)>-Q]N[.D;:_KC:#YW>*R/\&TT]$CPD2Q\"U_! M(Z!K_,;IN:Z/_`=&ULK)U;<]NXLH7? M3]7Y#RZ_[]BZ^:)*LBN6Q(M(BI?:YYQGQU$2U]A6RG(F,__^-`@N-8%%(]', MO(SBCPO=`!H`@1;%>?OO/QX?3G[?/N_O=T_O3D=OSD]/MD]WNT_W3U_>G?[/ M?Z)_79V>[%]NGS[=/NR>MN]._]SN3__]_K__Z^V/W?-O^Z_;[%L?'Y^ M_]T:BW,GW_%QN[SY_N[[7)W]_UQ^_1BC3QO'VY?I/[[K_??]K#V>/[>?KE:?=\^_%!VOW':'I[!]OM M'V3^\?[N>;???7YY(^;.;$6YS==GUV=BZ?W;3_?2`M/M)\_;S^]./XSFS71V M>O;^;=M!_WN__;'O_?MD_W7W(WZ^_Y3?/VVEMR5.)@(?=[O?C#3]9)`4/J/2 M41N!ZOGDT_;S[?>'EV;W(]G>?_GZ(N&>28M,P^:?_EQN]W?2HV+FS;BMQMWN M02H@_SUYO#=#0WKD]H_V\\?]IY>O[TXG%V]FE^>3DQMCHB%4;NQL$1F!;IY061)9$4D M(A(328BD1-9$,B(YD8+(ADA)I")2$VGZQ.EXV48=T?%&[7:\)5-9&@^38'0Y M]2;!083H+(FLB$1$8B()D93(FDA&)"=2$-D0*8E41&HB39\XL9`ML1,+NS]^ M8PY6+U_O[WZ[V4D?RW(SL%!-9!]L=\?&B!NBCNAF;-&1J\-L65HRD;6R%T9O M-[`ZB!#&B$A,)"&2$ED3R8CD1`HB&R(ED8I(3:2Q9-0N)TZ(Y+;+(9)T01>A M_^R^M1'Z]7`9@VZX+!FW28\VI`LB2TLF,JM[X;IP9]WJ(#J$JS-D4Q?FT!.3 MZ>10JF_ZTC6='D0PO2;3&9G.#Z7ZIKV36W$0P?2&3)=DNCJ4ZIOVMD[U0033 M3=^T$V>3<^!`SW0N(M(#^^&$&@58J!QH=: M)HH"SE*HK+/9U85WOEY#H,XR('66*PHX*Z`RZQZ2,*,KS^,&*O58`JG'2E'? MEM>7-52V>9<7Y]YJUT#0.G/'B3E:'S%.[$G<&2<6C9WU]FKB+HH+DV&4M5Q4 M.DX.*-"V%0K*QJ#7FS18.EMR;^JIO'MT#%M:B411OZ#7P2E4EW:P7GN+YQK7 M=47*@-17KBC@JX#*;;`7T0U4P0:74&DE*D6!2M10N97P[G0-5*]5PAUI)D-P MQ$BS"05GI%GDK4C>/7(Q.JATI!U0H,TK%+2SZ&IR[5F.(-`I&P/IE$T4!9RE M4'7.SJ?>PKJ&0)UE0.HL5Q1P5D#5.;N^I,6HZR!U5J*,.JL4!9S54%EGX]ET MY#6M@6)@-3+YB"/&B$U?.&/$(F\U\N;K0DK0:G1`@<:M4/#:+@3CL6]G'A]V4#0.G/7$I,K.6*<&+FWT[3(64O\"BQ,FM+9T90Z:R+@=1CHJAOB^Y0757MK)N.IMZ];PTSZBP#4F>YHH"S`JI@ M\S90J<<22#U6B@(>:ZA>:UX#P<":8M([_;'RES('Y@M&?PA9)-\WX$:SZ%03 MW=LO@;3)*Z#)H6#4H;'.JQ@JM94`J:T42&VMV58&E=K*@=16`:2V-FRKA$IM M54!JJP926XUCRYW.LN@$0_2+!TICQIOF%ME'+&S"8$1HR6C%*&(4,TH8I8S6 MC#)&.:."T891R:AB5#-J'.3&R*1]_OXT,E:\$'6HEX(SWW\;ER>$0E4POX$M-5\"J?E*"_;->QNB6E4PW\!6:]Z9L-(Y`Z$_.DO7 MFG'CW:%>[R\8+3O4S](QBE!0NR<&TNY)N&#*:(V":BL#4ELY%RP8;5!0;95` M:JOB@C6C!@4'8G1A?_U_AH"=98!J;-<4BR!U&.E M*."QALHV;W8Y]LX##02\AS7A=6Z^X6QN*_?F[%"R[=R+YJ(KV,_2*0JT;065 M[*WTP'/MC:8(*KF]J^K*.ZG$4.F!,E'4+^B93Z%R*^'U\AJJ8"4RJ+02N:)` M)0JHW$IX';V!*EB)$BJM1*4H4(D:*K<27M*T@>JU2KBW$Y,BZN__?C($;49) MCO!8<6[&@UDX[Q:Z4!4*+A4%VKR"RDZOJ]FU-ZXB"+1*,9#.Y411P%D*5;S<:UH# M1>O-'20F/73$(+'9)&>0#*;AO!HLQ@>5#I(#"C1NA8)=_N[DP.2`M-^)M M3Z>2CX-U^@HO@GF==3&0>DP4]6W1O:OS:&?=Y&+BK5YKF%%G&9`ZRQ4%G!50 M!9NW@4H]ED#JL5(4\%A#]5KS&@@&UA0_?_>3&P\GZLR7`3(,IMJ0!:,EHQ6C MB%',*&&4,EHSRACEC`I&&T8EHXI1S:AQD#MO974Y9MX:N;YL9!MFQ.+OY37EHPSA:A#O80< M5'K;6';(2\AYJ]9*55B!(T8QHX11RFC-*&.4,RH8;1B5C"I&-:.F0Y*L&34H.!"CXQ)R\D6?OWIVR-F8S$0+IK2Q0%G*5066>R`:;GYJ!0;QF0>LL5!;P54(5WI5"I MQQ)(/5:*`AYKJ&S[QN-+/V?00-%Z7WA=V:US7 MC44&I+YR10%?!51N@[UO@#90!1M<0J65J!0%*E%#Y5;"NRTU4+U6"7>D'9=Y MFW#FK4/>FN15:J$J'6F#*3L::9W*3J.!!^=@6>=L#*1S-E$4Z.`4JLX9/S@' M@3K+@-19KBC@K("J<\8/SD&@SDH@=58I"CBKH>I6HX$'YZ`86(U,JN77$RIF MU^X=S#IDSGZZ7%QY&YZ%JG2,_%+B#06[Q!L_.`>!K@0QD$["1%&_EMZ`3*&R MS@8>G(-`G65`ZBQ7%'!60.7,>$J\0:4>2R#U6"D*>*RALLT;>'`.@M:9NY:8 M--,1X\1FI?IGBXE%SEI"B3<5Z3`9*,>)-Q04<6\4>E_A1%#IK(N!=-8EBOJV M:*QT];*S;N#!.9A19QF0.LL5!9P54`6;MX%*/99`ZK%2%/!80_5:\QH(!M:4 MXQ)OYASIKRF<>.M4O5S,8D8)HY31 MFE'&*&=4,-HP*AE5C&I&38<&$F_FI1`1:L&_>.TP4JH+Y M#6RI^1)(S5=:L&_>VX?6JH+Y!K8XJ3/]9Q)OK1DWWAWJ!7?!:-DA&9NH[(I1 MA(+:/3&0=D_"!5-&:Q146QF0VLJY8,%H@X)JJP126Q47K!DU*#@0H^,2;^;% M(MX-KD/.QI03;ZI"+):*>B/.SV2LH.HV4A?^M]T1!+IKBX%TUY8H"CA+H;+. M1M,K_QU>:RC46P:DWG)%`6\%5.%=*53JL012CY6B@,<:JJY]UU,_L=A`P=O2 MZ7&)MU;NS=JA_!D]"]<5["?>%`4:MX)*=E>'Y5U>>^G^(#:"ZK44D$V\0:5G MQ$21FJ>#5`J56PGO\+.&*EB)#"JM1*XH4(D"*K<2WFEN`U6P$B546HE*4:`2 M-51N);RT>0/5:Y5P=H#FC2[.7B+\2$(K]X;@8&+-NXDNNH*RI.EB-5C0B^L* M!>W\&G@6#@*=S#&0.DL4!3HXA:J;S`//PD&AWC(@]98K"G@KH++>!IZ%@T"= ME4#JK%(4<%9#99T-/0L'Q<`Z=5Q*3D[$=$<;S*QY6Z%%5]!9IP8+TB#I5%U* MCI^%@V7=M\1`.@L318&>3*&RS@:>A8-`G65`ZBQ7%'!60-6?\O3XU@8J]5@" MJ<=*4E: M,E".[B0K%!3QX79&G1E!I;,N!M)9ERCJV_(&9@J5G74#S\)!H,XR('66*PHX M*Z`*-F\#E7HL@=1CI2C@L8;JM>:9%T*W\>RM*?8%S_:%L8_;YR_;Q?;A87]R MM_MN7MX\.Y>?HQ^P?;/TS?AB;I[DDFC3E4NYTB89_"L3*2/'TH$R$RDC*1&^ M(F^P_M!V@6]+WFS=;O-]/A;G`W9N)N)@@'^8SC](A[#CFZF\.GN(S^;-H%[: M-M@T:=E0PVY&)04S-\F'H2O7W-SON,K=:%K\B#/_-T\(H\LS,W3^1P&7G<1OP,79&G5J1'A^HFSZ!(CPY=D2=*I$>' MKLCS(=*C0U?D!Z9S\]-*KIO\<'&^L@DE;RC+;P[GYA>%7$9^+C@W/P;D*_)+ M/_$S=$5^,"<].E0W^?F;].C0%?DQF_3HT!7Y:9KTZ-"5I31TL)W2S*%Z)=+( M(9Y+$X=X)0TNR"NUI!^'KL@+LJ0?VRMGA[#(F^N_ MW7[9%K?/7^Z?]B"/R2$9X?_Z\'[_Q<```#__P,`4$L#!!0`!@`(````(0"F MRL7FJP(``!D'```9````>&PO=V]R:W-H965T>>^W+ZN99-NB):R-4F^,H"#'B+5.%:*L<__IY?W6-D;&T+6BC6I[C%V[P MS?KCA]5>Z4=3.NNV)* M=D"Q%8VP+STI1I)E#U6K--TVX/LY2BD[+$WHIF%9&E38`.N(3/?6\)$L" M3.M5(<"!*SO2O,SQ)LINEYBL5WU]?@N^-Z-W9&JU_ZQ%\56T'(H-;7(-V"KU MZ*`/A0O!9G*R^[YOP'>-"E[276-_J/T7+JK:0K=G8,CYRHJ7.VX8%!1H@GCF MF)AJ(`%X(BGUIC#QIC_B,-YV(L[Z MWO'O]O59#/4^1*#L0U^3='G>\'RJ^G:I'7@JY2-I?VS'!P;.W=C,V[0./*4] M1(#]GX-9>-Z!F[@7WPH'GDKYR*F#Y92V;T>8!HMW^^$V3B4.D4D_9J]OFA]% M_KY+KBO^B3>-04SMW)B)X08/T6$";F)7^-?Q--OTDY$,'V`R=;3BWZBN1&M0 MPTN@#'LOVL\VO["J@\QA/BD+,ZE_K>$7Q.$2AP$8+Y6RQP4(D^&GMOX+``#_ M_P,`4$L#!!0`!@`(````(0!!`$YX<0,``/P+```9````>&PO=V]R:W-H965T M M[]?^G]]/-[>^IS3-$YJ*G*W]=Z;\N\WG3ZN3D"_JP)CV@"%7:_^@=;$,`A4? M6$;52!0LAS<[(3.JX5'N`U5(1A.S*$N#<#R>!1GEN6\9EG((A]CM>,P>17S, M6*XMB60IU;!_=>"%.K-E\1"ZC,J78W$3BZP`BBU/N7XWI+Z7Q``T^Y)MEO[]V3Y$!(_ MV*Q,@OYR=E*U_YXZB--7R9/O/&>0;:@35F`KQ`M"GQ,,P>*@M?K)5."G]!*V MH\=4_Q*G;XSO#QK*/05':&R9O#\R%4-&@6843I$I%BEL`'Z]C./1@(S0M[4? M@C!/]&'M1[/1=#Z.","]+5/ZB2.E[\5'I47VSX*,H\!RF:T]4DTW*RE.'M0; MT*J@>'K($HB[]P*;0.P]@M?^W/=`1D$"7S=1&*V"5S`=EY@'BX'?"D,J1`"B ME3*H#5=&,"IC5G`K#S90EPF[92)7!I,>0>DN&\5%@*N9B,))Q6]W8#&3&F9: M(1RC`!EN%,%0BSIM.\<65,?T2,.YJ$NC^7"&I^N*?UQG=E'ENXQ`VJNZ1F&/ MZLQ5O9QJ!+M2-C(Q=ZE^8.#<-U/)GF-H/^=.VH MF84-D;*'N)9N>RP!JBY\^;011#?4;*C#4D?K"*?3T?RZ)]L;X!97]X>4(=?3 MHL<37O!:,J]XLNW`43MW"-!W>A%^;^K,6*8I&6()%S825X8<2]&XQ]*'F@)I M=X4RU%&FCKX0CB=#/+4[`^EJ#5'/%XQ\J#<8=".#?=V!=+2'^7Q`XS8+&R)= M#2+J^5J&'VH0!NVJG4-1JWV'C0YQ^5`;=(.Z;`LU:CMKV8$F8W+/OK`T55XL MCCA'A3"B5-%JQKL/<6O-^&1Y#Y)X7:HW,'L5=,]^4+GGN?)2M@/.L3E7TDYO M]D&+`C8*$YC0,'69OP>8LAF,*6/L?SLA]/D!!:JY??,?``#__P,`4$L#!!0` M!@`(````(0#YNQ:K^`,``-,/```9````>&PO=V]R:W-H965T\LQY995(>;%W@Y7O.JR(>9(6I[W[W[]/ MG^]<1TA:)#3C!=N[[TRX7PZ?_MA=>?4BSHQ)!Q`*L7?/4I9;SQ/QF>54K'C) M"OCGR*N<2GBL3IXH*T83M2C//.+[:R^G:>%JA&TU!X,?CVG,'GE\R5DA-4C% M,BIA_^*<^?6O*DW^20L&V88Z806>.7]!UZ\)FF"QUUO]I"KPO7(2=J27 M3/[@U[]9>CI+*/<-,$)BV^3]D8D8,@HP*W*#2#'/8`/PZ>0I'@W("'U3W]>]&Y)5$/EK\':>F9!/*2*Z3GP1DN>_M$]@D#0&,1CP76.L5S>W?AA,@WAZ M/XK>(Y7TL*OXU8$S`R%%2?$$!EL`'N8#1-#W'IWW[JWKP%X%%.'UL"8[[Q7R M%AN7!^T"GXU+T'AX$+,)#,'F!T9G#(R)Q9T\:$,[S,=&K##ADC#H#)5I;3X, MPV;[.K+VB5H^-XV'%1ENW#`4=L/@-TMF&-!=!;#$:2A0H]NP'0V0ZE+7T& M&QM6Z<4:VG6JQ7"='<%8['*LA\L1@+#-9Z.\[6"U*>R5),#.GITHY=V!-M(P M`(W=W()6R2)WJ*13@F1T0.5?]V=@3':^;D?RM4@>`MW[T*5-KQA3O_[8RCU. M&]C4A,+J)K="&)--Z&Z$$#9O*Y43T4RKMPEITP"A3JO//M%!O^UKDTUI,T)I MD1@$?34PI@%*G=Y?<.[Z0A`8D\4I\D1AHDQ]40BTJ<^)=!0`.87@_/L( M:I7=KK7)YC/V,E\D#L0H0>O8&=,`'XC?/M"SCQW!A1U*QF13&KDXD$72H+P[ MT>J;`HB%=3$@0](P2^[4RDZ4(76(/BXM=N1%ZH#RV\W@F#J0(768ECNUK$/( MR(5=I)'K!UFD#'QY@> MP%#4ZY]U-'T/4>OL&+7)KDSW)J)'*#UCY*PZL3]9E@DGYA<Z]'.J_Y!T:JDI[8-UJ=TD(X&3L"IK^ZA6-9Z:%,/TA>PMYALN(2 MIBGU\PS#,X/1P4?N1\YE_8#MV8SCA_\!``#__P,`4$L#!!0`!@`(````(0!= MCK!Z_P(``+\(```9````>&PO=V]R:W-H965T<&P(,K4YI94PW#T.=5;QA.I`=;^&70JJ&&?A49:@[Q5EN M%S5U.!Z-IF'#1$L=PUQ=PB&+0F3\3F:;AK?&D2A>,P/Z=24ZO6=KLDOH&J8> M-]U5)IL.*-:B%N;%DE+29/.'LI6*K6NH^SF:L&S/;3^.Z!N1*:EE80*@"YW0 MXYJOP^L0F):+7$`%:#M1O$CI*IK?1C$-EPMKT!_!M]I[)[J2VR]*Y-]$R\%M MZ!-V8"WE(T(?<@S!XO!H];WMP`]%6XK+0[9MARH>260+\!K3N&TQ/-@7BOR3'T*E\3">J09(4L*9U1 M`ODU./NTC)/Q(GP"-[(=YM9AX-ECHAX1@II>$LCP)9VV9Y\9P9@9[4(IMR[@ MI_DO9)`F'J;!RF/HZ?ETN`AP7A%Q$O=E.`4.,_$P28\8*`#(Y84B&)KDTQY[ M[$`^YI74,#!^:BQ^/,6Q>Z-^7&=5]'[O(K[A<3(Y7?!TF/6\U0@>IG*1B9UG M?V!@[OQBSM,B>$B[BT`A_63&R2N^X5GL;9?SJ1`\3+6+N'/"+^'Z/;P('O+N M(L>\$4RT+_CB1MN%PR2[T'0X_=/3K8YPNU_LE$4?9$,"")VHZ5T'1+0[$.S8 MN`VZ#YV@QKWKJ;9VQ?8\?F-CP,5QV)1]"`1X@S4[\,M=%^Y,;K@J^6=>UYID MZ!P_ADOG+75]C_`M='QTK^G:E2M)K4O`#.43"#65?N M`G(?1G9@-5PBTL#%85\K^*/`X4`=!0`NI#3[#\@<]G\]EO\```#__P,`4$L# M!!0`!@`(````(0`F`TY2,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@ MH@0!**```0`````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````"&>TOI-F-(RQ(U.[G$Q!F--X1O+;%0`FBW?R_KNCJC)X_D?7EXOH]R MN=-M\@G.J\Y4B&0Y2L"(3BI35^AILTJO4>(#-Y*WG8$*[<&C);N\*(6EHG/P MX#H++BCP22093X6M4!."I1A[T8#F/HL-$\-MYS0/\>AJ;+EXYS7@(L^OL(;` M)0\<'X"IG8AH1$HQ(>V':P>`%!A:T&""QR0C^+L;P&G_YX4A.6MJ%?8VSC3J MGK.E.(93>^?55.S[/NMG@T;T)_AE??\XC)HJ<]B5`,0.^VFY#^NXRJT">;-G MNS?7)MXW)?Z=E5(,=E0XX`%D$M^C1[M3\CR[O=NL$"MR,DL)2&UL(*($`2B@``$````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````G%91;YL\%'W_I/V'B/>5M)VFK2), M+KB)]1',;"=3]V)YQ&G0*$38B]K]^EV@:6GG(G5OQK[WW.-S+K:#+W>WY>2@ M&U/4U2ER]_^1-C%751I5UI6?>O3;>E_#=?T'6U'O= MV$*;"4!49N;MK-U?^+[)=_I6F1-8KF!E6S>WRL)G<^/7VVV1Z[C.?]WJROIG MT^E'7]]976WTYOW^$=#K$2\.]E]!-W7>\C-K<;\'PF&`]ONRR)6%78;+(F]J M4V_M!-_EN@S\X6(`[+C.?S6%O0^G@3_\#'BN2AT!<+A5I=&!_S01++1J1[X3!V."X^A.>?NP@8/8]L$7HFL/"< M.Q8]XY[0T44)O2%Q94$O2:K>[:(>,G_<0T33&*<Z4!6(82G4Z+S-0O*OCC$TH MYQ+X@B/+)>R#M[G.R"M$F%RC9(7E$B.^8J!E*K@S%D417<%BQY6*!>`S'&&R M1I<)=J>0=`UPE!',98K=6LPIC;^1)!G`$A`QG9-786-\A1D#)1@&_)5[:PPG M;2-FB(EK*1@"P:+6&3=3+FCT_X(F,69S1 MF=%JE(KD6A+.5\#Y0<;6](Q19\IX>[@;U^FY%.H'G`;.(J]8/Y8RW@%N7B]: M8`Q^O!/<\"];80Q__-]VXX];<>94=CSGW)WC_KUEK*TJX#9[/&[;VZ4_J]V. M]PEOLWRDR+CE[OV_M'R,TKCG;OR_/!\K\.HQT$GK%-9Q%CSXX)9U]$R0PQ+/ M[NT7-W525#_-:B_J6%E]?(H\GPSX3C5Z`Y?TLP//UP,CV?PIMH,!?X3^_`\`\```#__P,`4$L!`BT`%``&``@` M```A`)0K:MCL`0``WA@``!,``````````````````````%M#;VYT96YT7U1Y M<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P`````````` M```````E!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`:799%/P!``#G M%P``&@````````````````!+!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"+0`4``8`"````"$`9=K;^=<#``!R#```#P````````````````"' M"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`'2F!MG[!@``\1X` M`!@`````````````````BPX``'AL+W=O&UL4$L!`BT`%``&``@````A`&LDMI@! M!```;A```!D`````````````````_1@``'AL+W=OMM`#``#]#@``&0`````````````` M```U'0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)=SGAE%`P``.0H``!D````` M````````````/B@``'AL+W=O0&>@8D'``!])@``&0````````````````"Z*P``>&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`-R:A1%$"P``5S0``!D`````````````````U#8` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`+K.@OY5!@``L2(``!D`````````````````SDL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`!$NCJK/"```I3T``!D`````````````````6[0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`"\C>0%B#@``:$8``!D`````````````````.=@``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`!)1%#7A`P``8`X``!@`````````````````P04!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+A" M&/&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)JR@J!_#```0#D``!D` M````````````````HRL!`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.1_Q7N<$@``.F$``!D````````````````` ML4D!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`/F[%JOX`P``TP\``!D`````````````````#F,!`'AL+W=O&UL4$L%!@`````P`#`` *`@T``$5Q`0`````` ` end XML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Revenues        
Equipment sales $ 1,353 $ 688 $ 3,320 $ 3,197
Equipment rentals and services 391 375 1,213 1,407
Commissions 5,862 4,659 18,262 14,858
Total revenues 7,606 5,722 22,795 19,462
Cost of revenues        
Cost of sales, equipment 381 282 1,015 1,304
Cost of equipment rentals and services 207 148 665 699
Cost of commissions 1,831 1,229 5,502 3,685
Total cost of revenues 2,419 1,659 7,182 5,688
Gross profit 5,187 4,063 15,613 13,774
Operating expenses        
Selling, general and administrative 5,507 6,591 16,843 17,256
Research and development 172 131 474 403
Total operating expenses 5,679 6,722 17,317 17,659
Operating loss (492) (2,659) (1,704) (3,885)
Other income (expense)        
Interest and other income (expense), net (63) 93 20 120
Amortization of deferred gain on sale-leaseback of building 0 4 0 31
Total other income (expense), net (63) 97 20 151
Loss before income taxes (555) (2,562) (1,684) (3,734)
Income tax benefit (expense) 91 44 35 (72)
Net loss (464) (2,518) (1,649) (3,806)
Other comprehensive income        
Foreign currency translation gain 29 30 64 29
Comprehensive loss $ (435) $ (2,488) $ (1,585) $ (3,777)
Loss per common share        
- basic and diluted (in dollars per share) $ 0 $ (0.02) $ (0.01) $ (0.02)
Weighted average common shares outstanding        
- basic and diluted 157,864 159,018 160,796 157,162
XML 15 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER COMMON SHARE
 9 Months Ended
Sep. 30, 2013
LOSS PER COMMON SHARE [Abstract]  
LOSS PER COMMON SHARE
NOTE E – LOSS PER COMMON SHARE

 Basic loss per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2013 and 2012, because the effect of their inclusion would be anti-dilutive.
(in thousands)
   For the three months ended  For the nine months ended 
   
September 30, 2013
  
September 30, 2012
  
September 30, 2013
  
September 30, 2012
 
Stock options
  1,780   1,810   1,780   1,810 
Warrants
  -   1,500   -   1,500 
Common stock grants
  585   3,260   585   3,260 
    2,365   6,570   2,365   6,570
XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 17 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES, NET (Tables)
 9 Months Ended
Sep. 30, 2013
INVENTORIES, NET [Abstract]  
Inventories, Net of Reserves
Inventories, net of reserves, consist of the following:
(in thousands)
   
September 30, 2013
  
December 31, 2012
 
   
(unaudited)
    
Raw materials
 $844  $909 
Work in process
  519   483 
Finished goods
  691   774 
   $2,054  $2,166 
XML 18 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE M – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GE Healthcare, originally signed on May 19, 2010.  The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.  These circumstances include: not materially achieving certain sales goals; not maintaining a minimum number of sales representatives; and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.
XML 19 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' EQUITY (Details) (USD $)
 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Jul. 30, 2013
Common Stock [Member]
Apr. 30, 2013
Common Stock [Member]
Sep. 30, 2013
Common Stock [Member]
Sep. 30, 2013
Common Stock [Member]
Sep. 30, 2013
Employees and consultants [Member]
Sep. 30, 2012
Employees and consultants [Member]
Sep. 30, 2013
Employees and consultants [Member]
Sep. 30, 2012
Employees and consultants [Member]
Jun. 30, 2012
Non Officer Employee [Member]
Restricted Stock [Member]
Sep. 30, 2013
Non Officer Employee [Member]
Restricted Stock [Member]
Sep. 30, 2013
2010 Plan [Member]
EquityProgram
Jun. 17, 2010
2010 Plan [Member]
Sep. 30, 2013
2010 Plan [Member]
Stock Options [Member]
Sep. 30, 2012
2010 Plan [Member]
Stock Options [Member]
Sep. 30, 2013
2010 Plan [Member]
Stock Options [Member]
Sep. 30, 2012
2010 Plan [Member]
Stock Options [Member]
Mar. 31, 2012
2010 Plan [Member]
Officer [Member]
Restricted Stock [Member]
Sep. 30, 2013
2010 Plan [Member]
Officer [Member]
Restricted Stock [Member]
Sep. 30, 2013
2010 Plan [Member]
Non Officer Employee [Member]
Restricted Stock [Member]
Sep. 30, 2013
2013 Plan [Member]
EquityProgram
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                        
Share issued (in shares)         1,044,332 1,771,000 1,777,386 2,333,500                        
Number of shares of common stock contingently issuable (in shares)       2,400,000                                
Number of shares authorized (in shares)                       5,000,000               7,500,000
Number of equity programs                     2                 2
Granted to date                                     3,790,000  
Granted during period (in shares)                 2,392,500               500,000      
Forfeited (in shares)                   373,500                 945,000  
Vested (in shares)                 2,019,000               250,000 2,845,000    
Number of shares available for grant (in shares)                     1,176,222                  
Options Issued (in shares)                         0 0 0 0        
Stock repurchase program, authorized amount $ 2,000,000 $ 1,500,000                                    
Treasury stock, at cost (in shares)     7,929,432 8,935,430                                
Treasury stock value     $ 1,420,000 $ 1,602,000                                
XML 20 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
ORGANIZATION AND PLAN OF OPERATIONS (Details)
 1 Months Ended 9 Months Ended
Jun. 30, 2012
Sep. 30, 2013
Company
Subsidiary
State
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]    
Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products   48
Initial term of sales representation agreement 3 years 3 years
Amended term of sales representation agreement   5 years
Number of Chinese operating companies acquired   2
Number Of Wholly Owned Subsidiaries   3
XML 21 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEFERRED REVENUE (Tables)
 9 Months Ended
Sep. 30, 2013
DEFERRED REVENUE [Abstract]  
Changes in Deferred Revenues
The changes in the Company’s deferred revenues are as follows
 
(in thousands)
   For the three months ended September 30,  For the nine months ended September 30, 
   
2013
  
2012
  
2013
  
2012
 
   
(unaudited)
  
(unaudited)
  
(unaudited)
  
(unaudited)
 
Deferred revenue at the beginning of the period
 $13,270  $15,198  $15,602  $15,228 
Additions:
                
Deferred extended service contracts
  410   288   848   987 
Deferred in-service and training
  8   13   23   33 
Deferred service arrangements
  30   20   60   75 
Deferred commission revenues
  2,076   2,037   5,355   6,116 
Recognized as revenue:
                
Deferred extended service contracts
  (245)  (283)  (755)  (840)
Deferred in-service and training
  (10)  (10)  (20)  (25)
Deferred service arrangements
  (16)  (22)  (54)  (64)
Deferred commission revenues
  (2,796)  (2,243)  (8,332)  (6,512)
Deferred revenue at end of period
  12,727   14,998   12,727   14,998 
Less: current portion
  7,684   9,418   7,684   9,418 
Long-term deferred revenue at end of period
 $5,043  $5,580  $5,043  $5,580 
XML 22 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES, NET (Details) (USD $)
Sep. 30, 2013
Dec. 31, 2012
INVENTORIES, NET [Abstract]    
Raw materials $ 844,000 $ 909,000
Work in process 519,000 483,000
Finished goods 691,000 774,000
Inventories, net 2,054,000 2,166,000
Reserves for excess and obsolete inventory $ 571,000 $ 576,000
XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER COMMON SHARE (Details)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 2,365 6,570 2,365 6,570
Stock Options [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 1,780 1,810 1,780 1,810
Warrants [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 0 1,500 0 1,500
Common Stock Grants [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of diluted earnings per share (in shares) 585 3,260 585 3,260
XML 24 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
GOODWILL AND OTHER INTANGIBLES (Tables)
 9 Months Ended
Sep. 30, 2013
GOODWILL AND OTHER INTANGIBLES [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
All of the goodwill was allocated to the Company’s Equipment segment.  The components of the change in goodwill are as follows:
 
(in thousands)
   
Carrying Amount
 
     
Balance at December 31, 2012
 $3,212 
Foreign currency translation
  85 
Balance at September 30, 2013
 $3,297 
Schedule of Other Intangible Assets
The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:
 (in thousands)
   
September 30, 2013
  
December 31, 2012
 
   
(unaudited)
    
Patents
      
Costs
 $469  $469 
Accumulated amortization
  (451)  (438)
    18   31 
          
Customer lists
        
Costs
  800   800 
Accumulated amortization
  (238)  (152)
    562   648 
          
Software
        
Costs
  619   541 
Accumulated amortization
  (413)  (386)
    206   155 
          
   $786  $834 
XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
ORGANIZATION AND PLAN OF OPERATIONS
 9 Months Ended
Sep. 30, 2013
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]  
ORGANIZATION AND PLAN OF OPERATIONS
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. The Company since 2010 has been operating in two distinct businesses or segments, the Equipment segment and the Sales Representation segment. In the Equipment segment we design, manufacture, market and support certain medical devices.  Our principal products are Enhanced External Counterpulsation (EECP®) systems, which are non-invasive heart therapy devices based on our unique proprietary technology, and currently indicated in the United States for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, “MI”) and cardiogenic shock.  In addition we develop, manufacture and market certain ambulatory patient monitoring systems including recorders and analysis software.  In May 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, expanded into the sales representation business via its agreement with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia.   In June 2012, the Company entered into an amendment, effective July 1, 2012, of the sales representative agreement (“GEHC Agreement”) extending the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company which owns and controls two Chinese operating companies - Life Enhancement Technologies Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”), respectively – to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio.  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and now operates through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. manages and coordinates our EECP® therapy business as well as other medical equipment operations.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment.  VasoHealthcare activities are included under our Sales Representation segment (See Note C).
XML 26 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT REPORTING AND CONCENTRATIONS
 9 Months Ended
Sep. 30, 2013
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]  
SEGMENT REPORTING AND CONCENTRATIONS
NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in two segments – the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:

 (in thousands)
   As of or for the three months ended September 30, 2013 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $1,744  $5,862  $-  $7,606 
Operating (loss) income
 $(364) $199  $(327) $(492)
Total assets
 $8,398  $8,040  $8,972  $25,410 
Accounts and other receivables, net
 $1,229  $3,510  $-  $4,739 
Deferred commission expense
 $-  $4,145  $-  $4,145 
                  

   As of or for the three months ended September 30, 2012 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $1,063  $4,659  $-  $5,722 
Operating loss
 $(838) $(1,358) $(463) $(2,659)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $6,645  $-  $7,704 
Deferred commission expense
 $-  $3,635  $-  $3,635 


   As of or for the nine months ended September 30, 2013 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $4,533  $18,262  $-  $22,795 
Operating (loss) income
 $(1,489) $870  $(1,085) $(1,704)
Total assets
 $8,398  $8,040  $8,972  $25,410 
Accounts and other receivables, net
 $1,229  $3,510  $-  $4,739 
Deferred commission expense
 $-  $4,145  $-  $4,145 


   As of or for the nine months ended September 30, 2012 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $4,604  $14,858  $-  $19,462 
Operating loss
 $(1,191) $(1,473) $(1,221) $(3,885)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $6,645  $-  $7,704 
Deferred commission expense
 $-  $3,635  $-  $3,635 


For the three months ended September 30, 2013 and 2012, GE Healthcare accounted for 77% and 81% of revenue, respectively.  For the nine months ended September 30, 2013 and 2012, GE Healthcare accounted for 80% and 76% of revenue, respectively.  Also, GE Healthcare accounted for $3.3 million, or 70%, and $8.1 million, or 89%, of accounts and other receivables at September 30, 2013 and December 31, 2012, respectively.
XML 27 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2013
FAIR VALUE MEASUREMENTS [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE F – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

The following tables present information about the Company’s assets measured at fair value as of September 30, 2013 and December 31, 2012:
             (in thousands)
   
Quoted Prices
  
Significant
       
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
September 30,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
  
2013
 
Assets
          
(unaudited)
 
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $8,076  $-  $-  $8,076 
Investment in certificates of deposit (included in short-term investments)
  111           111 
   $8,187  $-  $-  $8,187 
                  

   
Quoted Prices
  
Significant
       
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
December 31,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
  
2012
 
Assets
            
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $9,124  $-  $-  $9,124 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $9,234  $-  $-  $9,234 


The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.
XML 28 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
SHARE-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2013
SHARE-BASED COMPENSATION [Abstract]  
SHARE-BASED COMPENSATION
NOTE D – SHARE-BASED COMPENSATION

The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the condensed consolidated financial statements based on their estimated fair values.

During the three months ended September 30, 2013, no common stock grants were made.  During the nine month period ended September 30, 2013, the Company granted 400,000 restricted shares of common stock valued at $74,000.  Of these, 180,000 shares valued at $32,400 vested at the grant date, 20,000 shares valued at $3,600 vest 50% after three months and 50% after six months from the grant date and 200,000 shares valued at $38,000 vest 50% after one year and 50% after two years from the grant date.  During the three month period ended September 30, 2012, the Company granted 500,000 shares of restricted common stock valued at $130,000 to an officer, of which half of such shares vest in one year and half in two years.  During the nine month period ended September 30, 2012, the Company granted 1,000,000 shares, valued at $250,000, to officers and 2,392,500 shares, valued at $598,000, to non-officer employees in its VasoHealthcare subsidiary in conjunction with the extension of the GEHC agreement in June 2012.

During the three and nine month periods ended September 30, 2013 and 2012, the Company did not grant any stock options.

Share-based compensation expense recognized for the three and nine month periods ended September 30, 2013 was $29,000 and $300,000, respectively, and $328,000 and $559,000 for the three and nine month periods ended September 30, 2012, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the condensed consolidated statements of operations.  Expense for share-based consulting fees with non-employees was $0 and $87,000 for the three and nine months ended September 30, 2013, respectively, and $128,000 and $416,000 for the three and nine months ended September 30, 2012, respectively.  Unrecognized expense related to existing share-based compensation and consulting fees is approximately $124,000 at September 30, 2013 and will be recognized through May 2015.
XML 29 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT REPORTING AND CONCENTRATIONS (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Segment
Sep. 30, 2012
Dec. 31, 2012
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]          
Number of segments     2    
Segment Reporting Information [Line Items]          
Revenues from external customers $ 7,606 $ 5,722 $ 22,795 $ 19,462  
Operating (loss) income (492) (2,659) (1,704) (3,885)  
Total assets 25,410 29,509 25,410 29,509 32,381
Accounts and other receivables, net 4,739 7,704 4,739 7,704 9,145
Deferred commission expense 4,145 3,635 4,145 3,635  
GE Healthcare [Member]
          
Revenue, Major Customer [Line Items]          
Percentage of revenue (in hundredths) 77.00% 81.00% 80.00% 76.00%  
Equipment Segment [Member]
          
Segment Reporting Information [Line Items]          
Revenues from external customers 1,744 1,063 4,533 4,604  
Operating (loss) income (364) (838) (1,489) (1,191)  
Total assets 8,398 8,595 8,398 8,595  
Accounts and other receivables, net 1,229 1,059 1,229 1,059  
Deferred commission expense 0 0 0 0  
Sales Representation Segment [Member]
          
Segment Reporting Information [Line Items]          
Revenues from external customers 5,862 4,659 18,262 14,858  
Operating (loss) income 199 (1,358) 870 (1,473)  
Total assets 8,040 11,319 8,040 11,319  
Accounts and other receivables, net 3,510 6,645 3,510 6,645  
Deferred commission expense 4,145 3,635 4,145 3,635  
Corporate [Member]
          
Segment Reporting Information [Line Items]          
Revenues from external customers 0 0 0 0  
Operating (loss) income (327) (463) (1,085) (1,221)  
Total assets 8,972 9,595 8,972 9,595  
Accounts and other receivables, net 0 0 0 0  
Deferred commission expense $ 0 $ 0 $ 0 $ 0  
XML 30 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) $ 8,076 $ 9,124
Investment in certificates of deposit (included in short-term investments) 111 110
Assets 8,187 9,234
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 8,076 9,124
Investment in certificates of deposit (included in short-term investments) 111 110
Assets 8,187 9,234
Significant Other Observable Inputs (Level 2) [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 0 0
Investment in certificates of deposit (included in short-term investments) 0 0
Assets 0 0
Significant Unobservable Inputs (Level 3) [Member]
    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents invested in money market funds (included in cash and cash equivalents) 0 0
Investment in certificates of deposit (included in short-term investments) 0 0
Assets $ 0 $ 0
XML 31 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
RELATED-PARTY TRANSACTIONS (Details) (USD $)
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended
Mar. 31, 2011
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Director - David Lieberman [Member]
Sep. 30, 2012
Director - David Lieberman [Member]
Mar. 31, 2011
Director - David Lieberman [Member]
Sep. 30, 2013
Director - David Lieberman [Member]
Sep. 30, 2012
Director - David Lieberman [Member]
Sep. 30, 2013
Director - Edgar Rios [Member]
Mar. 31, 2011
Consultant Managed by Director - Edgar Rios [Member]
Sep. 30, 2013
Fast Growth Enterprises Limited (FGE) [Member]
Sep. 30, 2012
Fast Growth Enterprises Limited (FGE) [Member]
Mar. 31, 2012
Fast Growth Enterprises Limited (FGE) [Member]
Sep. 30, 2013
Fast Growth Enterprises Limited (FGE) [Member]
Sep. 30, 2012
Fast Growth Enterprises Limited (FGE) [Member]
Dec. 31, 2011
Fast Growth Enterprises Limited (FGE) [Member]
Sep. 30, 2011
Fast Growth Enterprises Limited (FGE) [Member]
Sep. 30, 2013
Living Data Technology Corporation [Member]
Warrants [Member]
Sep. 30, 2012
Former Director [Member]
Jun. 30, 2013
Genwell Instruments Co. [Member]
Related Party Transaction [Line Items]                                        
Term of warrant                                   5 years    
Number of shares of common stock called by warrants (in shares)                                   4,285,714    
Exercise price of warrants (in dollars per share)                                   $ 0.08    
Shares issued on exercise of warrant (in shares)                                   4,285,714    
Fees for legal services       $ 66,000 $ 187,000   $ 60,000 $ 194,000                        
Term of agreement                 2 years                      
Restricted shares issued for consulting agreement (in shares) 18,500,000         600,000       3,000,000                    
Consulting services                                     10,000  
Unsecured notes payable assumed                                 288,000      
Debt repaid   0 190,000                   190,000     95,000        
Interest rate (in hundredths)                         6.00%              
Receivables due from related parties   (6,000) (159,000)               8,000 6,000   3,000 159,000          
Lease term                                       20 months
Monthly lease amount                                       $ 750
EXCEL 32 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W M83$Y-S@S96,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9!25)?5D%,545?345!4U5214U%3E13/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E)%3$%4141005)465]44D%.4T%#5$E/3E,\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%#0T]53E137T%.1%]/5$A%4E]214-%259! M0DQ%4S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K M#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E M;%=O#I7 M;W)K#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I M=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO M2!296=I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)UEE2!&:6QE3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)U-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S$P+5$\'0^ M)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,C@T-&0P9E\W,#$Q M7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T.38V7SDV8SE?-3@T-V$Q.3'0O M:'1M;#L@8VAA'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DU.3QS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'!E;G-E"!P M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C0\3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPOF5D.R`Q-C0L-CDU+#,X,B!A;F0@,38R M+#DQ-RPY.38@3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA&-E<'0@4VAA'0^)SQS<&%N/CPOF5D("AI;B!S:&%R97,I/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,C@T-&0P9E\W M,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T.38V7SDV8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO"!B96YE9FET("AE>'!E;G-E*3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(&]F(&1E9F5R'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XU,C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'!E;G-E M6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO&5R8VES92!O9B!W87)R86YT/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6UE;G0@;V8@;F]T97,@<&%Y86)L92!D=64@=&\@ M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3H@)U1I;65S($YE=R!2 M;VUA;B3L@=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA28C.#(R,3LL("8C.#(R,#MR96=I7-T96US+"!W:&EC:"!A6]C87)D:6%L(&EN9F%R8W1I;VX@*&DN92XL(&AE87)T(&%T=&%C M:RP@)B,X,C(P.TU))B,X,C(Q.RD@86YD(&-A7-T96US(&EN8VQU9&EN9R!R96-O2`R,#$P+"!T:&4@0V]M<&%N M>2P@=&AR;W5G:"!I=',@=VAO;&QY+6]W;F5D('-U8G-I9&EA2`H3EE313H@1T4I+"!T;R!B92!'14A# M)B,X,C$W.W,@97AC;'5S:79E('-A;&5S(')E<')E65A M3L@ M=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA2`F(S@R,3$[('1O(&5X<&%N9"!I=',@=&5C:&YI8V%L(&%N9"!M86YU M9F%C='5R:6YG(&-A<&%B:6QI=&EE2!R97-T2UO=VYE9"!S=6)S:61I87)I97,N)B,Q-C`[)B,Q-C`[5F%S;R!$ M:6%G;F]S=&EC'0M=&]P.R<^)B,Q M-S0[(#PO9F]N=#YT:&5R87!Y(&)U6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4 M:6UE'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQD:78@3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE&-H86YG92!#;VUM:7-S:6]N M("AT:&4@(E-%0R(I+B!#97)T86EN(&EN9F]R;6%T:6]N(&%N9"!D:7-C;&]S M=7)E2!I;F-L=61E9"!I;B!T:&4@8V]N9&5N2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!O9B!I;G1E3H@8FQO8VL[)SX\ M8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6EN9R!N M;W1E'!E;G-E3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3L@=&5X="UI;F1E;G0Z M(#,V<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M2!O9B!T M:&4@6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE.B!I M=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE.B!I=&%L:6,[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3H@)U1I;65S($YE=R!2;VUA;B3H@ M8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!A;F0@:6YT97)N871I;VYA;&QY+"!A2!E=F%L=6%T97,@ MF5D(&%N9"!R96QA=&5D(&5X<&5N2!B96QO=RXF(S$V,#LF(S$V,#M4:&5R92!A6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE6QE.B!I=&%L:6,[ M(&1I6QE/3-$)W=I9'1H.B`Q M,#`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`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#@V,CPO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXH,S8T/"]T9#X\=&0@;F]W6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX+#`T M,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q,#`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`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L6QE M/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#8U M.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`Q,'!T.R!M87)G:6XM6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXH.#,X/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-#8S/"]T M9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXQ,2PS,3D\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXY M+#4Y-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`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`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M+#`U.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXS+#8S-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXS+#8S-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)OF4Z(#$P<'0[(&)O6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O M;&ED.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI M9#LG/CQD:78@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXT+#4S,SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,BPW.34\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXH,2PW,#0\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M*3PO=&0^/"]T3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXX+#DW,CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXQ+#(R.3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#$T-3PO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#$T-3PO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\ M='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&)O3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P M.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@#L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@8V]L6QE/3-$ M)V)O"!S;VQI9#LG/CQD:78@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#8P-#PO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ.2PT-C(\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXH,2PR,C$\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U M,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX+#4Y-3PO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W M83$Y-S@S96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D M,&9?-S`Q,5\T.38V7SDV8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$)V9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA3L@=&5X="UI M;F1E;G0Z(#,V<'0[(&1I3H@5&EM M97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA65EF5D(&EN('1H92!C;VYD96YS M960@8V]N6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4 M:6UE2!G2!G3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3L@=&5X M="UI;F1E;G0Z(#,V<'0[(&1I3H@ M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA2XF(S$V,#LF(S$V,#M4:&5S92!E>'!E;G-E2P@86YD("0Q,C@L,#`P(&%N9"`D-#$V+#`P,"!F;W(@=&AE('1H2XF(S$V,#LF(S$V,#M5;G)E8V]G;FEZ960@97AP96YS92!R M96QA=&5D('1O(&5X:7-T:6YG('-H87)E+6)A&EM871E;'D@)#$R-"PP,#`@ M870@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!W:6QL(&)E(')E8V]G;FEZ960@ M=&AR;W5G:"!-87D@,C`Q-2X\+V1I=CX\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQD:78@3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE&5R8VES960@;W(@ M8V]N=F5R=&5D('1O(&-O;6UO;B!S=&]C:RX\+V1I=CX\9&EV('-T>6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE M&-L=61E9"!F6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&)O3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[ M)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`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`Q,'!T.R!M87)G:6XM6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXQ+#4P,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXU.#4\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXU.#4\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE#L@ M=VED=&@Z(#4R)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@'1087)T7S`R.#0T9#!F M7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQD:78@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@ M8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@ M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P M=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<^4V5P=&5M M8F5R(#,P+"`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`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N M.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^ M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`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`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`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`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@ M;F]W3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`Q.'!T.R!D M:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3$\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M,3$\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXX+#$X-SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXM/"]T9#X\=&0@;F]W3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/"]D M:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SLG/CQB6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M M:6YD96YT.B`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`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`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L6QE M/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E M969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U M,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3`\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE M/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXY+#(S-#PO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`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`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM M28C M.#(Q-SMS(&-A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@ M3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C M:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W!A M9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A M8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O<#H@(S1B86-C-B`P+C5P="!S;VQI9#LG M/CQD:78@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B M;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T M('-O;&ED.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`W M-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXH,BPV,#8\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXH,RPQ-SD\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M*3PO=&0^/"]T3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@ M8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!D=64@=6YD97(@=&AE M($=%2$,@06=R965M96YT(&%R92!S=6)J96-T('1O(&%D:G5S=&UE;G0@:6X@ M6EN9R!S86QE M6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!R961U8V4@=&AE(&%M;W5N="!T:&4@ M0V]M<&%N>2!W:6QL('5L=&EM871E;'D@2!C;VUM:7-S:6]N(&%D=F%N8V5S(&UA9&4@=&\@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^ M)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B;W)D M97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O<#H@(S1B86-C-B`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`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX-#0\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXY,#D\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXT.#,\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W=I9'1H.B`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`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4 M:6UE2!M86EN=&%I M;F5D(')E&-E2!O9B`D-32X\+V1I M=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE28C.#(Q-SMS(&-O;F1E;G-E9"!C;VYS;VQI M9&%T960@8F%L86YC92!S:&5E=',@870@4V5P=&5M8F5R(#,P+"`R,#$S(&%N M9"!$96-E;6)E28C.#(Q-SMS($5Q=6EP;65N="!S96=M96YT+B8C,38P M.R8C,38P.U1H92!C;VUP;VYE;G1S(&]F('1H92!C:&%N9V4@:6X@9V]O9'=I M;&P@87)E(&%S(&9O;&QO=W,Z/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO M8VL[(&UA3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO M='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`X."4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2!TF4Z(#$P<'0[)SXX M-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@ M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#(Y M-SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\ M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@0V]M<&%N>28C.#(Q-SMS(&]T:&5R M(&EN=&%N9VEB;&4@87-S971S(&-O;G-I6QE.B!I=&%L:6,[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@5&EM M97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W=I9'1H.B`Q,#`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C M8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT-CD\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT-CD\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF%T:6]N/"]D:78^/"]T9#X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-#,X/"]T9#X\=&0@;F]W#L@=VED=&@Z(##L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@ M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF%T:6]N/"]D:78^ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,34R/"]T M9#X\=&0@;F]W6QE M/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU-C(\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXU-#$\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UAF%T M:6]N/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`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`P<'0[(&1I3L@ M=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UAF%T:6]N(&5X<&5N3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U M.#0W83$Y-S@S96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#(X M-#1D,&9?-S`Q,5\T.38V7SDV8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[ M(&1I3H@5&EM97,@3F5W(%)O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@8FQO8VL[ M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI M;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US M:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!4:6UE6QE/3-$ M)W=I9'1H.B`Q,#`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`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q,'!T.R!M87)G:6XM3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE'1E;F1E9"!S97)V:6-E M(&-O;G1R86-T3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXT,3`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXY.#<\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXS,SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U M,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T M.R!M87)G:6XM6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXR,#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`R M-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXU+#,U-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXH-S4U/"]T9#X\=&0@;F]W6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\ M+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXH M,3`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,3`\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C`\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C4\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T6QE M/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\+W1R M/CQT3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXQ-"PY M.3@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXY M+#0Q.#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A3H@)U1I;65S($YE=R!2;VUA;B3L@ M=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA&5R8VES92!P&5R8VES960@:71S('=A6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2`R."P@,C`Q,2P@1&%V M:60F(S$V,#M,:65B97)M86X@86YD($5D9V%R(%)I;W,@=V5R92!A<'!O:6YT M960@8GD@=&AE($)O87)D(&]F($1I2`D-C8L,#`P(&%N9"`D,3@W+#`P M,"!W97)E(&)I;&QE9"!B>2!T:&4@9FER;2!T:')O=6=H('1H92!T:')E92!A M;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S+"!R97-P M96-T:79E;'DL(&%N9"!F965S(&]F(&%P<')O>&EM871E;'D@)#8P+#`P,"!A M;F0@)#$Y-"PP,#`@=V5R92!B:6QL960@=&AR;W5G:"!T:&4@=&AR964@86YD M(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA2!#;VYS=6QT86YT M6QE/3-$)V1I3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y M.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!#;VYS=6QT86YT('5N9&5R('1H92!!9W)E96UE;G0L('1H M92!#;VUP86YY(&%GF5D('1H92!C M;W-T(')A=&%B;'D@;W9E'!E8W1E9"!T;R!B92!P86ED M(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&%G6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!4:6UE2`D,3`L,#`P+CPO9&EV/CQD M:78@3H@8FQO8VL[ M)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF M86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N M="US:7IE.B`Q,'!T.R!M87)G:6XM2!F;W(@)#(X."PP M,#`@:6X@=6YS96-U6%B;&4@=&\@=&AE(%!R97-I9&5N M="!O9B!,150@86YD(&AI3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!C97)T86EN(&]F9FEC97)S(&]F('1H92!#;VUP86YY)B,X,C$W M.W,@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\8G(@+SXF(S$V,#L\+V1I=CX\ M+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQD:78@3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES M<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE2P@=&\@96UP;&]Y965S M+B8C,38P.R8C,38P.T1U2!I2P@86YD(#(L-#`P+#`P,"!S M:&%R97,@;V8@8V]M;6]N('-T;V-K('1O(&9O3H@8FQO8VL[(&UA2XF M(S$V,#LF(S$V,#M4:&4@F5D(&)U="!U;FES6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!4:6UE2!B92!G2!B M92!I2P@96ET M:&5R('1H6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!4:6UE2!O9B!W:&EC:"`Y-#4L,#`P('=E65A3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA M;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM M2`R,#$S(&%N9"!H86QF(&$@>65A3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@8FQO8VL[)SX\8G(@+SX\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I M;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q M,'!T.R!M87)G:6XM28C.#(Q-SMS M(&-O;6UO;B!S=&]C:RXF(S$V,#LF(S$V,#M$=7)I;F<@=&AE('1H6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2XF(S$V,#LF(S$V M,#M4:&4@F5D M(&)U="!U;FES6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE2!B92!G2!B92!I2P@96ET:&5R('1H6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@5&EM97,@3F5W(%)O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3L@=&5X="UI;F1E M;G0Z(#,V<'0[(&1I3H@5&EM97,@ M3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P M,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T.38V7SDV8SE? M-3@T-V$Q.3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3L@ M=&5X="UI;F1E;G0Z(#,V<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA2!C;VYC;'5D960@86X@86UE;F1M96YT(&]F('1H92!'14A# M($%G2`Q.2P@,C`Q,"XF(S$V,#LF(S$V,#M4:&4@86UE;F1M96YT M+"!E9F9E8W1I=F4@2G5L>2`Q+"`R,#$R+"!E>'1E;F1E9"!T:&4@:6YI=&EA M;"!T97)M(&]F('1H2`Q+"`R,#$P M('1O(&9I=F4@>65A2!T;R!T:&5I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3H@ M)U1I;65S($YE=R!2;VUA;B3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[ M(&UA6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;CL@;6%R9VEN+6QE M9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM2!O=70@;V8@ M86-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N65A M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,C@T-&0P M9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T.38V7SDV8SE?-3@T-V$Q M.3'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE M=R!2;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M M87)G:6XM2!F:6YA;F-I86P@:6YF;W)M M871I;VX@9F]R('1H92!S96=M96YT6QE/3-$)V1I6QE/3-$)V9O;G0M3H@:6YL:6YE.R<^*&EN('1H;W5S86YD6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!B M;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L6QE/3-$)V)O M"!S;VQI9#LG/CQD:78@F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-#DR/"]T9#X\=&0@;F]W6QE M/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX M+#,Y.#PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-2PT,3`\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#4Q,#PO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(] M,T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA'!E;G-E/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`P<'0[(&1I6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG M/CQD:78@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UAF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@ M#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M+#`V,SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXX+#4Y-3PO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\=&0@ M;F]W6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[)SX\8G(@+SX\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;FF4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@ M;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[ M(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M'0M:6YD96YT.B`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA'1E6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2PT.#D\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXX+#`T,#PO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T M:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@ M8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`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`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C M8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA'1E6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q,'!T.R!M M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2PQ.3$\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXH,RPX.#4\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^*3PO=&0^/"]T3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXR.2PU,#D\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXV+#8T-3PO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXW+#3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA'!E;G-E/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXM/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X\ M=&0@;F]W6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO M=&%B;&4^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y M-S@S96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D,&9? M-S`Q,5\T.38V7SDV8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@9F]N="UF86UI;'DZ(%1I;65S($YE=R!2 M;VUA;CL@;6%R9VEN+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G M:6XM6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S M='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&)O6QE/3-$)V9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#@Q,#PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`@/&AE860^#0H@ M("`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`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`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`Q,'!T M.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM M;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM M6QE/3-$)V1I M6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXX+#`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X M="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`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`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE M/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I M=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`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`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`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([ M('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I M>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL M93TS1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I M3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T M;VT@#L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@'0M M:6YD96YT.B`P<'0[(&1I3H@=&EM M97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!M87)G:6XM6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQD:78@3H@5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M#L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O M;&ED.R<^)B,Q-C`[(#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R!B;W)D97(M=&]P.B`C-&)A8V,V(#`N-7!T('-O;&ED.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L6QE/3-$)V)O M"!S;VQI9#L@8F]R9&5R+71O<#H@(S1B M86-C-B`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`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@ M,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,BPQ.3,\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,S$\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@-S8E M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N M=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O M;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI M/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T M9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T.38V7SDV M8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P<'0[(&1I3H@5&EM97,@3F5W M(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M6QE.B!I=&%L:6,[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M5&EM97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[(&)O'0M:6YD96YT.B`P<'0[ M(&1I3H@=&EM97,@;F5W(')O;6%N M.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F M;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.B`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`Q,'!T.R!M87)G:6XM3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU,3D\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`W-B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@ M,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXW-S0\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M-'!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T.38V7SDV M8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA'0^)SQD:78@3L@=&5X="UI M;F1E;G0Z(#,V<'0[(&1I3H@5&EM M97,@3F5W(%)O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P M<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I M9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE M6EN9R!!;6]U;G0\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED M=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXS+#(Q,CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@.#@E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT M+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`G5&EM97,@3F5W(%)O;6%N)RP@ M5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W!A9&1I;F#L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD:78@#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B!T:6UE M3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`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`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L@/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M M9F%M:6QY.B!T:6UE'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@8FQO M8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT3H@=&EM97,@;F5W(')O;6%N.R!M M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXX,#`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W=I9'1H.B`W-B4[(&1I M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV,3D\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@-S8E.R<^/&1I=B!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,C=P=#L@9&ES<&QA>3H@8FQO8VL[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]T9#X\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,G!X.R!W:61T:#H@,24[(&9O;G0M9F%M:6QY.B!T:6UE'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE#L@=VED=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G8V]L M;W(],T1W:&ET93X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`W-B4[(&1I6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[ M('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T M<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXW M.#8\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3H@)U1I;65S($YE=R!2 M;VUA;B28C.#(Q-SMS M(&1E9F5R3H@5&EM97,@3F5W(%)O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/'1R M/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&)O3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[(&)O#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@'0M:6YD96YT M.B`P<'0[(&1I3H@=&EM97,@;F5W M(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA M#L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M'0M:6YD96YT.B`P M<'0[(&1I3H@=&EM97,@;F5W(')O M;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA#L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E3H@8FQO8VL[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^/&1I=B!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!M87)G M:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@8FQO8VL[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z M(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXQ,RPR-S`\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q M,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXQ-2PQ.3@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXQ-2PV,#(\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M-2PR,C@\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F M=#H@,'!T.R!F;VYT+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I M9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR.#@\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y M.B!B;&]C:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN M+6QE9G0Z(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,SPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS,#PO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q M)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`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`Q)3L@9F]N M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#`S-SPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@ M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[ M(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE M3H@ M8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UEF5D(&%S(')E=F5N=64Z/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,C@S/"]T9#X\=&0@ M;F]W6QE/3-$)W=I9'1H.B`Q)3L@9&ES M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT M+7-I>F4Z(#$P<'0[(&UA6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@3H@8FQO8VL[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXH,38\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[)SXH,C(\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-30\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-C0\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T3H@=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T M.R!F;VYT+7-I>F4Z(#$P<'0[(&UA3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,BPW.38\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,BPR-#,\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXH."PS,S(\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^*3PO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXH-BPU,3(\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N M="US:7IE.B`Q,'!T.R<^*3PO=&0^/"]T6QE/3-$)W=I M9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'0[(&1I3H@ M=&EM97,@;F5W(')O;6%N.R!M87)G:6XM;&5F=#H@,'!T.R!F;VYT+7-I>F4Z M(#$P<'0[(&UA6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA>3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,BPW,C<\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.B`U,B4[)SX\9&EV('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C M:SL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@;6%R9VEN+6QE9G0Z M(#!P=#L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXW+#8X-#PO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9&ES<&QA M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@ M3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#H@,24[(&1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q M-C`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`Q,'!T.R!M87)G M:6XM6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#`T,SPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED M=&@Z(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE M.R!T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#4X,#PO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z M(#$E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA M;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#`T,SPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W!A9&1I;F6QE/3-$)V)O M"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@ M9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#DE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+#4X,#PO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA3QB'0^)S,@>65A'0^)SQS<&%N/CPO2!/=VYE9"!3 M=6)S:61I87)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,C@T M-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T.38V7SDV8SE?-3@T M-V$Q.3'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1E M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#`\3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C M.5\U.#0W83$Y-S@S96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,#(X-#1D,&9?-S`Q,5\T.38V7SDV8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#(X-#1D,&9?-S`Q,5\T M.38V7SDV8SE?-3@T-V$Q.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS M<&%N/CPO'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y+#`P,#QS<&%N M/CPOF5D(&5X<&5N&ES=&EN9R!S:&%R92UB87-E9"!A'0^)SQS<&%N/CPO6UE;G0@ M07=A'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO65E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO&-L=61E9"!F'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO&-L=61E9"!F M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-L M=61E9"!F'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2!M87)K M970@9G5N9',@*&EN8VQU9&5D(&EN(&-A'0^)SQS<&%N/CPO2!M87)K970@9G5N9',@*&EN8VQU9&5D(&EN(&-A'0^)SQS<&%N/CPO2!M M87)K970@9G5N9',@*&EN8VQU9&5D(&EN(&-A'0^)SQS<&%N/CPO2!M87)K970@9G5N9',@*&EN8VQU9&5D(&EN(&-A'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(&5X<&5N'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M65A M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@R,S@L,#`P*3QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`@/&AE860^#0H@("`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`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65E65E(%M-96UB97)=/&)R/E)E5!R;V=R86T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^2G5N+B`Q-RP@,C`Q,#QB65E(%M-96UB97)=/&)R M/E)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO2!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPOF5D("AI;B!S:&%R97,I/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!S=&]C:RP@870@8V]S="`H:6X@'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!S=&]C:R!V86QU93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS M<&%N/CPO'0^)S,@ M>65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL M('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM+2TM/5]. M97AT4&%R=%\P,C@T-&0P9E\W,#$Q7S0Y-C9?.39C.5\U.#0W83$Y-S@S96,M #+0T* ` end XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 136 199 1 false 41 0 false 9 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://vasomedical.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://vasomedical.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) false false R6.htm 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperations ORGANIZATION AND PLAN OF OPERATIONS false false R7.htm 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES false false R8.htm 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS Sheet http://vasomedical.com/role/SegmentReportingAndConcentrations SEGMENT REPORTING AND CONCENTRATIONS false false R9.htm 060400 - Disclosure - SHARE-BASED COMPENSATION Sheet http://vasomedical.com/role/SharebasedCompensation SHARE-BASED COMPENSATION false false R10.htm 060500 - Disclosure - LOSS PER COMMON SHARE Sheet http://vasomedical.com/role/LossPerCommonShare LOSS PER COMMON SHARE false false R11.htm 060600 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://vasomedical.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS false false R12.htm 060700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNet ACCOUNTS AND OTHER RECEIVABLES, NET false false R13.htm 060800 - Disclosure - INVENTORIES, NET Sheet http://vasomedical.com/role/InventoriesNet INVENTORIES, NET false false R14.htm 060900 - Disclosure - GOODWILL AND OTHER INTANGIBLES Sheet http://vasomedical.com/role/GoodwillAndOtherIntangibles GOODWILL AND OTHER INTANGIBLES false false R15.htm 061000 - Disclosure - DEFERRED REVENUE Sheet http://vasomedical.com/role/DeferredRevenue DEFERRED REVENUE false false R16.htm 061100 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://vasomedical.com/role/RelatedpartyTransactions RELATED-PARTY TRANSACTIONS false false R17.htm 061200 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://vasomedical.com/role/StockholdersEquity STOCKHOLDERS' EQUITY false false R18.htm 061300 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vasomedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R19.htm 061400 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS false false R20.htm 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsTables SEGMENT REPORTING AND CONCENTRATIONS (Tables) false false R21.htm 080500 - Disclosure - LOSS PER COMMON SHARE (Tables) Sheet http://vasomedical.com/role/LossPerCommonShareTables LOSS PER COMMON SHARE (Tables) false false R22.htm 080600 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://vasomedical.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) false false R23.htm 080700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetTables ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) false false R24.htm 080800 - Disclosure - INVENTORIES, NET (Tables) Sheet http://vasomedical.com/role/InventoriesNetTables INVENTORIES, NET (Tables) false false R25.htm 080900 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesTables GOODWILL AND OTHER INTANGIBLES (Tables) false false R26.htm 081000 - Disclosure - DEFERRED REVENUE (Tables) Sheet http://vasomedical.com/role/DeferredRevenueTables DEFERRED REVENUE (Tables) false false R27.htm 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperationsDetails ORGANIZATION AND PLAN OF OPERATIONS (Details) false false R28.htm 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsDetails SEGMENT REPORTING AND CONCENTRATIONS (Details) false false R29.htm 090302 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsConcentrationRiskDetails SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) false false R30.htm 090400 - Disclosure - SHARE-BASED COMPENSATION (Details) Sheet http://vasomedical.com/role/SharebasedCompensationDetails SHARE-BASED COMPENSATION (Details) false false R31.htm 090500 - Disclosure - LOSS PER COMMON SHARE (Details) Sheet http://vasomedical.com/role/LossPerCommonShareDetails LOSS PER COMMON SHARE (Details) false false R32.htm 090600 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://vasomedical.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) false false R33.htm 090700 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetDetails ACCOUNTS AND OTHER RECEIVABLES, NET (Details) false false R34.htm 090800 - Disclosure - INVENTORIES, NET (Details) Sheet http://vasomedical.com/role/InventoriesNetDetails INVENTORIES, NET (Details) false false R35.htm 090900 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesDetails GOODWILL AND OTHER INTANGIBLES (Details) false false R36.htm 091000 - Disclosure - DEFERRED REVENUE (Details) Sheet http://vasomedical.com/role/DeferredRevenueDetails DEFERRED REVENUE (Details) false false R37.htm 091100 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://vasomedical.com/role/RelatedpartyTransactionsDetails RELATED-PARTY TRANSACTIONS (Details) false false R38.htm 091200 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://vasomedical.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) false false R39.htm 091300 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://vasomedical.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) false false All Reports Book All Reports Element us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent had a mix of decimals attribute values: -3 0. Element us-gaap_RepaymentsOfRelatedPartyDebt had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensation had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)' had a mix of different decimal attribute values. 'Monetary' elements on report '090800 - Disclosure - INVENTORIES, NET (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090900 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '091200 - Disclosure - STOCKHOLDERS' EQUITY (Details)' had a mix of different decimal attribute values. Process Flow-Through: 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Process Flow-Through: 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) vaso-20130930.xml vaso-20130930.xsd vaso-20130930_cal.xml vaso-20130930_def.xml vaso-20130930_lab.xml vaso-20130930_pre.xml true true XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
CURRENT ASSETS    
Accounts and other receivables, allowance for doubtful accounts and commission adjustments $ 2,606 $ 3,179
PROPERTY AND EQUIPMENT, accumulated depreciation $ 1,326 $ 1,161
STOCKHOLDERS' EQUITY    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 164,695,382 162,917,996
Common stock, shares outstanding (in shares) 155,759,952 162,917,996
Treasury stock, at cost (in shares) 8,935,430 0
XML 35 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
GOODWILL AND OTHER INTANGIBLES
 9 Months Ended
Sep. 30, 2013
GOODWILL AND OTHER INTANGIBLES [Abstract]  
GOODWILL AND OTHER INTANGIBLES
NOTE I – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $3,297,000 and $3,212,000 was recorded on the Company’s condensed consolidated balance sheets at September 30, 2013 and December 31, 2012, respectively, pursuant to the acquisition of FGE in September 2011.  All of the goodwill was allocated to the Company’s Equipment segment.  The components of the change in goodwill are as follows:
 
(in thousands)
   
Carrying Amount
 
     
Balance at December 31, 2012
 $3,212 
Foreign currency translation
  85 
Balance at September 30, 2013
 $3,297 
 
The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:
 (in thousands)
   
September 30, 2013
  
December 31, 2012
 
   
(unaudited)
    
Patents
      
Costs
 $469  $469 
Accumulated amortization
  (451)  (438)
    18   31 
          
Customer lists
        
Costs
  800   800 
Accumulated amortization
  (238)  (152)
    562   648 
          
Software
        
Costs
  619   541 
Accumulated amortization
  (413)  (386)
    206   155 
          
   $786  $834 


Patents, customer lists, and software are included in other assets in the accompanying condensed consolidated balance sheets and are amortized on a straight line basis over their estimated useful lives of ten, seven, and five years, respectively.  Amortization expense amounted to $41,000 and $126,000 for the three and nine months ended September 30, 2013, respectively, and $137,000 and $155,000 for the three and nine months ended September 30, 2012, respectively.
XML 36 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Cash flows from operating activities    
Net loss $ (1,649,000) $ (3,806,000)
Adjustments to reconcile net loss to net cash provided by operating activities    
Depreciation and amortization 266,000 286,000
Amortization of deferred gain on sale-leaseback of building 0 (31,000)
Provision for doubtful accounts and commission adjustments 23,000 (7,000)
Share-based compensation 300,000 559,000
Amortization of deferred consulting expense 87,000 416,000
Changes in operating assets and liabilities:    
Accounts and other receivables 4,304,000 12,303,000
Receivables due from related parties 6,000 159,000
Inventories, net 71,000 (47,000)
Finance receivables, net 0 14,000
Deferred commission expense 521,000 (491,000)
Other current assets (138,000) (170,000)
Other assets (349,000) 61,000
Accounts payable 99,000 39,000
Accrued commissions (746,000) (2,126,000)
Accrued expenses and other liabilities (678,000) 496,000
Sales tax payable (13,000) (1,000)
Deferred revenue (2,875,000) (230,000)
Other long-term liabilities 195,000 154,000
Net cash provided by operating activities (576,000) 7,578,000
Cash flows from investing activities    
Purchases of property, equipment and software (126,000) (344,000)
Purchases of short-term investments (111,000) (70,000)
Redemption of short-term investments 111,000 70,000
Net cash used in investing activities (126,000) (344,000)
Cash flows from financing activities    
Proceeds from exercise of warrant 0 343,000
Repurchase of common stock (1,602,000) 0
Repayment of notes payable due to related party 0 (190,000)
Net cash (used in) provided by financing activities (1,602,000) 153,000
Effect of exchange rate differences on cash and cash equivalents (18,000) 10,000
NET INCREASE IN CASH AND CASH EQUIVALENTS (2,322,000) 7,397,000
Cash and cash equivalents - beginning of period 11,469,000 2,294,000
Cash and cash equivalents - end of period 9,147,000 9,691,000
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION    
Interest paid 0 5,000
Income taxes paid 61,000 411,000
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
Inventories transferred to property and equipment, attributable to operating leases, net 57,000 8,000
Fair value of assets acquired 0 291,000
Liabilities assumed through acquisition $ 0 $ (291,000)
XML 37 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
CURRENT ASSETS    
Cash and cash equivalents $ 9,147 $ 11,469
Short-term investments 111 110
Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $2,606 at September 30, 2013 and $3,179 at December 31, 2012 4,739 9,145
Receivables due from related parties 21 25
Inventories, net 2,054 2,166
Financing receivables, net 0 16
Deferred commission expense 1,959 2,480
Deferred related party consulting expense 0 85
Other current assets 374 220
Total current assets 18,405 25,716
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,326 at September 30, 2013 and $1,161 at December 31, 2012 418 473
GOODWILL 3,297 3,212
OTHER ASSETS, net 3,290 2,980
Total Assets 25,410 32,381
CURRENT LIABILITIES    
Accounts payable 441 342
Accrued commissions 1,591 2,337
Accrued expenses and other liabilities 3,970 4,627
Sales tax payable 164 177
Deferred revenue - current portion 7,684 10,580
Deferred tax liability, net 112 112
Notes payable due to related party 3 3
Total current liabilities 13,965 18,178
LONG-TERM LIABILITIES    
Deferred revenue 5,043 5,022
Other long-term liabilities 366 171
Total long-term liabilities 5,409 5,193
COMMITMENTS AND CONTINGENCIES (NOTE M)      
STOCKHOLDERS' EQUITY    
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at September 30, 2013, and December 31, 2012 0 0
Common stock, $.001 par value; 250,000,000 shares authorized; 164,695,382 and 162,917,996 shares issued at September 30, 2013 and December 31, 2012, respectively; 155,759,952 and 162,917,996 shares outstanding at September 30, 2013 and December 31, 2012, respectively 165 163
Additional paid-in capital 61,441 61,229
Accumulated deficit (54,065) (52,416)
Accumulated other comprehensive income 97 34
Treasury stock, at cost, 8,935,430 and nil shares at September 30, 2013 and December 31, 2012, respectively (1,602) 0
Total stockholders' equity 6,036 9,010
Total liabilities and stockholders' equity $ 25,410 $ 32,381
XML 38 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended 12 Months Ended
Sep. 30, 2013
Dec. 31, 2012
Sep. 30, 2012
Sep. 30, 2013
Accounts and Other Receivables [Member]
Credit Concentration Risk [Member]
GE Healthcare [Member]
Dec. 31, 2012
Accounts and Other Receivables [Member]
Credit Concentration Risk [Member]
GE Healthcare [Member]
Concentration Risk [Line Items]          
Accounts and other receivables $ 4,739 $ 9,145 $ 7,704 $ 3,300 $ 8,100
Percentage of accounts and other receivables (in hundredths)       70.00% 89.00%
XML 39 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACCOUNTS AND OTHER RECEIVABLES, NET (Tables)
 9 Months Ended
Sep. 30, 2013
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]  
Accounts and Other Receivables
The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2013 and December 31, 2012:
(in thousands)
   
September 30, 2013
  
December 31, 2012
 
   
(unaudited)
    
Trade receivables
 $7,162  $12,193 
Due from employees
  183   131 
Allowance for doubtful accounts and
        
commission adjustments
  (2,606)  (3,179)
Accounts and other receivables, net
 $4,739  $9,145 
XML 40 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES (Details)
 1 Months Ended 9 Months Ended
Jun. 30, 2012
Sep. 30, 2013
Sales Representation Agreement [Abstract]    
Initial term of sales representation agreement 3 years 3 years
Amended term of sales representation agreement   5 years
XML 41 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
GOODWILL AND OTHER INTANGIBLES (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Change in carrying amount of goodwill [Roll Forward]          
Goodwill, Beginning Balance     $ 3,212,000    
Foreign currency translation     85,000    
Goodwill, Ending Balance 3,297,000   3,297,000    
Other intangible assets, net [Abstract]          
Intangible assets, net 786,000   786,000   834,000
Amortization expense 41,000 137,000 126,000 155,000  
Patents [Member]
          
Finite-Lived Intangible Assets [Line Items]          
Useful life of intangible assets     10 years    
Other intangible assets, net [Abstract]          
Costs 469,000   469,000   469,000
Accumulated amortization (451,000)   (451,000)   (438,000)
Intangible assets, net 18,000   18,000   31,000
Customer Lists [Member]
          
Finite-Lived Intangible Assets [Line Items]          
Useful life of intangible assets     7 years    
Other intangible assets, net [Abstract]          
Costs 800,000   800,000   800,000
Accumulated amortization (238,000)   (238,000)   (152,000)
Intangible assets, net 562,000   562,000   648,000
Software [Member]
          
Finite-Lived Intangible Assets [Line Items]          
Useful life of intangible assets     5 years    
Other intangible assets, net [Abstract]          
Costs 619,000   619,000   541,000
Accumulated amortization (413,000)   (413,000)   (386,000)
Intangible assets, net $ 206,000   $ 206,000   $ 155,000
XML 42 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEFERRED REVENUE (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2013
Jun. 30, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Dec. 31, 2011
Sep. 30, 2013
Extended Service Contracts [Member]
Sep. 30, 2012
Extended Service Contracts [Member]
Sep. 30, 2013
Extended Service Contracts [Member]
Sep. 30, 2012
Extended Service Contracts [Member]
Sep. 30, 2013
In Service and Training [Member]
Sep. 30, 2012
In Service and Training [Member]
Sep. 30, 2013
In Service and Training [Member]
Sep. 30, 2012
In Service and Training [Member]
Sep. 30, 2013
Service Arrangements [Member]
Sep. 30, 2012
Service Arrangements [Member]
Sep. 30, 2013
Service Arrangements [Member]
Sep. 30, 2012
Service Arrangements [Member]
Sep. 30, 2013
Commission Revenues [Member]
Sep. 30, 2012
Commission Revenues [Member]
Sep. 30, 2013
Commission Revenues [Member]
Sep. 30, 2012
Commission Revenues [Member]
Changes in deferred revenue [Roll Forward]                                            
Deferred revenue at the beginning of the period $ 12,727 $ 13,270 $ 15,602 $ 14,998 $ 15,198 $ 15,228                                
Additions:             410 288 848 987 8 13 23 33 30 20 60 75 2,076 2,037 5,355 6,116
Recognized as revenue:             (245) (283) (755) (840) (10) (10) (20) (25) (16) (22) (54) (64) (2,796) (2,243) (8,332) (6,512)
Deferred revenue at end of period 12,727 13,270 15,602 14,998 15,198 15,228                                
Less: current portion 7,684   10,580 9,418                                    
Long-term deferred revenue at end of period $ 5,043   $ 5,022 $ 5,580                                    
XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES, NET
 9 Months Ended
Sep. 30, 2013
INVENTORIES, NET [Abstract]  
INVENTORIES, NET
NOTE H – INVENTORIES, NET

Inventories, net of reserves, consist of the following:
(in thousands)
   
September 30, 2013
  
December 31, 2012
 
   
(unaudited)
    
Raw materials
 $844  $909 
Work in process
  519   483 
Finished goods
  691   774 
   $2,054  $2,166 


At September 30, 2013 and December 31, 2012, the Company maintained reserves for excess and obsolete inventory of $571,000 and $576,000, respectively.
XML 44 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
SHARE-BASED COMPENSATION (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 0 0 0 0
Share-based compensation expense $ 29,000 $ 328,000 $ 300,000 $ 559,000
Unrecognized expense related to existing share-based arrangements 124,000   124,000  
Restricted Stock [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 0 500,000 400,000  
Value of stock granted   130,000 74,000  
Value of shares vested in six months 3,600   3,600  
Value of shares vested in two years 38,000   38,000  
Vesting period for first half shares granted to an employee 1 year      
Vesting period for second half shares granted to an employee 2 years      
Restricted Stock [Member] | Officer [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)       1,000,000
Value of stock granted       250,000
Restricted Stock [Member] | Non-Officer Employees and Consultants [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)       2,392,500
Value of stock granted       598,000
Restricted Stock [Member] | Vesting at Grant Date [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     180,000  
Restricted Stock [Member] | Shares Vesting at Fifty Percent After Three Months [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     20,000  
Shares vesting after three months (in hundredths)     50.00%  
Restricted Stock [Member] | Shares Vesting at Fifty Percent After Six Months [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares vesting after three months (in hundredths)     50.00%  
Restricted Stock [Member] | Shares Vesting at Fifty Percent After One Year [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     200,000  
Shares vesting after three months (in hundredths)     50.00%  
Stock Compensation Plan [Member]
        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated share-based arrangements $ 0 $ 128,000 $ 87,000 $ 416,000
ZIP 45 0001201800-13-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001201800-13-000026-xbrl.zip M4$L#!!0````(`$F`;D,R":25=Y$```&["@`1`!P`=F%S;RTR,#$S,#DS,"YX M;6Q55`D``UDZA5)9.H52=7@+``$$)0X```0Y`0``[%UM<^*XLOY^J^Y_T,F' ML[M5(<&00,CLS"E"R"RU,R$;,KMWZ]:M+<4603M&YDAV$LZOOY)L;&,,F!># M#-K:#QFKU6IU/]UJO?+SO]Z'-GA%E&&'?#PQSLHG`!'3L3!Y^7CBL1)D)L8G M__KTW__U\S]*I<^((`I=9('G,;C%S+0=YE$$>H[MN9P#`P^/W;O.ES:HG%7. MJF=ET')&8XI?!BXP&HU+4`*5LE$%3P-GR!P"'I'G\K9!TS21[;$ST+1M(,D9 MH(@A^HJLLU))M/[^3&W`A27L6OR)/YX,7'=T?7[^]O9V)KZ<.?3EO%(N5\\Q M82XD)CH)Z&U,OB\@%\7/D(7D[S/T;U5)S7O0.)>E(2G#:82\=$)(O&$Z MH>72<`E%LAA4J;C$9>.TSL1%*9TQ/0HY0XRKUY0FE*1 M0&RR]%JR2%0QIJLP;*97X`5IY.Z(SJ'G)2D5T+LY2*\@2E+Z\`J9$U80_Q@B M"YO0/C.=H2"OEAO5V\!OY M;4!1_^.):+SLG5DGX-QG).,"-RQQT;L+L/7QQ)1T1MEPG5`\21M2(^)B M=QQ\"[]B2WSO8T2!%`Q-]6:BI5;GUY-/9?[?5;51OJK_?)ZL/&GJ/*6MH*41 MQZ1C)=OG^J'N+0^TGX38P@AE8\(E*DM40L2*56F4JN6H82M68?(UUO3D4Z"[ MA>HTC/)5(93HP\SU]2&P?Q4R#TJVH8]*84`5TT=E&A_;U$=QG&P*'[GIHV)4 M>``MF#XJ)?Y_U.')%W?T7#9T3WH+UH9/+E"C\'!187XWUD8Q.[OHS`PIS.GU4$6>3UPDZ> M?)J0)7K[\WEJ`Y%@YVF2J1H>LYB[_6\/C\0_@Z\';761SEVG]_CX+-^#-F*/ M:"3FOH13#0:6]?VPT%#5<4#E.)!C0IC%\CH.*!4'A%PYEE((VRPT"9VFM&&F4'@S*%9WD:98>!,K7R,B,<,>6E M88VR`T&9L?J(F;B`G5?V7]4H.QB4K9?]5W-#62U$6:V@1U!KJZNSMJ/)U$'? MN-CB'8JYC M3ESK%O41Y59N.<,1-XK4?Y-22%[DV8<_L#OH$`N_8LN#=F_`H7@#F5BO&LNS M$!PTV+51MQ\1R<:Z_3XV$2VV9^:CFPC*4TK:IC=-&3YJ+Q4!Q?&;G4U4]N@W M]PX)4-$>CFQGC!!K$MX(89XM7I9@Q?:H;0)3!4^6XW1&FVE'FYGV97`TC?2C MF&6L@8R_I)]*0O8[)\#DY0G1H3\]"#XTW<_=X\J MJ3AL1,LR%AKZ#O?=\0.B8M;4[+N(/@TH0E^Y$(."Y@@9H;ZR'K0/'(T/=`GZ M$\&"SSIWG2-OR>^F=*^Q/[-GKG-=O66>OF6ND:%WS..O*6L\[!0/NWHH>[>I M4`^_Z\E`4@MZ*J#H5$#J*KXX^V!#4DSD+L''@IYJE"Q)FC5*=`*]/('6*-') M]/)=78T2O269BA+>*0O;GHM?40^9'L4N1JS];MJ>A:P[Z@R%*CW_<:%NOPTI MX:DGXTFGOVT\3F<08:X[DC>_"@ZU_+24`.Z4NC1>=XI7_];A(2P[[`*N,]K2 M:)V=]>6(UC^@.-!3\(O".T'JE*;TK'.G*-4Y0!%S@./%J\X!BI<#J(;6NHZN M:L)5G>BJT.KB+O&J<]9"Y:Q'BE*=`Q0R!U`(K3,[-CJF*H#4_<=4U7:,=H=2 M'5.+%U./%ZUZ7E7$>95J>-W=SI7.`0J5`RBU8R6P>0DC>19J\OL$C^@5$0_%?IH@>K`$T5=LQHL*'C.6]WGR MR-N\GNOC2NL`J?W.PZZ%K$"M+4?\[))Y-&A:W'T-J9DU71V;"A.;U%JF70-( MXIP_9L(6`=&QX&A>QS6,UH%1ATS\DEA/%&)Q+OI(@#2_ZQI*ZT!)9TNJ94NJ M0:JN![F"#G(*79!>`T8Z,BD8F8H-*9TW*90W%1M*>DE`F24!A8"4O+.NLZ6" M9$NJ725?&48Z6U(M6RH\I'2VI$JV5'@HZ6Q)C6Q)-2"MO+FK8Y)",4FA3=TU MH*03;T42;X5@E-Q`>40V9VT]<*'&W.<(XSFE>/3J9APOD7!J]OO8QN);6VK" M5]Y?/9=_$NIJ_]OC7\6148>(4>!PWG'*KJ3H;&2ZMI8AI?>A5-OO MT;C?(\+4]+MMX7X_/T6\`IAO,46FZ]!;^(JM+QAQ)0R+_K-YJ\!$Y@>+E*`C MY,QF@897\>&E\!:"AE?!X:7VFHN&5_'A=1@3Z(EFCP=0XFKL>O_.:IS%:=L\<^>[19^KKYRG$]V?"]>>3`PTJF# MBJF#6O#:(#.]<^@0T>-+("2LTCJO,U$>HU8$4<][9MC"D(Z[??_W>'@9.J:! M+US87JB)/2P6&WF^9+'B4*9AHBQ,*M.#T]8?^%@%)I\1>4.VW>$R4$\>^VDY MQP,1.3#-5\%^]IMV_=B)V!#D2I0_7Q0[C?$'=@<=8F&>!'K0]G_*"#*AOK%4 MTLWX";LVZO8C(O^$[W!D.V.$6)-8T>SD0`ZM;%=7DT/!BS2F4Z2YUX4U<#5P ME5X?G'<"60-7`U?IW;=Y%PTU<#5PE3Z5D$P5PK-O\MW+;E_^(NQA_?#SW"ZJ M]K/-:HW-/CX>;$CNX=`_:2_^(4J*C8=XEX*H,=VQ_?[H[9CD?S1MV/S#5(KO,+TB)A+L>DB*S8&Y954WHL? MX>YC$]%)LA2T=X#8RC77G*?(97A=I0-3.(D2EE3`;+/=(W/*2KD6+D34U'1/ M[8('X()Y+8W45E\:J>W@8++8DMVC*P70T,/;JKXUX3^E0%5]JI##VA9VD_(Z MOY5<(E)P+-2^K.`XN;%O'=2@K-IBGO(^752_W==0IF2\T*ZD\]L"C(DZO]4. M/,>!I6&Z(WDB\G`=2X5<;5;3&IPS!TN.$9Q;P\M!1$Z%#H\DC^MI&U(N0J1<:*2HAI2+U9%RL:.I M@D:*4DC98][N$>S#Y%NYG'QT9X@@\RCZ%`@FULS8A-6D+,Y>\)K'NS*'-V;. M1<6H7W_KW:[+NII@+=?O9M0G:MQ[0T2AZ\PD,9GEB2LXG6.LN5M$G"$FBQM< MIMQDB[-,)Z6Q?F=1V\4)_KLNYL4AJ_Z7B!^J\4#C,UL(_2J4F[ZDE>@ON;/A2*OD% M%L+788DH`$%(>43]U!73DT]]:#/>L9F:84LMCU+9#F8FM,&?"%+0)A80(2W> M;D#GDPFJMA_VEHM0*O%\71R`6,0FE.?6,>7-=?`@`VBJ+!,:GR2S(/'0/9=- M*$A;CB?@#V3;I>_$>2.@QZWF$&2!#F,>HG&)?&)!^ZL@G5#ZA,LENW=\B1:R M24KVNV-[A`]78VX[&U$V*T](X1.L*D>B>K+]"7(>TJXX)VQQ):?(%66+ M/GF,>E9(P^#Q'HB0*K_)[`I8R,3,Q8G&/W$E<2\I:F9Z[W7@,$\18D):P8/X6M!W,WJ8@ M6(E#L,3S9CX.K2322FK87I^7]*)>+U_P&)!G7T02-9+H"K2]!].&,@1?,UG8 M*%\V[%%-4IQI:5916*UV<5EP,%5S`U.EZI8TI>+>C5OXW]N@U\0M-V!R5.?R-I35653(-961->BR.*3 MXI9#3)G\2>P\8O8]%^!,-2-:N1G?(&(.AI#Z2ZD3YA'38#G8M4MAR3EQR3U7+>F,PK`7`!F5JK&D%PTC M]S$K@V]MZ+W;TU9A7?/*V(YK1F2G@-.=3E9*YNDXHM]PC*@;M4IJ!]):V)'< M61R($S6J&PC^`,>^U$L$#N@V&H8OC%1!IUGG)F(6;58OTD&P3,2X^8/W18%X M8!0CMAP!L0=).?U:JJVD:W9>&[OM0!;%5])'@2P=H!Z7U4^^H]^*700644'2 M1^2;P-JX;,QH?WX3NY(\D]*KU?H&DG_!\!G;6-ACF=`QTDU476W49T:9=/8Y M"YM%NQ>U2JIV%PC[\-A]:#\^_0F:][>@_=NWSL/7]OW3*8"FZ0T]WRLM,:4S ML1S$4SHPH;N-D?&_;21OE1"K.11+\?^1WQ^H,T+4'8O3 MZ51(^<`).Z3EDZUEG9HQDYFE<\]1SBQ*KLTNXBV3T[8=4\)%GE(I/8M[;Z>DU1F^1TY]#;@,_L]&F3K)NG=;.Z MR-QDX522:;PWZHUMJ"26WP'D0VBF,S$:<SBYU,LO8F=6)(6:+LY!I!1K&)BRUL>ZY(S!DR M/2IGO+P'INU9?*SH4VIC)D(4TX3Z'K5T:@^3+=$F95J36MSH3873,(.29O['4#J>@`YH+QN=]8\^+QN MKSG`[NQX/#G`?GQR9J-'$9\T+I-'.PMCR'W832\J%=PWCFA1:;\+Z;LSZ3$M MI.]K\-K=JJ]*@Y?<]#H%=Q!3\#NT/01N,3-M1SQ1,J-Y22Q()65$N-:N_)61 M//PSCWU&:7_S''GJFV*30Y$CJFE*?'Z%]+O8112[\AWYX)6X,!]L+?[X!;TB M&Q@_SN(?^F69$T MM/?0M+'*LH6F1B5YD'A#Q6W6X5U+N\M`NK%%J)\]7I@KRY(C#XE"6I4NQUK,KE<9EN9'2?'J[&>Z$+Q!EJY>^ M&Y>--/NER[W>@Q3K=V7#%R<,HVID-\H*+Y&LWZ.UGAJY6L5&V63-=$KW\B(Y M9]T1-G;P&LF5?"9I5]#([16:JVKC*O^PL_VW)JX:]F4L:O<& M,LS$VLA#',;BH'@\E0C.88O'[AX<\3BR>+OA23PR?6,[YO<9M4JNW7Z<9Y-8 M,8X1PPD_P4TR6_Y*VS]M]X.%7P%SQS;Z>-+G]*4^'&)[?`U^>,)#+MP]>@./ MSA"2'TZ!_'(*>"J$^Q^`I&;X/^@:&.61^^'DGR_NAP1'T7P)VES<:V"COOL! MR"^8B`3Y&HAJP,)L9$/>XK,0.N`[D2(AQ`Z[3VUP`TK@IMGK]$#W#CP\MGOM^Z?F4Z=[+^]QMAX[3^(Y1M!LM;K?[I\Z M]Y_!0_=+I]5I]T3/SGG7YO5R49]"U3Q3<#[Y>Q&S7:M,?GA#OL:>'=N:J\7Y M,/_&D/C>9BYW&Q>Q?2A,7,/`_7%"9]7:+G'V-$#RHHA\731XU=(2)^7%E1'" MN)=:\K)2'Q-(3,R#%9N$1P8&D$\EGQ$B@`]/(T@Y'9]B"G;4DO=1WK`[F-Q# M$,TA]V$3@A]/OIWU MSL#G9O/AY"=IQ9%'F2O(JK&F1+$5S6*H)QH5'REZ$1=,Y<(]9RZJ1)M#FO/+6WP:8&^4-`?2.J(F#FWK4L<_X M]%U6<$:8!'L9W-VA?T_P-.2]EN]2U+>Y<<3EL?B-,/"CJ(J9]"'>G@]C<=^, M3S"E7T6T/\EFL(4$0KFE>:HD'H86FH:@+Q8JII)DS@WS(9[B(6?'/#M8?HI9 M4"HZ+.3TXN)^X*J2*QF'+/R?.@!B$X>C(VP>2X^S>+B0ZUR` M3*F4@)]_GR[!-1"K[W'E","<'?/PX`>AT(9SX"ZP(**A>&@Y$9\HXBF_B(D1 M>(4UAO`[M\=D`);^SA-A;QALJKH#R-'9[PN0NA(6PJG%7=EAZ$U^XBRKVM'C M(,*+`U<3#A"Y76;O\'TK-GQP%L(IN0,(X>H.'!:SE.^EBPP7.K2T,9-.ZM]SYA`:\.#B4+G>W(_1R.Y.(WEFIG_#%^2QH0*_F@ZD:#5A@'.IUQ,X_#_=QZR[A:=Q]UJ MOKJ-J>OC+UFP'JKEO@`C`@O(6$:R$Y?@]>/RV:.2S-1@HGC14XXQ:%;X^8+@L#\!U.F#&4]VO#$ M/?@W8KGGH\J!\ZW%"H(_VKB"^297@",.7BU>'(5;@;(*A(-.OW19GO%97]SV M`@\\BYD0&GOS_\R'R;N_Z+W6N^Q3M@"RY52)4_J(`WVCV+%^X*$<$Y(2(5V. M<&9X&E-.R4X7_*;T[*RX@BJ8@Y"7+76%J0"_'4T%PR&E_ET@^&W>^5Q.^V6T MH\D#*N!G7-@F+@^PP!%\$;1*)RQI1O8Z7=L6R1H]FK&$ILB6X\G_E`T:7T7D M^&@;@0'I6C"KX"%#!QS<+5Q'Y0"UP,3=FH[H+[CG'(U;R;!_%>/R(G_QN([D M&P/#:+W[=/;+:?JG_NZUQO`;-C&?I[TZ,Z%B'*IN)YL+?I$A MN3C_@SD26@XN'QC?)!0:>S;P?1R+RU":!%CB1_/NZ0P(D\_9YO$F^[KIEO-% M)):%H(SRP'VBEN@@A\D&L`RP80P7G%&A*ROGT22[]B<6.&&!<%?E=9CG&./E MH,?B9L/1I7\>]R$INQS+V]?DKTN+!JQRG?+".^&,3N&@?3T#R+;ZX^98KCV- M?8U\"QQR+H^&LKA(G_A)Q@KBPNUBRO[LN7?'Z'?#ZOXV/,ZN7$49QD+Y:OJ+ M#HR4#"HA05"0$2"ZCWL'E&'?-]`U]CPC%%V((E?A_/D&EDV!*3:=@O?/^5_D M:9J4],NQ)%S27:6PH3$8+)/3ZD-*Q72*H=LTAHL+B$>8ODMJ].&#T`C^#EWG<-^P5ZC'7JFK78V@4KEDO=-7=P35BEUW>D-UAZ!7.:)J M##MUC$!\R+V@)7=-GKL6ABU@;OC`Y:>9A-7R+N7[R>O)RQM4@A3WG[2'53!7 MWK="HZY>2!)'?6RT#:.F8>=0"A[W(\QP,NH+UIGC%A*F*K!QY,*B\2@?G+;F M8?UU#0?BRX>C9J9195IWRO?U,W+VR/N5,W34X?V6+V=?\L M.1`JMW:],7N2%1S$D-G(Z>69+% M@K'ON1B3@:VXR4O_"@.5"4G"E*<_!O&O\U)J5HC0G(S'MB-B[&3Y(W_Z_%%Z[.)0M]3.7?:WR.7Q<<3\ M@0;0O=ASP#-7P*-1_F2Q.*5RLN#TC`8&W(8>1:(/'F:41YR_F,],'XKCCZUY MQZFRWC3&Q2EW7!#]+8*&TH.3P#%YJ!*)L?%T'JR.Q#Z,(!#H$B\:+?$,UTP%-'M[^*0O8<5LAP;3T/)8V,"/?)\ ME!7O2DZ=T%YT5&SJ)'?LG[T5J1IX]MJWX]2O>YN+:2YI7YY9N//`TK^+G[;= M,#Y78C*@RGZ('IB;;2;.(!Y#^:/AX880Z_P[/N\(T\=H1;E,])5D)\ M.G3N`2IQ/"9_Y"S5IFDDB;,(HD5QR,(1,=:1.!P@\YVP-A:TEQT-$V?K!46X M_$V2I1[Q8%YZULCEX9/G_U%ACW:U22>;\!895G8D3?&LYSR_LXJABV^!_=:U M';`5?L1?L1]V2%"Y\SZ?H-RFL\;D%JO&+F$Y!.#&DREEM,3[O_+IW+-5N%-T M=O1NM]\=#KO&M+#G=;$CPDNX.$-XSQCJ_>&PMQ'A8G&D,;FKO8#D]7<-]4)= M\V*C6R<F9@K[T288$D+#Y?8GP^[;!8NO3%@F@D9)G42:S"_*DU[?G%1[&J;>FE MHYC7SQY'5"*9+8XH!I89A??@K/UW17"=9*^MH16&+*(Y1X>+/>QZ`!4T9/T! MY&Z7EO+PYO7EPK#6W&77B_6DE=^>%6OA13#Z[0;-;KJUT?*(Q:=PHFS*L/[ M*D_=FW$]&).IFV;E[L15[O$TWCB=0I)^?0KMV"$& MS9"$.$AY90?S#VM./8I/9N3K2X]@SKS\_OD]^/SWN#<@PY`S]\C&@:W0-XJ%KU8MFS;U*UFD8V!L6/J5O%E@,&=E<@3O\BB;S*S-&#XW`(J M\=1__&@-!'=[,_/;O)YV0/MJ>M37YV-A'[2OHF1&IU`N=*^TKZ:">J^[-NU9 MZ!4=.6A2C"/.JIX]("T:3D>Y&=1[PS*JD\:W2^EJP.[-!,-V2>E*,&X55VZ[ MHW1%T';*[-P,I2+%Y=P-0C^2^PM)P@^[,D.NR2(=(Y8Y$VMEXF`O62=)%]B# M;#_G;,Z.N@TNVI;2;69=JE8N+E>=ZAP[X\Q49/?\FMS)8^*IC6J$#PNFJ:SE MK5!7J7!XIW#38S7J9G-D5Z@2G+0B=J5/LY9V5E&Z9+@%6BJ->*V:SW4.?L,B MT.U>(4ZR"3,V&>8NZ5Q>!;I.":U6%KH)N-Q!R$FBI9KGK7,'8C*:/56RZIKKXSW%2@IFWTRYW-(C6GHM"V2`DJ$C:S)"NT M\?[Y)*N1IOZYVI+*F;NO96=E[,Z=74L/VO;?Y>K_)"5F184@K(OM.5A8=OU" MH>7#G1W0'/IS1_2JD8#K0>Y7.*&[6SD<">9[46"ZH^#U*NQ,(2:W)"WN.!-S MA$>G<*]>_!U,3"OY.V[FR1Z%]TA3ZZ^%085B4"X,RI>#FHOIT$\_X;%*I.FG M5[=>&'H/KTK59VG3[%:4&CL.OJWDDS45ES61^C"NQR:/!#]#&?1"79;W&BHNR+FM+FQV$ZSWY MYN2G5_+?2@.1&KYK;I/0YPG=!<_]!."-OZZSK;%3,7TH;%EWK;)!U?<\NY<&R]"-(/$T0,`@8)<#HJ0L,"I91ED"# M-,G0^D/RRP@;Y=@P.K232=@HW:_2VFURVPD;I=Z9UM75Q88Z0;.=Y@"4W1;% MW1'>$47W0ZFL3CJX:`9EZ1%(%H*DHPWIQB@""5D2`LEA6)+#C;-]YD'PEED1 M>'-NR":>CW=*D?>FICKUM=Y`G6`UF5P5,3+4.GH#+"YAA.P(841AC#3$CM09 M@)N8HY'MWAW+K]^RSN1;2G<3HG*?/2`^Y/X#&VT_/K>(6;N#_:WGC[B?$G'K MF-8?2`H;>=&MPV-IU`C$ZA?RKD1:3=656K5NL>U8Q(2ZAJ*N.ZCSN#NACE!' MMHY0IR;JFFOK6XP61SV]@:._1N_WY3__#V(]_/CY.MXCC%UGV,/LG/L[$\_\Z/I:OS.FO MI`M1S@3^N.+CGUY91DMOM_26'GKBT[#=>O5SP4>?XN+W-X*-%\#&*V3C]QH3 MWVB8_V&/YW&U9J^_0,0F7O_%YY]S]@!MW`=,%KRZYI.0/]QRG[5;6HWS]*ZY34*?)W37 M=E^BS*?"F,N!4/0;#?0;-W(6JUN>^OM>`#QCKL!*G7^@98K=RZ?-_45KT5U= M'(:M;5FQ#1$1.K:-#H/00>@@VT'H."3;L:(C5.^&?W4G:-L'#1;`5'GX'46N M&8WLD(]FUOU[<=M5<)&5].;D"%%V-@+-GHM=6H?$#;4PH9A M-,!N'&B!C),1.-6VYP9T,68M)!S<)6:$#<(&88.P0=@@;+S$\!E=C4D*5HF& MCD*7[-`*6$6$&(,&K(,)(7M$R*!#""&$+*QV,6A`*3MU8FET<28I506SJ[Y* M$3[VB`]=G?L`""`J`L0@@!!`%M'0;@!`*.I&-VLV2:4HW$8`63@I$T`(((MH MZ!%`"""+:.BK=9?%K0H9*R!BHF=75UL:%.T&RG.0!EMT5Q=X1W1-']4"JK MDPXNFD%9>@22A2#I:$.Z,8I`0I:$0'(8EN1PXVR?>1"\958$WIP;LHGGXYU2 MY+VIJ4Y]K3=0)UA-)E=%C`RUCMX`BTL8(3M"&%$8(PVQ(W4&X";F:&2[=\?R MZ[>L,_F6TMV$J-QG#X@/N?_`1MN/SRUBUNY@?^OY(^ZG1-PZIO4'DL)&7G3K M\%@:-0*Q^H6\*Y%64W6E5JU;;#L6,:&NH:CK#NH\[DZH(]21K2/4J8FZYMJZ MG*?\0V@"?]*_\GY@_/G''Z+@^,XT)V^3K=XKZ4E^L`/+\8+(YSY%">Y7`KVSR_\X9;[_SH^EJ_,Z2)M1M0M@5ZN^/BG M5Y;1TN%_+3WTQ*=AN_7OXHM99S?/$W[RS0[^'1.2IT-2\8I%KBV;_K75,EZ! MSVS9#Z83_/3JN/WJYWZWU6K-Y4)*8MG8SY+R*PD33KVX_,I>.)"0$U.3$E.) M#<-!?VT^;`<#[90#[6UCH-=:>^RGV:G5^/']##VC(R&CTLB[[>[Z^#]W4^1C M>OM-G-Z^E_&?NXGPW5%"2"4.&&TE]7\-%FRD_X/.0#4=Z.](!XQ6OZ+!DQC'/9[(K8* M$OJ]04<)8JL@06\M4;*YU*:@C3^P[`:)32>)])_T2HI]3A;&PIC)#*VK<6H3 M5V(K;%H[JK80\QMR:7/'>RN\VC`&LU#OE,;5#J.UW:;C:M>QO?[B&.^&'-O` M_=T*J]9T@P?M]D(':$,N;7W^VVG,?)MV:LMXVEE4N3])G>B'EOM_L91J>Q\]X.P]_&XBB%ZG9JIP'BYMJI78:2M^E'[6;= MM^N-EVUJX);MU,["U%U]4US=F-_89]N\M1T[M'F@L0L>:NQT<7@57LJ]LTD4 M4)\S@-(>=DI]I;#@FM1/?&C&Q)BEQN`OA^-',1>3PS>R]]"\QU M_IUE8%RJ=45_:GF7^QE786FW;%R]C<856+X]$61X8X#8$SNQ+"]R0YRTO_J> M"Y^M>'*Z\$+VS$-V,O(F(2#TGWA2E(FCHB66)6WX<@S-9JU.-PIM_H.'28O+ M./%S(4EKZACM]S?B'"V.X0K/T7ZO,?&-A@7`[?&\8[4UIWT5B-@D[>OB\N:, M7;!C=G5V>G9Q\_D?[/SZ^M>S#^SD]/3RUXN;\XM/[.O5Y05\/CW[`D]<%T_] M%@>V:!@I-VY]]D/9$>)]^^"+/8"MN>=N8#]R=NY:W@-_ MFQM?^NFKSP,@TDR$4O9B(V7S>Q2$]OBY0%"[MTM9P)+K([_U(]-_9F@I-9%* M M?/Z?R`8I,VA/>`8L])`#F%/`16=\/.96B-+GIG4/&.8/DJ`G<=N\Y9C@)(YM M<8T6_"I;\GGXS+Q(O&9:5O00.29.%)[`7RG=."7;+O3NPE05?P>H$YV:@@9X M/_<;YI,+:DH'^M'S<\19$L'X=!!STP=&P+Q8'`#09_O9$`H$:?TC?>K+# M>S%,%.\S-_U@+D[,G#6&EX)ITD?V2##PWGQ$V3'[86(B3`0+A:$PW6?9X,#0 M^^_$T9G`<^!U%.38=J$9&T8V\0);NF?`K\@!`$%_'M`K9`9>`##!,H-[-G:\ M)Z"V0H+,&BY,YEFEPDL,'L!4PN>*2Q"?>D$(=%W?`XB.;\T`OOIJ/L>!@$6^ M5=KTY3C?<-RN:%8T^A[;3)I,TWK(RYKULCZP%&+Z.W;]R\G5V?'[DVOPM4XO MOWP]N[@^N3F_O-B'>Z7"#'.3::*PN0[:=[0`[.3ZE-UX$]MB?7V0\M!HO9L" M_!1O0X1@_N?T+?CU*-<$M@VMYGY^K;&G>QOL>#K;F([#@IS^F$_HYJ$QY$"F M]\P1F&!SG0C3\=B=;[K2,"0_`\N1'FFAX%EI1OTL`B)M.>H,<#Z0:Y0R\Q.` M=Q.ODR0I7CH)@``?Y-,F_/EH.A&?M3^'@J4/D8^20)Z&]SX(X`%>O,?97D;Y MP(B*V:?=TA)OQA-W!0`_I:QB(3[!O`F=C,H=E%PW+D[PHI=X]EK05V[.D?W` M]J?7B%UFW]==X3I_B-$[GV4^!_2WY8>Q[ M#X6.Q,-&:VYG`_%#H3?/E2Y!H:?PR9.>0EE'RX28&\$2*1KE4NQ.#P)$EY/G M/"G"A"A>`JM@HO\"'B#W-7Q9VJ%[TQGC7T$$?R3L06:`U9CB@G@034G"@]I` M.V>X.M*=&["6'Y;1%3\):QPO=XR"Z#>R1CIC\C9I[-?3IEY M!S)'DXKO_2T"AN!XR7(FVH`2F\')?$L:ZW(1,8D#+G41OYF:$@^6W7FWW,I[ M,_P;?IYR$G"!M;Y<<`'\G3$4VHKO?M=NQ?H)*IBNXK3X-V.0/=CMRK,B[@R<`#L>B53I5TD"Q8<4B+*C=XWL%:P(%U]9W&[K@+*S!'$F^.'FS7 M!JMK8E]I>^_$CQ@B,GUIY\7;TWOKM5Y'KKVX.Q!FN MY?(4G>AO("UD1C!/&9"8(M-@B6].)K[W3;B]SC..JB-'%/+3GC>, MUHON[MD74\2UNE66[)NMC+/%>\2EDY**?68-'O&/\,!9\OM&&X7%_>#RMK=` M7:6-P+:^$G5GIH_1I(!]!1D+9FL,V`U+1)3S!]N)0!)%@I.7X)U$/K9UXH[B MQY=MV4\/H9T?@O'JY^/6FY:1#6!)7[L=R,*]OK*!Z,H.I%]Q(*U7/[<4'<3" M'>6:8/7Y\OJ:?3V[PLC2E\N+.-BTA'`*WBT(WIU-!9A*^7NH3FPVU4M=@"U\N$).Z4`GP;GBB:F(WP<*24N@,Y!?)]YXSPD4C#-U&[^/V63@H M/D=A0%NR@J?(?9NI)]:OC".];6985^Q*+50$>'X^D!,(UGXJT M8!3WT73$#W(K4#(X7EFD82()SG3W>!2C(<4I(D)"83U//+93<^*\3O?@[F)A6\G>ANG>KM68]/%$9>GDQP=6:9G'MP=";O&5_Z=R: MEM5CK3?=2T,J^,-99< MW#5_2YC+W-RG$7[E98I6[CPG66ZXT_ M*6*77(Z0KUF3KW\A[A6-BXF=B!)Y&KOQ0M.9+DR)]3'2*M^Y*P6*;(J[C7O- M"FKD&TL[E/V)WO*_8U^RP@X#`AF9:L#UT<-S[\&SY[.3X13Y[$#VYZ MH<9PNC#0W'ZV3?9J,^]*%)_$-(+SD+OUA'WA)A:9$G41Q:!$*W-'$#?NCG)M M)$UQ0=5?]EYL(F!QK0EFNV//?XC+E-UB M$?EY%<5C)#[DI)J5ZL6**(!69`.2E?!A<1B_.,8Y.6"R=E%2<+VMRVR?MV(Y M@.V5K1-4E45N=;:O3P412W:)GUR21"$F$ M*E;-J?<\3'6'9-OG+V%Q@1])]X5*5S6_ MCF1H-<`^9)#T'BP?3']/S!$.O9HTGBI,KZ\#;C_*(ZGD(A?IHA_ M=3T2\DL7LMBO:H!TR2UH/-3.L4]89CA,;G$W`'4DZ/7NF)]$)%X2+XFWB>*= M.GC2`"E3W?V#JWE\]!EO_&3ZS,4S32EU3!#9$40,@@A!9#%$V@01@L@Y"?=+9+X"$U]0);7OUNJYEF(5`ZW5[]6H>U1D[\5`@\IE M$RP(%@2+%S61U'F]36FTITDNWKGPZ!YDJCPL#?Q0'!D/N`Q+B(?8'WRHR:M;Q,S]%*A5IT;N(MZL>]>!KF\[[KESSJE!Q9+XN+(U M\>:06,ODL)50CAKB5H,*`MW+!!W-G#1S[B&661%I5(=^?Z5PJR_U=E\!=Z#I M@_X6E80*,!/JMAN8(L01X@AQA#C5$-?DF77#2Y#R?N:^,@%?WHY!/E.W/OMA3F,I/U0L64V5'M0[ MMZM>I6DZG;V%1'&;Z@92#@1)H#D2H")*C3>Z5&SYI4N8BBV_9.F2T_3R94S% MELDAH&++9%#JRQ@.=1THU.C[E%MTQ<##2IY2[`@6!`L M7M1$4FKW?X[0 MS+)6H*[BYB>5^:5BA.4+':-=YT*'2F`2ZG8;=2'$$>((<80XU1#7Y)FU4C6[ MY/.//T3!\9UI3MY^-&W_-].)N#R0=.*./MOFK>W8HH2;W0MHPLX`A\,<5'__TRC):>KNEM_30$Y^&[=:KGPOQ MSRGV?G\C^'L!_+U"_GZO,?&-Q@+NV^-Y[%XIHKK\4%F!B$T"JA>7-V?L(Y.` M&!BZ_HY]/#F_8K^=?/[UC'TY.[G^]>KLR]G%S741!777-"SCSN]1$-KCYP*# MVKU=)`Y`&]0OO60B_3'SOT0YLSQ4!Z)/K4S8P6BD[ MC=:[''YC11#Q9W&J((?/]`T0P%'N];C%W,^OW^2T-_WT*_#&3_K7V!A[?12] MV@$;\;'M@BMQ_AF=`#*#L.T`>/@S(SSP<+ M9(L?0M]T@S'T8S(GUN]G=F2_X6\TT7".;O[-#F5'>=(Q'@\-"Y/L/,OV3"L$ M]@$-X1/G;G(88V+ZH6W9P'7D52B:?\CXQT9FR-_L`Y(E"KM[/(X]Q_&>P'(R M8:0#X#0/Y*;(V/,?3,%1\]:+).-B^*9*WG\72.$&"4]'R.,<:$1>M%CL(UG5 MCDH5QRBHO>:3,,ZG`EBBD97(SV59X;?&6\%^;*])LBC3Q!U_*HA(4HZ?04HA M\,F:%T,L3E)'H)OAO1<%()]X>VR!.%+'1L4*M*LUS6(7,?0F;]E?.K>F9?58 MZTUW$DZ=U%\CXVV[=,R243TI84D?\U5N_UD)ZI6RW5QPA)_#K?=V2.C9-4DD M0A+A3@BE^CR-+_Q`=7Q?NH2ICN]+EJYJ?AW)N'X94QU?<@BHCB\9E/I<`BKQ M^M)%3'5\#T#(5,>7W`*JXTLVA0J]DGA)O"3>PL&3!DB9"OD>7'U%*N1+$*D& M$2KD2Q"A0KX$D?4+^;:;B@XJY*ON(F!7)"CAH),$2`(D`04EH/ST>Q2Y9C2R M0S[:EH^VM0F72@53J>!MU+_98X7'@=;J]VK4/2H5]6*@035A"18$"X+%BYI( MZBP57!KM:9*+IU+]X$7,W$^9174J/2[BS=KE'_5MQSUWSCDUJ%@2'Z^]^-.6 M252W*JT:XE:#"@+=RP0=S9PT<^XAEKE&>46JIDPU'[.UH#[H;U%)J-(HH6Z[ M@2E"'"&.$$>(4PUQ39Y9JX9>E^^=UQRNKW[6_^7M&-2SS%)PH4[W61$VE&$+ M88.P0=@@;"QUC.9?,U%W-?>4'RJ6K*9*#^J=VU6OTC2=SMY"HKA-=0,I!X(D MT!P)4!&EQAM=*K;\TB5,Q99?LG3):7KY,J9BR^004+%E,BCUN014A_>EBYB* M+1^`D*G8,KD%5&R9;$J]B9E4C9?$2^)MIGCSUWDW0,A4:WG5?:7&E\"D6LL$ MD6H0H5K+!!&JM4P06;_6LM%4=%"M9777``=UPH)J;[+`4R,/3^NV!FLWG9EK7I M((FO6]Z.X^?D9C61JKW,KV?-\#K3"QP<"+?(L';V:BH?'G'W^( M@N,[TYR\_0BT_X:D?[`#R_&"R.?!#;#S/;+MYS_]#V,__OGX^*/MVB$__FP_ M0N/G;FBZ=S9V+`ZJ:>S7@(\CAWVVQ_SX%(3B/7`?_@I@C/_\(M(N_G5\+!M+ M^Q4MB@:S]D1SLC%L"\;DHFBO^/BG5Y;1TMLMO:6'GO@T;+?^/;^1X/WS%_-W MSS]US"`X^68'_T[H$F1)HE[]_+7_CQPK*I"T#D>^@DAP'TPE^>G7)M.<5NR M>`MGOT!C)Y85/42.\,A.'CP_M/]KAK;G;H237*/Y-A4QF^U!KRHOYPQD<^YN M`+_M,7V?BYE9\BT!=V:[K76/O'-T!++=L)[N57:*M,7$7EG,_G]+MPYHS=F=$+'FX$37A?D0E<[W:K,@V(7HE!FZ.K)C:MC*1>IS*2 M5F7*!K-"/=Q8909H5YX`5F7#9J,6UF0)[?WJGNFJQ->M^?N9@(S6UABT'L^=OU_?2M&<`:[-VRH$Z[LP[QGRXO/_S]_//G(H6?/&_T9#O. M6E:H;0S[4\0DK:W?;146M.&A)=W&7VCLQC?=P)%NV\D(]]C$R?IY].0>SSV] M+%"_3&3=4FK+^YH9@]@/FX$;RW:XV#]QBXN)/:X9O4M:.7%GX)&UD&Z1+1WH MSX4-S*F-R.\+.Y'?:W)O4F,!]^WQO&W>E3(YEA>SJ'$[].+RYHR=LW3?4W_' M$D"SDXL/[/+FE[,K=GYQ\>^:VM@'S3` MOH`P_JD;XL\G,V`^M_#0PXB!8L[=8_9P-`''_6!7%*01J[Q;62B?!?<<-<$, MV36?A'%!O);&$*VBRWR9//S6T*#;8,+%32C.L\8FD1]$IANRT!-$F-9_(CNP MA;7PQNSCIS/FG$QA[O%E^E_`"1VDZP'A!=-Q#V3#/H-.) M2!<*^!W^6]H%[LU;\+;G"I,4]V;=@TYSI#+M%WTW$RN[0]]/P=LMP&@6*'-P M43C"L9R*I)Z0!![^_I;9(?QH;6X'2JW/D8WP\Z(`\#*;;Z7Z+894*;'Y!:Q. M3=]_1GMY\N!%6[O>96^UK*CX-]5RJ:N6RV"P5O;O3M4YOL4'O9(9]X/2>95* MHQ<.:6.SK39)HU]3D8S^+C7IH^=SH(19D>]SUWIF8;9@)DU2,WUQT&VL/JTY M-2TZ^-ZP^6IV%;VYFE'JAW*I'R(L0ZD?^:C;JF&*$J7=-%("G2$KJBT2JL4V M;N;$FSR\*A8:3D/*I@PI8Y#-#D(,+5GF1(1=_LM'(%_<68%?`]SEL)+=+T?L M?F&8+4AV#.-'BL$G)&[-X.8VXT'KV\P,+Q0^HO#1GF\&7G'25C>"1%C9Y;5! M%0(2ZD*%@HV-O\+J*'+-:&2'?+2MRSUV8YLHH+R'@'+%1:CB2^_XR-)B^!/L M2/$/6@);V4GJ]QH0`!?YAQ3I5FK/J-,;JA_A)F`0,':UE=@(2YK/$3-S*5%D M7-7<1CSJ='5EM.DU(4,E9+0'RB*C]KJX1FXK#0UM[8&K=;9P#76V<+/@:^T[ MN%LFL9YBT76JPH[%3,AK,O+:=4[/NQ1S50]XN=-;\ZQ>?5>!'`NZH8&P0=A0 M/URZVSR:J8-):VVJD/8*VT-47J MM&`#PE!X`X*0L4]DZ%UULHDK;DU5C7O2QA1M#ZQ`8[=7IR;0SA1!KS*-O4Y3 M-T4W/CU`FU,OU;5H4IB,L$'84#^$NML@.R80@A>T1(MZ-.AD<#_%7:E")E6I05$Y?]44&;:%-*)62T!SUED4'Y4FH$ MW@]E;\!HU:D+M"U%T*N>JM>MLS*R`MM2E#%UZ*Y%D\)DA`W"QM;VW1<5P%;& M"Z7"ZYN05HM2]&M=BNU8P(2Y1F)NT.XT%'-;*O7O5*]!_U)OZXSKCA9K^6O3 MQ?SQ/]NUG`@OZ;3=^-:`^*H`VXWOR[3D_0)X?UW%VSJA#]&\#"O+"T!-8)5O M(ID,/2]X)[`#YCU"A]"-[3,.7'L0S44!'T<.//;(Y268W,7[91_Q'VQ[##^P M9V[ZP?1EG^77=N9BVXQ_FR#Y2%GDQE=V?M?1LPM,=:,G_AA[@BSXS^=<_.0B MT0_`_ON`<1<9-EN6O7CWJ&RRG;L@%=:(Z[=O%(=;#-7'GV?O(:YV-7!V+['O M!0'[ZGMC>^:^:_&;_&G#.Y/U;@^>F[HV.6N[!EKZ*]#2U0?]K9%BI*08%4CI MM'K;XXJ12J@**0#=?F&_TV3L^ZY2+GO.0ZV<8Z5S,$^%$%4=Z*WZ;Z2KC;DW'&[7[C$?8NT'I@D5K,RQWIO M0)+8EB16L;''W6Z7!+$EX[3*#'-L='O&OB0!+P-;I1MV])Z['*:2U^6\@T?C M)^/G-C4%[3+\S?2R98I74IFAOG>*5\16I\S8[IKB5:;J?IDJ+"4X1!V`Q;(] MFDLE#[["SQM2U]'G($"V7A]9JZE2KS)5/C=1IA^X_/0:UY4?^)C[/BQQ3N]A M^U^0"M:MJZQ[HA.+,N/@/)X:2Q7[S(0 MX-CFK>W8H5UE0'$[G[-W-A92;\F09KOBS?&VR$?/)=]-7V\X?&?7T1$X5\5`!IQ]`6N M9.-?9=NGXI[FI1;WW[FWGF_P2F?3DE[$<_Z7DV]V\.^,VLNQI%62*@E=P,T6 M1A"&RU"_8!3*<[6`K%UQM;TSGFZ574L5L:'#7#$0\>)UI+\/'5EFPQO-TX+' MORN>UJ*0'8?G8DH5.YZYT-;46>&,P&IU8>V;$EZA1NG M404\)F_$+VSJ7QF#_K+1%7K<_9!6]*6,]C+SO>*(4J.!RU.)T9Q34-V$G+@C M\7;>H]A0?)UV:YG>+>A=I8&OZC"#E)[5,VNW.L@FC MM-<]CW%%@<[&*NL8X[D+&AYZ?J49)/?PIE&Q_I+!Y+K:V1!6-"W]90)980P? M;5<L0OU6>"A+1K*H[YV-:=6##",BV-^SXP$.\\_%:8RXO.9L@WTN0 M$>\>;C8NH^@5S"2E7/.`^'I/&`\7\F\6#>*OS-O`<'N+Q;NE*/<_2&?_P MF^E$XHQ/VM8L]Q;3V@)29WRZ>:WOEG282=KZ,M*+UG@IZ>DC&KIJ=G`/$PP> MM<;#83S$.'WRRES2D_?$:_#2Y7AM]HOS&#,G&I;VLZ?1+).(.)+3+WJ>U4=S M93XQ3"/P;6AN+L'PU)?DH7/&?F$R=65@Z/H[=G[QV]G%S>75^=DU*./9C3KI3#OE3"X>()P3 MM$E^#$U-I"+9@?@24VK&GN-X3[9[][;B`"V.,VM"#?[^EMDA_&CM<\Q'(O_* MBP*8$X/7)4-)D_WD6I([3IRZA[.:^#N8F%;R=R$5OM5:,Y5/9%"O6;5GM?Y8 MG$D9>I.W["^=6].R>JSUICL)XPH>:]>*V`-QL[19'LH'B#/F)F29%+K%Y>?JK::R:Y$3'!6'XP=NQ6C49<+EBT7C5$&,Y1#=5U6?;9=K M68!ZY<%Z%+EF-+)#/IKQ#FJ"Z6YJ.>Q1QKLB00D)J%1&?*>*,K7$7JPJAUG$ MM'IQD_IKEW3JK%U"1<1?##"&K094EU>G=OA.#>K?/?\//*8P\3V,VI-)5;-` M7Y%N%UE9-76H-VS`)2>$D#TBI-]OP!JG MYLO#J3XNU2HMH\W06MVF5BLEU#47=7JOJ769J4;NMDY8G(1L=O]9'$&<0G7F"'[,C.59L. M[CT_E.G8=OIV4%+U+?WMHVG[>"J7YPX?KB,;?::HVJ(NMC'&_XL\+/+QU;>! MI3(A%O6??3']/S#E$:^Z5OWSZ)+4=HC_>WAK5]=,,X`7G%L3HXE MX6Q;'8PUU&<2S&[@2M8G(@M-:/UHT9VP"TJC&5;-''B^#''X'@D;=0D0=)2//9:%K2=&YF4%ES\POVUBEHMRP-YT".]MPW715LH\# MO5##MQI=./=%#WPF8SCW2/R$OF'BL%'(!BWIH6X"U\ZPKDB;EBLGM("^7,VA MM8(VG4)J9&G3VZ&O"O2Z>B';OS)](N1X]I_(#F?2J?,2<$?7H6?]<>\Y(^X' M\OGU`H3=3L&-6-;-MJFNPM^VT1[,5YW%5'M@DQ$%(8)!%G,L+6Y6-7-6-"B: M$XV5E!JCE-I**;6?IE)J3TY/+W^]N+EF)Q8 M95O"J=WNAMSD4V>93"J=X/:&*^X"!&?G0=ZAYX-/@->^W.7W1%(.]]\%XLK` MM+B?K#'BY_!OBD5/U:T7RN*E+%Y5B%LKN>CEITU2%B_!42$X4A8O9?%2%B]E M\5(6[TO*AI`KZMPZ@A(BE$K8[&MZSU#_G#M!8_?0T`U-'S8WT^REI_-^2*Z> MXG'!83*MBF82Z4W(UR2$[!,A[09D(QZL#WN"X75QLP.>'GF%$1&_7ZL\M**2COY"X\_2'JMV]N@RG)OD[2ZBDF MI?7;=>HHE78@U%6H$ZGIG6Y#44>E';9VF+&X6M))\#6@#R?3YZDY-A^NDD;BH^=>T\BT8C?$,)7Z;/61#=_LZMD(5>;DDBLKVBVX#_)\*_)MRWO5&`"6"1,Q(MB3:=9SQS M&8@[*(6:Q6/16#2!)0XLYZQ[\70V;&8'[-8,^$ACUKWIWO&9ZA*'`H@*D3=6 MOEY,D<-A%%A&>L0<+P@$.(+("5$H8O<$66^[\K2XJ/;A13Y@(P`SPOT`1?Y@ M_H'2^4]DXR7F$_-9=*")SO,]FKX=I,WFD"%E*'(L9V$`/=R;(?3Q#%T`E+D@ M2/XV5;WDR78>ZW*E0\62MH_#IR?P+,\2S]B"12^A4'&(.%IZ\ER]H@+^A)GY-H+GN;#O MZ!WPN]A&HR@PXV]$[_B)OAK[B<<*$3)2('WH#A,YY_8FS$0\`LAJ@ MR(W&IH6&!__`U'GIBD03@$LH/;PG/)12XWP)$P^88M>R)_!DYMD` MS,[<>S3&(W;V+>2^"S^?X@3!_4GD!)+LH[.STZ^H7(CTQ6?KI!KT,0OA$7/: M@;!$!87FA=YDR@7N=Z0&X\LBD,*"YR#D#\!?Z;X@B:[G@LH^F@%.2O?<],7T M!5[\6CZS]"Y=>]ZCG?W+"?7S$,#6R#R[H7R MH5!^=?'L);L.13(^.@=1(+31,@.9G1_(U`S\Q8T_PS0,,ST[LM_P-^A:Q7?! MNJ_%971WZ"FDM(]-V\'IYRBO2[]\S,$;WC*M*.3LX=FS,+4&I&*[8].WI#QD M+[(U,PQA236E5U_.\VW)\6(KWAUW;0O=2.N/4IB`]<`EWCWZ!A67,!#`SV)?T3?UJ9$[O`'FU3 M=&ZFCOV3'=Z#S\2R5J>$C=[4M+2QD_OLX;1I3$U$Q'WB+N#=86<.K!5\D&%B MRHXN_G%]]A;ZPD8\,&4LW[C(O>+?@.]"=6:'\2B]WV2,`MP<^Y`>WRCE&`,W M[@YEE]H.=#DGW,*J%0D>$MN8:%)G(.8J^R[RH@"U)JYN,:MEB=7\@#.&;8DQ MGWI.]'!KFZ5PF`+&WR*7EQ3E$R>Y$S&:"%-8NR&!(.+Q6);7BZ?8I*9?3%PI MHS+Q%F69><93>@?V#CI,TN)L&##JL:C?(?J!=]@SZ'`@?&.8L/'1'#TME.@8 MNY9/)4`7PXWS:KI:?@4)CSDVSHO0!Y@C`5/IQ">J:MF^%3V`*%PQ51RH)P:8 MR3*4@(OZ-'!,*UZ0?33!C'_RO2=0YS,Q)\(Z#(CX;#\(]!Y]%(IGLO<^"#>X M9[_9V!\[#QS,[D.YR@66F,K`*B7+2C?T/2<0?L;I/:HZSSD@\BW,=3Z&GL;I M%"VP=Y-,9/C[YW#T9@J-G\]N9DS_>]O[!N8.%"N2VGGJO9E]$Y^:MDGY&I13 M^;((-&$BA=43,ZMP0.3,D,P48B3F9#IQ&U^5@Q'OCH2ZWT8"J"X'=O@PDQ7G MZMCD,/1ZQIYC>^6Q%P=,O+U8L'A9NA^)>4S0,HY\L1LAH"DH2BUOYG:R]!U! MC0/3N2S"!@3YNR.^>Q:^N]Q1+DF<**U6]?&ZRYWALQ1FK=*Z2YM6-9`HM MCC1#46[VRYOXF6D,9Y>IF6J!T7^7=[?9)\>[%>ZB/WF3'W1Y"G""\Q3=[P3# M\@U>@\47B^MX>I8R2'3&PQ1C.86`C[=5EY1-^:2)KYEB`WC]Q&&A9<9+K]0% MYZD_[Z6!@H,ULG_'R)98J>2`B9$30-Q<&"V#A)S-!`"*:Z>Y:I3#-E;(>8S- MD5ABQ]6ULF87K=O8T37H,4:=V.GK"D&JV:A1%H$"=^G4A!GCJ^\]VDC"+3AS MOP;"77G-9($M5+V3E.*9F!0/L86D@??/^/:YF[Z:O;EA:99CW9BN^U2]9T7& MNUJMG.-VI[/E\7X$2R;]O97'F[Y:HWQ[+:/*@$NZ5F3`JPE8[[;K&"X&_4O& M`'8*S-=G^'%C'`Y:,XJ7M;XA+2MCI#/<(BW]56CI]&;TLS92"N7EEI%B=/5! M15H6:,=EZK6MK!WIJ_69@VZ_DKDOZ5F1\:ZF9OUN?T:$*X_72/85Y)*>S\G6R^;#2;-2?(=F8I7BFCQ(ZWV>[Q"=Q^'@>R=FCR9.KT=RM M0O-L)RG1F?<5&_L9YJ9/)`]LZIGT>]WIU<-,#[52MYH#HO?;>G^GU*WB:'1[ M_5VR;C5WHMZ7JCYO,ZP2\.A=7"@6+A_,0<$&=-4 MK,(+4;U]0TZ<)J>T=BCXM,^*$C<,A26^VM`WE/BQWNFW%9'Y:E!?5>:M&HS; MYH-:2F:_U5',!J\FEC5M<&`PK[VT-AVYCC0&T;A*O%C8=SG)4]8G`5 MH:R'P79O<\W;HANP"@,VG!3TX>;*N-;$M]J6PMRUD@H"*UZ_L^59O-T=*&(_ M5QOXBO:ST]O<6:E[A;+*<->S3(/V"L(5!VWD77%S8[/B(?G,1A',?L%BSC1; M.UF5+C0M.$%.6UC.)>LD@MH:J*L$K^&@U4H M^^CY'(\!RN^M9X:Y*X$C3>>=:;NEE.)1-Y_?#LAENX\9.X[9RUW.=N*.; MK.&3-,E/7*)\8W[;T-,N3O9;H5%YGJUZ.1;Q;%5GFGBVNFO7+C%'V^.9G)HJ M7D@F'J[OUK1VX:;(^QC-BELSQ9.)ZXPI])(M.3R.!#YF M^*RQKXZ)B4#);7+">9TWO!LO?C]Y7;P,BIBYW!L.LW#`MGK':HQV-8@6C]?6 M--KK['KDW/W$2TGX=) MJ^+F:(V=!T$TNU^>/BT>%H]N>E*HI,DM$E=EZEF9N$`2%]R;F/IO1B$PW/XO M)J.)*\+QVYG39-,M7XN'3K(W*S!5+UX+W&H50+ZPB_V,HX3_VQZ'+<"RZA@D MQ-:1PQ+*9<.[I;H"US>D>F+Z6+X+-`XI'GF.@^FQ,&5(ZI<0_]7T+WT1SAH) M'?O*?=%M%?:W9X[>M-ZT]'FCF=?3WD=6(J)MCRQ&FA>%F'PLLJ)7A-ME[M7Z M-277^KX&L;GBE`_"LS@?!7%QIF_,[?RN=C2`M6\I7X/VZ[C$0D5W+MP!I_`$_7"F&M/&^+)?\FOKCT-$SN''$^VA.\?\[_(C9; M)`T)"4NW6A(O9XH+4\3EQYM?,$ZO%\6Q^))QEB_5,`-H'6>]4\BG6M3!KNBN MXL<7CQM5HCL6+1.R97FQ5[T2?AYLU+\(OCQ%?1=%ZSKZF\Y4W;K_G2IO<77V M^>3F[,/QUY.KFW^PFZN3B^N3TX,N7'>9E-@1=6E:?0V+0_&IZCKLFEN1+]/Q MOB;1PY/I@DC_RWT`]I>I"B$RZ_\H5WE$/)6O1%*:UP]]!!&JNJC09.>*+V$Y M%BR:2?VYN#*GC'0*7X^9:$72HCVIUS'Q;4M, MSS(/'-9RD\NB*`O,8CY=:R`D+C@D.1)TKRLJ)+0+&J?Q$2/2JG.4WRP M=28`G1_YK1]AI1-CH,5E7SZ8C_8H8_MGF\,L^8!5H'!N&-T!-JYL#PMY8%F( M-+_F]EE4JWCOF?X(.9S,LJ+HQRC](ZX3=2KKG)0*^HO_AJ6](B@G/MIFD6MF MAM"*RY^30EEB)86-(D/^(8K@()Y,+&F3T8:%4KF/E:ADE97?$(JG]Z8MQA63 M)"@O)>@74?PW*WQG0FNN#3X,9E2Y6`5'5NIPS"=0(%FDZCVW_A#D9_P3#>)_ M[+WI8YTTS*?[_#6IUP<:,0;_)$@K3CG\#A0HK9^%Q^1U3GL<&*@<:$]Z!SHL3; M[$7UTX6/9,Q\/(>@5HZ@86>&H+6),&:("&/VCD0NENNE)7Y%?[D%Z<&:`=0W MH=&YTHXP%P$?;20'Q2?4_AF@YV*99E-4\?S\^53+D(?R$9J7*IV9:KTH`>FY MOT>NK,(HYK1YU8XLV8=0]NE9<`X1I8IP(ZN]SK9TA/WFJG>5%Z"[Y>$3I@]. MU39+S-\L"=,%*=,?IYJT9*4Z66M33F2R6)W.$MZAAINBM)F8@<4Z$'_CWR8B MU\V;M=?MN://7(A)4DD@L2#44H=5C?!=)%KC--P_@?R\=;W MS)&XA,1^N`5'@L>;6H_(%"H5%5>,?%`[<*YT%HT`K(& M4U8-+9F29-W,2:Y210Y,60WTD\S#G%(H_%I,SL+]PP^YU]%L8*$[4=,79I&< MK8DF^*P^T+HM.8]D?IVH4V=;(1]-.Z73;H?&VOB>>!>C86*"$/-![(C:.5]3 M3VMLWIJ.*,"'NBJ'#FKJ2L6,9V_\_0V;\F"2HO`CULNZA.8"GJ=6#F&N-I^F M=?A$`5A)SQ@0%9^8MC`IHB:"*"/[X('Z_3=NU/)` M_4'@YBW,`ZC8"HQ/6^N$^IL M6948;Q80PX]COR/\46R?!)YCCT0;B6R">\Y#X7.B#PJTE.@++R^] M8UD0.>9D'A2R2F%:^A!I`D*D:MB!(-J*O4W4"F3SO(DOQ\4#-2X?Y"H6F5'- MKK`QN6^KMA5ZX83&%88D5+E5V2%:\MA(0U4$C3ER7J,?828/%O MUONKB$*8KAL]R&5CTE069UA6[%N;NAAGE-SD@:S*U4'-0_`[P8^R9@7%O6PM M9'F.(RW**%.659=D5ZN2U\X(B&\;*>E?=!O?KL/B4LVE2NN.IA@TU9/>'2X9 M;!7+<+#:*ZH3.UR4UC?%'(H:@CZ3-QXG[MDG[HJ"JX4JQIHH8XQ&-9Y9Q?NV MZ>"<+\KL@B^7Q"%DV=!"O[OW?,6E,K`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`;F$^>-PI*<[M6)+YP@4Y9'[72MYJM:;<+-0)W0-]*FP/MPM5[6Z=OQ?L, M!H/JY,7?E^87YE_<'':S\V:A_5IHVC3ZNQV:-HI);8.D#=>%\TB2+KPXGO]- MI)IAO;GXDJ&YE47%2YA=*EZ!-^(7-JE^JO=F9ZH%?>QV`-6JN978Z`H#R,P- M?@W-B<$D)S(7P>0Z?F9SK8(!SC>0N6ZV3O0J:M<>SL[INZ=YQ5J,_?G&:YWS`8`VM8^ MQWPD,E>]*``M"%Z7#"7Y&(K#T19WG`F>-G;O\$21^#N8F%;R=SSN)WL4WF// MF$XU17HH2'>!=%^2/A@]I/W$I!S+K]\R8_)MU?[8 M+6:P^)C?]9;]I0.K%ZO'6F^Z$W!6,9VCF*?%!(_"D9+$S=)F>2@?(`Z,T!PZ MXSX2,F\=7&H"L7$7%6E8#OP503[#G/5!/GL2?>8`[!337._)-R<_O9+_SF5< M?I!(U3NFA,@)CHK#<28/[,6B\8><$:]@SLMS9E><.M:PU/7VNQ+JE0?K4>2: MT<@.^6C&.Z@)IC4S6ST9[XH$)20PI?+L]@[XXOD_O?J+97$^'K_*D1M3AR3, MI35V)/N]ORZUZW(H^U.4*_.)8=:/;\,Z;[&JK#!R_:^Y$6P)-Y5QDJ-I#1*^ M6ZMGP>:TZ^%Z70\ZG1K593,V+)($`6/'P!BVANH#8XY)?;J'6?D%&]2_>_X? MF/X\P5J?`9G4^DFH186Z>@-4B!"R1X1T!FWU$7*P?NM'V[6#>SQT@OOB9&75 MU*'>4%=?AP@A>T1(O]^`-4Y55[9B#+N#$2L/F0`H; M>=&MP^,99B^KMI5(JT47#*W5K5,;=BQB0EU#4:?W>@U%7V4Z$Q9'S=>?/OEE.)"K$8J8#UG>*PO2,=%)9@'WE M/I.W(OU3],46W*Z0D9GO,^LRZ1&S%W+]78Z3WI)[D9IU>F;7]?MRIV*8/"_B M)YE#P70!5/Z?R`8]$#^$]U@5&ZNN\2G!R_*?4\(7DH/?>0*"K&Y_4F=QM8IT MXD%9'.Z66V:$!<&P)/%XS*WDJ(^-%:.!L$#4S/0B9X0%-4T`TG&"I*HEOAIZ M!FBNBMB^W=L"&Q#QKO%W9 MRG9JUU!_._5:7O`R$?5[:3=5S;TR7>L/6NKOEA%&]HJ1@4X8(8R0'2&,'(`= MV<(AXR:X:W^7=S23IZ:H]ARKKSF$C[U:UVZK`=:5,$(VA/"A*#X:8D,.-J1V MFC\Y=$?NFL*JU!UTU5$=+6C%X#C"UAA*P((419A#3$BFPQW0D=M]J/ MF%4!]($FGFR;QIHR4-J].DTGY3T1_%9)4M:Z_3JM,L&/X$?6C^#7#/B56;^- MTRKKRE5PG0<##8*6\2MF4:"EK2+:C=-GQ MDMAF>=;D;/AR3K02.T,JDMX6K_IFTOA*!X"IE2AGTWV6JC`P]/Z[@'GA/^#,Q0WD70Q!B0?/X>B[FP*-Q&7QO'#YA-F7\B!DP MF=$9R"KG2%PRQEN?_5"&YD:E/F:&Y>`+H5,"DFJ'ORE1@+#2_!+BM29:4H5P M];!(%<)KLTN'5R&\XOI7\1,*7X5CO>14`L&.%/^@):!2B56CO]L33`&=62HC M88^EWSL]JEM-P&@J,-2Y$V"WEO3$LJ*'R#&Q"IR9NSZ=C*N:!W6..EUU"E>_ M)F2HA(SV0%ED5'=55PETJE:IVE!G]SAWP:,"8%^%Q'I24.I4A1V+F9#79.2U MZYR>=RGF#<_6YFWQOG85R+'8AF.QE3C8SME"V#AT;*@4+MUMON?4P:2U-E5( M>PY=>P@;A`T*GM(V5&,4:-"$&A2$$$)(<[Q6VIHB=5JP`6$HO`%!R-@G,O2N MH2PR:JXI0!M3M#VPJ!1+KTY-H)TI@EYE&GN=IFZ*;GQZ@#:G7JIKT:0P&6&# ML*%^"'6W.;IQ@CQM2I'6D$4E;%#@E+:E7K8*]?0&9,,00O:(D&Y'G0R/!OBK MM"E%RK0H*R8N^Z."-M&FE$K(:`]ZRB*#\J74"+P?RMZ`T:I3%VA;BJ!7/56O MN\T:PY0Q16$R"I-1")6PL8]]]T7EU97Q0@^DYGOU"D"[+_7>KW4I1O<,$.8J MG/YO=QJ*N8TO0:A\N4#I+0>G]_`&T&^[[-3T_6<8-CMY\")7U,?_Y'FC)]MQ MYE]MD#RAZA4&OT=!:(^?*]UB,$5)@9"-PLR.@\P,[SF[B]G%GLP`;`WT*X+/ MH2=^+;O%X.P_D3UYP)L)`GZ'_[[)02G]A'<@6/"VYV*IU:0W2P@799OVB_<7 M%"\N6'X_P2I6A/*H(EU[L.92E$K9U[3[/VV3%V],42'[#5%+ MM8[G8T3YTSR#@?HG)-^;CNE:,`.';,5+*@YS:W&/A6[;FJ&KD^>VRZ,;:RK2 M;H]N?/1\#I0P*_)][EK/+/1--W#H^(;"T=(F7%Q>[]2T*)#0L/EJU0NX*)#6 MR$`:3'O#_J&&TF:"6:4ALVL9AV%7?()'!F%Q=NZ./?]!S#T:NWU.GUCECM#X MG;317)OOG^,?*<@VWU3=W',,;<%_KH>7?G(_CI#L.GJ`!I_9 MV';!TMFF`^^FC(?.?1%(BYL*F!W`YQ"_#^_9+7>\IZ4AM$6&.V7LFO>%;AKU MVN!N4*?*1:Y+5!>?*6NL+,!7[&!>@"[?9@5."BN53>LO-(['XHDD]"9OV5\Z MMZ9E]5CK37<23D7"MG(D<+N4+@BRZ)UUXX)L;M2YYG&5)$`2(`F0 M!)21P%;.=G0-]??*KN(P,QM#4PS(X+YK.LR*[VNA&BYJG>_0M7ZGSC/C5+SE MQ4"CJPUJ+>Q+T'@QT#@F6!`L2E+>M%ZM-1>:1X0?`: M<&Z!2T8.F5(Z=-3NJ>./47&G_0-"'U)Q10)&J:4PZCRB2):B\8#H#-59KZU? M_>V%N5TW7F@ZS!29Z.1K*:4P`ZT]5.=Z-YIU'S'<(-.ADR6E*4JB= M;T\:!H4_"!HE7;>U;A-,+4&#MB<)%DK`HJ/UVPV83`XV4O:!C[GOX%@JY2><==5-^C MFG%4,ZYA->/J/+:S?XE1S;B#J]=#->,(*A6A0C7C"#54,XX@L@6(4,VX';E- M5*UI/D9V8S1(`B0!D@!)8!<2.-B#?U0SKE&'-G2MU:OS]@4ZS_-BH-'1>MT& M'+$F:.P>&G0"D&!1TG57ZQL-R*8^T(S9K&878TUU/@@J%:%" M=3X(-53G@R!"=3ZHS@=EV%.-`Y(`28`DH+($#G;CENI\-"KHWM&Z;762QV@_ M1B%HZ`/-Z#4@;9^P05NX!`LE8&$86K\)^3`'FO.05?HXPE(?KP'H%CAEY)(I MI41'NM89J)/H0`G]^X?$H-]2!@\TX2H$#+`5K8$Z$R[9"B4@H5)J`Q7_H.(? MJJO,0&L/U2FI11.L4M!H=D`1(`B0!E25PL!NW5/NC84'WGD*)0K0? MHQ`T](XV4.B6><*&0MB@+5R"19G)&&J=)I0+.M"_2P?O[3_S#VXY^/CZ?B59Z8;G+BCC[9KNEBU(VLB[1$\+A>9><7'/[VRC);>;NDM/?3$IV&[]>KG M@MLXQ=SO;P1W+X"[5\C=[S4FOM%8P'U[/(_9*SFB[=Y23[1`Q4:;MO<2:T<@.^6C&.U`PN5=)&5-Z]::1\GY/_4CYC6^.>'X=0?%Q MI<(:?4UO0@(<06/WT-`-31^JD\VSRR-B3;"L'R(>UZQXF#C>,R?3N@42ZE&D M00.TB!"R3X2TU4F1(Q]VYC`NAM=-U\)(N\]&7G0;CB-G*EZ^V/22+NU0E[:R M%MPY6P@;AXX-==Q:H[]+:YL[4F>.?H^"$'>5R"N1 MIN3%HCL6,:&ND:@;UGQWVBY%O/$1RY4//:;'+./SERP]G$'D<_9/ M?)Z)%_XU<^*R<*HS>ZU!)RMW>@3PXO+FC)VR](2D_HY=GWWZ MW9Q??&(G%Q_8Z>7%*7Q[=7)S?GEQ7<3!+N["PT62/7[>^SG4^%`I>[3Y4\!L M\"5NHP!\Z`!/HK+PR0,L"!@&4VS%\ZC9W5+Q(\(-P5]*KQ**'WJ3T]'TTTUI MRW9GWO$1TC+B`7`.]$"#\;C1V+3"R(__]/_@0K.0@"":)(IV=G;Z%66` M#%E\=$%RJX^'/!\YO&R93B(I(:#0FTQ9F'Y'"AI?QJ^!T'N,-HYRU^-(@N?73!ZO.U.^(0/?(0=81.VQ8.Y$E@D-N:)NIX$/6; M&7B_<-,)[RT3K%D0W0;VR#;]>$@!LR+?A[=AC(DD`\_A\*Q;V[%#&XB(0&%\YD4^,^]\SL7[3S;P]=/9+Z=S!YB`G<,< M%8G!)*.#P8ECUQ@POC4#H!.&[J6E3&W7`GF5MGLR>K!=.PCQR4<OT$F2%L'K=\`^B*]"CW$3NEND8_*$O^4%H,JN%X*5@;4"2L8,0]^^C>2Q M:&@I&W:B^EHZ&'&`2@-#?VTZ>GA`;$N)VJ!1>>DEUTJF]M)&>(7X/>!2 M$+/T@/TV9IHU#][5.,^L8H+G^G*)I2TV)M^=3D(H=C`O/R#?)MU?6U\:P3H+ M/+J_=M7[:V$BYLLNL*WS$,/^)487V-:<@J#^H6VZP):@4A$J=($MH69UU-`% MM@21I1"A"VQWY#91;A-EEY$$2`(D@4.0P,'6(J0+;+=Y-&(+=:+[G0:4]B1H M[!X:76U`N;@$C;*NJ2@AP:*DZ[Y2A^]7]^B4>V?6U1WA_[>OXZ`$/E0G9X5F6X6`<=0V^LH@@RR%`H#H#-59K]$]MLE1=+K' M5E6%&6CMX4`9C:')52EHM#HM@@9!HPP:P[XZ\RQ!0R%H&%VMHS?`;!QH!(RN ML6V:0NF:85#X@Z!1TG5;ZS;!U!(T:'N28*$$+.JN+=.DPJ9-<,_H&MNF:!(9 M6()%J8&MMXP20>/%0(,L!L&BN1:C:KQLS3H+.1]M,[(W3.)7HPCAG`(4>RI# MNPJ)ZA8%5T/<:E!!H"/0*2U1`AV!CD!'H-N@WN\NJN]1S3BJ&=>PFG%U'MO9 MO\2H9MS!U>NAFG$$E8I0H9IQA!JJ&4<0V0)$J&;.BX&-6):ZHFD8$E6)1TW=9Z;7+)"!ID,0@6+\IB[+\V!Q7ZV%4Q M!BKTL:="'RZ8T"5U/NH\\K)_@5&=CX/+L:8Z'P25BE"A.A^$&JKS01"A.A]4 MYX,R[*G&`4F`)$`24%D"![MQ2W4^&A5T[VC=MCK)8[0?HQ`T](%F]!J0MD_8 MH"U<@H42L#`,K=^$?)@#S7G(*GT<8:F/UP!T"YPRL,U$ETH(3^ M_4-BT&\I@P>:-=7^(*A4A`K5_B#44.T/@@C5 M_J#:'Y1U3W4/2`(D`9*`RA(XV(U;JOW1L*![3Z%$(=J/40@:>D<;*'3+/&%# M(6S0%B[!HLQD#+5.$\H%'6C.0U;[`TM_D">FE.X"QNZAT=-Z34@4 M(VC0OB3!0@E8])4JATN'QJC:1U,UB0PLP:*DZ[;6:Y-+1M`@BT&P>%$6XV56 M^_@]"D)[_%QP^=J]I3[?C>#F!7#S:E.?[V-'.A_Q8(2OLQ%T.!#,.%6:#]RY_E-3M;I MIX_5ZTY4I670DK3T>RO2I7_&) MY^/APP]V8#E>$/G\!M#W'E'V\Y_^A[$?_WQ\?,V!=/=.8W?^21?.'%')U./G\EE!*PL7`3[%1__],K"T;7TEAYZ MXM.PW7K%(M>6O_[::AFOV(A;]H/I!#^].FZ_^EGO#3KM5JN5'U65;OO.]2;,BY]A7'I?:/;VVA@]V!/CF_-0*ZV\4=13F)F M-/C<>WSL-/?4AM1WN\-IVDL[V1:MJZD\JOL^::VJQ:U7/QO[Y&IUO01*V\9@ M75*GB#CQ?=.]XZ)ZSNTSRS_WU7P67Y\\F?Y(8UAE)WQFYRXH1(0_!.Q23'_A MO>FRRPDV%V@,'(`QMW&"M5WVE?NV-SJ^@(XNQV/;@J?/'B:.]PR.RC^_B.GP M7\=?'7@?X9]]=<6A$]O"5JY#F-:R7RJQ-C>H]\_9(_&`Q'CD:'*#$6.Y@:'$ M(TG'<>[*42S3@G^+=F^>)_SDFQW\.QN"&(&D_]])?&X.M7^WP_MS%R9^>Q29 MS@SEP?OG&SMT^.4X>TAT!@R.^9NP-^X/>7MA/DB2\`_DL_QM&E]Z`5_#3K<" MOK;":$5`.Q^#B^%,"%T%H8M1V.ZWN_M&X2=H'$%P!-`(L/'@]7$B_1T:K)A. M04V0$/G)]X)@F2NQ3[''C*HB:[U5R4_8B%4+A;I8X;U8Y#R&KUP``NN#R`FQ M(Q+Y/$T/P)<^S1A5!0Q&>VC4H_FU@V$/TEW#CB]F;V?/JK9_'B[FSQY9\QM( M$Q-+S9")G]D',^2*3C3K^!>B4_%@$`_UAOL/@7@C_N(D%)WCP"M-'(/]@EDT M%K"'M/K-E=A!&GR*GPX@HAI)(`^^C<'. M(M_3O"50U@7*O!%NM_67`,IN34Y&`S&Y>+=%@9W"I6CLI6CLJ1::K;8PTZML MBV\1?8D',XI\7&!/)*/S_HSR()GV0EX@2&H+V*_(RA5`TI#9;2E47MKL5ML2 M>EWHU#"[743B;*-!4=;Q-5LO_+L>P][?RCY\M=A%G' M'=WUM46FZ_V>81@UR&P)X:F,,@9+=69F%-Y[OOW?PLHVX7%[ZSS.^J_.W'85 MYO9K4XAY%*_-U>TC=SY76ZV>WM_4RNR$J[&U8>=!$"UGI)QZDG=JYZ^D4I*R MYCI>4!@3N*FQKT,`94.JPOPYG-XBN"LR?U&PGYB_5>8OWA!X*N'!`9]D)3^'VZ7GV3+G[L"Q]02]D990TO`W:#-UH MZTMI*TZT"VC+K<%B%\26\$6W.3Y>)W;5[WPN'?%%^QB(&"F@#V(9*(64%QPX MEM?9`^`.83_78 MFY`J*$T)K<+J7CV<_LUT(BY6#V(RN9,AF$V.1^.O<20G3XCH2%!S6S3B;_J!CG7Y,=RP2T>WEL?(2UR*I^9\^[_?;@]Z+XWS16BC)>;VZ$]D0P>1&;2RE4 MD$.=E$.=6CFDET8O5N30O>>,N!]\'Q_NT=BY:SG12&@RUJC!+=00W)K;2)1\ M8J''P$G$0?J>*+8!+X0<,!J6\BMN/MG6C9N.6\XW?.---YNTNE9HK==J]V8Y MLS$M#>=M6F9L>679&JN,75S>G+'/3%;7&ABZ M_HY=WUR>_N\OEY\_G%U=I]_WW[&S__OU_.8?>RW')D>%#[QE=@B_6OOD77Z& M.-0J=;&#EQ6JPTA)I2IQ^`KZ7J;[G`1R=0T\(`U<(-&*KL$:0(-%0!+NA<6^ M)5DNUOS3A=8TM*5IP*:T<-RZM!KEM(*?K(%9E.7N@.JV!G/O'%JGB"L2+AOH MM%JBN?D-C#W_`4]U/+E@Y_"!CY_.2@=Z[C)S-++1$*-MXM*8_J\(E`,PK$A6 MD"YV$8]LM#:;;%']R.4BLLV>P(.&D8K@-IM@=#L+S0`=DK7 MIBM;-D/K+EWVMP@$HO_>RTP$\=#`;BCI&EM07`42,@I3"E";^#W#'3"%8J` MDWY&J"`1=,%QV"W/*46NY=SD-'7""?P.=&@DFCTLY&A:X!4D]=,3O,\E[,'\ M9C]$#\PMGJ(J*LS3O6W=P^//2&+<7]DP[(!U4;=S^KT4_R]UPK@I<@8X.O%M M/'N)TGWRP&"!L<#J"%QZ@O$:#2"'7$U.-LCSCU^3]9MDNQ0(A]':"*D)8!:? MC244QXB9%S>>9@-?!$\&W6(]-86^L/ MI9'R9_;:9VP?@"K5J#*C!W)T/?=X^5[:M%''/Z4Z#3O":,J>QFDI-^DM#>(? M[\T1>Y2Y1;'?\FCZMA<%<6'K1)G^%CG/3._*D7SQ,%*5!X*%?DC,/YBV:/HQ*4?!GK'J!%H,;F)-AO):R65UBS5P M7O5^3S,,(]47K*$\=;3=3DQ=R8@.5G7.8[]+0@2<_J$AG/[$VS:=/%X2E,1! M[U1RX4*,)C*:@M5<99(N]^^1F_.Y45;`(Y@/8B\?O_AT]LLI.TG\[QP*V_VI MA4NIMK7T85';3*$(>9+G:95X9EJI,DTJ8=>L4LU3(/`.QX(>9$/2C2S++7XJ MT9$#!>Z%ETZ`@K,+G-4ER[\X`ZM"^?>#939@_@1<6B=6Y'DKEK+U6FX70BI) MR68%OA)-4"F^T]]TLVKV4B>>0#&#Z#8`YQF&#BIANQ:@/Y#)MYF2X.O&FU:N M&/[\M=725=/:42"-];6A,=0Z<0:%1LQ"0@&2ST!-$J[%DP*HXPB7 MA2.$,Q`3VA:\\!RW$R_`IDP`'X^E7Y5?`.K2^&!?V9OY565L5I*5(^A)LG-4 MY9:DJGO\Z;&"F\2?NY:649R7+1X=2!X2S\@SQ6OE;8'/.75$8K;=VNFJO;&?\` MUD^P?%IS_(D/$#'>6SP$+N/-WCK,ZF(H3 MF#G-.SY;>N8R"@-8KX[$M6OOS<"VY`6$MA-AYDN!-TE[<7-3Q2UR+8EV3MQ1 MW,H&E4_%--CMZ[UI)JQ'A^ILJ5XK-V;+H-<)ML_639TT;0^FH'W%I^_'*>;14M-Z!JYS;%!_?FK\8\? M?RCK-"4^R=-@IS#:.Q!AW"83C;+3"'YTPRGZT]0.^4:>B/CQM9S\5DSI\N9W M3'R5E>'2,431QN/!4)3O3;@XU0<*A*&OB=Q9-`L'W/$I M4^Q\.K@/`7ZURZ>'G.OD)NOCQOL:]P"0/DO:GSY9?IFT_5DT?<&7@G79#9S] MC$UUDO6"&+K0)9C%W9;Y>?(@]Y82&W=M.D+-)F#MH9VXX%]J^/)\ M-_U:90,(9JR;F+'*C6:3EHE99R!G?.?XL_V(DOU@AB9\8=V[GN/=@:7P_(GG MR]&D-CM^L]R(QS\*OM1HP$_&8]O!`._H3(0WD]M$$B]:QF8P:.NY&.P4+\6T MI$8_Y5:.R)0?8AEP.<;`[X,M3BJC/,7MX%,#Q.UJMT[K1GP5[]ZH7<5TM7OY27,IM5]Q^R%(]C-&7G0;CB-G M^F9Y*WV=F2.,'4^5;!+]I,U\]/P/<2,G<1LBIS1IX21K8,.!'NTCNG"I<)+;W&Z^6 M7&HVR(M`AZ7"FVXL@H7#JET`U_:W%\E^&-<^F3^?A=7$,O>2N`:P?L%=;[4P MGKW?P?43G[*3I'C_Y-H7"\PO:YH->WLESG&Q).X-+:],K52-J$TK>[;[PU8V M)>^(L2DRQ3I3[)X??^+N$W><*8B=>F_*`2#>F[/DZJVVT(K[S75[ZF51L]:7 MF#-IC[D(@SSPR3[P],.B*%0A M9@,55A,\21'M89/8`,9E2E:"9]R2P$RB)?,JE-0'U\4%_[H):^82EY.X'=JF MLTZL)WZUEEA/^Q^I,"LVNM\1%&ZAV6P$V8Y*X;3C@BL:IM8BTB+'YQ'GK&^J M7[(P+%9L*ZQ\IGM;811S9OB-1U$Z^:TYBNNI,KB`'/X-'#=;GKE\DJ&U^@** M^:JQE^Y9W!4L+N.7U`HR+G0N.L:@V]<[4\[JW('EPE$S82AV48B\S\:'-M^3 MT`=&;RHD6=+%5HA<)1#9'>R#QM7"CYU>=[@/&E=Q%_3.H#NH2F16!'4ZA=1E M@?UM^>(U/Q;15'+Y27)A6[KL7G_%L7CVQY)<\4@7$U!AR'@4'_/]-AKQS9.' MJ]WM#3@GVX4$9`..0POQS6<86!W;ODABY#%!3]Z_D=L M_A=H75*6KI#2A7(=UYK__%5/G)!5^U_$FH!CCM;V>',MVM\^&UL550)``-9.H5263J%4G5X"P`!!"4.```$.0$``.U= M67/CN!%^3U7^@^)]EN4CFV2FUMGR^-ARE6?LLKV[>4O!%"0A0Q$*2,K6_OH` M%"%>.!H4)4*NO,PA=C?Z^'`W@)]^?I^'@R5F,:'1Q='I\G&4 MQD,4!X0<_?S//__II[\,A[_@"#.4X/'@=36X)G$0TCAE>/!,PS3A$N+!X]/# M[=W]S>#L^.SX_/AD<$47*T:FLV1P^NG3CX/AX.SD]'SP,J/SF$:#)YPFO.S! M91#@,(V/!Y=A.,C(XP'#,69+/#X>#D7I(8F^?Q9_O*(8#[C64?SY/2871[,D M67P>C=[>WH[?SH\IFX[.3DY.1__Z>O\X/!VG^,AO@)3P;B[U^?[C;<2Q33.1Z3`(7'`9V/ MQ/?1+Y2.WT@87D;CAV2&V5W$Y4W):XCC:YP@$L93E&@X-:*WR+"?D-ABK]B)*KZG+MEF_";Y;56\XI&8QS%>,S_ M$=.0C$4C]9SP/[,"'B97*)[=AO0M_C5"Z9CPKVVT;U7,[HQZ6(C66+2[//Q7 M=+Y@>,89R!+?\39\CN]IO&-['37HUA5?4"@:N.<9QLD.[-2)+QO!E0S2,//` M/?]_I6C\GF`N=J.0,*0[*S,EI!HA#2I%AZ)[HZQJ=EYRUDM,4/R:=16\BY\B MM.!=QNG9"(=)+'\1#CH;GISF_=D/^<__OHQCKH>4'*)7'%X<57],2"(LE3^. M^E)5=C4U9>L_Y^H6/U<5+H7XDE5U1RR00O@_*_%M]LK+D&"1T4U)2-,;LX.A<#NC^-_\-R4+ MT2OP84ES.P'T?0.XKCAUMU(!YIQ08!H@+0?VWSP"MG$. MI0&\"X^L"#`>#T'2QEHS4(`2O1[&J)&A)V@.8'R.N=4.:W"Z\D]C+NCC;!JKA?FW\CV&D\P-X!/PF-='3>1 MY'Y1DW@8;X`MYABK!>1Q_;L_<95KNJOF#$7U*;>]^LG#^!ET-\>MRIC'ZT=_ MXO4\HRQYP6PN%(V3;,6Q%C<32>X#-8F'<0388HZG6D"7\\CFPJGXI6@P9XA- M<5QJX5>6YM/*4&],#0P>AM393F!#:Q"7A_L?_E1CL24B-@?X7V*%8XE"`>X5.WE_?7I#F;LH"%.1 M;O+(>R^!L"1AY#5-Q%SAA8HUE=E&#&N[;Z**!3H7+O@WG+\TRAS MB7)RI/DLYT&-SQ\)D+R])R5UH,Z0ER_ZD(/A*"K`[8$8!4Y:KVSH8]+^"`URKHCB;N%?_; MM,G6S3O2PK^1<H)FGU`_ZF\?)+/4CZ61B'7AL_-2"S.KVHS->VTQ7*.B=8+ MI*M3ML`FZC!>3=HRB?,/W5G6\2-:-?/+KD+$E9\0/#;D>+MQEK.]H9R^`J>] M^0`8.0GW-S4TM\"2P;X(J#E^\!B3%'K+&K!U++]"$;M:]@<#,3``FK0/]. M@.0H7N\6/K:QNJ;W+UHOJMQS-9 M4HE;7D$YZA(2I22:%CC[@B>4X5+#,,2K#8D06]UQ9,:@).$]E+0Y,;;# MDOK;/F/C$X:F="*+_*2H/*7?@>NX<6+%6K%?.2%/*8%/0])A%HO$HA=E3S0BIRI+990H9GDZ8>U[YG.T1@]E(]QT M4WK"+CM544JSBU!JK2>KZ*PBZP^-`(=3L($5E.HEK[M=G43_>MZ2)6;(FG&J M`J>OH=:9XQSADB!?FR6IN#*N]8^5L!8?#R.J&F.<@UK(`8Z=/.A?P3V+J:LU M"5&YHN]\<-.J`#5-M2M.4$C)[KLM<_LWB-YH??.^$,NJVA63^O?Z>DGQO'&)&>00"9/<=+*9CM@H&(]G'M:^@-; MDPCI%10R5([HNV?XQB M_(J"[R\,13$*DB+%_Q$S0L>_(!(]X8!.(_('KJ\X;"&AM#3L+,%S0&WO%3C: M6I4%7-CZ@+T@M*'>9U]HT,G#10UU.@G=9V9%M7:4]5FWOSO4P[\ARL:,'#1? M^&2@FO\DT[P2#5:E?Y*.R[']YT,;_2==7)&L2`W=;2/G6@1T4XCU6]^)=%]#O M2B%+/^Y;>J_B^4J_KHU>#VMY;,1M./@:K_^N;YNU8#5>(JUC[3/M5ZCXR.B2 M<`1\6?T:B^3[]<7O?-QRR>&Y)(H'3-P9BX1A,&-_5Z"A50;D%WH9\.@QK'UB MK>86=T9Y89H#8Z]C*=>HTRV<4A][`]VJ3]-H86;DTB)-PW7X8(.XHU.\:0J4D+->EMLKY&I/?%G!IJ'7PJQ!?_@` M,[N@4V@UBI*@\FD.JJD15^Z-F)+%W()=?XUQJY3+*;0 MM7O^E!?IM&/6-VE&YL-'H(-SNFWLC.6J[FOL&90[N0O#?\2`]WW=`.']-G`3 ML,S4OIDO0KK"\I9NEPX4R&^>-9KX#Q^;;B[J?CYI*EHVFA[=S_S_PPE[0FK7 MIQ6C@)5SU?28`^D/#G:L+=K*$6[_KY>S$GQ;P&B\8#DAF M,?]WB/-([NC^SW&JQ<6#;WU4-8#@U<+1RQ!;Y@I?F79F#=-7,>`AI9 MH;N>'W'@!W',+O<_5<.],Z^7\63*IYQ492>U\DOCK6"$,&OA:&8^?$`Z.*=3 M2)K+E7.03AX%T=RBEZDN+GF[I>R:IJ_))`U+D_?B$KCB$(UB")IMX6( M0\-=!X[:`GWM2N_R#0H-!.O5HI9,4-IG6UE:.0"GIHDS@JTZ'##N2,G:PZ5\N3W>B/_HSMGGFEP%]0 M=N!P+@Y:JZ:N9B*Y(*3GK\CQI"XKQ,S\<2=Z7RGCE1QJK-)>FC0<3!\ M"^B82_'WW":?GW+4IRR8\2YF?0\]C;*'X^KX`3/43FR:&`X.2ZY.V`91@+*\ MO"BHVQ&5O9/?Q8A*6:I_M?AF,L%!\C"Y>>?HB*;XB7=9#Y':![7ZW(8U=[@; MZ^$A<0O7;(5%MW(MBX5[OM3G%A'V&PI3_)5;D[+U53[7.$$DC'N[O6=]>&6C MVC6)@Y`*[6IUP4HGW]/5T_7W=(<2'G:;G?F,=Q,!?++/FF\/*&WO@4H=UY:4 MO9(!+\''W?G-C1!V-,&(-VNR9F+/<>-D*QPL-K%^O=%LR#GF0ZK>&WZC=NH# M@4X\Q0/K$)[^GI`/0_HF[CU0;$,6NFK\T897^L6-M\<*[Q1TNIU7JFT!I.3L M47NW$CW,3FUJ:ZV$)M):W5.3'A*DX#:W1)"Q`/_V"?(SO_+$@.8`MX5*YI?J MJ`X((#!+VV%#*]NO.V-+9^P\&%Y(;5;-YXA5GTK#WN)3K^/Z3(TG]/85)9@1 M%,;97<'B`3"V5.3:0AGJAAH8^GSJ01$AVL+,VB,-A50YFK=)\Z_EW6A]*][Q MFN&Q?$#:#@X[1QT=)@Z/X0$V%(8/DSC_%IPW:O].V?[(4FSM2J_5R3+,/ MAQ'G0;01]U95#8KQT6$Z3[/\!L-IKO8"[*[1"NBO7@.C3CMP3*7BF\L534&; M\CR\EMQ@1O:",AQ^%7([V'+R`X>6RNCN@)1+;[O(G'\0?[RB&/-?_@=02P,$ M%`````@`28!N0UU%RK?('0``L,P!`!4`'`!V87-O+3(P,3,P.3,P7V1E9BYX M;6Q55`D``UDZA5)9.H52=7@+``$$)0X```0Y`0``[5U9<^,VMGZ_5?,?=#W/ M;F\W,]-=Z9GRVG&5VW+93G+G*46+D,5IBG``TK;RZP>@2(H+=@(BJ/1++^+! M63]L!]N/_WI?QI-7@'`$D\][1Q\.]R8@F<$P2IX_[V5X/\"S*-K[US__\C\_ M_N_^_A>0`!2D()P\K287$9[%$&<(3!Y@G*6$`Y[%^GDZ./''R;[D^/#HY/)XP(N,4PF]R!+B>S)Z6P&X@Q_F)S&\20G MQQ,$,$"O(/RPOT^EQU'R[1/]XRG`8$*T3O"G=QQ]WENDZPE0.GJ$04)#F9Y]>JAII2EL;(78`X0`N$]>`5)!GKHR.-DK-H7 M",.W*(X)A*;I`J#KA%2)Y^@I[H5-%:[&*E\GQ/84(@+T6Y#VT)+#R%@QTD;# M;%T=\Q;*0M=7CES-=7XVNWCS+45LK/8 MPYEKR.?EKE4UUU:9=8\9`^46KZXQSD!8H(U(ND,P(?^NZ&"2:'-V:*^KM-!)NND>+7>,UKK$_IVALV[0?@=HN^NSUNE9 M[>[L='36IW#VYFXN>U\G_6X/A<\"'.'I_([FJ4GU+Z8M*^UT?A[@Q54,W_#/29"%$?EJ M-I0P$./.J(WK%@"D&REW MI!U*2(>2UPAK1BO)VH9YCBWJ,[Z#LXS"@B#ADC1"Z>HZF4.T-.Y1Q/SJ:@9H M5FI:_+.N;+6X%27I01@M#PJ:@R!6P`=G.:U<):.K?#_DZN;<+&A%_DUK$$SV M0S`/LEAA<*6L(X.W78WA,H@4@FVB<,':AKXYJ_TE6#X!9%/9)E\+FBZ(4FB6 M/8']RA$6]65RKVM-0!(E$:UO-^2_#<'@/06D4:F:(ZING^;!F5CCMF\H+01] MBGN5+/7MVU54-NBRJHW6&-:JY'YC?ZNJ:$ZC[,I6F&A:%2B;<%L5II!SL"I/ M)PMC5;`H,V55D')JSFYO)\I46I6DEJFU6P4E66O+S;]B^MZR5_47.;;;Q+)6 MB!RW>\Y%*B\S;K$-="Y>OF"]K?;0N6R%30[;'*PQMW]LMQ:7*N0*E"K$<-:0 M&]/-R1`QIWGY%&\>X*=\GI?A_><@>"'SO:/C`Q"GN/R%IE:.]P^/BMW(?RU^ M_FT]%?LU"D$1DZ_!?R`ZSW!*C$'$`^":C+.K;&\`9:[N@64_)'O5C3(1N$GJ*F:P(T*V44*03#;,@?Z!D<$'[>2Q&==]`?R)B9 M=%V7<3Z>^KR'U\4'K`A-RT[?HW8'PRIRX'&FX6)R\J)GMR6QM`8\W4=0I4@Y`E8H, MYH2B7\57!!J7[RE`21!7-:YEO1)M8;:$=B#H:\4/ZEG<&,$HR*%U0\+?BVI2 MY)>H$>4R:0L7`HK"-TR*D6!`;IU)Y)E<>W9>=N)]BC%(VR%N_EC87?XXDD`R M;3")7$K+M5(\*%FI0DBN)P+#/S@24I78,_9JO@H3N%J M<^BD;#4X;#5%JXNF_CXQ09J1U`*%?QM/\K7:.G>686(^QF4BD)&'5:(M82BF M]20[JP\HJ.<&=F)666P.1+$X+V8YA4K,U!SS6W-Z/WR^52VF4&Q-(]@BAGE8 MFXS&%<9.WG&80+(RJ6:1%"92]6+I+H]*=]>]4$&%/&8N54Q4;C;@$`T[ONSF M496,8?3NF_PICT//^L:)4#XL)V*%:JY&4EDY+[%C]-`X61E//R(@%T M#A'IU4F#P8PXYVMA?^>K;_$4JR\,7Z=H-__SXT'+3#(@_S;89CSNS5S#(:NE M4&>V5(%,1ECAC4_X/24W:$I.(886$G%\*?KIMV&'KAU+-OO]CF35@T'*JR`- M4J^AH6&E.B+$3#WI?ULJLM)L8B)>\(=(EAD&6Y8%TPQS,[UU,I[T5L>2L]49 M2&:+98"^,3)NP"5;11#HK=28 M^MD4F`!!/F@8``J*XP5-+.B.$A31X,W8X!R!,$H[FK)7#%1H2T2(:7T9*C`J M/=0S5-Q#5.QS/(C9>M$^[.`)2/EX0.M0(W\8(#BG..S6XN_G%+^?4_Q^3O'[ M.<7OYQ2'6N$7/B`VV!X[JM596ZM3A(+D>;W);+4AN0M6^2VI;P$*;WBG*JTQ M++<966`XW!9&4^6G+_FNCR^$,,77R1U`$0R_H.YY/8<2^@9`)&&HK43VT`FW MX?O&'J;>NN?[UESH[,6@)[_Y,5K)ICIQ8,IF M-ZJ&'2\ZP+^Q8FY&>;GX`N)^2W)KLU-%?VQ%;:D?:@_..PR2VFF4JY8*5T[BY!2.:!;255-WG1PV'W M_L8Y.^%:3GEUA3LY M.U%)MA4'^_7*H>9E51QVVV?M`BB9PS#/8Y)+X^SP[5XEUY?O=B^8LSO"<>1= M!X,B>YJ6%69$1WW7ZK-/V#"_E4.HYC=?;J:SA#4H-IYS/UT_X?D@J2G4C_T* MQF9MK%F_&T>WPK%O27,H0G5WD)&(X;80L^&ILMFGOR_K\&_HH;1QQTC^]YI@ M+J)[[>"8ZP)K?_56*X-P5_96JH,W)[+NR9P"1;/\+7DX8Y_$$M)4#WKA1U-+-:J;2]5GWP8IIZQO=>11[BC6U+VS#<0) MM7&S;S%7Y>[-A-0=XVQ>)%1AJ\#AC]IDM&+P M##^C4`DS'PWRJ[WY[`41MC3^=QUC]A![\"@S;_JV$&;QO=\]`NWNE&*Y9I[F MN[4N>#<-R\B:F_,89$..(Z2U$BH;J!#03;?.Y^FPVE:[(-*K:)ZNBBLUVWNK MV$-&T_+,'2Y*Y7V'15^7:.'%0)C#/EZ@2+7[R@A&G-**(.J4'CN$Q.ZP"J". M*#?G6V1J3!-`]V89@8=95A$ZK;)C!X[(%59ATQ+DYI2+M/$K-O29]5S,PJK= M5JOPV'$C=(;=#JLER8MG]QH6\CNI6JV$@YG61Y7VGMQL55'-VK./8AS*_$B>GF$EPGQ\(J9 M?3`L741,N_1P62C'"(9]75D'OQM=:4W0UM&+19NM0KR3@_(5Y*PDG'MC MD)&G9BRC-!.EM(;C#)/)?D!4O%Y MI6%AZDU"-S^94%P=SC]FPB2HGRYI$7@U+Q8<$!'9)4<+XXQ'BZ$7;=&O`5VR M2)G197XK'-#Z-H*8BJS1#6>+EQ>5MOR]RQZ#6**BLJZBPC3 MW`HQIMT(Z)8K&P?U<@,U&FY0`\U=5F]YK"J7-U/J2GDQS+C.;]I:JH%4C;AP MLXQXU^"HY1RG&)1IXL6H:&VL''-2NG)NS:?;-:2INL0IR`1*>+&!U8;!K,4Y MZWPM#H"&6))SAG)7CG9:*RPJ73_/,XXEN]@$,#=UE&_+5HI6J-EX,=9GS]:[:S%2_4=DV6-7*#K=,I8DM MV,\M3%`*)3<0IR;QSP6\SMJ)G]!CK3XYQIYP5LA3G%ATQ M4]$*E&UDL2B'GG!IM490QVPF;%3$-=##$N-72U73\%@9*):2PS;:. ME&.O%K58&IXH(^5$&2DGNX04MMG6D7+BR0+9Z6Q&MVS3.<8T70!$YA0@>J5S M!WP+TG*EK-3,OGR:!TT(_J,MR?L"8?@6Q7%I[W62!LES1.T=?%F06@ENHE?Z M,FZIU7H&V$F^E/56HTA9@96*#-=F<=7[&8-Y%M]$\TZV3Z.(U`GU(D,U9SI! MA4;V-YHS!7%Y*Z8DQH\A$M\DTLBB@)?&`73$U! M?HRC^,I^01!K-,H-HU05J=7V[`*>NS?:[.D]N=JLC MEUZAT-2SO=U#B;C<\R$A'@E,M&PV@8E,0`&3OWERI%I@EOBXM&K!SE%H><'M M[JG0!)"Q!TS`I".L`-;?1[2'@6_3V>IK\!^(SN,`LXX)&Y24]W;=DIX16)EO2,W9E^IY8V.C+/8MH6%J.0';I`39=>_`*DFSP MVRY;ZM1N*N[,]5NO&"B4:#U)("PQ6%7_"E]S7:Z3EI[W,(ZO(**W[K=4;^T[F25$S$KBH5T3B`H62B M`11X?+T8*K24NX7)3"7^73HV!.ITHT0!U]#^0*BS]F)YO*6?&`'BN(\TVM9C M[,EJ'(N5?,_B<1'^`]D!1 ME9P-"P;Y*.$A,[L_3!@2O%A5YEMSMGHDPED+REIEI#.L1IFM+B/W;%)4S+;0 MOG#$C&_IF&\8-4OP&J&\@!1DFP*#K@_K04B(.8X+U`!7DR:&W$:*C]/8EJ+, MM3:=(DHP&GZ)5P,44@@IOXK'%R9'D%=+MXXPU%F!]`I%HE?K[,%(Z=FY_D"R ML.+*>4_LLDB6/P#T&LW`.>E#Z5D(]BJ;&G'A"1FQ=\-F1N,`-6U6C_YFB40F MP,T[\T"1\1425*GIDQEQ-6M_OQ"4<2:V5;3>(L8NZF;I?R:D\8LZ\& ME]&5NV/Y=",)L*JE)O$5\.Z9!^6$E]Y_'&':VQ6J<;9&2,AJ=TJSR4826T4[ M34++9]W-@VYUX3I_;Q*$+P%*5Z1-23#I.&AF;N@5[$*ONY9>G21#`5%5\B*$ M9'>9M1AT_GF9OGS((Y!>+8JZ'!!V`:J)6YED]N7VPBP9==CNGCL M+=V+U6RF%9?O`,TB#.X0&714'[6`J\A"A%8IB[%"5,\W5G`I%>EF&)F_@X2O M,<[H+9^E$I7\]EQ!C;J<,FY,,ZIJG1<-9V?/B,`EMW-3)ROA3&=KR,(C-@BW?!TN'FQ M')V_7[2N_Q<9O4_Y#J`(AO5VX0JB(KG0KG]FA>L/OFD4'@%@>OE#N^G6%%9? MOQ[NR!2"7"J\WD$H)#8I!OV+KLBL/\8-+!G&29:8GPZ^SV+ M<&[/789FBZ`84)[&N7#R\RU,`;X+5G0MG%[V#I-GVC1>@*=VCV*59^%N2SQ' M@#L7WM,%JR4="H1_'!3A]^`E6.5Y]>F\;CL#N"JD53)11#H"F&G8JHL>,>LR MOWZ/J0Y@J3&17Y$#QW]_3I%JRV.:@7'`%^ MC/V@BR8=026VAGX*;X8`:2HOP/KOZ^0B`_1-Z9JY-'W(/%MB5KA:3-9/J]Q%$E&>%?MZDXE/&P7*.\RM,TD6\ MR@7=K;NTTR6]B;P5%RE==7*42S>"N*E:J1M'`=\RKL.F,3<71G',P6>KQA?A MW7(&/#K7S&GQV.I1`:VTBP6?:&=?S&260/QA/*<(U.QCG";0+RC>8,$LZ,GM MKD1;K^96Z="]V4S0F@:Q]XWP"!K2&/U=@$'ZH8*1"6\80T4:$ M5V<(#"+?V1L_8.Q9IP%L!5]X!J!O^-WM_+^($)@1XHO@-0IO(D"&E,L@86XA M52$MDR-"4@\&Q]V-HQK6\2*[V2HJ9N9%52Y5%(9:&-Q1A+-G`-UNS3\G30!I MD(*$=VT9^W.U5[O]VAEK)(GF( M>6S<[)JZ@F@)D+#7$Y&4-Q`S2;R,DH(U\ABQF?3<,L6)T!>0O($XWBP.X7/( MC).DC!R6$FVUH4U( M.^Y,E8XCK"2G)`*].!G14HV9F!#2E&?5V33#):;4H@W5K&O`0<0X/X[.9NC% MS-4XW)T4S;`!9V6C^D5^C!ROB'[+,`@I,XC=3!8A[UV-]2&I%RW MIC<9WW".*]MC6#\FU9.AGP<8;L%;_DGKX$*GD,J!A5JA@6JZ15C(CC+P/-1H M]7NK(SWD4%/#B_$!8[?SN@DJ-QN6!^T0_9L.=*NSP+5#&RVHVF7*WP5OQ'0G MH.[$P_:K@BTUO1A4&;ND:=-IEBX@8MRRZXQ_WRZ3SW\GZI)KOSOH8>QK[.:@ M?"EO7>GO$'Q&06=L*"8JG,@CV@D$*GG`/HQX8GLN%XDN33#1N>PQJMSL-%T` M]+@(DNE+GHW[0N=R('R$%V32;JM1-9/:MZG5E;H3\!\F1AXUR[IV>/&&@&-K M\76RGC=MMT)WQ&ZG1M?$?J_2YE$:79VN&>+'U1K.S+V":`ZBE+Z#N.5ZS97L MO&HS)'^OW;UB-:8*SK#%C[T$SBS^!>`A*CA;K//:W1;[O6J;1VE,];IMB!=W MV=A*";T&44SSL*3Q^L*[R]"A&,NIRJZ8/WHT=Z)TZ&5KG612]$%[519QE7@;*\7U9$N1-04_>% M?7P)9?>]O,@!J'X)X@R4&IY#G'X%I"H(T24IPH(9M\CNX4W-.XZ!QU6B[[5- MMJ_WD=J.><:+K_RQQ+=S#5!OOEN]&LAR#^[(NPXZ>7N:-N[#&L',&R!30H-)U]"JNG[/P&ZH9,+W;>EBHQC^2P/[8`,OR9 M*V8HH43]>I#K#.IQ\NH,E4:D.H>*!HH5Z[B46K"$QZ+$X7)W\0Z50WX]9!YH M8G^L^;_^<:!A+J="0(GV+-]O3C&UB[IY]K:0^^YZMO9+O3UJ^ M'W8^63[.R>DF?XW2Q7421J]1F`5QI\@C-7TZWQ`Q1BYNA;3>1;1&]/,++_#(7YL#"L'29]-$M/=P@TC&" M85]7LIX_MJMKGC72U=&+H?%6(=X9FOH*\74,:8K,;]40B_*BR9O.Y]$,L"]% M8WXK7-/Z-CX/"/Y7HR!1EH3.E.>4=<%UBQSJY5!.(/<2G7P MYL*]>X!3%,U2$.:[?I@#2R%-]=X'D\;7S5E]6E"HYA&M/2D&^JS?$&'JX4=3 M2S4J3AZQ;\OG$M0W-[<(=A104E]L`TTL);QHI*I+3<_C`&,R3*>*BBZ0YM&U M+X_NTNW>+$C5*'"?-#?@4,$FYJ7";8[Y MPRT,3EYT0`9Q[0P,!XRL\.)HO="JW1BM%EQO1J[K]V+XHU;N]S*TW>\##2X$ M=1'*[:C'LLMI_;12A\/`%T=3C:(T[S[6"R9I1+J39!8!7-X@G:M5*$7_>"+] M"_GEOU!+`P04````"`!)@&Y#ZFW2#NAV``#>@`8`%0`<`'9A`L``00E#@``!#D!``#MO>MRXSB6 M+OK_1)QWP*X]$5T5X:Q*.W?W[.J9T0ZEKUW M"$=KL@FCN__X[I"\"9)U&'[W?R;_]__U[__CS9N/.,)QD.(-NGU&%V&RWI'D M$&.T)+M#2BTDZ/IF\6%^.4-G/Y[]^.['M^BWOZ M#JWNR3XA$;K!AY3Z1M/U&N\.R8]HNMLA+IZ@&"_K3__/I(RO\UX0\OR3I(^4^NJ3_=QKO"P+N?2E]2"?:O-X78&_;H MS>G9FW>G/SXEF^_R(K+7!DX*\:>.?/Z;Z-?[^2?^MA2EAD*%Z?)GTZ^'4/;] M8K+#-WB+V'\_W\REVC__Q"1^BG!Z&=SB'77)U=/G!_P?WR7A_F&'BV?W,=Z* M[>SBN#3#OL[/[.N<_H5]G?]96?YI2/'N&!97)`UV,.7D]KIE[;@97N@KJ$^K M*O(5Y%>F/,5'^,HU-\,+?8WCD&QFT<9]P=NNH`J_3(/X"%#I.AO^`]R76E#4 M'7MT2?]J^,5/*8XV>%-X9K85L9.[YL&66RYMDW7#ZHZU(B06_AQN,,'K'^_( MXT\;'%+#IV?LCS?LCS=O3_.&XG_21_\]W=/2T?^E'W;!76&._Y+_^$[X+@U3 M]@-:[WYJEI;I-\I+FU1RB->XY:%3@O_>W>ZLOE2CHK.BR8SN=]0M2RYP].;S M\CL4;F2RD_(18L_^_:>JS-W?.8V;51/$ZZ)`]$_-C\@E?EH3VEX^I&\:OV<; MD[VL%HCFX^7?@MO[*VJ(H90@B>Y/QP'=^2&.F5^:Q@6[O^$@IL'K@K*JA0Z= M6/X;Y6(#4"DS"@50C7T95I5JD_PMREXC]AY1`<0DQ@6QMBJ)^6=O0ENF4:!< M;?%(@+\@ZP-C6ME4"]"NE,E_LT1F`,Z%%J%`KC(N0[A<9U*\0MD[3Z"MKC=B M^)F;H!:*%XA6V#H2G&<1+>[S;WBW^\^(?(V6.*!=:KR9)\D!QRV0&2B2`F\^9W)H0**92)C"'@>VC M\N17LCM$M'OS_"'[+=RA[Z0/: M9=5&#+^R"-TM\2:JA;:.BN8\G[K!#R1.P^B.=MS3@QC4:M$&MF6B@R$N-@R+ M=*4/->`5J@7NBZ2^E$&9D`_XU]0PL:L)$1O$6DU2J"P?E1NRWY-HF9+U[\O[@&)L M<4C9I#I;'2'&MH%"$^A*A>&H5Y@'IH#>DX8/.@,E.;@@XI(G*)-%-6$ON&*" M`]*GIH0L4NBV**7U5%]"D$O^?0JV-=4Q,#OV#PR]%?4K`3M]5O M`##-#$'#N&93A]Q2M`(K>^0'.AO?GZB_FQB#3*H-NTIS(-*V07++?]7,7 M!`\9W/`N38HG;=SEC_][^C6(-ZPP'6J%[XK%5,UW/>$G+`4$!E6&14"4 MRT_X(PY%](4]_?]&7ELEK!1B\"U;ZZOJ8@R8"OWQT+E>DT/$!LBOR2YKZ6J^ MN$+3JPMT?C-?S<^GEVAZ?K[X?+6:7WU$UXO+^?E\MJ2\R*V,S0T]"HAM?;58 M(]5I4$AC>6P^)=-HLTCO<7R#USA\#&YW.+G":3XI)::6F4Z393H=&,*IO=AR M+^UND!`2T,BK`1<-[$P*411$&T28,(HKZ1,4X=0+XAEBI,M!\RH4TE&M+F"F MB;]C@?/4!IV/.+XE[:TE/?%Y"@704R.$(K*E;U&PVY&O;*L5VI(8; M=BBH&UB3_3Y,V"X[%&S^?DA2EBPGS,"_G)W\Y>U?4)"B)84BWM]21^_>GF0; MY9CJO[P[.?W7GYG`!?6?O3_E[\]>.T5.C\V1T^.1Y`PX?3+S",*.LS_B=[T" MCP7.L^.!\YU5?M'=&M@3H>^@$/I.A]#7#LYWQP;G.P_Z`%7AM*F_2K25\8M% M@9@H,FZ=WYOR3^',A'52]DFFIS\(\/7*%Z,/^2R?HQMR^O825WNK6AHTRFH:9*W>J8#(D/ M>#./UF2/5\&3*`F2"%2LZ`@,YT/+I)O41NQ$0P61TB1[@%+VQ)MNHJS>B.F7 M[J"\)=O"M]"2$RA`)AH2\_8HR)()]@+E<."O7BX,Y`F"-0Y&3@)8B98!;8[. MR[4!TD$RO6PS\,ED88`OMNXN'"K]&7!"H5^RHUJ@X0P=`*"18^YA?^"#=A?X(<;KD-_6 M0/_>8?;'--I,]^R8J7_RY]&4 M!2D(\!`?9)DTX0#.U>3Z9G$]NUG]C>\5FOW7Y_GUI]G5ZH0MZRZ\H$W-S>@! M!1;:Q"VL.M$*Q$,KN`&6VH=0R,>Q:7Y,?\P]S8S"1YP-:%R2A"W&7&Q7P9,\ MXMEH=P.;F39<_#+QYRA,6;@VC$;&%BRN@W`SC\Z#AS`-=FVZJZ4*6LNDAM)7;!>4IDH7 M2CHJ-"?52_1`W[X)([3.WH],-4U]$JN/WZ*.6*%!$97-$:E0[I];D1O,/E_( M%[Y6I%V1\R"YITWZ8[C!F_?/GQ,V^+]X8)?7A='==)V&C[R_(]M[[]!%24(7 M+@8S&+Y0L/1W5CYU['#D=E*SS(@7%[;Y[M(=MLK_7U#IZR,VSVQ=)89IV M2`K;8PVO&6%>_9KP`O=V&NY`E5C-^ZJ!X>9-2J`B2$J&A M84YH%C10J3PH0XU<<7))JYGR_2)(`[3"Z_N([,@=.Q`S?B`Q[\3ZLK!)7;?$ MIB9:;!3*-_BDL#@>(W;<.-[P4S??!Y3`K+M!^QJ\VF;93$>;(59*!6,,E88R MR,@-**-L/"H99FYH4LJBA`F_85?U;E`0Q]0XYC%[9*+9080,J<`6$8WT&\2T M\#@J4?E1'A](?)$?Y-%=)"F9`.ZC6Z.MA2X`>XV]&9-8=?EKE\NV_G64MK,W MF?8^LV5\QMN#C`#4?9?_QF;:8<#2_['1#C>YW<"C]E>9!4U033TIZZPU, MZC+%$JFQK\8VJFS2ITI:3%/J-:AEX&$\*M&.Z2;<'=+P$2_Q^A#SP9O9TWIW MV.#-!_I166)\2//2SX(XHOW^Y!K'/'6FO^W033XA;1;$A+$YE+\0I0"E.6"! ME-$`S,^D;@HEI2T:/S)CV<[F=66.'4S(%=@ZS-PP>J"I`^\'H^_#*/LK^6'D MV`,*>^(0=:U(!F&^$?#@ROM2X^)E&.%YBO>=9`38+$QTK)D=-T"6!?$H1K;+ MY#!,-ETU(V5E#LT:D?*\&2D+F^P.DNQ&*O2%V47<\-B#\=#PAXN20NB!!LK2 M`V"L;)7:LW#);GZ\(/L@C(S"8%=<&=[JXD["5N7`?3CJ^+(/,RT3LO!QPB\D M15\R42\#@@`(6J*+*\N$P)6FGIAM+YX1SCANO'\6&Q!=4^/>$TP6H_8T;F*C M*IM'N8Y!,1VF/UKOTHS(BYN#CL`3N'3'%)"@&9#**6!2I/]MXX5M/N;W(0CC M7X/=`5^$R7I'DD/<66^ADRM"IEQN:,"36;8-5_H;7S2>E!%'J3O)7H\<%[15 M22R_>HN3,I4&H]1V76(%;@93YZ4W4$X+I)P@)H&X"*ID7@N`9).&@Q$TZF0@ M+U@^,RE;0Z^2:832C@P(-5I603,^A0,](41ZD_//-S>SJQ6:+I>SU=('\,MJ MK@-\Q8<68;XEWL6[T-[(4%=B7`EN8%3WA;/)D1XB!WHXMS8T>(-?/7!-$2N' MJA*CPRL8N!EOF[:KV[+!]N=NS![UK&R.S2K:FX97U>"J&EK8!M91W\1B]6=' M?K)B/M`Z7W(5>-,C4:U&DWU311LJ;3L!XY&3=9$BRU957.L]^'&>CW7U*@.1 M2?V.'X:$\4<8>("PZ"C4&,>8>G#Q9YA##C==&.GB"S!P.(@8YJ$BCQ%95?D3 M_]55I0P)XKH:,PB\#Y(P66RO*1IH2`KR,W66X5T4;L,U.T6G7\_/Y;.3>)0A6"3QFFD%CB-5ZJ!E> MNI$I!=8$013$)9MH<\=-L`5I=2-\`T_-#*KLH,(0^L),(6YKY$Z];_22-,J^ M\&O4!."0A!%.DNGZ'X`<3;(W+,YE>Q#87VR'(HUU M2!OO8A(^"]J6P'@K2W9$. M62K+0-C3S^1SQ+=R44)%3+2XXHF-=QSV>.-=D!N`7W6,&P8?;8BS-Z^)<'W+ MZPOQX/I4D"4Z"NM8+RNWA6K&3E!A#G%[J#)X@KC)XB)FWAUC5M_0D+1'S.X? M1#6$VTMAZIB=,G94("T2^P]+I!Z#'3NJ8YJ>!W'\3)-BOI*L%2"L=/)*,-09 M&+*,O$!VB&P.5$D+Y`ZJW1;$&5;/[+&Z M3(,X!4'K&11:S]1HO<5W8<0VK'P[F#T[-F;/O,MZKGE%SZ-UC&D.=X&S_QHE M/VI590XD4W5":+$S\(4R/9S;TUIA;G(U6Z'YU?G-;+JR"LBESL MU[/1,'K$"3M8+8S0GD3X&>V#^'> MFJJ]M+'FHNDT]P^^H`:F/-:MJJ4'@\6$7)U=N==H>;U820B%8%W+VP]&!HVP MN6%M>VQ;QO'I!C>:!5,6QUP[K;6J^7M$8L0%3E#%P]H9<^ M,D\V8.85]48=5F,7V62WU["1@&*=.-M6477_9;L4^RD7Z8&E\M#P9.7.P=[# M7@501B![@Y/SQ:=/\]4G-B^4318M^$["V=7XVPA[@HE`5'$K.EC9:02#'B4X M.J[A6ME>KF$AS=K02BF;/JJKU0[0\VA/WQA8ES6%1P2[]PV=Y%2S7KHVS1S8 MF6A6WD#'FGHX'AP)6B<&JMHV;\[HZHT_.*E24U9SBYH1V M2=\CD748-4V(^/W58C5#G\8>*#*H;S/2]:*8(:$\H`^)^&AW\\;Z&FF$[VM4 M:;T'($C#(OPHK<2#CA%=G4GV.)\P^9B-UGS)!#QHA,051PR_=1?I#=$VO@5V M7"`!M&LCM&X-@],6#EXZ`!3="#L$C-T9R`N4[9I?'-(DI9U'&GGE,4XJV@UW M`E$XO'>,.QJMTK@SI()8O2`%GU(Z*:>:*BF/YI1,$""FC;*FI`3J:$FX)+'N M&&@N8JS4T1",M2+O278187*":G*O"UGZV#P(6IY$;.&&782M2:<79?_GQ[=M3]!#$Z)&)_!LZ^_/;D[=O^?^*(!PO+SSW\IQ,/L")L@14L*\ZSM?_?V M!-&*?,=U+O`Z?WK*GYZ=(*KW@-?L8J3=,W7RYS^?_.N??S[Y^<]2)_6&H;!*\ M%0?=::1D23;04702N]##;G(75JE._?0W82:=1V5_DVCYF6T&-:');[JGJBEM M^L"+ZR!>Q,LT2/&&4[:X1E#.$9U&ER]R#3CNR'PXXI'&G2&GE%9:_"IS)S^W M&UC@0TPYDPJ4TD^F+*&BVIQPEM.LUC]9DCZ]P MNMBN@J&2$KM24,`[4@R]LI@@PHFUC71X8M, MJ<47M6VW*(+L+^O\#(#0:1M#F0CZ_I)BZ8<31&79LG0J?8*F:1J'MX>4G^1( MOS1MTD>_>PH6,'>K(:&9G4HCX,XEL`08RH*ZZU-.JMTEHZ&]$-M+O'*4Q M/T[U)DQ^7U&/XHW*>LF2>0K)P7R3VH9EFT/<2[#",]3O.\N\=0)RFA3$X1F36G:*6G:7JPXTU064>8+ M$T%QRC&:QP^LE0F.VCL_A!M8KQ)[\=?"&``!16W)%6F(5=-2\FNCO41 MZ14_$%HP+)E3$KXM2=1Z.Y@W#7NP5!&95K.CJS$I'WHSS2.N'V+T4=M@;@@V M\2NP,2)DDW2Q_4C()EF277?=E_!M"=G6V\&0;=B#A:S(M!JR78T)>\A/C`QV M;(,5.Y;]8>_!.@!Q+1&C3]L&;D.P"5R!#1^`.XTV2QP_AFNLP;!$L`OGCB`< MLENF'2RZTK@R!+U(>;)BWM$Z9T&,'W%TP*,ON]+6KY@(BIJ0^Q9"B$F]'B1)5U,-A]*X:ZE8R8H2"2-M^V4CNE8O M0>A0F(-/%5J6]:!O*)0X+S,$Q)8+!KL,\TDNZP/<.]75@;CH(XM073*Y@^2F M!0]3!NEY>*8*VA0"\.0[G0M'>;/:6[]6H76PW0O)*]2GUME4CVGC(#Z?SLS3 M>'2+\29,.\,UXK$1$]F"9&K9H?Q260>EEH$C):NT^I-,!`F&[3T9<3&J==*C M M(/[&%QXH*HX8?^D6YKO"#:3+;(V&[PM\F\XCVG(=6+X\CU),@9?>!"G.=LY6 MP_PM(-HKYE_*1G$@28Q1[XN M\!;'-'"Q/58X2GAN.&5WW-QA5O3?PO1^'FW"QW!S"'9\D_K[(*$_('CF)QZ_ M?UZQS[785D*"Q4ING93-GALG@P.-BV)!IJ).2Z@.7\X<3_@K-NI2O?1B/9=C M*I!C`J\=*5WX:T95=[_(@P!,>RSGAY@-J$O#9U>D$_SJ(F"AJS)J&W@,SBI6 MN#&+'BVU2?&&WWL9)@D;'L)/##*CYS.*BA125_SA9<2KI,6T:5MSA`_`;%GN MH`\T3FO8X.].4/[V9>-"FKOV`X8/^>B2+44Z+_DKB8@2J590[$@!X;YEUT5. M)G9A@GV1IO^145:A`A(HOKZ8!BT%$1.$-D?GPDTV<:B]Y\Q8OL4/A3P04Z0> M7'!&Y\R$/6H;DXO9A]G-S>P"WDJB*6:?SX MPC31\6]&@U*OD"!W;".V;;/[8H*X97E#`@ M@#'<%>`&3;!K-JURZ^SS+],@3BUQ8)IA-U2$2$CO,;K%=V$4L+ M"TVJ;0:,X=O'!$;/'+6CA6U+.)S5X)`_?HGU?091WV?^-&KOGVLC9OHKXGMJ MBQM%O38L*W3^'":?AJXM.&5D<7)^ST02%$:HS;Z1UQWV19*W7#$G79S,U2)HB],&'%I7XE205JRMX MJO+G#5,WFY"M<)`MII*)2?A8B0%3L##LDG4M'S9$:ZA.RG_^U2_B="I1P171 M!U?3H]!0,:)IU1L25$25'JANHZ)MK`"/6#=Q20]LM-+34O`0[QMW`QW&(V7;7CY=-*VI:^G/6 MNPTTC$@IK#M33EZ*CH$W]N4+(Z_HYU8N(97*B=E7EX/E7&79_>!=QY<%S5JZ MG2E.KS@DJ%8Y<\0UH.1+I:)@2=NN2]Q8C;X9;"G4N.J-F]/O)IU7F(`ILQ&V'J`"GS^O&G>U4QZUTMO0`EFUT]0)?):$&0V^]X#01[-R+<2 M?<7V.;V"4?<6=%N;W,7QNK:6V\TT1DRZM1YM)#,`A7&7UFR#EUS7O#OKT<:K MO(#JK5=B(3'=H+=?-N+)'FY!(GR5]?'U#,4F`KI'@TF5S^9TWN(G9KO3IZ2L7% M<50@#LN1C@/CV/IS1I8(W['3'"SH(G-IP1NQB4GU;Q0D1>SU:Y9+7O]R+BGK M2$FJCJ:"7A(O1X";J_5#4F=#D298.W129LJ5Z.L$GEDX'XP\'T+\*GBZ#(/; MF(=8<3*"4;05WB2P0U836'8XPJ_R9,$VN7[$L#9[0+A=Z/D$1]F1X1UWK M`F9I*T?,*J&:B%(*^Z[A!1[&E9X&(:L>P*D0JDF=H"N<>G8F`AS*-,%[.,S& M#=L/,5Z'_$P<^O<.\\-QHLUTS[I2_^3/.]';7*4,XB8J@\FF=^(DI!N[5?// MT,RD+LG/SP]J(F.3SP(:I'_5M9FHUVX2TM3;D1`)V`J8.X0`XVD3C2>H%.;` MG'XSP)2V$6Z0.6Z+D:SC\($59;&]PE^GV=6-871W'9.(_KGFH_7)%4G_AM/I MACRD@@&>`3;*-J67C<&4[N'52:O3OQQJYO>U.[F9G<^N5I=_0_/E\O/L`DW/ MSQ>?KU;SJX_H^F9Q1?\^GWVB$LNQ0\$0[!%`*+1C10]SS>#1NSQCD0*PX1M0 M`B=\X$UCJ/&J&(_\V);/W7Y!N_8 MQ"<_.+1[T++T<`D8:V44'&AM,'\&^7?1EP`ID9JFPSU,EK],;V9OWD^7M&]Q MOOAT/;M:3E?SQ=78[(8!)W&"D';X&&2X&6\`RC@^DP";+I"R."81;QS+\SIH MGZ1N!^6&BB.NN:TWM\P8*JSYU"WQDGC2AMLGYKV(U."V7GS9R<4@QFP3`XFQ M8T4SH7O0Y;T0)0&)9'('TFS`GR.58;#9)SQI$=(S.`GM]HI-BA*.%YD.^`.M MN=G^84>>L73MDEJJB"4RJ:%!0FP7E/U*%TI:*S0G]"5BQ$"X>#TR/37U2*P^ M>HM08H4&4U0V1Z/`+(C9<3? MLK>5@13KZ1>2@L.*H*+H$,N3WW!X=\\Z",$CCMG-A>PV$-IO2)BE!)%#FJ1! MM*'VQZ7V4/P14#`T0T-/@_70,:A,OH86NQ!B%RI]+).:RKQ%RDL$A6,R-.;C3+IYL1D`Q(RSY*3M MI"]@3B6AU)MA9"CP&.8>MN@9-=O8;O$Z76QG3VM^?,0/@8[-L;NS[[=$6B1YS0[M'T:Q!ODA5)@UW]/9N6RI;X2D\D<>ZG""[N_`R-1*Y* M!I]:.BZI,M`Y]3WY',75X1#Y!=PHSI?M4`;CIS#AFPN2VMJ=H#I";>RPZ)Q% MY,B`;05<5RX;T=GM[_(Y3,#U)ER7WP4]^S;R@S,T) MXHZ:RP*9JW)[DB\G];R>4"+KF+WX6#)JUS"B7_/YMW!3')3T*?@[B<\/24KV M.*8=V35M#8.[=A2S52NR-F.UH='5T!%\3F7G6!G^;$Q-JG^SOF!Q-"B;I;P_ M1)L8;]+[9.SI25O0D&$5VHH3AA8:M+?R>D3,PC7PEDZA`,N:7R[^ALE7!]UQ M%53HG*!*Z]O`KJR1?YN@2\G%1Y9:1@W0)=@%2(9^0$&.#`B46U;A$2UVH`>V2&^2O4+E.T]NI%178@?@BF\N MPGE+O`MWH;W14/\A".-?@]T!OW\N__PEQ#']CO?/E[21V0GNQ+%3RK^2J=)` MHIBY@62.E4<5E2P,39@`XA(GJ)3QXFX<2W"0(577)*"9?IV1-A['I^@T27": M3*--[03<3SA@&Q0VB^@&LPL\PNB."EP1-L>5_9.M;DT:=\&W60QEMTWTX7:A M8L'0DC@)%T"%,HHH(+YJ00?ERGP^E%U!D&OP921U$^@+U_,%Q:N2+&JNI!PL"VBI!18KOC,V0HTV5;4=PY@,XIX#:_ MP!?)RRS#9KN-(Z>3:1YI:&Y1,UCD(!MVAW.5FG@2A^"9X"+E,-@Q!._+21+B MRQZE\@?5,^1NYU(XO-A+MQTAS72A@I^)-R=QS<*Q4<@RMM<8>FEV@VK]H]J8 MC!>#GOV@)0HYMC4NB28F9H2!PMS_^#%@0%#KS#T"IEH=VX!9UB78/#EH:7S+ MK=H%70(.3S$)"NEX3`VYIKHLG#S MZ.&0)GR9PCOA148&DNU8+9*$HE/7MI.$1^K&B$@2[HMO\Z,^75FS*\SA_PZ.PZ_S@;QZTS6 M5/&#C-%"UER=^4RG=OUKZ"2H*#V=SLSH=.8'G<(H3/$EC96;>912?(2T1GE\ M_)S@[6%W&6X[BSPM5`J"&:D,99J!$_`-V!9.E00T-3/)_HUV]`%;,166TOGB MJ9$Y9X,-TK_N6BPTT&[0T=C;D2`)U_NW<`B!1S86P$7?<%E4"6=)U@G*\

KOO1 M6FY13?"DW(G-5!'3]65Y2D^8&5%?6_>F04!HR"P>*,K@8V3X&).DL_+$4%S/ M_5S<'=FY@R.QN^ZK)YTK$Q-^NYNW7&S6LQGY.G5AS#:N:4BOFAWSXW,EXO]L?W0),9KU75 M;$SOMA%#EHM]^TCVZ7I]V!_X:<_3/8G3\)_\`$YSSFL,Z*DO->`N`DA<&@>" MG[-`$.$[9J+?&*NF$#W#@LKHI/82!;6WWD8`';;,`H%!;1O'`XDMP["@+,DH M<#_"Z*W./3S2=2.[R0FJ4V'Z!Q7ZC`&[XX*GX\-7.)6MIK=2TC>)#25W<:'F MYD@Y<-=C3_:W#4VRF?W.E.()BG#JSR)\.YR8<5I2B\8TKND;4K?CT5.V6K'4 MBIV.66D]U<_.S^^9AE;N^E,QH^!<2#Z?&6?/M+X,,V>6ZV0P=W&,Q*_F:ABV M#!*ZJ]>(-/NX[LPBK+]Q%1Y/?+RDTZ%$/7';**UD*CCLJD%6)]6 M82VKT%FD',%I6S>MS]-ZA5(?+ZXV)<%'5YW=@#*D/L^@FJFV4=-J/*/5N%A< M_#:_O'P9U7;6K]K./&@'5G$0)3L^###=_/V0I'O!-;MFPJTV0R8,A%2Q>?`% MNT;N3("M,##Y0&(*%7`4P8:V&PS(C0].H"+5:_S&[0_&HUO?HX?W\Y&_F$AIYH$K#9OH[% MY#:S(R*[30F.#FSP5L?.-2RF:ZT2/]2KNW:F4O3HK(@QP*YIRHZ!=A^:NANR MV]%1,BMK4FY_=4!;/=[NL@CI_Y67I[ MN398' M-F5NY;0F>WQ)R_.!_NQS$J5A=*#)X.(! MQWR,*WF/MR3&F=PJ>,+)[(F&1!)OPBB(G_E.FBOZ&:DF_:2T?'0[+!AZ9W9=5%1Q<>Y\PT^B6VZ#=(&8$IQJ.;M`]*_EXG)^,5W1?RQ7]#_9C06+#VAQ/;N9KN94 M@`\#G2\^7=_,?J%J\U]G:'Y%_SVCX6JQ7/Z`OO\=I8\^?H>YS)_>`#)^05V^&$LA9$G.@H=#DAL>D.-4K5.ODA^-<[<%-AF#D4T,)`QN3XB&BJ-F'2<)6P^99P^AT M,40"Z5E9'4JI55LD,_%S#.A!IAEFW@:C+DL]^'OT?2'Y`UN04Z(QEWZM$)1G M)L`8'#E;:15PNE['!UR_Y5(;_N4JTA9`I`+.Q*X3X`S(U)\=&R5F)OGS(O1G M=]`2?J[%KI+UC8X*<"@9J:X\'2>[VFI:RKQY1,R+`V9CN3>8GXES'<2LE.=\ M%Y9@E*:'LCQ=4RK#-Z`*=\=)Y/0%L&Q?=08G-WB-0W[E3((V!YS-\L29/.T7 MQ3XRVPA3ZE;7L*:U+;#"CJ8YUI;@Z/!VF2P:N(9%]ND?T-;4\GC8]BOOY`=T MY:7+UKEJ&S6YBK0I$ZF`,[SKY"C-EM2M':4E9O(3U-8Y\K(3G'SCK0(12K:J M:TQ'T:ZVFI@R;T<"HL,&1NX0`H/R,8D,FT54G'X#V#1N/V#`Z5=;07MK;"]8 M;-BGLE%3C%`(E%R,5'3?.QRID'JU'*\2&)L4;FN3Q5[X14@D( MW=B$LKH,1B%2WEG,W.Y!P>GKYCZ[#<]5[=130K'V5/?>"FK?J-I.$$-F<["Y:IF MLW`-/\?`VQ%F@EO>!D/-8";XYG5#T'HFN"\&_>QE3:,-;Z9J`[G&G2V%KK;/ M)=1UUO42>#O*J)W>?[_^F,Q>U2VKIH_C2L8W#IL`R:BOIJE?TRZ;P(Q9STWJ M_]B(=M@$&7@&!;.\:6J`/.O-W'R[(#=NP%RAW*^&K=7ILIEMDFF9CDZXG7-J M^SG>M)/$\Z!1B>[DD\>33E)@V`P^])QZ:ANP&G)P/P$E\N5Z#DKF$PB0NIFH M2L?GR2A@S-I-20&!UK.6)=M>'=V=!P]A&NSDFY,M%>7MBU01GLP25T<91],X MM^2UREA^]F3"V$P*P;SIX>ED;3#\K][Q6H5L%#F>_6JQY]$C;4Q*;3-(*9*7M4D,6G+\U MZT?IXW3]V5&UK3^I/?#@%D2SJE:235(C.GK5U-2,ZMAWC2F'S8#`TR`XR8-] M3?"U(%F%]Q^D,8L:OA;.9@Y"K2J"U2`2=:U\E18KC4K1WW)&8F^?/Z M7(J7D5V!"B7]U+6F(V%76\U%F;\Q+.]@\[\HQQOM//>MVU7E\]O:G2 M=S.E)/=XA&786N<])IDT-LNS'ZH3@+QKO4VAI)]<,JM=HUDFN2F#^29=.4:, M`]E1O$6(FO/SQ#ID5PF5C!8+#::MR"PL-Q4>U`24*D[*DY2KI7%A?OAV<4JG M%WTZ9<42FVIHDT@DWV2*W.+H=!">M]A]U8(^T$F+E3$7,#<^8[$E7D':A\,5 M!74A0*ON6,5*2H1,+PY4S`82GW\-=@=^VOH-3G#\*,C'=((E5N6"@Y$K,PV+ M8XT7-:J5RI/B7VA+8H2?UCC)%S??)K1<*;L_)3X/BVL3\`V)U6$^?/)ZB$(!<^ M052J"X97^"E]3UW^ M+F.90K3-+Z$H%+,$QITL2]:Z,R*53'TRO_IU=K5:W,QG2]J>S5:>,$I5RR(N M:6I#PB*!EI`_4NN.P02?-"D<#<%1/4U"E0SZPJ00%QM]J2\LLG3YT$!H>9$! MT:9"%H5KK]I1E[^"(@8UYC*J5N:-T%^(>[>85E`K(BRWOJ8$NJQ7(X)JJ0U< MN591SN"2YJYUF\H]?>FUJXM,FNKM1IZA]7L&WHK5#-M4[5FC,W_UTBKV;%C% MGOG0I%3-G72CHE92GN8#;D64VG;2<9:ZL4S*FML*V[F]1_NN])6LSL5,]@E* ME32)F#?7H^8E^XW$O_-%8FR:R6@D2J_1YI!*`XI+\\6 M.S]D$I[PR@``(GZ9U9"$9W)E(=]TOD;E79*R>Y*3#T$8LQE+7`4'`>7TPC6V MJ80!B"8W#\TQK2<=O30&)I4,X]<:QVFX#6FM4SR1+=K@!Y*PRXS#:+T[;/"& M"27W)$ZS\V/#RL/HM]8:083TJ<@N%>5Z;1;J/(Q&P$M\%^P^X$[SUGF>__K: M\X$,*BU!DJ5M5,6+INR$_<67F.S8<\3"8[@>>YZQ6PU$\P6;*"U%ZH!LZ8V' MO6K%K?BB,[E`@4:!P%!8=DQ:K^70C9I(72C1*E::K)BW\MX6;T[R5E0=,?W8 M+2AW9!N8EEAR@@:PJ0*Y>7LHG'XWJ;TX*:Y+>;DPD(RM]<'!F"/\M1)-D^2P MQYM3>9AK2W3C7"4!!^W"IH.-VG(OA@AO:-41SLYL8F]0>A^3P]T]"M;_.(0T M30U)Y`WH._4I1KVH`J2H+X0EL&_:<@,2%P&P;;\'/IHA$.6O7C(8]#'0`@V> M1,'JG#]Y'.S*="-A708.YI55EWE?QXLAVEMZ>?;GX4TNZKH4`U_\Z:7(KYW" M*<9^VYXKD+B(AET/O1#23@JKMR\='OK(:(D/3Z)C<3>?>,9.+RCM&8/-U\E- M@X[DZ+S8]9!:9X!^OKF97:W0Y7SZ?GXY7\UG2V_X(*M797])/T4GUU%WGSR9 MH!/25D\2N:PJGW!!E:YU1VR1.K)N0)J[#8Z3&>TWI\]Z,AFI"48LU&J`/525(T=L,_%IVI/5 MFIK4F(>F5Q=HN5J<_^\7JRS( M.LMZK][2UY*VEG1U3E.7G6V5PR'<;'3!ZP.3T08E->D_(I@S\J0K&=0#2F!$R:P)H_ILK'LE`UIVED'*!_/.)!`8ROVL2 MY/21=3,_4+Z3:Y*(KS*^:_,&F4 MBX]-*AN`D/X5V"*>@7:#BL;>1B/G5;#'BVTC9ER0?1!&+09HY?(OI9`;R#VI M94C"Z9RH6*;6G;#7;`-+LXU"7S*9D?FDKUYB61--YDA5ZG31V!V1(RE-$A?; M_*H]$K6S,KE`R8JNP&`ZM$TZ&'N0.E'S0*@T6=Q\G%[-_]_I:KZXXB,'UY?3 M*[3X@!;7LQO^=.0I7$4U$M,/WX9]6[:)=[$E)\@`ZX;+S=N#XI2%1?:"!<;: M1_*G@SP$$Y*N;1]0C-DIO<+I>9#<7\?D,=S@S?OGSPG>%'<3A='==)V&C]DH MMGC:OK^!(GSV,#"41-8N0=.0OMZ5%.QG=,*4T'9'OB:(<0)M"P44E!HCD[0_ MP`A4E;\IF*-B"ZP84!PJ>>C(A@N4[1V"P??TPR_ MO.TJ5-#M,_K^D1X/PR.6SOW/6(.>NQ&BJY:YA$ MM=50?7\HR/U0H_Q+SE>'Y:D0^6F_O-1ELR5QY[K94KB%`[.^V2H5?6^VG*#9 MKMD"A;.'S9:@@;4;@C$P8-W?8'%8]!/.2>V(]AF`,J[QO M*FLQ!*,MB6\A(A]&[A\B#`RH0X32@)L0H7!YA!"A]]XC1.B,=D($*11\#Q$F M`-.'",,J-PH1"EL&(4);DC%#1':)[B5)!/W;[KN*V/5WPSE;67/1$>U8U]"M M)<\3\!T9^TA?<840@^_8P7@EUH)O6Q^Z9B&[9%W+5M5Z^G+K5=[G,:Q8#WLN M@B#9.QWIG88<,?TXUH";W#5,SM$:<*L/L[WDA&-8H@&18/1++%P.LTGDT/$BD7+&]$_UWP%-]N@FZ^- MGT=UF3!:AP\[1:<:S&+9O`%8'!PQ!I$:C,]8:&(U-/H$''TJDRM%C9FBP_7U]?\A`Q MO43+\U]F%Y\O9VPA_=7BZLWY=/D+8A>`+7E$8>OL/\ROIE?G_%_GJ_FO'AR6 M9H\I,K"Z6\'!U$0C!-CY'9/H95\L&PB8/3W@*&G31RM7$5DF-YRX8LOPW66- M)PT[%;KYF4N$[_%WTATR>U!^"TR08;-,;$RJM8EQ=J@,=F1CJ,MO$]'K4/^UL<+[;+E%WW/(]^ MNP_7][.(?H7G;+JPNTS$7*.@LHG&4`KK?8!2U]B=DK*&5B:9(#NR@_(E#>\. MY)"@A&NQ;<)?F1[Z-4C(+SC8I??K(,;H/DC0+<81"AX>2!@Q4N.G]>Z0A(^8 MTOR!?E`*/]KUH/]D%Q]_G*&:]D48W$4D2<,UFN^#.]:T/\1D$DH5DYNU4VQNW3,O6"+6*( M!(&8T35M/9>#8\V`ALZ5"4$DRC6&G-\S`5Q;U[@F^X<@XI<;Y#I^L$=1[P+Z MJ&M(S)^NCHA`,LM.H04W9J%UTQ]7IW5@52)H^NIP)!N!``#2F&,.B^TV7./X M$V8%;.%4^"[_^:UW`YG0L`:9E9_DC]"7[.'(*];$=4(,/F43MPVQ M.E0%^N.!LVBA\ND:V4HNK5P!6KG<4`#++#N8]]#Y4N);J3NI%H?GLXHCI]'Z MBB66==!B@4REP0BU79?(`?W.YJM)$N#8Y0$`@+(0V\&$" M$KOPT=^-/[`T4R<0BD5AR",-^(7'#E'2_4L57OTR3!:2)>!"<7*(*00&!H1.F8 M=#'@)W.BI+Q8*=\\L,X74P5<8&26RNN-F'[I%G\ZL@TR2"PY@0)<6BL!A%'3N:I$;%.N+LQU9;J1KBX#A_#**F@ZI'!@B/*6 MWB2[Q'VZ7,Y62P\V;*@K3PQS\;>6`KT2EV"];6];` M"01AP8L%SGA7)=2&##>.)[E^GF2MGU%:Z:"[((P\B$'N&-$.8D[Q)XB"X/XZ M8=31+_(R#A=%O,9Q2#;T>8R#!%_@[+^R$20P@P;QU=2@PUAJ5H1CQ4VKTO2- MD19.BBYGW9`?8\AP,#4,>O9`,0]P9K9-@YE-2<<-7)=A M:"2"$`%$:-K5D)'*F9;W!(-3(U$$ACCE1=!RF;&Q"N&Q>^RW]^ MZ]U`)C2L0>97(L,JM'?E)_DC3]:-B^N$&'S*)FX;8G6H"O1'!.H7!V-:Y,`;\SQG@(WS'MLBK\@9C MIVHR&!F95"^S+=?L-4K8^[&Y8HP&TK>^VJS2Z3:I9N;I*``$2S?,W0W'WBD+ MSYD@WY3?1&(FC):O&XF2Q,0%%,=-5+(2KDB^Y>XZ9@NVT^=KBJ%T&FUF].G# MOMMGM%=LM0TFBD`4U;MRV%88.S?AK:&QR76.M801]B&7/4&XD.+G925DFWX- MXI&'F7H`24!FNRH6*W`V9-"^42S5ZU6,M[$J#IKL%1>01!IJ29658( MG7\["#5M5,`@.FI30L%S%>SQ!=D'8=1N,X0OB\:A]7(HS1KF0$=J19:5M.DJ M3-@SQ!ZB+]GCL4=KQ55#3#YH"]<-N0:`!19&!^KT*>RD-H)7+9!FKX`@RHRY M`&C-K@D\2_$Z.-E#3Z#9J`X!,-N?40Q+)B4"9:4]'B2I+1S'>,.'L7X-=HF1"_X9. M3]Z^?ATERH%98?Y@-3_OAL9/8H($.,Z[C%I:YP@U(R6VYP")P!@U7VT4:$VD5G5K2-2M&#V!,AT= M>>J6/2'.=1`O8KY+?L/;SFL<\[(J2:13$A)*K@1*+ID;=T33>#0GG=)0EX!E MSX.3;T-VNR!.T`/M)7`B>L5#+6*DG#2I3Q4_9?IRKJH]>L+;+*`LJNZC0:LG MD%8T?0UI!^U?S;[K1K#KRK8E;%N0-H?U#KW7;:((#)J&45)C^M:QIJAK(CL^ M1N0;66.\23[03_A;$,=!E,Z><+P.NP>,FHB63%.)#J:9W#@LQ[1^U`33J$\* M"<3PBW#^DDU(?\WDQ^:307T3^WII,TFNU:21SKH7'%H&.[S8FJP"L5(2\$JE M!,@PN1L'6^&L')N23V-H/_`-_S[NA;$#BL23IK5I)R=CP93 MP(%N&Y=OPTW`3'C^%Z[#W/TJHB9I^W@_>&9`O9 M`BL.:AXRL@J-VU9[%BW+QX@]?YFU+@]S5M4^O#O[BWB]!E^N005._W+*!+Q;N&$`)6)?Y1T>2K5:G-18 M=XQ8R!"M=30$KEGHKF^G:>ZF.4%78Y\)"0TM>8P'P=:8L?^&!H7PD5WW+CN\ M7B&1?PZAQ$"Z"&Q"CAK*S:NH(=.:3,_/%Y^O5DL>P+,#4F]FY[/YK]/WE[,E M9<1LYX:?T M_:Y[L$4/S9(F%IJ#Z6/LR\$`H;UW->OLK$UN9I?3U>SBS?64Y52KF^G5F MAKC>Z*W),3$M2<2.`^IQTS1A42_#",]IKZ\]VF@JKFZ9:N)NZ%PZ@$WMC'SU MH&W3A)RJZ`N31%S43WIV@:#GI+"RC'A8:AJ0K^7%"\()]WK*!02D`MKSV37I MBCC&>S\E2BUR^+$'5%%E$OCK]H)V9640]V)/J*S!D_;\S<0U_1O`,0&U@R.T M(G:C!08F%)T5CT8,#'%@D-B9C"6H-4TR.,]'&=X_U]\(=FC;*VHX*%)TQ,:N MJV/P4NJU#T,EQMJ-F@=[QWL`Q8"DZBHTHVO7A@EQ99Y'I/!#?BS)8MMHS_%M MM[G4BY8T58D.)J;%[3.W$+K;-3F/\'TB]Y/ MH\T%?L0[PN?M9T\/.$K:0#:2+1,`I>Q@*BFLPV;C>D=J*NGT)X4(7V2RJ83& MII!)79,>5=+FD$*M22*M_3%)E,;A.LTWUPEO.%'*5*01R0PG2]7(FBKD1B\ MANNPVW\T52CYH%<83`Z="UBF&'I3T\;(R&3:6%7+7XS-'N/Z)WUKJ,TKG6Z3 M9&:>1F3<(XX.F&\4FCW1WF04[,X/24KVM&/9(9N!;,DSI>Q@BBFLP[)+[TA- M+)W^I!`I]DIG0FA=2(U-,),Z)SVJIDTKA5J345K[HY&)[;2[9#>3W@;KWVM# MM-EES&EVB^E'&A!N\)K<18+3Y`98R+]G+PL#Z=C#)R1)^[M74;>OUYW613G#3"+EU'['(Q:OG-KC#-1&X/X8X=F3$NUX>`CX"AH1D7>ABK1XO> M91F'$69#O^;S#`.*X8`:IW]P8R@N?"#'F&LZ69&3/`7X2,@FZ6ZW5(G4VLBN M"`#EVT:A6SF)?1U7A6J3ZH(B1KJ1\TQEK1'SK]PE2%NZS0"Q-2\0K@:W&M?0 MD.ZS29BDP4[7/'7MFZ*Y!/**^4%QWC'P!\<&$#9&KP*X4+MM!3;!]HA(;%M6 M]6G96_9@PVR_FE:TY.95[4L+3(LC60:KD1+'*[!%KQ*[#G;MJ3U9P+NUP-7' M6*9:NFKPQ96`%RU45=ITAQ!7,:_MHR8ZKX.DZ6X:7][%$85,O70^?*FD(DLCMNPJG6H]:YF@L3+@02H.G8E&D!]0Q MJ/4VA2.SS`_>4W?2!5*"Y+W=049-E-Q^9X=%C?X\V!G2[*#A6-J)?GG*@K1EK9<3"V M:@5AC-6&,LC0$2BE['PJ.69C:E+(A#C).A1\\34CW>B4LX4)&5:%+5(:6FBP MU,JK![2=1FFX"7>'-'RD865]B,.4XH`VOKO#!F_8$HMSLG\XI'R^;K$M5C$5 M-ZKH"0[MH!,*X!R`!0VH(ED/M^NV`CDKHEDT`G4ZJ5M#5'%/HGQ=+TLC'FE[ MR7:2%-:SQ54U^RS,73!U^J[PA*@KQ'WY$OC`Z2,,D2X`*PNF4+[$81?VEW@9 M$>"ZP\Z*=_QPP#K=N6%&[$9LJ&RKHT$W"J`OO-E&WAP<]I(#@VQLX`5&AE%' M(,I?]"&,PA1?TM^SF=/>M-"SD6GI%L(BI<^6FZV7H MU2R^&1EKA*U,XPU7094.RI3R:.1-"#*&D3"TV%2P+&+H;(@C@9EG#P@^-&0I M@P"D15Q= MTZ`?[[*V8)UDN1BQ,O;I<$C*M@PP25AK4*D>U!;I/0U,G33,E^!DC[1>>9C5 MX(ZQL7Z9F:OA&2N_#L9?K/T[P/YICZZ(CP,C8]!".[1Q3%[X,3@QHVE!^OQ; MN,'YI/7[YT_!WTE<[M1EAQ8^L+U@T=T2W_&3C-0=EL$6.RWM`(M@H:=W&=ST M1X86QRPP#?/2B%.Y`73[C+@)5-HX8<]*,ZBPXUL?8SBLA?$+!%>R<-;;N#B\ M#2RK!]&.;1W[&NYV^OZ!5+(3G0228%&G8]M--)&Y,8L28NT&^\_OJ1FKRNA=26%E),FIVE,24D]CV@$HYP4O"SZ,MB?=\ M].#]<_Y2G2A86^A0S\("&"6-?;JAJJU[,PK;66U0.W];:\%KRKQM+R0\:]#M MX2=D?R\\R**"L3%QM+`LBP]1A(TMO@\2O&&CCSA*>&&G<$WMTP:U4VBNDT> MT&J"N5W$#7L7XH!8(`Y\<`"4AL-A+B1!$J+<'H1.LULFU&&RAXU.2+2R`1;^ M++RZ"77V!3`+:[9V6Z,LL@LV\U&6QA4O?@6K/E@4!J:>T)`%(0MSXH!C71X/ M@HM1)JD=1.EEI5\OS\'@BY5?AQ.N?H<]OL@?F;S3D&T#H-=O;N' MZ%_E`*XO<:4?"/OW]6Q&@:P,#NCS.9J/M?;M8$ZV5QD-TV-"(C].T8[)' M.UT[!GW\F+:=KM=L]#RY8C>&71*:5$RC31Z3H[L;O,;AH]E"J-Z6NHM)[2W! MK1RU]>UHF6C/8ABN">UE?5*H\4WZV6*I2M:;9KH_#L4+-H<`0KHZT]:H9"EF MO[*-%W;D,?*R?==Z$5\L5(I`8J0R-&(8.`$-#>;^E#'`U,Q$F7.@+TP:+F]7\ZB.:7EV@\\75.7UZ,_7K0G-M32O89'`4TM:=FGT!9 M142IK^,@$F[TQ]P?`!A/15E5)8N^^#-LXQ22LN$8)Y@<=9@E*^(%V0=A)&X2 MFN^:P;]X!T.JS)J#-*EAV(`F-?F2#U^RAW[`OE4G78!W/Z40R9F8`+-U_1'! MN:,V[S[B",?!;AIMIIM]&(4LPV);.\6W-]LIE7`V4QJ,*DOOQN77L[,GW4%4EL/GN+'D+Y!AT4%IUAQ"J;UR]W4/KI M!Y53.580SD+$R\>,+"L?`)I1'?DV4D\<%)6^"551R^[?=QR5YI)^1A] M3[LW";.=_.!C`'3+.6U4=0YFDTCMI!#Z\._PM[^LP`,W5GG\A.;#*PUA-CKQ,[@=7((KGI`'1>)WP%Z\B.34`/424-D,9 M4#"6.P,)NKK?\O)BZZ5L9228P:&1\Q)N5>7@(G@1%]NE<1(&+UOK-8=FQSZM MZ82#-D1\%((+*!Q>"E>+`I7TY04[;<[\*T[&&'D5NW4^[-IVZ^W01[.@+VC` M55CP<<8]!$699,]>02K;EV%'&860H_=8(Q#-$AQG^$'TJU]0@'D!`ZOB0OL2 M78XZI)H'LE<_GNI7&#OZ2*H?<>Q%CJ%J?V=S3.-HJ:_8K?/4M^W6VY:I65`O MQA_ZE7F<=DE0E'($=W.(V1:)ARR8?`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`;NPV8 M"/J2"8V>E>MKNLU'?94(*"=6ZK!*97M@1\<96U\2[]R`*8-V0[Z!98\K/+>86_\E=67QBP[3KJ&P[BRZA*6^<5>PY?%HP(3; MPVGE$@:5IT6@S]>79^+Y(4PG^7;)$T1U,HFQEU`=`:RR+8P.T3KJ]D)6RAO\ M0+EP3SM`US&A'=)]M4-GNB>'[A$15DKU)L5`"8*Y6C?@>9>I1RUOS0SEM(U+ M8?2029_4=]D%7,$#SIICIT;DB4TGJB1;F;1S0[PDDJG6IW8;P>`0"-0T0* ML.*X25*ABZ<-/[`.)\O5XOP_?UE<7LQNEG]"L__Z/%_]S8-X!(_P=MQR@BM! M?`/STXF#P+_`.[+")N[@13LN4T__H"HPJEXN5T?OC@S^-4Z2&B?)C"=QT3IY M(6FP*AT9/F%E(]\!@F\62;(3SB^);8#G"H?=N%(Y6M%]'7T4%%&1@, M:E%'?8D)-;N5?H^)58=-JL8K&$PE#2-B*JC205^8%N)J/BS0.`J(C1LP:!2/ MV@P=;I-P$P;Q\V)[3O9[$ET',8Y2\?HF(^&BP=$(#V6NTCS\R+F).R5-]08F M'P*:Z7R,R=?T'LU8GO(0APE.T&6XYW?#?__AX^P'7Q9.F6&!]*FQ%@&5>@W6 M&7AP#CNX5L+(U3#,L?:@%&(+R#,QE,F]8JC)@CT@UL8-ZP\/.[YS*-@51XC, MHRV)]X%J4[2=5AGH#;4&4\_(#^@R#"N7:BJ:6YHL/U]?7_*S)J;&;:`88,JLTV58T,-#EKX7,T[J[8SUQLY]$F M?`PWAV#W6YC>W^`=+V-R'SZL"$T.:$HI//6RIW;^;:VU!W+:TA\DM_NY5G&\ MC\4)5V(M;Z6&OE(]5%=D(,Y4/3EALB_*"$C5-P.!I:%Z0.A5AO$"0XP#VGE\ MYIU+OLFLS7VI0$%O@G2"J\(#7:?B(=R//\2G@0$PKL$6UCFR#31)+3A`&ULV2F[<'UVD- M7M^Y[X0`H.RSF25Y9P@IH$RE=<-3N-^*`PZQTR+?@O8E3/B%1C" M=_DG:;T;2*^&-?!P+K*NXDQ7?I(_\N4@&7'-$(,/VD1T0ZP.78$^=!5;A4J# MU9A"!U;5?/H*ZED2NLPKNAN,!M?T&52C*+1L5<5G916_V!H^&UK#9V,V-SB\ MNT_Q9DH)'=SAQK6ZBT.:I$'$EM:_#Y)P/8TV%^'ND'9&38<9*1JPGD:&DJ.7 M6P>+UP<51,FY_H8G;]`M>\QGNS;9BY'I.0QJ!++B6WSO9:\1&`:4:#06@'6P MAA7!#0%8`I(KHUP;59?0YR-/-1,GZ'U)EXL_Z*((]!0E@[^N[M MS^_>\E:4/?EO=A?B8CLM#FMOC^.)WQ9#=NVW/7DL*HAM&[4AZP-?'<>6O[3* MJ;`O8IY4?'*#'^A/R.Z4O,>(7ZA)J11$M=/NV0MV!&P0/2/,-^QM4!BEY,>1 M!SDD-4GTG[\U;-$49)"6&P`&Q.!PK3)L`P4VOE54?O'\Q=6O;%S*O(+[]^YD M%JTZ=]*A&I5UFVH^>PW5+.GA651SORZ>I,$YSZX(D8T2RE[GA>^^'@+`MC7P M1D?B0(I!H?QD19L4'-T%V57>#(WK4H[56Y`D8=)H>49N;*252`P^?!.F;J[[-&?7\* M(LK_#;I]IGVS&*]IN$5OT&QS%\3H)B2^##'W`H2DA;("!&@;=8&W.&83:[0S M=H<3OJH>;ZZ#.'T^/\1QMY]DKI#_1!.%(0#7VP=OZXQ=2EE@:(&WA]E9OJPM MW.1:?.E0@M;!0Y@&N^S`WP0%;%$[!0N3C#.#Z(%91&D<1$FPSFYT^'I/.VJ( M1#A_N:9].OR$XW688)0?P8(HY9+P+@JWX9I1,HRVNP.F5$"$]N%I+Y#0%CC. M#/P;?5L;VC5L,MVI'H#LP`3*S(E52J689;)T.1""9S4(-IN,VO66^(E% MYI&7U3E#H20C`T1AMVGLT#:QZ; MQZPMB@;N$@<)NXVBG=^Y,)U_6EC30S@-61+P[-)!X:1A`MP7SU@?BXLNP\I\ MEH3FL892YR'WP-,\7/A@>5[SI,69!?R MLHV=84J]CIRU.2$3<0SB9B"$]%*&3/BB^Q0-8/)0%Z4Z6AR@N>TK'_"$HE&1CJ1!8&CI^JC$/.W)JX*PWILYJF'KS+:!*-C8*@2K0)&!*6\$- M34GX@JYEL&.CL/GZU>S,2,FB7VN]_$-8Z`VACK$;\,3!UK.44W:&\OENKE*N M.6:M?\(TV:6W-=5JH>+(28$]BLB0"FZ2T=A$R4Q+IT<#,$Q68>T2!KHTW\CE M4;&.EJN@I@Z:^K&X]DB0E:0ECC$[,&&Q\@6XE,[:+PQRSRKD%A%7'6V_">1* M4A_'R(4=&38\PSO/^J/E;52*D1(CE4$="`,/@+U2"V_RGH2QD4DAR@=, M,V%4DT9?"OFQ.Q8VT"!]JZ[5T3!0KSHGM&>Q+@XU[GL`NSI_^'U(684"2AAT!K'*3LK_"$.UWCD3H"HOHFZHH3G M4/#LL(M5'B,:='7-O]SJ__^#A# MO^!@E]ZO:5,U^E9$#3Z(15VV]R>)-6K[E%0F70$/:LNBVD,OR/$MC$F*%MEE M;07(>H%V+. MZ;>T2U=I96TT7_J1+2FA1NOOQU[7K4<"L:FT)C&D*B4S-$:=@0RFO=6ZZ`CWC:)55%-)CAU$M!HA%?;6S"[%&+;M0F70%+J@>B]I#+UCQ'DN)D.*] M)^$3!"G2+LL`J("&SNN8/(;,SP<27Y##;;H][*;K-3O^(9E&FZH,U#A_9%@!:D.ITD(BD?$"M>'G" M3_2*B@-.TGLVJ?/P$).G<,_.$,G/"HDP:\?8.2=\\TBVN?3[M#H9A7V.=3ZB MQX[^R!:7X\W8B\4'<9$`<:,9Z_I8*^-@_Z*,$1Q@FMHAWL'#`FVB2U5KQG[# M7)`T_*.08>`89U^WH..?0PH!3HJS/T@Q#!$>D`+X<)1BL"/:K&*:&='<0S@$ MH1E..Z[)3X7+#HY_7H44$L:J[ M]NY]K;>EY\C?!F>;A-PDT8L'WB+?@92N<_6"L]A`0:X^"!U\R?E!0FZGS7 M5%1>=_*5B[YAYV]N4%(31MDC&I6K#=4C!UQ38!#[VFNR1Z-84LC(@6/\P41B M0T=#D$=CA\3 M?39K_4`BG,V6L0_4RPRA!(BB^!17^%$2@"ISN0:QTDVL4,%:/^2CQK3Z&UWPMSFI1PPIX0% M,:S&)DU$TB4UY*9^I_O7 M[*#VZ3;%\8K*XT\D2N_;H\9&LD7FK)8=E$>H3,/GS`;>Y'F$5IF/%3]@^E-I M&>[X:$6^S;X\/)^IT8A(]=">*R(&2'3'=^NSNY;&SF:-8$%L:Z^56ZC4JL1" M;]PI\H#25Q,W_3''$E<=Q%X5HF3I*@RD!BX@TMH'/%7`R%=_8)T9``M]3_OG M]X=H$^,-_>3FF:J6H6BC_@3*A(200VP1OK95N MI-A7:/VQ[E-+-0VFB#$"FOP2RY?44IES`U28QEYMOP=$:1-?OO1LF>9@9$C: M]-[0`%UDQ&\;%MS)T7F>%[[V?`A`2S/@P;-M60K&IN!D%>YQ>1G'-KMJ.[OE MB47)XJ[ND:-4MU:(ZH,V`5>*E!AK*8%5*$R0Z9@TJTH:2B[+RGL1U24)$)KZ M`@T#\V@=,^,7N/AO=C[%.3\V+;G)[@&X#B@%6K7?0[,\*L1"<]AA#L:.'!PF M8NM;<>B#G2D^,A/F2NC[3:[V`]HR M8^].^#[].&&6\KVBV1%&V7%XX7Z/-R'/5(,]56$*;#B39:EI?*"_[H1+)X0% M^?1^]"-5[*E$AF&\?6Z&L9':01J6CH_(9*AS6JR=0G&8G^22$[A0084.RI50 MKH6XVC<#8>G9+\XQ/'`HS=*;V=#:SQF((WS'E*6#:SU\0V&97Y[*&IM_YL,$ MVWI+$[$VA07W_,#6;P;&DH&Y(\#8\=3;ZBOY&PYB@YTJ+4'Y-I52$'A5=V[W M&!M4FJYL%G37-8VWIGPEZ)EI>3_GU@&!8F6WH+JTJ[IS'=62[H99=PASMA&E MY:,GMJ1;4`HHO1+DF.\\L8,._)Z3FG&W&TY:CGH"2+K5I(Q%GL^Q]024^0X3 M.T"!-M-\VF[WS`>2BH4[_&3X%A:U;LS9N7A%>)`WK0+R`-JL?^41"R._T*4_W7=/6.`BC:O(@WQ=XGJG\*6F<"CQR@VT`'F)5S4U"R75* M1NG,ND,F3*NM]]$3D[3=%J/P1T]6L8!A1])Z#P8/_-$Y?$="T:UBL^;)]"D4 M#D>J)>OCD3+)P5U^L6$W(Y)*7^I>OT*5CTD677ZV]B(IAR51P-5\&'345#6Q MJQ-!5U^LU.SKJPP[1!+@R*/:25\,E1ME,Y$235P(?6%B8Y_9"(D#W-F\R":5-6'4X+60+*:8!MNNF/J':0_;6!K2^9H)]AMB^F[$*M+:A`PVTQ"Y#RG;)LEZQP M'$$GEO]0N=@0'LBL@H=6C2,I!Y1Z/*"V9\M3?^;&M55++*JA"7B91HEUM4E7 MF($)FSH/O=!"@^6O%4:X`#]6Q9->/0A6)-%Q$%A@[WJG]4:?OA5&0O'+XG[V MULM!U\DV;(''.J%Y^0VP76D>U]@SQ%ZBKVRM-KLA_+&ZQ^Q]<0+X17D"^+:V MI-8=(Q[XX7%S]1%MIK:M<&W+5):T"=5@,`5V] M+;1K@1YV739##<>/'['-NF9E5U>;5NW0ZZ8[!@&G#<7&+2KX[+M)%1M>:`7+ MKF$VK6#8G>I/*8XV>)-?(WK.MK0$ZS01[U@W$BYVKFN$!VT,5MJ&W\ENXDZ^ M75BOW?-*99Q;1L7%RNO"]MC;T,V`0JRKL[7W6*E7[4$V,.\6C4#;U8W\#,`A MV[Y>0*JX=[D4\R3<@D-+MJ\="ENN+Z.;WL68AX;I;<)]MT>S+53DE]()5(!O MZNIX`!R*M/!FGK1!AN+V+G7-:6_PZJBK;O&2^3H& M&"&7K5NX'(S(LS\0J5K9[@*1#C>EI1_";?I\G>V::M_B($S;>^L+M[`9Z:F!I\=3BDCX=YH-Z!SX(/V>(K;O9-IM#FOAN_% MXU,FLL7PE%IVT'B`RC3\X)2!-_F8@%8YOXZ5'85#4,`/P\FNG`F>:?EVQ30* MSHYB9),L7TG\>W%68L2.4Z1"M!4+LA-UV$Q-2R'[YUV0CW!1B]4\#4-BD"1A MDGHT6V.&,V(+A]8`A$JM&G_0&W<*9:"1+1,W_4',QK7*>4`JA&I2GC08P)"2 M#6K!8&I@?UMKWZJC_8CC6Z+H:AMYZX^MLSJVVG/,KQ);DGXT$+9`>\[S*&1; MI=A*M\56U7=OP=1:KSP+T%AOV-%+AF[`DPU;SXI3EVP,37+Q["13FB"HQ[-& M/P#/%CUD2,6V3UPR-%$[;\G*Z=&`"W7LG:5+&,B>5IA=&6'VFX"L]+`[IY@= M?-"=A2_`.0)KOS#(/>M&VX0C-VXB-_BFD"L]W\XI2JH7R'R\3&L(RL4WP!$;I1DH@A5;KJEZ<76_YD(NP<1!V9#!_FE^( M69Z%4JWJ&3EAT50Z,:ZB)CG$\B435.;<(`DFHU#;[X$AFBMM M7F-`/L<9N$Y??LUTQE[@:`H&8E]CHJD;J6)KHD;CP#'F(&S`:5,_C,E,D,((C0)WMZKO$BY(%>:3.]H MIY:=Z%]N:JC=W9+?V,+7+:TK&P@',3O=C#]G[(%QU@#&BP:#I$'M"0;@,T2K""PY.U0F4)X9VA48 M=B)CVQYX@REUH3B'4:@Q^13\G<1\8U\DYV)-?9A269@(=95VCH+1ZE7G8AC8-XM(H&.4C+R,P"+IU(P,L"5\'ME MV)(=M`0%+O&UZOYM>V3A:5_SHFYK%_GMOZ129,]W07,O<7]9V9AG<3#=U*C!@MZ.S9P`$=&_7$V,4L<0^+=>`,SU7U9VY<=X+SGUF5`H!^U65M$F+6GO1HUH:YA MD];2=4GMAJNC-V*F6LM-3 M=1J^CMYH"=WW/U6G:\WX2*ER-.YEM5L2H!D?JB.M?LL#=1IVS$_3$;@_+MJ/ M=("4T"\@SLV/CJ(XST:_7D;[!8[OOB=&00$\CL\QMXV:0DT<0B"5[=8DY57;B@MF_&A1C@!2V29/=R@=N'S9 MPA/@>0Z67B&P>L:Q^B871\V#JOP[!.T(6)6LG':(5=#5U7EJ=0^CA3K`77O&WN"7QO0K@.Z&/CM[D_)X MD(0O[B[ZZ<6V*1*C+;.#[JFAHC-_EYGBAV=&91,U]KJ9ON`C`(`07@IH;*E] M6:!E$8[-`M";**T]@^*_=G-E#\1_@X!77X-Y',2[N$JX+,`2TT^^Z=_F&>M+ M&CT#?4B^:]TY;_9,2V#,>S.#!@U?P@V]O);/'(*R2&"%"G4DT)J2A@+#0AR= M#6Z:/V/7L#P0-X#&R/\F@6_8!CI&OHO+H]\)1[#%+YN71[^#&(]NV@)O>83F M=;?#UJ6+RZ/??8N71[>KGV@K37@![;O64(=('19#H)='OS,<\16)EY='O_-D M0,RZ9M671^NK%N;RZ'=.QD_%QBTJ.+L\^IV'ET>;5[#Z\FA]!9>CD?7??4G_ MH@^+1_3_V-8K^N3_!U!+`P04````"`!)@&Y#7J6N;90Y```&SP,`%0`<`'9A M`L``00E#@``!#D! M``#M?5MSXSB2[ON)./_!I_>Y[CN7FIC>#?E6XUA7V6%[NG:>.F@)LCA-$VZ2 MNW M/QVA?(X7:?[P\T_K\E52SM/TI__^K__[?_[^_UZ]^H1R5"056AS=;XY.TW*> MX7)=H*-;G*TKPJ$\NKZY.K^X/#MZ__K]ZP^OWQZ=X*=-D3ZLJJ-W'S_^Z>C5 MT?NW[SXXGE2,94[Q;_?%UG+X,.;;5U2"OJ_ M5RW9*_K3JW?O7WUX]_I[N?BI$9%^!E32DG\?T#M]?,.^;DD)HU3!>JLV ML=[146V_`F?H!BV/Z-__O+F0EO[XAE*\R5%UF=RCC%3)BE>;)_3S3V7Z^)2A M]K=5@99B/EE1;-E0ZWRDUGGW9VJ=_]AQ?C-&O`>*Q3M<)9D;.1F_H:R#:L8+ M_<65:54B?W%I9=)/T1ZLW*EFO-#7J$CQXBQ?3"\X7Y4KX6^KI-@#5(:5C5=@ M>JD-1'U.2OR(%ND\R5[/\6/-_00_/J;5(\JKD7&/C'\I*D]1E:19 MJ1>?,GY%1[6W'S^\9<)!N%J+?%OA^6\KG"U(1SG[?9U6FQ&2*IA9"WB#,MHT M3P1)F[LBR,3(AZ$.I`QGE/-T%Y0]$#;Y`8]X8(.&_4`,B<_ M%:R&LO>_F[3\;8P2]I5-I^"4^HP7_ZIX2/+T#\:.L+_.DOQJ>?6$Q@L/Y>QJ MK+MC7LK!4-P=5[:4%LQZQ8J#FZP#GYY[QN0KN%`XSS%`M(QRM'ITM& M-VO%"1:)+E>'[H9*!X/D-,.CXX'1V9`X?C"<;!AT/P"Z'OJ<#7I.ASLW`YWS M)9R[M=N4H^\DX^X(@8^3,BVOEM?TC(UT_V;)<5*D%:7KC),X2VW',O,ZIEJ4 M3;`:&S5ER!<$4ET7]#!ZY88J.ZT5\N3I%R=9_A;^<\\62]2\M5N*F%1 MS71*[4S'K4<4-;^NF$\==WA) M?NA5AKY7B*B_-1R5=80BK-JVX@S/>W5E-`("%SK-Z"^_JFJ9W9=D0)IOYU49 M/9+[^2>3(N0SU1-6Y(VY5HT!V>%BB>:O'_#SFP5*WQ!%W]-_4(W?OWK[K@G= M^`_RTZ^U!#?H(:45Y]67Y!%Q*JI(&I7$)'T5NHB8%7UUDF+>?WM(@),*W M7C]=UL:6:LU4SKKGP'O"Q@F;B647I,-^_Q^T$8)#0M-#QX`F,GBH=1R#CP'G M!B#O0@?(R;J@-CY/2^*L_X62XBQ?G)*!C,.(CJPQH9PL&J0`-;4#BYQY@Y?W MH>.E5N\KRK+_R?&W_):LX7&.%FS7LA`Z%@UMS\%(::.!CXG.8QR.M(8&2!_B M`-(O."-+ZZ38G*<9*DHA@"0T/>`,:"(#C%K',4`9<&X`\I]Q`*3QF-NM);I, M7HMQHB;M3V0DI)&A!J3QJ&F-I((&0W^*`T,,^2=DF'W`A7CR*Z3H(8:CB`PH M*OW&X(/CV\#BSW'`HMGKIV>%;)N]O%I7]!X"O5`B=C"``GTWHRP0&88,M!_E MS?3/R2_\N*6AXC:;!E31``BFIQUJI+P;J/PU+JC4EQOT M8!'0">'2HXL4,')=74"FQ[T!S<=80'-'V$IPTOW$0:/^%!T:!!J-`T#-L-VJ M"WXS=T9D7C#@9@D_0Q%^:XS$?8NFW54ZV34\Q[%M^>!W:5O]MC?W!%NT2AK. M`7`TT2`"HN,XE\!Q;A$R=E_V[V\&IKTD/TQWVFIR.#T.P\NDO&>JK\M7#TGR M5`,99579_L(CNOGYUVW(P]7R/,V)9"D9C7&9*LYJ38HT>(`5&=F1[8TP*TO2 M&!)UQ1];M\Y]]*Q"LU>DU$1"TU-H0.--+QIV1`-PR%\TBO@YR1"-K*Q.DJ+8 MD.4HBV+D#\I,RK2G9K`RWKRTNNVPG=)]-RVL@IV8P5C[/H\?X017N*CN4/%( M@XK+JA=6VSH]!4GKY(0DX2(&H!(0(&).OH_?1SA390!W8P#>N9J4:9TMK$RX M$+)1&H@I(&O[,_MG5-QC+GF(1ZSM]&LNJ%PG1=6)I>9@IB/G$"8G#Q]<0%4- M<27G:G]Z'PBDVJLQF\[]E08^HD^-_?J?PH6%0@4@!/H<[,_B`VGN+[A"U$U> MXB3OP%HZ4H'I&ZL"Z,-%BZFR0`@!V-J?SP>"J_9*X@DNMS;@][L4).UVEY`D M7,``5`)B1,S)_GQ^-"QDX?JMG*ND>$!E9SC<:%I=6X#'@*)`!(B`JFN*#P5? M^[/V0)P(F[OW3,"!24[06%-$$"Y8M.H`P2'B8W^:'@@85#A0V2R:UG?0\.(V MMS@,KP8)2+U93&LJR6:TR&126^UXQ+L1>5W@)T3\/[T_S([+?E^G3W0[;;B2 M@Y`V9E23!H@-`]UT$%&SLM^BK`:)9SW`I[G`)M<(K.N>7?% M?%_><3)%^H+SN6Z6-*093I2Z-`$V-D0;7/B^>C-V MV#`^9B/,/H7011K%BCQ6V2$;UI0L22/DXC18R>=@<<%6WX^`%K:@@C%5_[ M!558:!H:08PD.5T?12*Z.!"DU=`"/2*>T0=RL"Y!=QB^S],2W27?E6,7D+H- M+=-1!XXE,VU-$*7E''TT1]-GZJQS1$%12)"$H.^#>@2!`T:KDX77Z3&+/NJ# M2QBL/JD5$W&GLSQ1X!`!Z68"$QE#WXD6QF.$8%X[H0'17 M^V#:_2_MOE?P"'+JKA0^RB+")(@=>.-M7Z%-03ORT*K$ECZ$6(6.5KL#./UF MM)QVV"]%M-XG4\WT4'I4JZ433[N#.+*%M=-P\@T\Q56R%TS!!0>[\>Y3LP-K MH05$9_U*PNZ!OX0P?`B!U33$D(IO]-O3$/Q`;!HM:B8`C!HK%AO2AS`7T@[3 M3J9#HEKBO38,>-VMS5``>`>NR4N@?^(M$G#!=;:'EK*.>",$ATI?Y/-LO6#/ M(16LO:NJ2._7%5WUWV':K8CN1'8BRL-%7B%B4=GH-Y(I[5R@J8Q1`0'B%BM':8&I4@`B\BHCS7NU[ M@NO&3)-LJ$RRD7*076,2>T_=G5P);1]5%NTIQ:0;EO9[SZ[%LI_=!K%WH#.= M_-!220Z\J1D9I`VU=W+V)JGH![N$;7E3V.YZ-KPR1X>@(3]Y<,W:<(4JRN'E M_0.OMZU?WC\(]?V#69;A;[3WG./B%*_OJ^4Z&Z8PEMQ1M2G;VL&L;,`IV488 M`9JRS:P*QR&_`>5]>[DWQEBK94O9H]T:?`'^UV:JDR^ M_>N$[7!?>"3;$/$YC.HN(!GY"]ID5[2(KU$R,4>(4=6=U<%ZY\+ M=EAPC0KVE+0R:$Y72!A')R]T@'O=5O;:;[2=7*AX9W)]#>LWT6?K:H6+](_= M]H@0TS)B(9:'Q`>/88U]]HO=H3#QWD80:791EFL07ON$"JRVA#\(3H5V\8'1 M5I!X8_E$6EVMJ[)*0#LSUIX@W>ZX1Y`V>Y!B6& MX?H_U/S6W%)[#.K7SFPC#,#KJ*>9U@(HA^#](2:T<,OL$:S2J6R$>`8+L\C>0M% M;]<*J@+M^Q2B2/N6X@!1J;?$7F/M6PGL<[/Y/@%\"?+5!?E&&`OR$F@97J#E MUCSEU?+J"16LLCH3BO`&V386TUOX92W+5F[)`:R&:ON`O83*[Y,`;2X[)#U> M5E-UGP`0406A'7V'KQP^4JDB$>BU(_'GUC2-@4%*<5Y+S'/[?,&`5[P'I5U] M;E'QG,Z1!A8"*@$R>E2Q@$.NFA4^>NQ\G$M*WH_?/0/444*P"I;2=%.=#6E" M;FV(6N"VEC`[C(=QI,B0?!6/>F&C0:V*59_O(L#F)F`(5[)TL[>AY4!K`0E; M@04/*/#S!)=D[<-F"G1ATXP(MV1M(YE#'(Z"+XWI>E]"!H5S[T_T$$.6>D!+USZ$(J?SM^N!V)'?)Y03V3)ZT7/QF.8IE:M*GU$C*;\9 M8E2HW2,!%O+60?3-B"U5[_<>:3UL3P#(/]ZUT`VQ!6F,%='ME$S?,LRN#HN! M!J+=IL15TH8-*Q-%#="D81OO,#S06N>2=:XX=(#H%#(`A8!5Y(\(`:8VT#$: M/-%1,(S^+?>M;KL8#%G_&E+P/:Q+$05"I"J98Z/+:HJ,=7M]5CG'?;4:X$LF MQ6#Z[1/*6GIONF\#XO(ZTW4MWR#Z1T6T#?X1$WGK&/!FPD`5^[U$RY_V%QG? M>">Y]&CO$B4END_FO]T525X258E!FK11UZA(\>)3DN8W:(X?*?84IM`'3W4P<<".JBB%M!2L#[\J;GI3`$\#0,PCO>R MX6YJ>4X,7;\AN2:*[@*JC]$2%TT8]5WR'95GWXG61.,T3XK-!;%7"7HH8`\U M]4*C)ZHIY"ZP/Q.#.\^D(DWQ',#>^Q[1N?$GQRA'PP,A#54/\P*J\/&J4\T0 M:P)V%A<:PWJYY0NJI'LHPF_M9*G_+60LJ-2`#]5])O:7"(/P#Y#GL.KE`OF= M7J)$IZC^6W;"Z(QANSOG@&&0YCTG0U+ZT*S)YIO.,FV6+]C_LKK?+/Z]+MD3 MW)+7ZZ:M!-`,8RKQ=Y;A#JAX3VW`G9R,5H!M`$\D>+P;8@)C2#H>@')W$T=. M>2!=`&Z-*7"LK'W$J]&1[$PX'W;A)T@.:F[:YV-\SJ)]3;?-7":9%>G(&J/+ MR8)1\#@ITSD-TDBS=34X"@!22]0=4'OK<=KVPJ:Z]ON3C#_M4%J^]D.K_!V[ ML+P9L+N`?92<7SLR.#5F.-V3.>?3M)QGN%P7TK#0D5Q@W5G.Q9OUOI+I[8J( M-GM&1?*`OJP?[U%QM632=])5J7W>.":-[6R9!.,A32&#'1E.[5>!4E$?82O- M-#=@P_;'=O[!VEV#JVN]^>$E'SI)RM5YAK\%D&&HDS)J*Y7TG1<]Z?!!1P&I MSUUQ*LYU@9]3TJ+'FW^21KK(MV%SLWF5/M=IL23!9=8,=OOKQ@Q>#A%LHRSL M6\OH?,&\'OG10X1;;+L-P_(.TQBD?)YFJ*?>'1[7[Z:LHGW?;Y(JO#4*Y#T] MSL@F11JCP8KX>_!P2MA@*XOU/<<4`E+?`A,L^G0O+]&NH?4(UP&R4W60?<74 MNHH*D:0`85K3C!2"IY7KO*9-QHJ.';D>,(;%]CDA&Q8'VP<<6'0_G&?^B/2TD>:$B/Y` M,_"QEZ^ODZ+:#$,X34ONPCKA)0\6I_;VVP]XC>2SN,`95C`JKVW'/"?)4UHE MF3RQN6%!22]0%0S(+)W!EVV+$\2A])D^E<#/VJS*2HVC+.OS*,.T]05=W\0R M@S,-8/VB+JVIUV+M'7JG/ETC>F6CX[R(UVL65%KX0@I+\:LN'#V`#6SC%L'J MBCTNAZ>"\$7^3%3#10IPN`):*4![M-'C4:ZY6_CUZK%8=H:.MOJ-'F0RRLN+ M2+$G*A(]!+5V<(M$4746"\W0`/D[S]-'C4&T!QZ,Q7]^O)J/ZHJ'SUHS2PT@6]5U>WX)6;? M[K58FZ%77D3E6@=%HL>HU@[.W>J@NGAOH@[UNRYH3K%JTYXFL,Q'S1BBQ22D ML!2=ZL+1X]3`-FX1JZYXQ%W&\,#;;EV(7Z@"TVLWEOR_6>5Z8PGRB)6KC27^ M52N;FU>!Q'AIEX3&\U%E4>B2_K!&>+!=)EW<`Q4>!@&C\A M42KQ[+.G!G)+=]S-M#WS$76TLWH M,YO_ODX+U*ZXK[,DIX]^G)%?V*Q]I*PMM\)F5DH!67.12\`BPR"53%]48?1$O,,D=H MP;+UTUNU-,F2'J9&A7;73$&%8@6JC4V<(!58DP`(-/\9TLP)35'=P63AT>/F(!!F"@]BA*!D',#;XF19'0-Z!1 M,4^'#R=#2`7S@"%I:&X4TK382'^0XU14RX_YP^KBW2%I9]WGN+A!3^MBODI* M,J&AJ2QP?EOA^6^2!9.^`+=:4A6(%8.FMG""1$"ET2^2B&:-FE?+[N7^4W3/ MCQ`0TL;\:M)(06B@OPOXJ:N+_M(AW"C6$Q7K"4JT$+6VC0O`FE3^8R]YX)-J M)TL>977V>R>^9U1GRR6:$U.XNX#>HP3ZJ\(DA MF8A15`>+OE_?_\CX&V@_)0(MGB>O$7B6>U]PWJZ?GC)FBB1K37&1+W'Q6+>Y MY&D1LU)M^E5H*8_7$.J7YZ^3E,\\+OJTO4;0_>2O`QDV"E8JQ748&.\Z,+S+ M,]ZMZ8OVL7EZR4L`!^'7W<62_M>X0*%2;00N.+:.CQ4#'*KLW*394`6N(]Z, M!?3N$-%L=T:=+[:;-Q?$.-+#6]-R[98HO)S+Y-/;Y'GL?8.Z?>YPY];I-EAR M5E5%>K^N6#X*O`V>9@\DT&=_![[*/>NMHW/)VM_^LC%2\*1FY3:>H=+5;M:E M5-$_.7.>I`6;K5\MZZQ"370G/YYKZ9J64=#%A5ZHPB.@J*@BWI"BSO55HM3Z M$2W><5!24#0V%5+$!1^]DB.`(V0^S=EN@+-&VVF+X:D8O!9'"8+V_J[K5?&0 MY,WK:40]>N?D:MF,DW,+!"E!NQ(0$'CS'VZ;&`/4[WL4)_4SUR.HU^U$<^^NACZ2 M75XMNV:@^\<%&<,(79-"D'C6:V*T.8WU\/;XZT`4V1.N6L+V(58%H;>N+VZ/ MV_0A3Y>D1J"56.J<:S\93K10P$[M1.7P41:/74FXZJ- MW.W>DY]\SW$&DDD.DC1D[2S`=IZ20JAN`WM*V#X?KU^[J,,XL"EW-T%#^S]XZY/?OY MC!+JGNJ<%-Y/`7?^4C8K@9#R9X%"4O]'GAVQ9'T51*M0-X0^"VHQ;*9KO^^J M:N@==(HY1S[&*M[%I3$"_N[H;L60=&4%Q?9&KH#"W]$R3O+R"ZY8Y,8"">RM MWV08Q:,]GK;CXX>.@%'/MU!*\9F9V.)6P!0 M`$(JUS6$O@UI+&RD*)_<7LJ_&TTGYAMYS_V$\>);FF6M MH[H@K/.'E#V7ZPO<'9EVXM318]J.;56V085A66^='R2GS!W8%3:Q4`@NPPX& M>*1Y^F[%2`;J:$SKCMSU\$_8>-M][\NA=3%@^G8'74_O[^1!)IOT<`%<0*=] M"&X"WI380G5NHU]7%]O+!]01>;=OCB6>:,8F=CN!J.XU3*&;0JHKD'1'`4:^ MW5[0D7O,<"863>\%+$IJS!&67P"W,1YC"WY#05UGG?G,H*[(_03+([C"&5&B MI+>5JHV_8SU6O>PP3_BQ/=_B/OH+51I8DVY2`0*63,NU84OPOQ9N!*<;^2]EY[&IW46^CH@D49GH=QKW+-")NVDWZILFW7%K*R_/#00 M.66.PJZPB85"99N+LERC12?TN\`Y M^>?<ZN)$ZZ3J^=XTWR4+LC&<6G-8\LE[)LF3FQC/7L*'AVM-5,/`W[BH(.D!\,,ZK"">X/FIK&H9<>]0 MG%BOVJCC\SW[ML.+TN\,J8WA6<@W"_[N)M':20V8>=ER&DZQS#F%&K?OSCR@ MZ/U1U<7J._K!^YY]Q8\3PK_#VE:^$S(RT8T"F,.`%1MX!UVQT,/\+0U@%/(/ MKR/63J^(^_?L`5ZB_Z%^HY58[RJDE`/O(*",+X@?KOC(B'UE1?$^>[%3B\QX MT@I=IL]H8!'@*&7,80!)`PXQ0]764,X@;""`?>KN`+;_N!A[S\/=R^V3K6S' MFQE]U?Z!;<@:7T6!EA;;15\ZRDLJAD89?V-%7V&L,V9-)O%35"5I]I)0_.`3 MBJ\?[U%QM61"E1?YUU4Z7YWE1+M-#8;AL^SP$FWX':3$`>4@-S;05$G)(8+X MF-9+WXM**Z+,'2H>B=`)F<;?":%C$`%FR.B0=]4?T-)#^$XD%;6;^N<)9MKK[E:'&[OB_3 M19K0XSL)T#34'-JDU(<'.9AA)L:=5(@&?/\9VT)9>]'`]U+YX&\:M-#:ON;9 MR"AS$%(ZSC4(Z(*^#P#5#Q[QK^!X",<]H&L,=+]<>MQCS,'N0DK-P6,VA<:C MMY.&%@:S[RG?R4"TVZP)2EK?#]V,Q!R,(&2GKY\.Q[A8H\R4[6984?4<%K#Z+=WA=1TOKV[;`6 MQ&8ZJY>QHIKJG(+*&N+M7]LU^D4^)\K0:^M\?(.;':!`@U,*NT5M6CJ>-^VQGY27)YH('#P.3,OW7T'5E MX@&1A0TL,0:KR?Y8SC<$VVA)M@AG>?G*DAA!$MDJH>(B6`=4T0`+IJ<=E*2\ M'1VK1;AR,U\\N%G`@>IU/'T(["1J_`')9%FIZKKBG;WMU#UCD9I?TP7:!J-_ M3OZ-B^UJYGBS-46[B:`^S1K-<7"Z-8*C-POW!10<<+*WE02\XMW#570X#`=NWWQ#GBS@0>K+]<,-2[9$_M%2@UKA&!8VF2Q[XB8MI,9`]NL7\I5PT;&AL;0PNKR*L M7A9:`:[/9?+$^+VG71^>Q*6"1?E1%JNNUC\VB]<1=3O:H@XO;8Y3/5X])\9M@D0\EEZD[(`](\58PX3X` ME%RJ.$_N_0!L=ZPBW$K0D7''7$,RC\\S`9L*@[7L#UVZ"KJ'6$/&\:Z8P9T? M&_<7G8'[%=61C+H*#LC0@_FRH1_6F'<[]]6SC7=S0:#;':D3-LCQE/+Q;4<9 MCJ94)MBH-J243EPZE/XT)>!+JX%LXL!O"&VKK9HV(,TEKW0[7;9'I!1(<.8Q-..&,%V'.,]WWXY?7TY?7TY M?0W)N;VJ,J'!,49:83QRP,]!X@D.%M>CWE(MM,S39]=:W=>^T[7N02DLN[5(PT<6`9ZFN!)S3;>@U6+%8_, M*ULO>"X')]2NKD@$=D(-.G"#'SK+V,6:JIJ]UGF?E&A!W_-$>;S9 MT30JS+XEQ4*3S\D-WV&6I[%\_4U/F1#BXP/AMW:ZV?_F#S/6EM]I4*>_IZM3 M<4JH":MHD31)%1[3(!!?DLZ)L[FM\%Q\BJ&DV:8]$-+X&\RG1`*&V82;!TP@ M49U&02A)O(>F3(VNC:C.XA1<>LIM?CL%Y<&"%&Z?_4!5*4^\*S#QX(OW,ASU M&ZXG";/X)!+$NP7L?GZ)U9,OZ47F<=6S#;)^M2%E4J2",_'*7\CH1!:]-`V_ M,$>IGK([[Y)13BZZ?+:IHU6+[_[$L.$^JSX1*%6GLI2$.K)&;#F9WT%3:W4, M5E$P],FXTUXGYQI:!RRWHIZGRVK3;'?.EA4J[DAI]!GGU:H43ZQLRW?1;E8^ M?#R--8HAT"RJ\Q%K8HG`V_3["/Q)2@/1-R@=/_;4!G&,O$%E/DZV+7%WE:-_ MH:2P0IVP+!!S7-GX$:FF8@#U6!G8$3ST#;.%_J:'Q/N[/$IPQN$RCHS0[G.JH1T92$6#$NUUQF@I6+$CYU)1B,+ M7.T4#R;OL64F'O7P6!_?;\AII*7M;2SER_2W-_W=R^QIPIGS5/+'>W-$:U29 M32]E#]$X8PB-YP(PC,^\5T_,);$SK/(BOT9%BA>?BN%+)1/6,+8!5#6$&](# MQR^)(-MU( M."LVA]*GW-AQDHYC+5I`)[],V&8ZQ380T>(BWQX9\F$H(.(V&$5#?"``-;+) M%##4"1#0<:]0U/;T!H(UGE8%M1WM(2--8I&]`6U7?T`'O MQ^#R$B`#RA\HDDTMMP\H`V1JL/RG`+#LWJ`P29;T0`HI4`[O+4,W!K[`=EP%?.7<"$F66>[-!6 M,&!;[,F'\6N7OT::EDAL(-#9`&A[_[``J+/!_C;9M\#[&"GP9AECCA9B_\T^<\77/T+53=D7?:0IW_L,C&USZY-74_[3MMT]1Q([]I72TS1 M(2>4O>W#L0:V31?D[S*$9>J[`"-EC303?,_:V[QHE_ MO!$S$*4JG+ZF=H4W94V!M90T)2*47&FS(%(5LNBH)D10G@Y.2-"-?>,(_&4- M@S8,!FC&I0'3L-[&FG$LXXVQ_)K0B4DEA(7P6V,W[EL48%#I8XX#CML4-Y'V MFDZ?S=JDJ4REW[>)\P??H\"$3B]S7`@XVL?]!;&8W\?$`QL/N)"6<2(CVWO5 MRG8(-]*?#HNEI1B!CX/!@(\*, MY=JM8CSQOFF_D67B]$\DW(@1Z['$>9(6[+[,9Y30$QYV!./[9&(KU.[D2?9N M$H2T`8>:U-ND92O6K"P1>Y?P,DWNTXS!L&F5Q55^0Z%)[VX2@B\X+]K_'B=E M6HH.*)SSYS_^%"-$B'T`0^P#&&(?#@MB8L4G@-B' M\8#QOWT'UM.@25--5:N7FMJY#F`N<$( M<\D.$B;A[7"5&,*1PDE2KFAR5?+7V>_K]#G)>@YCMY7`1P28EFLC!>#EHG8M MPC,`6Z.Y]S"]S7X#L>)U-!?L(L8C#-TPXJ9U=,2'AV,C\TP,7ITL\:YI:@OI MP:JE:T]EY72'!U&H429&IT*,$6%A]!:9[["P:>??$\S8]C%-=R-VO`>DH-,J M1^VL/Q]52>.JV2(_'IW-YS12@^I^5:U0071%9`)(="J_H,KW.6E'&LGQJ(*B M@820PM^8WMA[)Q4Q\PG!$QH&9@%(VY%=2>K-&Z@:!QLIV._7`KYLK%7RL^^A M043HGZX1#=78/H@BQHR&JGT(2T85*E)@:H%`(F45\3HAR_"W))^CIHRP>+.0F6C<5##V#Z_Q'#]N?=Y*]WUR0E^TR#FJ:TTF]U"0S)?!5!V M=A6EE%YW49E4-\FWS\39%&F2T1:X6MZ0]BV>$7\&`R_`ZZTHX*U+0YH/6RC= M[]>*6MH=3QWWN/?IF79?MBG M:&`R5,0.#XR/RSFJSX:GN\Q-2C&U;Y$2\J`0$$8#$9V2=H`1<'7TA,C>5S?4 M!WY+LZQ=P5T0UOE#2E=POIS*VB^PGMB[,;=54E2^ MQZ=6G;LBRW9XM_K)IQ&TN!J8@X&,N+0P0%2T@@R,HZ19X[2>(=?WT?K M'P:BVWD(BT5+[2'.K'2=5'20%=X#%'YK-.2^^0NGLVPGK%:/BY(SJX1Z7XYYO'[W MA,S#R/*[N$Q+"4P4%.V-%A%%C)#1JSH:.,(JXCU$J!/GH.(6+RLR!4&<&62I M5.%E=NE5(66B!)V%.<;#$%9IQ'>5+:8_>.R\`-PLO`@L%MNTZGAO+EO,V=5M MHYG1RC+#Z6K7-,NPUGCG`0HU+V67BPV*Z"?.EP%KWY"'V`-%S:D>&D6Z@_M?ISK-6-A4'QF>8%*OHV;9>Y#J:2/J#7I& M^=K[:[^\.+I@5#!]>VE>3^\O.4!?MMX[XW>D3:#;:WM`L-V888J(0W"WS& MSTR6BYR34W[QTZ1(8P-8D5!@H&YR=?-Z]"%&[3)T(4I_`>$MS(8H6.3%,G&.HPCS?"GM>X_6N.'_+T#\2[6"BY&%$"\EB1 MI=/<"<($E42?O-)H2!M<$3Z804US^7GLL&:QO`OF4K3)3!9;S?J@2X[+[E$\ MK)Z#67)(\E\KB<2=U'^B6$-$@92TPI",<^0Y*CBUON!\#D'/D$X,H"Y=I!B2 MJNH"1EWF4V3R"\+*QMM-LFT/Y_M-EX<0`02/UE`:71[:H#2[.,@'6$VL3\/< M(!893MJDVK#D141MNIST'>C3R'7-RR5](09&OGTN1D<>0)(8F9#'F]X79;X8 M"QZ#U#%&/+S9#2:E(#K(O*`&1**"09A%&!LD)Q"HZ3[NYS0MT)P0GR;/Z>(R M1?>H>$QRX:DLA+2=NRE)/;X5(;4U-M*/?R&"9\L&+B4[^_'J&17W.(#I?J.> M$BI*<$0"A]$`&!^?,W)])PW&R,MU5B6Y+(6*^/,V^(+_'&@[:O2`M.201>2Y MTF_7]V6Z2)-B<[6D42(XOV;6%0=I@8C;:8N&.%"0&.D(@8R.X8B!*B0($"T@D"$!DC1]G470P0Y[AX1(5RH%>1M'=Y MA22!-B]`'TCCBMDT3?NG`)KV$\J_H2R[R,EZ>\VB14^PL('UA&W*805AH(T- MU@W2Y"IF34&55="#2UB'F]HY;BM(CQB^T1V%=9`#KXY M=/7'>RYZ2^S$-IW/?E^3P9JF-L0Y[>2"#2T0;3M=5M-ZTY<31[ASI:1I+W^) M:;SI]36AYP?B=8[P6Z,']\V;NU#;'*N5Z/=X(2O:HSD6T^Q4[=/%@OHCA@&: M\YHJUNQ"GYCE#SQ>F7A'1T.4ILIXXS8E=KB4W`Z`DJO/5RY'W0N0K$<:GW.' MBD>Q5^Y^Z?OD^DMH,^2A4;%*%]"$^+(;_M'C%7E"2I;=]FK9J'15W*0/J^K+ MFHX_5\M;-%\7:96B\B3),K0XWC1T94/(P]P1MW:?>RRW*)#IUF;F:!Y=?^3! M+6'6/A^N*_`2L?PHP@%(]KE]OF[P.0HT:;0RQ\N088.(OT3JOH[7)=&O M+&?SW]=IR6YW7Z^+^2IIYNRSC%5.?OZ"*U1>)QNZT3C+%YPAI-O=9A5I%"`U MT-8<>VKF#:0^1@HIJL0NDD%%AR(#G[?[HMM?X\""C(];/;%MIS:!@QA M\_PSSJM5MF'27==C]^P1KP=>0DNW35,GI8NBP:%ZF@-`P;D%A-.+%C'%VQ@& M?4P;%=JI-=YGG\%WW;&;F^"P8&GQPRA&M<::0X'M6*YP1J0OZQ`OW]D3:BDD MN1+$'WL!LT'E06`[O\?$M2YHY!PB&*H[V2[3^/%F1]/Z7YH)2YT;P1'?0;Z$ MT7S];4AG24Y?7Q<$E8L^M1O1O4_>A1?&BHL_<@JXSVY`.9-?WPKCO<4?.S)U M/WH;;226PQKY^X-&GPG;M><*>XL@5+?+'D*TO:O!$BN'$MGL?V3MW4:)_298FX],8HBO:;6Z MR!?I<[I8)]G`)L1.=]34].W4EDCQ8MHTE7`)%EU7XJUI!O)0%=@ZARYY5NG3 M'3YC=^V%4Q3+TFTDDVEIAT^W/3YE>(-0.Z$FGS1.ND::2/]X;SK5]-L)GI87?VJQB_6_^=M&M0;'3(%\HMU:GK*)[ M5%DL2[ MJ\34N'IBX[PX":>4H'OUA2,X6"1JK;$?&(K$B/?U!_%XBO9L^]V;-J/C7AI)>KUL?M=\CXW'!#.M]Y*I@HPMFH MG*"?8Z)'X$\=EIE9/@N4?M\F01]\]^83%);'>DWZ'7S(JWU/GN,1L0O5]D(, M0+,D'1S/LY,,I,.$HY%"!/M,&]Y')IU=9&:YE&22<\<0NL,` M8!AFOH,OZ!O[9)3G8%`(DM^@4RC\6L3$17T;^HRMRG:.MDA.*"[92J_^V[%]$`ZRB0VGJ(CN1(TWA,- M:SOV#3%;5RM<=-^<'SLTZ_B/':GE_`^D$TYM^4D&-OFFY M7WV[/ M29K1'7+B-#_)7N.8L!K'^\'#:G[T+F[6#D%U::WHD:=`MC9,]Q3+]="MXCVV MLXIY_^@]%&#QH+JE6%[[W-'>E]\T+.,&/6USL+/C@]UAE##=IEFA;N`-H-"A M]`@;&TT6>`,09$2::=\@OJ.9B=?%AJG:#)@T.J(8'.T#*-ML)"K*`\$HW!I3 M`%-9^X@TTD%,;WK*_9)D:]3J=H++ZC,BO4^)34T1$4BE10X1K3#[3`Y;J1@C MLF@'D5-NFN!T=WB8/HK=@:R.GQC<8_-+$NSB*8`A:LI^_?V$S*/KC35),[T\ ME%9,PSH?5I42C?-YBDK?V9I5HJ7E/,/$8R)),F>KLIW;8P9E'88T)1DJR:RZ MVR7;URIH4:==,H"+NM+K(TRI-LOHU357EG&K&Y;8/M(#+^1L)39H-V]N" M&\L`M=;/LX!K"RT_\>R1^3]CL!F7:Q/:P,M%`S9;6]B!S:"VR%,JVXU)V,K) M<_>&36IF$R-0C2X[OWSBTWRA?]R3R1?YY?\#4$L#!!0````(`$F`;D.DC*`W MK@P``$1\```1`!P`=F%S;RTR,#$S,#DS,"YX7#$Q"$AH25$#0MOK7=P&2$K_$+U\NO"F?3!.[P"Y^P&)W">V'O[\ZMO*, MF4=<>M,[/QOV%$Q-UR)T<]/SO3[R3$)Z?__YSW_Z\)=^_PY3S!#'EO*T5R;$ M,VW7\QE6EJ[M<^C!4Q:&/M5FJG)Q=G%V>394QNYNS\AFRY7SJZOW2E^Y&)Y? M*JNMZW@N50SL\W']ED3;#54V`*J'?]ZAUZ>GEY.7NY/'/9!CH9G@_^]3!;RK$C6C%4 MA7$#8IA%OM_A8_=KY#W)SJ,6P7+1'Y[W+\\C)IO07Q/RO#XQ.Y+HL- M4>IR)-:U?!6^W.T(7;OA&W@GYO8ZPL/`:T7.]K60XJ;G$6=GBZF4[[8,KV]Z M8KWTHT7RRX[A,Y`O(F&NC0O`$%U7:V`A5#29J5L]%17*6#!]N^KC^AG!1HH MXN'1T$Z:6RG0Q#5]8>)'U%(I)WROP1YECEQ,/858-[U"BL/8T>A'U'X>P@DP M',+)%?40?T344H+NE%A_'P;I3M+]^QZV=/JS?$YOYY`[)"GB3.V8ZHS)19G/ M%[Z-<'@3/&.76IA"__#@N3:QA`]QBVQQSBRW&'/OD2+?(EPST7RL*LM[55TME7>'$;[K\&R. MYP(QF(PMYJ*'VN`FN4N0/G\[TLJ[Q(@=\I60/TRYIZ_UG8@01"P`EG;L.C`G M6V`@SUB#N,+!,]>KM-F;]UFX2BZJVX/E"OX\J'-8(?I4T1>J,5II0*",YH+R M86&H]\"F?505;0[_J\J[F;YLGS'RME/;?:F]2'(8"U?"9=.5,!XM M[Y7I3/_4G1%%2.ML@RCYKY04MNT"S'M\)P>HEA$5(OACY)@=$Q%]13?N1G/M MWW*KRIVZ`%N?W,`=5"FH;I%'8`X!= M;:X2,"^R8-Z.EIK<ZX_SE3:_4Q:P8<>:VN&; MQG>)-\+`&7CG,H&(/$7!V:(\L1G+R4H0O,PBN%3OA.%4#'6A&Q*EX/0$]VN^ MZO;C";RVX(2*L%@Z.W#JQ>+8$VTER/R0@\S]R%#[L,/4P)N!5^"POLL"L)C5.!D$A`\@&V3J'00I""8(L(^(MO'#QB) MB9,N7X!"?E,)$#]F@9B.-$/Y.)H]JLJ#.EH^&H'#UT&1@B(\UT4DID.8S`QL M8O*,GFSLS3$/,"FA*0'G;UEPPD,^"+WTU3WL%T,=J]K'T>U,77ZOS-55!U0* M*(T^@X8N(S%@4N]*@/@I"X0V_PB[0C>T;M;S9_W.=:T78MO1TM=`7;HA8ND' M$!01E.!QE<7C3M:V!@=.NG/!'B-&<.6@6$?^.$YGGY9 MC,+Y,(O"1)VJA@%^E*'"]GCLSN_TO!O8%NF:'6)\OV((G%8S%G><;"U!(B?Z M-]29R-CT%R-C]5F!``.GTU48_E71?WGH[;ZW"&0R84Z#N'280U";1%T8WK,L!01E&"2$XJ+ M"$-;!6G,,`@7`;DZ[W(FN29+)#[LO>9Y/K9BV2SF4G@TXS%(1=H2R')B=.'D MSE>SSXJV7#["^1)/=AGZ')['79C2+.6U0D>?K"IQ(8`_-4U_*>^"[KM/".69 MESAJ)UM+8*J:A>EPJ96.B4-31%""3O743(=/LQQ-'*A*E"6(-.2SE9"4BU,SL=9!53/'&8\IN*H:F2[NG`:'@'9((Y M(G:UJR`1;2%<5PUOA"COPNX["&L'4@D0*U.7P-@XE.IP;(ICXC^#>+_6`_8D M>RG2%TV0_EY)#*B($3OT:]XH22)<2%*"8HW[)1U*-?(="81.-Y>@4SWCT4%3 M)^610*>0H@2@.DF/#J)&68\$5M5(2T!KFO?H`*R4^$@`EM]4`E"EU$>'1OW< M1P*:"G0E.#7(?G2H54M_))`ZT5:,3K4$2(='S9LO"6#*B$H0JG4/IL.JQHV8 M9(!TLKD$GXKW8SIDFMR424!4@:X$J[KW9OXO0/LP2!4^"5XDRZ.(XBC$$>DA MA69J\\1+WFP0VB7JP`1U?6:N*3M+UFC)91Q@FWO1F_ZQJ[-7SXHJ212*4U3^ MI5"<-(]X>+,`.:5QJL@08PN?WRR)C(K8OK8H<;[HG[<+XX.S0LT&TL09#_^] M61[\:FYKRW)@DD]OEH$B8LIR4>=UA#AR!8_]8P?-Q/"(65N(B$<\-!$@78KF M*C@:*-X@^2/Q$S(DV&S&$EQ]T4\?(#G_\>UR\-HR\";C)R>5[UA])"(F^?0E ML(A7#:LR!Y)%_->/^,1,7(J9>(,4/PR8*$5440!)+8;]H3_\J7\^K`=`I@): MQ5$C!C'P^V::YM,+YY!V2KM-63I+D8Q67TFCL5LJ\FECIK&<)Z M6""JR?OX=6B'CLIF+.PX*&4\::WPLS1UZ,-P_)MX"H+ M/_N73$M0,TR6"+RV_.#;FL:Q(YQ!$-A_\CCALM3C'7/]741*@*2G4&+;(H=Z MT^-,_+@&`34#F6]Z:V3+6H62>`>`N]9*CA2-<5IX4>[#M\%&\`?L/&$6DS[; M%(@?%`B\MEP'D2\A??!_$^&CC,MX*VI6>F&^`3FF4=-3T&1)E`=/Q%^6N]8NE;F,P+%5NXBJ/RV%T78((+>R8)LG#/R MY',AV$=+/`_%-1/B,&^Y`*@F"J)M^T#9NQZ7%_+U)$GRB![B5^'AB?-*9+6&)$2 MB[S$[)F8>"20V`3?IC,&I("F;=;C"$6(1%:;TR1M4P:.KV8/95G,&3JKE47Z\!!J8Z.]O= M8YQ!ZC1)VW#*\2_"2Y!9PUE*VC;E1"E\S"*/,:-0?G/;E)!7X+R/V),74M<< ML]46',`'E_)M?!^5T(5J@4XPO+A2^L>Z(U+:V_0]S-BA?+L_DBS07CJ)+XA9 MP3=)#38I\X.:F.(ZQFJ+J+Z3GY/OA!?>T@HG0I:12">!!O@J._)W,Y M";>E!E=K'+:R=$6.N7UQ/V/$2FSR@:AEFTKN=7LOEU]D_1SA7268>GJ!ID5RQ^;1%'%")JD;#,^'&172#6T37'WE M,LT:AM3B%I7H,IMA*2-LFV)%&>.<#&PU\I9E8)/G*I^2-=\O@E,T'?EDP]CZ MO&V#.$HJA-?_PL^#.4NWF*YM:FGBWAZR:WTLJ<'3OIQ\E/H*(LP%SCBV-YJ4XR@B_D1`F5XV(KO6U,[6L+U';L48]L4SWXT*O/O*G.T M3=40I(5DFKIL2IC'[Y$=6JM#0CU2*QL:UV!MG]^7UF&)39=:S?2OP-N^"0B3 M`Y>GL@:7;5BX\N<_P>U5^.]_4$L!`AX#%`````@`28!N0S()I)5WD0```;L* M`!$`&````````0```*2!`````'9A&UL550%``-9.H52 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`28!N0Z7=54\J$```U-L``!4` M&````````0```*2!PI$``'9A`Q0````(`$F`;D-=1`L``00E#@``!#D!``!02P$"'@,4````"`!)@&Y#ZFW2#NAV``#>@`8` M%0`8```````!````I(%2P```=F%S;RTR,#$S,#DS,%]L86(N>&UL550%``-9 M.H52=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`28!N0UZEKFV4.0``!L\# M`!4`&````````0```*2!B3`Q0````(`$F`;D.DC*`WK@P``$1\ M```1`!@```````$```"D@6QQ`0!V87-O+3(P,3,P.3,P+GAS9%54!0`#63J% F4G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``!E?@$````` ` end XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
RELATED-PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2013
RELATED-PARTY TRANSACTIONS [Abstract]  
RELATED-PARTY TRANSACTIONS
NOTE K – RELATED-PARTY TRANSACTIONS

On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (”Kerns”).  Pursuant to this agreement, a five-year warrant to purchase 4,285,714 shares of our common stock at an initial exercise price of $0.08 per share was issued to Kerns.  In March 2012, Kerns exercised its warrant and purchased 4,285,714 shares of common stock.

On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was also appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company.  Fees of approximately $66,000 and $187,000 were billed by the firm through the three and nine months ended September 30, 2013, respectively, and fees of approximately $60,000 and $194,000 were billed through the three and nine months ended September 30, 2012, respectively, at which dates no amounts were outstanding.

Mr. Rios currently is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company’s consulting agreement with Edgary Consultants, LLC.  The consulting agreement (the “Agreement”) between the Company and Edgary Consultants, LLC (“Consultant”) commenced on March 1, 2011 and was for a two year term and expired on February 28, 2013.  The Agreement provided for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy.  

In consideration for the services to be provided by Consultant under the Agreement, the Company agreed to issue to Consultant or its designees, up to 18,500,000 shares of restricted common stock of the Company, 3,000,000 of which were issued in March 2011 and the balance was to be earned on performance. Mr. Lieberman received 600,000 of these restricted shares.  The Company recorded the fair value of the shares issued to Consultant as a prepaid expense and amortized the cost ratably over the two year agreement.  The unamortized value is reported as deferred related party consulting expense in our accompanying condensed consolidated balance sheets as of December 31, 2012.  No performance-based shares were issued and no further compensation is expected to be paid in conjunction with the agreement.

During the nine months ended September 30, 2012, a director performed consulting services for the Company aggregating approximately $10,000.

Through the Company’s acquisition of FGE in September 2011, it assumed the liability for $288,000 in unsecured notes payable to the President of LET and his spouse, of which $95,000 was repaid in December 2011, and $190,000, bearing interest at 6% per annum, was paid in March 2012.  In addition, receivables due from FGE management aggregating $8,000  and $6,000 were collected during the three and nine months ended September 30, 2013, Receivables due from FGE management aggregating $3,000 were advanced during the three month period ending September 30, 2012, and receivables aggregating $159,000 were collected during the nine months ended September 30, 2012.

Biox leases a part of its offices to Genwell Instruments Co., Ltd., a company partially owned by certain officers of the Company’s subsidiaries.  The lease term is for twenty months ending December 31, 2014 at a monthly lease amount of approximately $750.

 
XML 47 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACCOUNTS AND OTHER RECEIVABLES, NET
 9 Months Ended
Sep. 30, 2013
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]  
ACCOUNTS AND OTHER RECEIVABLES, NET
NOTE G – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2013 and December 31, 2012:
(in thousands)
   
September 30, 2013
  
December 31, 2012
 
   
(unaudited)
    
Trade receivables
 $7,162  $12,193 
Due from employees
  183   131 
Allowance for doubtful accounts and
        
commission adjustments
  (2,606)  (3,179)
Accounts and other receivables, net
 $4,739  $9,145 


Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.  Due from employees is primarily commission advances made to sales personnel.
XML 48 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2013
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]  
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC. These condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.



Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2012, includes a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.

Revenue and Expense Recognition for VasoHealthcare

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured.  These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement.  Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets.  Under our agreement with GE Healthcare (“GEHC”), GEHC pays the Company a commission.  In accordance with the agreement GEHC pays the Company fifty percent of the commission at the time the order is received and fifty percent of the commission when the order is completed by delivery and acceptance to their customer.  At the time the order is received therefore, the Company records a receivable for the fifty percent of the commission and offsets this to deferred revenue.  At the time the order is completed the Company records a receivable for the remaining fifty percent commission and records this as recognized revenue including the amount previously deferred.

Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded.  Commission expense is recognized when the corresponding commission revenue is recognized.  Cost of commissions includes commission expense and, beginning in 2013, costs associated with the medical device excise tax imposed by the Affordable Care Act.

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.
XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
ACCOUNTS AND OTHER RECEIVABLES, NET (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Sep. 30, 2012
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]      
Trade receivables $ 7,162 $ 12,193  
Due from employees 183 131  
Allowance for doubtful accounts and commission adjustments (2,606) (3,179)  
Accounts and other receivables, net $ 4,739 $ 9,145 $ 7,704
XML 51 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Sep. 30, 2013
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]  
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
NOTE N - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Adoption of New Standards

 
Other Comprehensive Income:  Presentation of Comprehensive Income

 
In February 2013, new guidance was issued that amends the current comprehensive income guidance.  The new guidance requires entities to disclose the effect of each item that was reclassified in its entirety out of accumulated other comprehensive income and into net income on each affected net income line item.  For reclassification items that are not reclassified in their entirety into net income, a cross-reference to other required disclosures is required. The new guidance is to be applied prospectively for annual reporting periods beginning after December 15, 2012 and interim periods within those years.  The adoption of this new guidance did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows.
XML 52 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEFERRED REVENUE
 9 Months Ended
Sep. 30, 2013
DEFERRED REVENUE [Abstract]  
DEFERRED REVENUE
NOTE J - DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows
 
(in thousands)
   For the three months ended September 30,  For the nine months ended September 30, 
   
2013
  
2012
  
2013
  
2012
 
   
(unaudited)
  
(unaudited)
  
(unaudited)
  
(unaudited)
 
Deferred revenue at the beginning of the period
 $13,270  $15,198  $15,602  $15,228 
Additions:
                
Deferred extended service contracts
  410   288   848   987 
Deferred in-service and training
  8   13   23   33 
Deferred service arrangements
  30   20   60   75 
Deferred commission revenues
  2,076   2,037   5,355   6,116 
Recognized as revenue:
                
Deferred extended service contracts
  (245)  (283)  (755)  (840)
Deferred in-service and training
  (10)  (10)  (20)  (25)
Deferred service arrangements
  (16)  (22)  (54)  (64)
Deferred commission revenues
  (2,796)  (2,243)  (8,332)  (6,512)
Deferred revenue at end of period
  12,727   14,998   12,727   14,998 
Less: current portion
  7,684   9,418   7,684   9,418 
Long-term deferred revenue at end of period
 $5,043  $5,580  $5,043  $5,580 
XML 53 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Sep. 30, 2013
FAIR VALUE MEASUREMENTS [Abstract]  
Assets and Liabilities Measured at Fair Value
The following tables present information about the Company’s assets measured at fair value as of September 30, 2013 and December 31, 2012:
             (in thousands)
   
Quoted Prices
  
Significant
       
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
September 30,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
  
2013
 
Assets
          
(unaudited)
 
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $8,076  $-  $-  $8,076 
Investment in certificates of deposit (included in short-term investments)
  111           111 
   $8,187  $-  $-  $8,187 
                  

   
Quoted Prices
  
Significant
       
   
in Active
  
Other
  
Significant
  
Balance
 
   
Markets for
  
Observable
  
Unobservable
  
as of
 
   
Identical Assets
  
Inputs
  
Inputs
  
December 31,
 
   
(Level 1)
  
(Level 2)
  
(Level 3)
  
2012
 
Assets
            
Cash equivalents invested in money market funds (included in cash and cash equivalents)
 $9,124  $-  $-  $9,124 
Investment in certificates of deposit (included in short-term investments)
  110           110 
   $9,234  $-  $-  $9,234 
XML 54 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT REPORTING AND CONCENTRATIONS (Tables)
 9 Months Ended
Sep. 30, 2013
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]  
Summary Financial Information for Segments
There are no intersegment revenues.  Summary financial information for the segments is set forth below:

 (in thousands)
   As of or for the three months ended September 30, 2013 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $1,744  $5,862  $-  $7,606 
Operating (loss) income
 $(364) $199  $(327) $(492)
Total assets
 $8,398  $8,040  $8,972  $25,410 
Accounts and other receivables, net
 $1,229  $3,510  $-  $4,739 
Deferred commission expense
 $-  $4,145  $-  $4,145 
                  

   As of or for the three months ended September 30, 2012 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $1,063  $4,659  $-  $5,722 
Operating loss
 $(838) $(1,358) $(463) $(2,659)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $6,645  $-  $7,704 
Deferred commission expense
 $-  $3,635  $-  $3,635 


   As of or for the nine months ended September 30, 2013 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $4,533  $18,262  $-  $22,795 
Operating (loss) income
 $(1,489) $870  $(1,085) $(1,704)
Total assets
 $8,398  $8,040  $8,972  $25,410 
Accounts and other receivables, net
 $1,229  $3,510  $-  $4,739 
Deferred commission expense
 $-  $4,145  $-  $4,145 


   As of or for the nine months ended September 30, 2012 
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
  
Consolidated
 
              
Revenues from external customers
 $4,604  $14,858  $-  $19,462 
Operating loss
 $(1,191) $(1,473) $(1,221) $(3,885)
Total assets
 $8,595  $11,319  $9,595  $29,509 
Accounts and other receivables, net
 $1,059  $6,645  $-  $7,704 
Deferred commission expense
 $-  $3,635  $-  $3,635 
XML 55 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
 9 Months Ended
Sep. 30, 2013
Nov. 08, 2013
Document and Entity Information [Abstract]    
Entity Registrant Name VASOMEDICAL, INC  
Entity Central Index Key 0000839087  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   155,433,747
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q3  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2013  
XML 56 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
LOSS PER COMMON SHARE (Tables)
 9 Months Ended
Sep. 30, 2013
LOSS PER COMMON SHARE [Abstract]  
Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2013 and 2012, because the effect of their inclusion would be anti-dilutive.
(in thousands)
   For the three months ended  For the nine months ended 
   
September 30, 2013
  
September 30, 2012
  
September 30, 2013
  
September 30, 2012
 
Stock options
  1,780   1,810   1,780   1,810 
Warrants
  -   1,500   -   1,500 
Common stock grants
  585   3,260   585   3,260 
    2,365   6,570   2,365   6,570